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Abstract 
The development of a vaccine to control malaria infections in humans 
requires the identification of antigens which are targets of protective 
immune responses. One potential problem for vaccine development is 
antigenic polymorphism of malaria parasites. Allelic polymorphisms have 
been demonstrated for a number of Plasmodium falciparum antigens, 
including the merozoite surface protein MSP2. 
MSP2 has been classified into two allelic families (serogroups A and B), 
although considerable heterogeneity is known to occur within each 
serogroup. The protein has highly conserved N- and C- terminal 
sequences. There are two central regions of tandemly arranged repeats 
which are flanked by group-specific, dimorphic sequences. Although MSP2 
is considered a candidate for inclusion in a malaria vaccine, this is based 
on rather limited evidence. The aim of this thesis is to examine quantitative 
and qualitative aspects of the serological immune response to MSP2 in a 
population of malaria-exposed individuals from West Africa. 
Recombinant MSP2 antigens, produced using pGEX plasmid expression 
vectors to direct the synthesis of MSP2 in Escherichia co/i as fusions with 
glutathione S-transferase, were used to determine the presence of serum 
antibodies by enzyme-linked immunosorbent assay. These recombinant 
antigens include full length proteins of serogroup A and B, and fragments 
representing the conserved, group-specific or repeat regions of the 
molecule. The antigenic integrity of the recombinant proteins was checked 
by mouse immunisations and testing of immune mouse serum for 
recognition of native MSP2 by immunofluorescence and immunoblot. 
The questions addressed in this thesis are whether MSP2 is immunogenic 
during natural infection with P.falciparum, whether amino acid 
polymorphism of MSP2 gives rise to antigenic polymorphism, and whether 
the immune recognition of MSP2 is variant-specific. In addition, the 
dynamics of acquisition of antibody to MSP2 with age, the lgG subclass 
specificity of anti-MSP2 antibodies and the association of MSP2-specific 
antibodies with protection against malaria infection have been investigated. 
MSP2 was found to be highly immunogenic, with high titre antibody present 
even in individuals known to have experienced only one episode of 
malaria. The antibody response is directed almost exclusively towards the 
dimorphic and polymorphic regions of MSP2 and antibodies to serogroups 
A and B do not cross-react. The acquisition of immunity to MSP2 is age- 
dependent, with the prevalence of anti-MSP2 antibodies and recognition of 
MSP2 variants increasing with age. Non-responsiveness does not appear 
to be genetically determined. Prospective longitudinal studies indicate that 
antibodies to MSP2 are associated with a reduced risk of clinical malaria. 
Qualitative differences in the antibody response were observed between 
children and adults; anti-MSP2 antibodies in adults are predominantly lgG3 
whilst children also possess IgGi antibodies. The expression of the lgG3 




Human malaria is caused by one of four species of Plasmodium; 
P. falciparum, P. vivax, P. malariae and P. ovale. P. falciparum and P. vivax are 
the most widely distributed and both cause a vast amount of human 
suffering. P.falciparum is the most virulent and responsible for more than 
95% of malaria deaths worldwide. 
Accurate information on the global incidence of malaria is difficult to obtain. 
However it is estimated that worldwide the disease threatens 2200 million 
people, approximately 40% of the world's population [355], with 300-500 
million clinical cases each year [356]. Thus, malaria constitutes a major 
threat to health and blocks the path to economic development for 
individuals, communities and nations. Countries in tropical Africa are 
estimated to account for greater than 80% of all clinical cases and more 
than 90% of all parasite carriers [355]. In Africa south of the Sahara, it has 
been estimated that 270-480 million clinical cases may occur each year 
[356]. 
Children are particularly at risk; malaria being one of the major killers of 
children in tropical Africa, taking the life of one out of 20 children before the 
age of 5 years [355]. It afflicts the poor and underprivileged most severely, 
sapping productivity and causing chronic illhealth. 
Social, political and economic changes all contribute to the worsening 
malaria problem, particularly through population movements and 
ecological disturbances. Construction and environmental change brought 
about by 'development" often creates environments favourable for malaria 
transmission, exacerbating the existing problem and opening the way for 
devastating epidemics in areas which were previously malaria-free. 
Yet malaria should not be considered an inevitable burden. A vast amount 
of knowledge about the parasite and its control has been acquired over the 
years. In most endemic countries, the goal of malaria control is to prevent 
mortality and reduce morbidity and the socio-economic losses provoked by 
the disease. The goal in malaria-free areas is to maintain that freedom 
[355]. 
The parasite has a complex life cycle (figure 1.1), alternating between 
vertebrate and arthropod hosts. Infection in man is initiated by an infected 
Anopheles mosquito injecting sporozoites into the bloodstream whilst 
feeding. The sporozoites remain extracellular for less than 30 minutes 
during migration to the liver, where they invade hepatocytes. Inside the 
hepatocytes the parasite undergoes a phase of maturation and asexual 
reproduction (schizogony) to produce pre-erythrocytic schizonts. After a 
number of days (depending on the species), up to 30,000 merozoites are 
released into the blood. The merozoites rapidly enter erythrocytes and 
begin the erythrocytic schizogony during which the merozoite develops 
from the ring stage through the trophozoite to the mature schizont 
containing 8-24 daughter merozoites which, after the red cell ruptures will 
initiate a subsequent intraerythrocytic cycle. The erythrocytic cycle of 
schizogony is repeated, leading to a progressive parasitaemia. 
The release of merozoites into the blood stream causes many of the 
symptoms of malaria. In the early stages of infection, fevers show no 
characteristic pattern. However, as the development of the parasites in 
erythrocytes becomes synchronous, typical febrile periodicity occurs [320]. 
After several generations of merozoites have been produced, a small 
proportion give rise to sexually differentiated forms - gametocytes. These 
stages are infective for the mosquito and when ingested during feeding 
emerge from the erythrocyte to form gametes. After fertilisation, the zygote 
develops into an ookinete that invades the midgut wall, maturing into an 
oocyst. The parasite then undergoes a process known as sporogony that 
produces thousands of sporozoites which, when released into the insect's 









Figure 1.1: Life cycle of the malaria parasite in man. The parasite is haploid 
throughout the human cycle: sexual mating occurs in the mosquito. All clinical 
symptoms are associated with the erythrocytic stage, and fever occurs when 
large numbers of schizonts rupture. The duration of the erythrocytic cycle is 48 
hours for all the human malaria parasites, except for P.malariae, which has a 
72 hour cycle. 
(1) - pre-erythrocytic stages; (2) - erythrocytic stages; (3) - sexual stages. 
Reproduced, with permission, from the Annual Review of Immunology, volume 
6, c.1988, by Annual Reviews Inc. 
In non-immune individuals parasitaemia is accompanied by illness. Most 
patients exhibit some combination of fever, chills, myalgia, headache, 
nausea, vomiting and diarrhoea. The symptoms of falciparum malaria tend 
to be more severe than those caused by other Plasmodium species, and if 
left untreated, are frequently fatal. In tropical Africa, cerebral malaria and 
severe anaemia are responsible for most deaths from malaria [130]. 
Cerebral malaria may begin slowly or suddenly after the initial onset of 
symptoms. Headache and drowsiness are succeeded by a comatose state, 
due, in part, to the sequestration of parasitised erythrocytes in the 
capillaries of the brain. Long term residents of malaria endemic areas 
gradually acquire resistance to clinical symptoms, and infections in adults 
are usually asymptomatic or accompanied by mild symptoms of headache 
and malaise [268]. However, during pregnancy women become 
susceptible to malaria, with increased frequency and severity of infection 
[216]. 
The clinical-pathological picture of malaria infection is also complex. While 
the malaria parasite initiates the disease process, subsequent events 
depend, to some extent, on many internal and external factors, including 
functional cellular and humoral immune responses as well as the 
nutritional state of the host [37, 130]. 
1.2 Naturally acquired immunity to malaria 
1.2.1 Epidemiological evidence for the acquisition of immunity to malaria: 
Evidence for man's capacity to acquire immunity towards malaria comes 
from epidemiological studies which demonstrated that the clinical and 
parasitological manifestations of the disease decline as age advances in 
residents of malaria endemic areas [91, 210, 213]. 
Pen-natal malaria is a rare event. The persistence of erythrocytic foetal 
haemoglobin and deficiency of p-aminobenzoic acid as a consequence of 
breast feeding contribute, at least in part, to the resistance operating in 
neonates and infants [62, 213]. In studies in The Gambia, the clinical impact 
of malaria then increased as age progressed [128, 210]. Episodes of dense 
parasitaemia accompanied by severe clinical illness developed and the 
disease appeared to reach peak prevalence in the second year of life. 
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Children gradually show clinical improvement, despite the persistence of 
parasitaemia. Parasite density and prevalence steadily decrease with age. 
Complete sterile immunity is uncommon; adults show transient low levels of 
parasitaemia in the absence of clinical symptoms [210]. 
The precise timing of these events depends on local patterns of malaria 
transmission and endemicity [268]. Nonetheless, in highly endemic areas, it 
is the young child who is principally affected by malaria and in the older 
child an acquired immunity affords effective protection against the disease 
[210, 211]. 
During pregnancy, susceptibility to infection and the severity of the clinical 
manifestations is determined by the level of pre-pregnancy immunity and 
parity [216]. In areas of high endemicity, women acquire a significant 
protective immunity, therefore the effects of malaria on the mother and her 
foetus are, in general, less severe than in areas of low malaria 
transmission. Regardless of endemicity, maternal malaria causes severe 
anaemia, significantly contributing to maternal morbidity. 
1.2.2 Specific immune responses to malaria infection: 
Immunity to malaria operates at different levels - stage-specific antiparasite 
immunity, antitoxic immunity and transmission blocking immunity - involving 
both humoral and cellular mechanisms [268]. 
The role of antibodies in resistance to malaria is well established. The 
ability of antibodies to confer protection against P.falciparum is apparent 
from the protection afforded to neonates and infants by maternally derived 
antibodies [92]. Field studies have shown that antibodies to asexual 
erythrocytic parasites are high in the blood of infants born to immune 
mothers and that these levels fall in the weeks following birth [209, 212, 
213]. Levels remain low for some time but then gradually rise throughout 
childhood and into adolescence. This pattern parallels clinical markers 
(such as the decrease in spleen and liver size, decrease in severity and 
frequency of clinical attacks, and diminished parasite densities) of 
gradually increasing resistance [210]. Furthermore, classical passive 
transfer experiments, in which immune serum or purified Ig reduced 
parasitaemias in children with acute disease [62, 63, 92, 280], lend support 
to the role of antibodies in protection against malaria. However, the 
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correlation between total anti-malarial antibody and protective immunity is 
poor, indicating that many antibodies may have no protective effect [200, 
210, 328]. 
There are several mechanisms by which antibodies could exert a protective 
effect. The briefly extracellular forms, sporozoites, merozoites and gametes, 
each present an array of stage-specific surface antigens and 
ligands/receptors which play a crucial role in the transfer of Plasmodium 
from one intracellular environment to another. Antibody could bind to the 
surface of these extracellular stages blocking the receptors which function 
in invasion or causing the agglutination of free parasites [59-61, 223]. 
Cytophilic antibodies can opsonise parasites for phagocytosis [88, 195]. 
Antibodies against the surface of the infected cells might inhibit parasite 
development inside the cell or inhibit sequestration of the erythrocyte in the 
deep vasculature of the host, thus forcing the parasite to traverse the 
spleen, leading to the clearance of infected erythrocytes from the 
circulation. 
Antibody may mediate parasite destruction through the activation of 
complement leading to lysis of the parasite or by the activation of NK cells 
or macrophages inducing the release of superoxide radicals and nitric 
oxide which facilitate parasite destruction. Finally, antibodies specific for 
the antigens that provoke the production of IL-1 and TNF could reduce the 
toxic effects of infection [189, 317]. 
A common feature of many malaria antigens is regions of repetitive 
sequences. It has been proposed that these may stimulate T-cell-
independent immune responses through the activation of B cells by cross-
linking of surface immunoglobulin [285]. However, such T-independent 
responses are likely to be less efficient than the response induced to 
antigen presented in the context of MHC. 
Naturally acquired immunity to malaria is a complex interaction between 
the humoral and cellular arms of the immune system. Many of the antibody-
dependent mechanisms require cooperation with effector cells, therefore 
an important aspect to consider is the isotype and subclass of the 
antibodies involved [34, 131]. The regulation of which depends on T cells 
and their cytokines to trigger the appropriate Ig class switching 
mechanisms [103, 301]. 
13 
There is ample evidence from animal models for the role of T cells in 
immunity to malaria [186, 314, 328, 350]; although studies on experimental 
models and in vitro studies at the T cell clone level do support the 
hypothesis of a role for T cells in protection from malaria, they cannot give 
much idea of the real effector mechanisms acting in vivo during infection of 
humans. Murine studies have indicated that I cell-dependent immune 
mechanisms are crucial to the development of effective anti-malarial 
immunity [268, 320]. For example, thymectomised animals fail to clear 
parasites or become immune to reinfection whereas intact animals develop 
a solid, long lasting immunity [320]. Also, protection against malaria can be 
induced in mice following adoptive transfer of immune T cells and antigen-
reactive T cell lines or clones [186, 274, 350]. 
T cells could act through specific or non-specific mechanisms [21, 320]: as 
helper cells for the activation of B cells and secretion of antibody; as 
cytotoxic cells having a direct effect on parasitised cells; in the activation of 
non-specific effector cells and in the production of cytokines that can have a 
direct inhibitory effect on parasite growth [21, 189, 190]. The antigen-
specific effects of T lymphocytes would be predominantly directed at 
hepatic stages since this type of immune attack is dependent on the 
expression of parasite antigen on the cell surface in conjunction with class 
1 MHC proteins (which are not expressed on the surface of human 
erythrocytes) [169]. 
In addition, the spleen plays a crucial role in immunity to malaria [190]. 
Splenectomy in humans can lead to recrudescence of a previously 
subpatent parasitaemia [122]. Controlled studies have shown that splenic 
function significantly alters with malaria infection of humans, such that in a 
malaria-modified spleen the clearance of red cells is enhanced [122]. In the 
enlarged spleen the circulation of blood through the pulp cords is 
increased as is the transit time of red cells [213]. Therefore, the spleen not 
only acts as a tissue involved in the removal of rbc containing inclusions, 
but also provides an intimate environment for the interaction of local 
immune effector cells and parasitised erythrocytes [123]. 
Clinical immunity against severe malaria attacks seems to depend on a 
complex regulation of the immune response than merely on specific 
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effector mechanisms, since antiparasitic factors such as TNF, IL-1, IL-6 and 
nitric oxide are also involved in the pathogenesis of malaria and cerebral 
malaria [19, 126, 189, 190, 214, 243, 245]. 
In conclusion, it is true to say that each transitional stage of the parasites' 
development in the vertebrate host presents a potential target for a 
multifactorial immune response (table 1.1). 
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Pre-erythrocytic stages: 
Antibodies blocking hepatocyte invasion by sporozoites [169, 218, 320] 
Direct killing of infected hepatocytes by cytotoxic I lymphocytes (CTL) 
[169, 218, 274, 314] 
Killing via antibody-dependent cellular cytotoxicity (ADCC) [169, 218, 
320] 
Killing through the release of cytokines such as g IFN that induce the 
hepatocyte to produce nitric oxide [169, 218, 314, 320] 
Erythrocytic stages: 
Blocking of merozoite invasion by antibody [42, 60, 114, 224, 238, 320, 
344] 
Agglutination of free merozoites by antibody[59-61, 223, 224, 320] 
Recognition of infected red blood cells (irbc) by antibody, resulting in 
complement-mediated lysis, or inhibition of sequestration [218, 320] 
Opsonisation of free merozoites or irbc by cytophilic antibodies, leading 
to phagocytosis [88, 183, 195] 
ADCC [4,105] 
Cellular cytotoxicity due to the production of toxic substances such as 
cytokines and reactive oxygen and nitrogen radicals [190, 218] 
Reduction of pathology by antibodies neutralising cytokine inducers [19, 
246, 317] 
Sexual stages: 
Antibodies blocking fertilisation [133, 169, 261] 
Antibodies involved in complement-fixing reactions which destroy 
gametes by lysis [46, 47] 
Gamete-specific T cells can block the transmission to the mosquito due 
to the toxic effects of cytokines [218] 
Table 1.1: Possible immune mechanisms against different stages of the 
malaria life cycle 
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1.2.3 Immunosuppressive effects of acute malaria infection: 
Acute malaria infection is thought to reduce the effectiveness of the host's 
immune system. This phenomenon is implied by 1) the increased 
susceptibility to concurrent bacterial and viral infections and 2) infected 
individuals are less likely to respond optimally to vaccination procedures 
[349]. These findings are supported by the observations that children 
receiving malaria prophylaxis are less susceptible to other infectious 
diseases than their unprotected counterparts, and also had better cellular 
responses to malaria antigens [268]. Moreover, the reduction in the overall 
childhood mortality in children receiving the prophylaxis was greater than 
would have been expected simply from prevention of deaths due to malaria 
[268]. However, a paradox exists; from a clinical perspective malaria 
patients appear to be immunocompromised, yet in vitro immunological 
studies show that individuals have malaria-specific cellular and serological 
responses. Although, it is clear that the immune response to malaria is only 
partially effective in controlling reinfection, many of the clinical symptoms of 
malaria infection are associated with the immune response to infection. 
Immunologically, acute infection results in a transient decrease in the 
numbers of circulating I cells and decreased lymphoproliferative and 
cytokine responses of peripheral blood mononuclear cells (PBMC) to 
malaria antigens in vitro [268]. However, rather than this being a direct 
immunosuppressive effect, it has been proposed that cells recognising the 
malaria antigens are absent from the peripheral circulation having homed 
to the spleen, lymph nodes or liver [123, 125, 268]. 
Although acute malaria infection obviously has a profound effect on the 
efficiency of the immune system, the specific immunosuppressive 
mechanisms have not been fully elucidated. Possibilities include the 
suppression of I cells by activated monocytes or macrophages secreting 
prostaglandins or immune inhibiting cytokines like TGF-I3 (transforming 
growth factor), or defects in early events of 1-cell activation and inhibition of 
IL-2 function [320]. Of course, it may be necessary for the host to regulate 
the immune reactions which lead to harmful immunopathological effects. 
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1.3 Development of anti-malaria vaccines 
1.3.1 The need for vaccination: 
An effective vaccine against falciparum malaria would be an important step 
towards improved health in the tropical world, particularly in children in 
Africa [222]. There has been a recent resurgence in the disease due to 
increasing resistance to insecticides, environmental alterations that 
promote transmission (irrigation and timber clearing), movements of people 
into areas of high transmission to find work or avoid war, and the increasing 
inability of developing countries to afford the basic personnel and 
equipment required for malaria control and treatment. Drugs, for 
prophylaxis and treatment of malaria, are also becoming increasingly less 
effective [73]. Resistance to chloroquine is common in nearly all areas 
where P.falciparum is transmitted, and resistance to mefloquine, a more 
recently developed and very promising drug, has already been reported in 
many parts of the world [352, 356]. For these reasons, attention has been 
focused on additional means of control, particularly vaccines. 
There is every reason to believe that vaccination against malaria is 
biologically possible, although there is debate about whether it is always 
desirable and the long term consequences maybe difficult to predict. The 
disease is most severe in young children, pregnant women and non-
immune adults (such as immigrants from non-endemic areas), but with time 
and repeated exposure to the parasite, adults are able develop immunity to 
malaria which confers some degree of protection [210]. Immune individuals 
are generally have fewer and less dense parasitaemias and are less likely 
to suffer illness when parasitaemic and are significantly protected from 
death [210]. 
1.3.2 Strategies for identification of target antigens: 
Immunisation experiments in animals and humans with attenuated 
parasites or crude antigenic preparations have demonstrated that it is 
possible to experimentally induce protective immunity to malaria [56, 57, 
80, 133, 134, 148, 150, 151, 227, 237, 259, 260, 289-291, 351]. However 
such a vaccine strategy would be impractical due to the large amounts of 
parasite material required, the possibility of autoimmune reactions to red 
blood cell components, and the possibility that crude antigenic 
preparations may also contain immunosuppressive factors [236]. For the 
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further development of a vaccine against falciparum malaria it was 
necessary to identify those antigenic components of the parasite which 
induce protective immune responses in the host so that these components 
could be produced synthetically. The development of in vitro parasite 
culture, hybridoma technology and molecular biology has led to the 
identification and characterisation of many P.falciparum proteins. 
Furthermore, the advances made in understanding the mechanisms 
underlying naturally acquired immunity in humans and in experimental 
models have been, and still are, fundamental to malaria vaccine research. 
Potential vaccine antigens have been identified using several strategies: 
proteins which are recognised by malaria immune sera [33, 344]; 
proteins recognised by mAbs which inhibit parasite growth in vitro [102, 
114, 238]; 
surface molecules exposed to the immune system; 
proteins which are crucial for parasite function; 
screening of parasite cDNA or genomic expression libraries with immune 
sera. (Anti-sera raised by immunising mice and rabbits with cloned 
antigens were subsequently used to characterise the P.falciparum proteins 
corresponding to the antigen-positive clone [32, 178, 208]); 
systematic immunisation of monkeys with P.falciparum components 
eluted from SIDS gel and characterisation of the molecules associated with 
protection [234]. 
1.3.3. Expression of synthetic antigens: 
An important step in designing a malaria vaccine is to demonstrate that a 
synthetic form of the antigen (synthetic peptide or recombinant polypeptide) 
confers a degree of immunity similar to that obtained with native antigen. 
Thus it has become critical to identify appropriate methods to produce 
synthetic malaria antigens which are antigenically equivalent to their native 
counterparts. A number of options exist and have been explored for one or 
more malaria antigens. Synthetic oligo-peptides have been evaluated as 
conjugates with immunogenic carrier molecules, as components of novel, 
branched peptide polymers - multiple antigen peptides (MAPs) [135, 229] 
and as polymeric synthetic hybrid proteins [234]. However, synthetic 
peptides generally correspond to sequential (linear) determinants rather 
than conformational determinants which are characteristic of native 
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proteins, and a higher level of protection has been reported for native, 
conformational determinants [49]. 
A large number of malarial antigens, or antigen fragments, have been 
expressed as recombinant polypeptides in E.coli. The antigenic integrity of 
these recombinant polypeptides must be assessed before they are used as 
immunogens. The importance of conformation to protein structure is 
greatest for proteins in which secondary structure is stabilised by multiple 
intrachain disulphide bonds. Eukaryotic expression systems have 
theoretical advantages over ones using E.coli. These are the synthesis of 
recombinant polypeptide via the secretory pathway in a microenvironment 
that promotes appropriate folding and the potential for post-translational 
modifications including glycosylation and processing of foreign eukaryotic 
proteins [49]. A review of the structural features of the antigen can provide 
some insight into which expression systems should be tried first. 
1.3.4 Assessment of potential vaccine antigens: 
Having identified potential candidate antigens and expressed these as 
recombinant polypeptides or synthetic peptides, functional assays are 
required to assess the protective capacity of these molecules. Candidate 
proteins can be evaluated in vitro by the effect of antibody to these proteins 
on cell invasion and parasite growth and assays for cell stimulation by 
proliferation and cytokine production. However, it is apparent that in vitro 
results do not always correlate with in vivo protection [54, 105, 226]. 
Molecules can be assessed in vivo by direct immunisation of rodents and 
monkeys and subsequent challenge or by passive transfer of antigen-
specific antibodies. In addition the correlation of development of immune 
responses to the antigen with the clinical status of an individual after 
natural exposure to malaria should be evaluated. 
However, the correlation between protective immunity in experimental 
hosts and man has yet to be established [34]. Many of these models 
represent host-parasite relationships which could not be sustained under 
conditions of natural transmission. Furthermore, results in one host species 
cannot always be repeated in another. Conclusions drawn from 
immunological experiments with rodent malarias in rats or mice may not 
always be applicable to the human disease because of innate differences 
in host immune response. In many rodent models, unnatural host/parasite 
combinations are used, and depending on this combination infections 
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range from lethal with little or no immunity apparent, to mild, non-lethal 
infections where a solid sterilizing immunity is produced. Neither of these 
two situations is compatible with malaria under conditions of natural 
transmission. Nonetheless, the vast literature on the mouse immune system 
and the many commercially available reagents to study the cells and 
antibodies involved make it an attractive model. Evidence from experiments 
in Aotus monkeys suggests there may be substantial differences between 
Aotus and man since prior splenectomy is required for successful infection 
[34]. Furthermore, the biological properties of infection are different, for 
example drug cure can yield the monkey resistant to reinfection. 
1.3.5 Delivery systems: 
Any vaccine requires an effective delivery system to ensure optimal 
interaction among vaccine epitopes, antigen presenting cells and effector 
cells [169]. A common component of a delivery system is an adjuvant that is 
a non-specific immunopotentiator. This adjuvant must be safe for use in 
humans; at present the choices are aluminium hydroxide (alum) or 
liposomes, lipid spheres that self-assemble in aqueous solution [152, 169]. 
Another approach to the induction of immune responses is to use 
attenuated live vectors, such as Salmonella or Mycobacterium BCG, and 
these may be particularly useful for inducing CTL responses [6, 152, 169]. 
One of the most exciting new developments in vaccinology is the advent of 
nucleic acid vaccines which are attractive because of their relative 
simplicity [345, 346]. A gene encoding a protective antigen is cloned into a 
plasmid construct containing a eukaryotic promoter. This construct is 
usually delivered by injection into the muscle and the gene product 
expressed on the cell surface. The nucleic acid is taken up into the host 
cells, leading to the subsequent specific induction of both humoral and cell-
mediated arms of the immune system. A promising DNA vaccine against 
murine malaria based on the circumsporozoite (CS) protein has been 
developed. High levels of protection were obtained in challenge 
experiments in mice and the vaccine was demonstrated to generate both 
specific antibody and CTL responses [345]. 
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1.3.6 Vaccination strategies: 
There are several vaccine strategies being developed, targeting different 
stages of the life cycle with the aim of either preventing blood stage 
infections or reducing the pathological consequences of infection 
(reviewed by [22, 41, 147, 152, 169, 224, 245, 274]). 
Pre-erythrocytic stage vaccines 
The first opportunity to stop infection is during the parasite's brief migration 
through the circulation to the liver. A vaccine against sporozoites would, if 
effective, prime the human immune system to kill sporozoites injected by 
the mosquito and thus prevent the development of the subsequent stages 
responsible for the disease and transmission of the infection to others. 
Such a vaccine, if successful, would be truly prophylactic [232]. However, 
partial immunity to sporozoites would probably have little effect on the 
course of infection; any sporozoites that survive may cause a fully virulent 
infection [224]. 
Sporozoite proteins - 
The main antigens involved in protection against extracellular sporozoites 
are the CS proteins, part of a family of proteins covering the whole surface 
membrane of the parasite [77, 232], and the sporozoite surface-associated 
protein (SSP2). Passive transfer of monoclonal antibody, but not polyclonal 
antibody, specific for the P.yoelii CS protein protects mice from challenge 
[52]. The first synthetic malaria vaccine to be given to humans was derived 
from the immunodominant repeat sequence of P.falciparum CS protein 
[143], however, it was poorly immunogenic with only one out of 17 
volunteers being completely protected from sporozoite challenge [143]. A 
second CS protein vaccine, R32tet32, was also ineffective [348]; anti-
R32tet32 antibodies were not protective against naturally occurring malaria 
in Thailand [348]. 
Liver stage proteins - 
Protective immunity has been achieved in hosts ranging from birds to man 
by repeated inoculation with irradiated sporozoites [56, 57, 134, 232, 259, 
260] and this immunity probably operates mainly at the liver [314]. Induction 
of sporozoite-induced CTL responses may prove to be an effective strategy 
[274]. After immunisation with SSP2, protection from subsequent challenge 
was CD8 T-cell dependent in mice [169]. Immunisation with a synthetic 
peptide epitope containing a sequence from a P.berghei liver-stage 
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protein, LSA2, protects mice against sporozoite challenge by eliciting CTL 
capable of killing cultured exoerythrocytic stages [314]. Liver stages share 
a number of antigens with both the sporozoite and blood stages, as well as 
synthesising stage-specific antigens. Many more targets of protective 
immunity are likely to emerge and it is hoped that some of these will not 
suffer from the problems of variation and non-responsiveness associated 
with the CS protein. 
It was recently discovered that naturally exposed West Africans produced 
HLA-restricted cytotoxic T cells that recognised a nine amino acid peptide 
from the liver stage-specific antigen LSA1 [132] in association with HLA 
Bw53 [145]. Studies in The Gambia suggest a link between the MHC class 
1 molecule HLA Bw53 and protection from severe malaria [144]. 
If a vaccine is designed that copies natural immunity it may not be 
necessary to focus on lymphocyte stimulation because malaria-specific 
lymphocytes are present in non-exposed people at high frequency [121]; it 
is speculated that these may have arisen from cross-reacting microbial 
stimuli [121, 125], but that they may not be appropriate protective 
immunogens as naive people are not protected against malaria. 
Erythrocytic stage vaccines 
Proliferation of the asexual blood stages of the parasite life cycle is 
responsible for morbidity and mortality, particularly in children, and 
therefore is an obvious target for vaccine intervention. The aim would be to 
immunise the unprotected child, and, thereby reduce the pathological 
effects although not necessarily preventing infection. Hence, a vaccine 
targeting the asexual blood stages may have relatively little effect on the 
development of the sexual stages or transmission. Although, in 
evolutionary terms, there may be pressure to increase gametocyte 
production in vaccinees to ensure successful transmission to the mosquito. 
Protection from malaria can be artificially induced in animals by 
immunisation with asexual blood stage parasite preparations [80, 148, 150, 
151, 227, 237, 260, 289-291, 351]. Furthermore, mAbs, human Ig and 
monkey immune serum specific for the erythrocytic stages of the parasite 
can inhibit P.falciparum growth in vitro [33, 45, 238]. 
The blood stage malaria parasites are antigenically complex, but individual 
antigens have been identified [7-9, 141, 150, 155, 177, 179] and some 
potential vaccine candidates are described in section 1.4. 
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Another idea is to vaccinate against the disease rather than the parasite. 
Anti-disease vaccines may prevent the serious pathological complications 
of infection. It could be argued that antigenic variation represents the 
parasites adaptation to the host immune response and should therefore be 
a feature of those antigens that induce anti-parasitic immune responses. 
There may be less reason for any disease-inducing antigens to vary since 
this would increase the chance of host mortality, which would be 
counterproductive for the parasite. Disease is caused by the release into 
the blood stream of parasite products that induce responses in the host that 
cause the symptoms associated with malaria. Vaccination could induce 
neutralising antibodies to these parasite products [189]. In addition, 
vaccines directed against virulence mechanisms, in particular 
cytoadherence molecules, may be specifically effective in reducing the 
severity of disease associated with P.falciparum infection (see section 1.4) 
Sexual stage vaccine 
The aim of a transmission blocking vaccine is to arrest the sexual 
development of the parasite in the mosquito and to reduce or abolish 
malaria transmission levels. This altruistic approach would attempt to 
control the spread of disease within the community as a whole, but 
individual vaccinees would not be protected should they become infected, 
therefore this strategy would probably be used in combination with other 
types of vaccine. 
During the 24 hour period of development within the lumen of the mosquito 
midgut, the parasites are extracellular and in continuous contact with 
components of the blood meal derived from their vertebrate hosts and 
therefore accessible to antibodies and other immunological agents [47]. 
Studies in avian and primate models have demonstrated that immunisation 
with extracellular gametes totally suppresses the infectivity to the mosquito 
of the subsequent blood meal [133]. It appears that inhibitory agents, 
ingested at the same time as the bloodmeal, react with target antigens 
located on the surface of gametes, blocking fertilisation or on zygotes and 
ookinetes, and inhibiting subsequent development in the mosquito midgut. 
mAbs, with transmission blocking activity, have been used to identify the 
antigens important for this transmission blocking immunity [46, 47, 261]: 
Pfs230 and Pfs48/45 expressed on gametocytes and extracellular gametes 
[46, 47, 170, 261] and Pfs25 expressed on the surface of zygote and 
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ookinete forms [17, 46, 47, 170, 171]. These antigens have been shown to 
have limited immunogenicity in individuals naturally exposed to malaria 
[127, 170, 267]. Recombinant Pfs25 protein of P.falciparum elicits 
transmission blocking immunity in experimental animals [17], but is not 
naturally immunogenic in humans because it is not expressed until the 
parasite is inside the mosquito. 
An effective transmission blocking vaccine would be useful for dealing with 
either drug-resistant parasites or potential variants selected by partially 
effective pre-erythrocytic stage vaccines or asexual blood-stage vaccines 
[97, 222, 225]. 
1.3.7 Multicomponent vaccines (SPf66): 
In practice, the most desirable vaccine against malaria may be one that 
primes both cellular and humoral immune reponses to a variety of antigens 
from various parasite strains and life cycle stages [191]. 
In 1987, Patarroyo and colleagues in Colombia, synthesised and 
conducted successful preliminary test of a falciparum malaria vaccine 
SPf66, a synthetic hybrid polymer of peptides from asexual blood stage 
proteins linked to sequences from the CS protein of P.falciparum [234]. 
SPf66 was tested in a randomised double-blind placebo-controlled trial in 
Colombia with 39% protective efficacy [233]. Since then there have been 
independent trials in Tanzania, Thailand and The Gambia, where malaria 
transmission is more intense. Results from the trial in Tanzania have 
recently been reported in the Lancet [5]. The estimated efficacy was 31% 
(95% confidence interval: 0-52%), showing a reduction in the risk of clinical 
malaria among children exposed to intense P.falciparum transmission. 
However, for most infectious diseases, a vaccine that cuts cases by only 
one third would be deemed insufficient [36, 353]. 
In conclusion, the discovery and characterisation of the antigens, the 
development of improved delivery systems and the increasingly refined 
understanding of the immunology of malaria, all give good reason to be 
optimistic about the future of malaria vaccine development [169]. 
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1.4 Asexual blood stage antigens - vaccine candidates 
Vaccines derived from asexual blood stage antigens are of special interest 
because they mimic the development of natural immunity in children living 
in endemic areas and may induce long-term immunity due to natural 
boosting of the immune response following periodic exposure to infection 
[5]. The multiplication of the asexual blood forms of plasmodia is 
responsible for the pathological manifestations in man. During this stage of 
infection the parasite develops within the host erythrocyte into three 
successive stages - rings, trophozoites and schizonts (figure 1.2) - antigen 
expression differing during the cycle. Mature schizonts rupture the 
erythrocyte releasing merozoites which, after a short extracellular period, 
invade new erythrocytes. The wide array of structures associated with 
merozoite invasion increases the opportunity for identifying a malaria 
protein(s) that will induce protective immunity. Initially any part of the 
merozoite attaches to the erythrocyte and reorients itself so that its apical 
end toward the erythrocyte membrane. Before or during invasion, the 
contents of the apical organelles are released onto the erythrocyte 
membrane forming a vacuole. Once inside the erythrocyte, the parasite is 
still visible to the immune system due to antigenic modifications of the 
infected red blood cell membrane. Since these antigens are accessible to 
immune recognition for a prolonged period of time (compared to merozoite 
surface antigens), they are also excellent targets for immune intervention. 
The feasibility of a blood-stage based vaccine has been clearly 
demonstrated. A high degree of protection can be induced in monkeys by 
immunisation with Plasmodium schizont and merozoite preparations [227, 
237, 260, 289-291, 351]. However, this is an impractical strategy. 
A crucial step in the development of a synthetic asexual blood stage 
vaccine against malaria is to identify which of the many asexual blood 
stage proteins recognised by the host immune system are targets of 
protective immune responses (figure 1.2) [7]. The main target antigens are 
1) proteins accessible at the time of schizont rupture, merozoite release 
and erythrocyte invasion, such as proteins on the merozoite surface, in the 
secretory apical complex and the parasitophorous vacuole; 2) proteins on 
the surface of the infected erythrocyte which may be involved in 
cytoadherence, rosette formation or metabolism; 3) intracellular 
components that are released during parasite development or destruction. 
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Many of these antigens are highly polymorphic and it is uncertain to what 
extent the diversity in these antigens will frustrate attempts to use them to 


























Figure 1.2: Asexual blood-stage cycle of Plasmodium falciparum malaria, 
identifying key targets for vaccine development. 
1.4.1 Antigens associated with the merozoite/schizont 
MSP1: 
The major merozoite surface protein MSP1 (MSA1, PMMSA, gplgO) is 
considered a leading candidate for inclusion in a vaccine directed against 
the asexual blood stage. 
MSP1 is synthesised during schizogony and is expressed as a major 
component of the merozoite surface in both hepatic and erythrocytic stages 
[149]. The high molecular weight molecule, which ranges from 180-25OkDa 
depending on the species and strain, has been shown in P.falciparum to be 
processed in at least two steps [28, 70, 86, 146, 149-151, 204]. First it is 
cleaved to several N-terminal fragments and a 42-kDa C-terminal fragment, 
and secondarily the 42kDa region is further cleaved into a 33-kDa and a 
membrane bound C-terminal 19-kDa fragment. The various N-terminal 
processing fragments initially remain in a complex on the cell surface and 
are eventually released into the plasma immediately before merozoite 
reinvasion [204]. The molecule is antigenically complex; the alignment of 
MSP1 sequences from many different isolates reveals 17 blocks of 
sequence that are either highly conserved, semi-conserved or variable 
[315] and there is marked inter-isolate antigenic diversity [206]. Additional 
diversity is generated by intragenic recombination [292]. The most 
conserved region is the 19-kDa fragment; it contains 12 cysteine residues 
which are completely conserved between the species with the 
characteristic spacing of EGF-like motifs [70, 193]. The 19kDa fragment is 
retained by the merozoite during erythrocyte invasion, and it is still present 
on the early ring stage of the next cycle of intraerythrocytic development 
[28]. These observation suggest that the 19kDa fragment, as well as the 
processing steps leading to it, may play an essential role in the reinvasion 
process and thus would be prime targets of vaccine induced immunity. 
Partial protection against P.falciparum challenge in monkeys has been 
achieved by immunisation with recombinant MSP1 [151] and complete 
protection with protein purified from the parasite [290]. In addition, mono-
and polyclonal antibodies to MSP1 inhibit parasite invasion in vitro [28, 50]. 
The 19kDa fragment is the target of invasion-inhibitory antibodies [28] 
[51]and the correct conformation of the disulphide bonds within the 2 EGF-
like domains is essential for recognition by mAbs and human serum [38, 
93]; this has been achieved in both eukaryotic and prokaryotic expression 
WE 
systems [38, 51, 93]. Antibodies to MSP1 are prevalent in sera ol 
individuals exposed to recurrent infection with P.falciparum [93, 115, 228, 
266, 270, 324]. The acquisition of antibodies is age-dependent [115] and 
naturally acquired cellular and humoral responses to MSP1 are associated 
with reduced malaria morbidity [228, 266]. Taken together, these 
observations indicate that MSP1 is a target of protective immunity and that 
the conserved 19 kDa region may be particularly important. 
MSP2: 
A second merozoite surface antigen, MSP2, is considered a candidate for 
inclusion in a vaccine against falciparum malaria. It has not been studied 
as extensively as MSP1. The characteristics of MSP2 and its immune 
recognition are described in detail in section 1.5. 
The apical membrane antigen, Pf83/AMA-1, is an integral membrane 
protein that is initially associated with the apical organelles of the merozoite 
and then the merozoite surface [75, 230, 242]. Pf83/AMA-1 is post 
synthetically processed rapidly by cleavage of an N-terminal peptide to a 
66kDa molecule [230]. Although AMA-1 lacks the repetitive sequences 
associated with other merozoite antigens of P.falciparum, there is limited 
polymorphism among the sequences of different AMA-1 alleles [242, 321]. 
Some regions of the molecule are well conserved; in particular, AMA-1 
contains 16 cysteine residues which are conserved within the genus and 
the intramolecular disulphide bonds are associated with a specific 
structural conformation important for immunogenicity [65, 81]. 
Characterisation of the P.knowlesi AMA-1 homologue implied that the 
protein may have a receptor function, as Fab fragments from AMA-1 
specific mAbs inhibited invasion of merozoites in vitro [322]. AMA-1 is 
considered a potential target for vaccine induced immune responses. The 
location of AMA-1 makes it accessible for immune recognition. Strong 
protective responses were induced in rhesus monkeys by immunisation 
with the P.knowlesi AMA-1 homologue in combination with exposure to the 
parasite [82]. Also, recombinant AMA-1 produced in baculovirus-infected 
insect cells has completely protected monkeys against challenge with 
simian parasites [65]. In addition, there is a high prevalence of antibodies to 
AMA-1 in individuals from malaria endemic areas and the.acquisition of 
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these antibodies is age-dependent [323], although no correlation was 
observed between AMA-1 antibodies and parasite density or fever. 
EBA-i75: 
A 175kDa erythrocyte binding antigen (EBA-175) which is thought to act as 
a ligand for attachment of merozoites to specific receptors on the 
erythrocytes [169], is another vaccine candidate antigen. The gene 
encoding the molecule has been sequenced, and parts of that sequence 
were believed to encode B cell epitopes. These were synthesised and 
used to immunise rabbits [292]. The hyperimmune serum reduced 
merozoite invasion of erythrocytes in vitro by 80% and inhibited binding of 
purified native EBA-175 to erythrocytes [292]. The protein appears to be 
antigenically conserved among the strains of parasites studied so far [292]. 
Parasite molecules contained in the apical membrane complex of the 
merozoites are believed to play a crucial role in invasion. The major 
organelles that make up the apical complex are the rhoptries, membrane-
bound electron dense structures which appear to discharge their contents 
at the time of schizont rupture and on the invasion of erythrocytes [263]. 
RAP-1 is a non-polymorphic multi-component antigen [262, 263]. The 
complex is recognised by human immune serum, mAbs specific for the 
P.falciparum RAP-1 can inhibit parasite growth in vitro [155, 286] and 
immunisation with this protein complex protects against infection [262]. 
1.4.2 Antigens associated with the surface of the infected erythrocytes 
Erythrocytes containing mature trophozoites and schizonts adhere through 
knobs to endothelial cells lining the venules in deep tissues. This 
cytoadherence of parasitised erythrocytes prevents their passage through 
the spleen and their eventual destruction in this organ. Because 
cytoadherence requires recognition and attachment, a vaccine that induces 
antibodies to the components on the parasitised erythrocytes required for 
endothelial cell attachment could eliminate the adherence. 
PfE M P1 (Plasmodium falciparum-infected erythrocyte membrane protein 
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Cytoadherence can be inhibited by antisera in a strain specific manner 
[157, 198] but the erythrocytes also express shared determinants. 
Longitudinal analysis of the recognition of the parasite-dependent red 
blood cell neoantigens (PDN) suggested a protective effect of anti-PDN 
antibodies [200]. However, the cytoadherence phenotype appears to 
display considerable antigenic variation [273]. The main candidates for the 
parasite-derived ligands that mediate cytoadherence are represented by 
the variably sized (250-400kDa) group of proteins expressed on the 
surface of the P.falciparum-infected erythrocytes and collectively 
designated PfEMP1[153]. Antigenically distinct forms of PfEMP1 occur, 
generated by a mechanism of antigenic variation [25, 272, 273]. PfEMP1 
appears to be the target antigen for naturally acquired antibodies that 
agglutinate infected rbc and inhibit cytoadherence [157, 198]. Isolation of 
the PfEMP1 gene will open the door to a molecular analysis of antigenic 
variation and is likely to greatly aid the development of anti-malarial 
vaccines. 
Pf 1 55/RESA: 
A well characterised antigen Pf155/RESA (ring-infected erythrocyte surface 
antigen) is present in dense granule organelles of merozoites and 
transferred to the cytoskeleton of newly invaded red cells. RESA, which 
does not exhibit antigenic heterogeneity among different isolates of 
P.falciparum, contains 2 blocks of tandem repeats encoding 
immunodominant B cell epitopes [177]. Interestingly, the antibodies 
directed against these repeat regions cross-react with at least six other 
asexual stage components [239]. Antibodies to RESA inhibit invasion in 
vitro [23, 344] and one study has shown that animals were partially 
protected against blood stage challenge by immunisation with a 
recombinant protein expressed in E.coli [64]. However, more recent primate 
immunisation studies have been less convincing [147]. 
In naturally exposed populations, there is an association between 
increasing titres to RESA and decreasing parasitaemia [341] and with 
resistance to high parasitaemia [265]. Further studies confirmed this but 
also showed that the presence of antibodies binding to peptides containing 
B cell epitopes was associated with susceptibility to clinical attacks of 
malaria [265], however the association between antibody and disease may 
reflect antibody boosting due to the current infection. In a cross sectional 
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study of Liberian adults [240], an association was observed between 
Antibodies binding to the 3' repeat region and reduced parasite density. A 
recent study in Papua New Guinea, found that adults having high antibody 
concentration to RESA were less likely to be parasitaemic [3]. 
Rosettins: 
Distinct from cytoadherence to endothelial cells is the phenomenon of 
rosetting - the binding of uninfected erythrocytes to circulating erythrocytes 
infected with mature parasites. It has been suggested that blockage of the 
cerebral vessels is due to adhesion of irbc to the endothelial and 
concomitant rosetting [342]. In studies on children from The Gambia, 
parasites from cerebral malaria patients had a significantly higher rosetting 
rate than did those from patients with uncomplicated P.falciparum malaria. 
Anti-rosetting antibodies have been found to hinder rosette formation in 
vitro and have been implicated in protection against severe malaria [342]. 
The surface of the infected erythrocytes is covered with minute electron-
dense excrescences called knobs. After being transported from the internal 
parasite, antigens involved in the binding to other cells are thought to be 
concentrated at the knobs and subsequently exposed to the exterior of the 
erythrocyte membrane. Potential rosetting ligands have been identified on 
the surface of irbc. These "rosettins' are of variable size (22-28 kDa) and 
can induce strain-specific rosette-disruptive antibodies [342]. 
1.4.3 Soluble antigens associated with schizont rupture 
Parasitised rbc rupture allows merozoite release and invasion of new 
erythrocytes. Since prbc development in vivo is synchronous, large 
amounts of prbc-derived lipids, glycolipids and glycoproteins are released 
into the plasma within a relatively short period of time. These elicit host 
responses that lead to the symptoms of malaria infection, particularly fever. 
It has been proposed that vaccine-induced antibodies specific for these 
molecules could lead to immune-mediated removal of these antigens 
without inducing the cascade of undesired host responses [190, 245]. Heat-
stable exoantigens in the supernatants of blood-stage parasite cultures 
induce the release of TNF in vitro from activated macrophages and behave 
like toxins in vivo. Mice immunised with the antigens are protected from the 
toxic effect and their serum specifically blocks the ability of the antigens to 
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stimulate the production of TNF [19, 317]. Thus vaccination with these 
exoantigens might provide a means of protection against the clinical effects 
of malaria and of generating anti-disease immunity by reducing cytokine 
production. Evidence suggests that the active moiety contains an 
inositophospholipid structure, possibly related to the 
glycophosphatidylinositol (GPI) anchors on the two major merozoite 
surface antigens and other plasmodial proteins [190]. Glycolipids induce 
the production of T-independent antibodies that are capable of neutralising 
this biological activity of TNF [19, 317]. 
At least seven exoantigens have been identified and it may be significant 
that most children in The Gambia do not develop precipitating antibody 
against one of them, Ag7, until they are about 4 years old [158]. This is 
about the time that they develop some immunity to the clinical 
manifestations of malaria. Riley et a! [269] examined the association 
between malaria morbidity and cellular and humoral immune responses to 
these soluble glycoprotein exoantigens in a longitudinal prospective study 
of semi-immune children in The Gambia. The presence of antibody to Ag2 
was more prevalent in children with asymptomatic malaria than in children 
with confirmed clinical malaria, suggesting that these antibodies may be 
able to inhibit parasite multiplication and consequently control the clinical 
symptoms of malaria infection. 
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1,5 Merozoite surface protein 2 (MSP2) 
1.5.1 Characteristics of MSP2: 
The P.falciparum merozoite surface protein, MSP2, is considered a 
candidate for inclusion in a vaccine against falciparum malaria. MSP2 was 
independently identified by several laboratories and is also known as gp56 
[310], GYMSSA [254], MSA2 [282, 297], 46000 dalton antigen [220], QF1 22 
[101], GP3 [110] and 46-53Kda antigen [55]. MSP2 is an integral 
membrane glycosylated protein with an observed size on electrophoretic 
migration varying from 35 to 56 kDa. The molecule does not exhibit 
conformational properties dependent on intrachain disulphide bridging - 
there is no significant shift in migration of the protein under reducing and 
non-reducing conditions [142, 220]. Unlike MSP1, there is proteolytic 
cleavage of the protein [297]. 
1.5.2 Location of MSP2: 
MSP2 has been demonstrated in trophozoites, "segmenters", schizonts, 
and isolated merozoites by immunoblotting using either poly- or 
monoclonal antibodies [55, 101, 220, 254, 297, 310], by immuno-EM [55, 
101, 220, 310] and by IFA [55, 101, 297]. These observations are consistent 
with observation that MSP2-mRNA transcription begins in young 
trophozoites and reaches the highest levels during the transition from 
trophozoites to schizonts [18]. MSP2 has been detected on the outer 
merozoite surface by surface-iodination [142] and mAb-labelling - giving a 
grape-like fluorescence pattern characteristic of antibody binding to the 
merozoite surface [101, 254]. 
After erythrocyte invasion, the protein is not detected [55, 254] or is 
detected in low quantities in the new ring stages [220, 297]. This indicates 
that the molecule is completely or partially lost during invasion, and thus 
possibly suggests a role for MSP2 in attachment to the erythrocyte. 
1.5.3 Structural characteristics of MSP2: 
A striking structural feature of MSP2 is its high level of variability. 
Characterisation of the protein by restriction-fragment length polymorphism 
(RFLP) analysis [108], hybridisation studies [201, 217, 231, 250, 304], 
serological analysis with mAbs [66, 67, 101, 109] and DNA sequencing 
[109, 201-203, 250, 256, 304] has shown that MSP2 is a highly 
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polymorphic protein. From this information, MSP2 has been classified into 
two allelic families: serogroup A (3D7/CAMP) and serogroup B (FCQ-27) 
[109, 202, 203, 297-299, 304, 321]. Sequencing of the gene provides an 
absolute means of examining the diversity of MSP2 and studies comparing 
information obtained on size and RFLP have shown that a considerable 
amount of microheterogeneity was evident once isolates were sequenced 
[201, 250]. Alignment of the many MSP2 sequences shows the 3' and 5' 
ends of the gene to be highly conserved, whereas a large central region is 
variable [109, 201-203, 250, 297-299, 304, 321] (figure 1.3). The amino-
and carboxy-termini, 43 and 74 residues respectively, are conserved 
among all isolates; 3 amino acid substitutions have been reported in the C-
terminus [321]. The central region contains two tandemly repeated 
sequences, Ri and R2, flanked by serogroup specific sequences. Both the 
repetitive and non-repetitive sequences exhibit a dimorphism; however, the 
non-repetitive sequences define the two basic, prototypic allelic forms and 
are highly conserved within each serogroup, showing limited conservative 
substitutions [321] and a deletion permissive area [109, 321] (figure 1.3). 
The Ri repeats of serogroup A consist of 1 to 13 copies of glycine-, serine-
and alanine-rich sequences containing between 4 and 10 residues. 
Variable repeat units can occur within one isolate and in different isolates 
(for examples see figure 1.3). Downstream there is a second repeat unit 
(R2) which consists of 3 alternative codons for the amino acid threonine 
[299]. Subfamilies of serogroup A exist, defined by the presence or 
absence of short regions within the sequences flanking the polymorphic 
domain [202] (figure 1.3) and reactivity with serogroup A specific mAbs [66, 
67, 109]. 
The corresponding repeat regions in serogroup B are unrelated to those of 
serogroup A, consisting of 32 and 12 amino acids respectively. These 
repeats display less sequence polymorphism than the serogroup A 
repeats, but occur in varying numbers. Isolates have been sequenced 
which lack the 1 2-mers altogether [201, 250, 257]. The permissiveness for 
variation in size is limited; changes in repeat number are compensated for 
by deletions or insertions elsewhere in the variable region. 
Despite the extensive differences between the serogroups, there is a 
striking conservation of the overall amino acid composition, net charge and 
hydrophobicity [299]. 
we 
As in MSP1, additional diversity has been superimposed on the 
dimorphism by intragenic recombination [203, 231]. However, in contrast to 
MSP1 where homologous recombination has apparently occurred between 
sequences in the conserved blocks close to the 5' end of the gene [66, 67], 
the recombination within MSP2 has occurred in the repeat regions which, 
although very different, have a short region of homologous sequence which 

























Figure 1.3: Schematic representation of MSP2 serogroups A and B. 
Published sequences from the Ri and R2 regions of each serogroup are 
shown [109, 201, 250, 298] . dl and d2 denote the deletion permissive 
regions of the molecules 
KEY: 	A Ri repeats 
A R2 repeats 
Group A specific 
B R1 repeats 
:1R2 repeats 
Group i :I*I*IH[. 	EE 
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1.5.4 Immunological studies of MSP2: 
MSP2 is a potential target of protective host immune responses due to its 
location on the surface of extracellular merozoites. MSP2 specific poly- and 
monoclonal antibodies inhibit in vitro parasite invasion and growth [55, 
101, 220, 254, 255, 282, 299]. These antibodies define variable, linear 
epitopes [101, 255]. 
The immunogenicity of peptides representing sequences from the 
conserved and variable regions of MSP2 have been investigated [165-168, 
276-279, 282]. Several of these peptides, when administered with adjuvant 
either free or conjugated to diptheria toxoid, elicit antibodies in mice that 
recognise the native protein [165-168, 276, 282]. In addition, some of the 
peptides induced proliferation of murine and human T cells [277-279]. 
Furthermore, mice, immunised with peptides from the conserved regions of 
P.falciparum MSP2, were protected from challenge with asexual parasites 
of the murine malaria P.chabaudi [284]. However, immunisation of Saimiri 
monkeys with a rAg representing the full length protein of serogroup B 
expressed in vaccinia virus failed to protect monkeys against challenge 
with P. faiciparum [252]. 
Despite the apparent protective capacity of the conserved sequences, 
contradictory results have been obtained for the recognition of these 
regions. Aotus and human serum eluted from immune clusters of 
merozoites did not react with rAgs representing the N- and C-termini [321] 
and Saul et a! [284] were unable to detect antibodies against conserved 
peptides in individuals from Papua New Guinea (PNG). However, 
antibodies have been detected to C-terminal sequences in individuals 
naturally exposed to malaria in Sri Lanka and another PNG study [256] [2] 
Antibodies to MSP2 are prevalent in individuals from malaria endemic 
areas [2, 256, 279]. Antibodies to MSP2 are acquired in an age-specific 
manner [2, 256], with the highest prevalence of seropositivity in individuals 
older than 15 years in Papua New Guinea [2]. A proportion of these 
individuals had antibodies to only one form of MSP2 indicating that 
recognition may be serogroup-specific and not directed towards the 
conserved regions, although the authors postulated that non-
responsiveness may be genetically regulated [2]. A negative association 
between antibody to MSP2 and fever was observed, suggesting a possible 
protective role of anti-MSP2 antibodies in natural infection [2]. 
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1.6 Aims and outline of the thesis 
The aim of this thesis is to examine the qualitative and quantitative aspects 
of the serological immune response to MSP2 in a population of malaria-
exposed individuals from The Gambia, West Africa (figure 1.4). 
The Gambia is a small country on the west coast of Africa; one of the 
smallest and most densely populated in Africa. It is an area of flat Sudan 
savannah with some mangrove and rice swamps near the river Gambia. 
The climate is characteristic of the sub-Sahel with a long dry season (mid-
October to June) and a shorter rainy season with around 500-1000mm of 
rainfall per year [66, 67, 128]. This results in hyperendemic malaria 
transmission with a seasonal point parasite prevalence which may exceed 
50%, and a peak number of clinical cases occurring between September 
and November [200]. 
Recombinant antigens, representing MSP2 and fragments thereof, are 
used to determine the presence of serum antibodies by enzyme-linked 
immunosorbent assay (ELISA). The antigenic integrity of the rAgs has been 
confirmed to ensure that they accurately reflect the antigenic characteristics 
of native MSP2 (Ch.3). Optimisation of the ELISA procedure was performed 
to ensure that antibodies specific for MSP2 are detected and the assay 
procedure is robust and reproducible (Ch.4). 
Serum antibodies are initially determined in malaria immune adults from 
the village of Brefet (figure 1.4) to determine the immunogenicity of MSP2 
after natural exposure to malaria and the relative antigenicity of conserved, 
dimorphic and polymorphic regions of the molecule (Ch.5). Cross-sectional 
(Ch.6) and prospective longitudinal (Ch.7) studies, using serum samples 
collected in villages around the town of Farafenni (figure 1.4), are used to 
examine the dynamics of the acquisition of anti-MSP2 antibodies with age 
and the association of anti-MSP2 antibodies with subsequent susceptibility 
to clinical malaria, respectively. The quality of MSP2-specific antibodies are 
investigated (Ch.8), in terms of lgG subclass specificity, and related to age 
and clinical status. 
The effect of the extensive polymorphism of MSP2 on immune recognition 
is elucidated and associated with age and exposure to distinct parasite 
genotypes (Ch.9). A field study has been carried out in Fajara, The Gambia 
(figure 1.4) (Ch.10). Serum samples and infected erythrocytes will be 
obtained from individuals with uncomplicated clinical malaria, to determine 
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the relationship between the specificity of the immune response to MSP2 
and the MSP2 genotype of the P.falciparum infection. 
The possibility that the immune recognition of MSP2 may be genetically 
regulated is investigated by comparing the antibody responses of 
monozygous and dizygous twins, and by looking for associations between 
antibody specificity and HLA-type (Ch.1 1). 
Each chapter is a discrete unit with its own introduction and discussion. An 
overall discussion (Ch.12) consolidates the findings and discusses their 
implication for vaccine development. 
Figure 1.4: A map of the western part of The Gambia showing the locations 
of the villages from which samples were collected. 
2. Materials and Methods 
Unless otherwise stated reagents were obtained from SIGMA Chemical 
company Ltd., Poole, UK. 
2.lRecombinant MSP2 proteins: 
2.1.1 Construction of plasmids 
pGEX expression vectors were used to direct the synthesis of MSP2 
polypeptides in E.coli as fusions with the C-terminus of glutathione 5-
transferase (GST) of Schistosoma japonicum [295] (figure 2.1). Polymerase 
chain reaction (PCR)-amplified fragments of the MSP2 gene were ligated 
into pGEX vectors, after the PCR products were cut with the appropriate 
restriction enzymes. The pGEX vectors provide BamHI, Smal and EcoRl 
cloning sites in all three reading frames followed by a series of termination 
codons. After transformation into E.coli, transformants were screened for 
the expression of the required GST fusion protein by small scale 
purification. Individual transformants were picked into 2m1 of L-broth 
containing lOjig/mi ampicillin and incubated at 37°C, with shaking, for 3-5 
hours. l sop ropyl-13-D-thiogalactopyranoside (IPTG) was added to a final 
concentration of 0.1mM to induce the expression of the fusion protein and 
incubation continued for 1-3 hours. Analysis of a lOjil aliquot of the culture 
by SDS-PAGE is used to determine the expression of a protein of the 
expected molecular weight. Sequencing is used to determine that the 
protein is in the correct orientation and reading frame and is of the 
predicted sequence. Appropriate transformants were stored as glycerol 
stocks at -70°C. 
These recombinant proteins were produced by Dr Donald Smith and Mrs 










Figure 2.1: Schematic representation of the pGEX vector. The 
plasmid contains Ampr  encodes ampicillin resistance, ORI denotes 
the origin of transcription, a fragment of the lac operon containing the 
overexpressed Iaclq allele of the lac repressor and part of IacZ. In the 
absence of inducer (IPTG), the plasmid encoded Iaclq allele is 
efficient in repressing transcription from the tac promoter. Sj26 cDNA 
encode glutathione S-transferase of S.japonicum; the normal 
termination codon is replaced by a polylinker containing unique 
recognition sites for BamHI, Smal and EcoRl and followed by TGA 
translation termination codons in all three reading frames. 
2.1.2 Purification of rAgs 
To generate fusion proteins for immunisations and use in ELISA, colonies 
of transformed E.coli were grown on agar plates (ampicillin@50j.tg/ml)  
overnight at 37°C. 100 ml of L-broth containing 50pg/ml of ampicillin was 
inoculated with a single colony and grown overnight at 37°C in a shaking 
incubator. This culture was added to ii of L-broth (ampicillin@50j.tg/ml)  and 
incubate for 2hrs at 37°C before addition of imi of 100mM IPTG. After a 
further 2-4hr incubation, cells were pelleted by centrifugation at 10,000g at 
4°C for 10 minutes. Pellets were resuspended in 20mls PBS and lysed by 
sonication at 4°C. A 5mm probe was used for sonication and care was 
taken to minimise frothing of the cell suspension by sonicating in short 
bursts for 1-3 minutes. 
Contamination of fusion protein by E.coli proteins was minimised by 
addition of Triton X-100 (BDH Lab. Supplies, Poole, UK) to 1% and gentle 
mixing. In order to remove insoluble material, the mixture was transferred to 
eppendorfs and centrifuged for 5 minutes at 10,000g. The supernatant was 
transferred to 50m1 tube containing 4mls of 50% (w/v) glutathione-agarose 
beads in PBS and incubated for 30-60 minutes at room temperature on a 
shaker. After centrifugation at 500g, the beads were washed three times in 
SOmls in PBS. Fusion protein was recovered from the beads by incubation 
with an equal volume of 50mM tris-HCI containing 5mM glutathione, gently 
mixing at room temperature for 10-30 minutes. The beads were pelleted by 
brief centrifugation and the supernatant containing eluted fusion protein 
removed. Fusion proteins were stored at -70°C. 
The purity and concentration of fusion proteins were estimated by the 
intensity of Coomassie blue staining on acrlyamide gels (section 2.2); see 
figure 2.2. 
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2.1.3 Recombinant MSP2 antigens: 
Recombinant antigens (rAgs) produced and the regions of MSP2 they 
represent are listed in table 2.1. Recombinant proteins are schematically 
represented in figure 2.3 and in appendix 1A. 
Serogroup 	rAg Isolate Region 
A 	 Al 19/96 Full length 








T9/94 (ii) N-terminal 	gp. 	spf. 	seq. 
deleted 
A3 R033 R2 repeat/group specific 
CH12/12 
CH150/9 (i) part of gp. spf.seq. deleted 
CH150/9 (ii) 
Gi 
T9/102 R2 repeats deleted 
B 	 Bi Dd2(13/14) Full length 
Dd2(5/6) Shortened conserved regions 
B2 K1 (ii) Ri repeats 
T9/105 Shortened C-terminus 
K 	(I) Shortened N-terminus 
B3 Ki R2 repeats/group specific 
T9/105 (I) 
T9/105 (ii) No repeats 
N Ki Conserved 
C Ki Conserved 
Table 2.1 Recombinant MSP2 proteins produced as fusions with GST and 
expressed in E.coli. rAgs will be referred to as Al, A2, A3 Bi, B2 and B3 in 
subsequent chapters; to avoid confusion the isolate from which they were 
produced will be stated in brackets. 
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2.2 SIDS-polyacrylamide gel electrophoresis (SDS-PAGE): 
2.2.1 Preparation of the SDS-polyacrylamide gel: 
A 10% acrylamide gel solution (resolving gel solution) was prepared and 
poured between glass plates using the SE250-Mighty Small It slab gel 
electrophoresis unit (Hoefer Scientific Instruments, San Francisco, USA). 
The meniscus of the acrylamide solution was 1.5cm below the top of the 
notched plate to allow room for the comb. Approximately 0.5ml of water-
saturated isobutanol was carefully layered on top of each gel to create a 
barrier to oxygen, which would inhibit the polymerisation of the acrylamide. 
After the gel had set (1-2 hrs), the overlay solution was poured off and the 
top of the gel washed several times with distilled water (dH20), then 
drained well. The comb was inserted and the stacking gel solution was 
poured and left to set (30mins). The comb was removed and wells washed 
with dH20 to remove unpolymerised acrylamide. 
2.2.2 Running the gel: 
Running buffer was added to the upper and lower reservoirs of the gel box. 
Samples were loaded into the wells (figure 2.2). The gels were run at 
20mNgel for approximately 1.5hrs, until the dye front had reached the 
bottom of the gel. The apparatus was carefully dismantled and the gels 
were stained with Coomassie blue stain (0.1% Coomassie brilliant blue 
R250, 50% methanol, 10% acetic acid in dH20) for 30 mins and destained 
with destain solution (10% methanol, 10% acetic acid in dH20) until bands 
were clearly visible. 
Gels were placed on Whatman 3MM filter paper, covered with Saran wrap 
and dried at 80°C for 1 hour under vacuum, using a gel dryer. 
Figure 2.3: Schematic representation of MSP2 recombinant antigens Al, 
A2 (T9/96), A3, Bl, B2 (Ki) and B3 (T9/105i). Isolates from which the rAgs 
were derived are shown in bold. The amino acid number refers to the 
position of the first and last residue of the proteins from the published 
sequences of T9/96 (serofroup A) and FC27 (serogroup B) [109]. 
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2.2.3 Solutions for SDS-PAGE: 
Resolvina ael solution 
Acryl 	 4.66m1 
(30g acrylamide, 0.8g N,N'-methylene-bis-acrylamide in lOOmIs dH20) 
Resolving gel buffer 	 3.50m1 
(19.2g Tris-HCI, 0.4g SIDS in 1 00m dH20, pH8.8) 
dH20 	 5.74m1 
10% (w/v) ammonium persulphate (APS) 	 20091 
TEMED (N,N, N',N'-tetramethylethylenediamine) 	 5il 
Stackina ael solution 
Acryl 	 0.50m1 
Stacking gel buffer 	 1 .25m1 
(6.06g Tris-HCI, 0.4g SIDS in 1 00m dH20, pH6.8) 
dH20 	 3.20m1 
10% APS 	 50jil 
TEMED 7p1 
Runnina Buffer 





2.3.1 Transfer of protein from the gel onto nitrocellulose: 
Transfer of proteins from gel to nitrocellulose membrane (Anderman & Co. 
Ltd., Kingston-upon-Thames, UK.) was achieved by electrophoretic elution 
[325]. The gel and nitrocellulose were sandwiched between filter paper 
(Whatman 3MM) and immersed in a buffer-filled tank (LKB 2005 Transphor 
electroblotting unit, LKB Instruments Ltd., Croyden, UK.) (electrophoresis 
buffer- 29.Og Tris, 14.5g glycine, 1.85g SIDS, ii methanol in 41 dH20), with 
the membrane closest to the positive electrode. Transfer is complete after 
1-2hours at an electric current of 0.65mA/cm 2 of gel. 
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2.3.2 Labelling transferred antigenic proteins with antibodies: 
When the transfer of the protein onto the nitrocellulose was complete, the 
nitrocellulose was separated from the SIDS-polyacrylamide gel and 
staining with Ponceau-S was used to provide visual evidence that 
electrophoretic transfer of proteins had taken place. Ponceau-S is a 
transient stain and is washed away during the processing of the Western 
blot. Staining does not interfere with the subsequent detection of antigens. 
Ponceau-S (3-hydroxy-4-(2-sulfo-4-[4-sulfophenylazo]-phenylazo)-2,7-
napthalene disulfonic acid) was diluted 1:20 with PBS/Tween. 
After washing (washing buffer (WB)-PBS/0.05% Tween 20), the 
nitrocellulose was incubated in a non-cross reactive protein solution 
(blocking buffer (BB)-1%(w/v) nonfat dried milk in WB) for at least 1 hour at 
room temperature. This blocking step helps prevent the antibodies from 
binding nonspecifically to the nitrocellulose. The nitrocellulose was washed 
(x3) and probed with mouse anti-sera or mAb, diluted in BB, for 1-3 hours at 
room temperature. After washing, the nitrocellulose was incubated for 1-3 
hours with HRP-conjugated rabbit anti-mouse Ig (DAKO, Ltd.) at a 1:400 
dilution in WB. 
2.3.3 Developing the Western blot: 
The binding of Antibody was visualised using 4-chloro-1-napthol. Prior to 
developing the blot, a solution of chloronapthol was prepared (30mg 
chloronapthol in lOmI methanol) and added to 40m1 of triethanolamine 
buffered saline (0.12g Tris-HCL, 0.9g NaCI in lOOmI dH20, pH7.4). H202 
(30p1) was added immediately before use. 
The blot was washed in WB (x3) and TBS (xl) then developed at room 
temperature in the dark until bands appeared. Blots could then be 
photographed. 
All incubation steps were carried out on a shaker. 
53 
2.4 Enzyme-linked immunosorbent assay (ELISA) 
2.4.1 Basic protocol for indirect ELISA: 
Microtitre plates (lmmulon-4 (Dynatech)) were coated overnight at 4°C with 
100tl/well of antigen in coating buffer (1.59g Na2CO3, 2.93g NaHCO3 in ii 
dH20; pH9.4-9.6), and blocked for 5 hours at room temperature with 
200j.iI/well of blocking buffer (BB; 1% (w/v) nonfat dried milk in washing 
buffer). At the same time, sera were diluted in BB and incubated at room 
temperature for 5 hours. Plates were washed three times with washing 
buffer (PBS/0.05%Tween20 (PBS/Tween)) and lOOjtl/weIl of diluted serum 
was added to duplicate wells and incubated overnight at 4°C. Plates were 
washed and incubated with horse-radish peroxidase-conjugated rabbit 
anti-human lgG antibody (Dako Ltd., High Wycombe, UK) at 1/9000 for 3 
hours at room temperature. 
All plates were developed with lOOpi/well of substrate buffer with H202 as 
substrate and o-phenylenediamine (OPD) as chromagen, at 4°C and the 
reaction was stopped after 10 minutes with 20p1/well of 2M H2SO4.  The 
optical density values (OD) were measured at a wavelength of 492 nm, 
using a Titeretek plate reader (ICN Flow, Buckinghamshire, UK). 
Data was transferred into a computerised data management system, 
Elisalite (Meddata, Inc., New York, USA) 
Protein and antibody concentrations were selected after optimisation of the 
protocol, described in chapter 3. 
2.4.2 Solutions for ELISA: 
Substrate buffer 
0.1M citric acid 6.0 ml 
0.2M phosphate (Na2HPO4) buffer 6.4 ml 
dH20 12.5 ml 
o-phenylenediamine (OPD) 10 mg 
H202 10 g 
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2.51n vitro cultivation of asexual stages of Plasmodium 
falciparum 
2.5.1 Incomplete medium: 
The medium was based on that used by Trager and Jensen [326], 
consisting of RPMI 1640 (Gibco BRL) supplemented with 25mM HEPES 
buffer (5.94g/1) and hypoxanthine (50mg/mI). The medium was filtered 
through a 0.22jiM Nalgene filter and stored at 4°C for up to 4 weeks. 
2.5.2 Complete Medium: 
Freshly made and filtered sodium bicarbonate (NaHCO3, 2g/1) was added 
to incomplete medium. The solution was adjusted to pH7.2 by the addition 
of 1M NaOH, and filter sterilised into 200m1 sterile culture flasks. 10% (v/v) 
of heat inactivated human serum was added. Complete medium was used 
within one week and incubated at 37°C for 24hrs before use. 
2.5.3 Culturing of Plasmodium falciparum parasites: 
Plasmodium falciparum ring stage infected red blood cells (rbc) of culture 
adapted parasite clones (31D7 and Dd2) were obtained from existing 
cultures. P.falciparum isolates were grown at 5% haematocrit with 0+ 
human rbc (Edinburgh and South East Scotland Blood Transfusion 
Service) which had been washed free of leukocytes. These cultures were 
grown under sterile conditions in 25mls of complete medium in 200m1 
culture flasks (Corning, New York, USA). The cultures were incubated at 
37°C in a 1% 02,  3% CO2 and 96% N2 gas mixture. A parasitaemia of up to 
10% infected rbc was permitted. 
Small quantities of blood were removed with a sterile Pasteur pipette to 
prepare thin blood films, stained with Geimsa's stain at pH 7.2 and 
examined microscopically to measure the parasitaemia and health of the 
culture and to assess the maturity of parasites. 
2.5.4 Isolation of schizont-infected red blood cells: 
Isolation from culture of live schizont infected rbc was carried out using 
density gradient centrifugation [185]. 
A culture which was predominantly at the schizont stage, and at least 5% 
parasitaemia, was spun for 10 minutes at 2000rpm, the cells were washed 
in fresh incomplete medium and resuspended in 10 ml of incomplete 
medium. 5ml of this suspension was carefully layered onto 8ml of 60% 
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Percoll (60m1 Percoll (Pharmacia, Uppsala, Sweden), 6ml 10xPBS, 34mI 
incomplete medium) in 15m1 tubes, and spun at 2000rpm for 10 minutes. 
Several distinct layers appear; the dark brown schizont infected cells 
aggregate in a thin band towards the top of the gradient. These schizont 
infected cells were carefully removed and washed (x2) in incomplete 
medium. The washed schizont pellet was transferred to an eppendorl tube 
and stored at -20°C. 
The remaining infected rbc were washed and returned to culture. 
2.6 Indirect immunofluorescence assay (IFA): 
Indirect immunofluorescence recognition of P. falciparum isolates was 
performed with individual mAbs or mouse serum on acetone-fixed 
schizonts as described by Conway et a! [66]. 
2.6.1 Preparation of multispot schizont slides: 
Schizont-infected erythrocytes were washed three times and resuspended 
at approximately 3% haematocrit in PBS. Multispot slides (C A Hendley 
Ltd., Essex) of schizonts were prepared with 20tl of the cell suspension per 
well. The slides were air-dried and stored under dessication at -20°C, in 
sealed polythene bags containing silica gel (BDH). 
2.6.2 Preparation of antibody samples: 
Working dilutions of mAbs, mouse sera and commercial antibodies in 1% 
(w/v) bovine serum albumin in PBS (pH 7.3-7.5) containing 0.01% sodium 
azide were prepared. Dilutions can be kept at 4°C for several months. 
2.6.3 Single-labelled IFA: 
A 25 p1 volume of each mAb or mouse serum was incubated on the 
schizonts for at least 30 minutes at room temperature in a wet box to 
prevent evaporation. Care was taken to avoid cross contamination of 
samples on adjacent wells. 
After careful removal of serum by Pasteur pipette, the slides were washed 3 
times (1,5 & 5 minutes) in PBS. Slides were gently air-dried on a warm 
plate set at 50°C, then 12p1 of a 1:50 dilution of fluoresceine isothiocyanate 
(FITC)-conjugated polyvalent rabbit anti-mouse Ig antibody (ICN 
Immunoglobulins, Lisle, Israel) was added to each well and incubated for 
30 minutes in a wet box at room temperature. After 2 washes (1 & 5 
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minutes) in PBS',parasite nucleii were stained with DAR (4',6-diamino-2-
phenylindole; 1x10 6 (w/v) in PBS) for 1 minute. Slides were washed twice 
(1 & 5 minutes) in PBS and mounted under a coverslip in 2-3 drops of 
Citifluor (City University, London). 
Parasites were visualised by FITC-fluorescence (green, serum specific) 
and DAPI-fluorescence (blue, DNA specific), with incident light of 450-
490nm and 390-440nm respectively, at magnification x360 or x600. 
2.6.4 Double-labelled IFA: 
Combinations of two mAbs with different epitope specificities and different 
isotypes were used to test for the presence of two or more populations of 
parasites within an isolate or to look at coexpression of two distinct 
epitopes. Each pair of mAbs was incubated (12p1 of each) together on a 
well for 30 minutes. An RITC (rhodamine isothiocyanate)-conjugated and 
an FITC-conjugated antibody (Southern Biotechnology Associates Inc., 
Birmingham, Alabama; dilution 1:50), each specific for the different isotypes 
of the two mAbs, were then incubated together on the well for the second 
stage for 30 minutes and carefully removed with a Pasteur pipette. After 2 
washes (1 & 5 minutes) in PBS, parasite nuclei were stained with DAPI for 
1 minute. Slides were washed twice (1 & 5 minutes) in PBS and mounted 
under a coverslip in 2-3 drops of Citifluor. 
RITC-fluorescence (red) was visualised using incident light 515-560nm. 
The proportion of schizonts showing (i) green (and blue) fluorescence only, 
(ii) red (and blue) fluorescence only, (iii) red and green (and blue), and (iv) 
neither red nor green (blue only), was recorded for each pair of mAbs 
tested. Slides can be photographed and examples of staining patterns are 
shown in figure 2.4. 
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Figure 2.4: Double-labelled IFA slides of P.falciparum isolate from The 
Gambia, using DNA staining and differential labelling of MSP1-specific 
monoclonal antibodies. a) to c) show one microscopic field stained with: a) 
DAPI, b) mAb 9.5 (isotype lgG2b) and FITC-conjugated anti-lgG2b, c) mAb 
10-213 (isotype lgG2a) and RITC-conjugated anti-lgG2a. In this field each of 
the schizonts gives a positive reaction with both mAbs. 
d) to f) show a second field, stained with: d) DAPI, e) mAb 12.2 (isotype 
IgGi) and FITC-conjugated anti-IgGi, f) mAb 10-213 and RITC-conjugated 
anti-lgG2a. In this field, each schizont is positive for only one of the mAbs. 
g) to j) show a third field stained with: g) DAPI, h) mAb 111.4 (isotype IgGi) 
and FITC-conjugated anti-IgGi, j) mAb 10-213 and RITC-conjugated anti-
lgG2a. In this field, one of the schizonts gives a positive reaction with both 
mAbs, and the others are positive with one or other of the mAbs. 
This photograph was reproduced with the kind permission of Dr David 
Conway. 
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2.7 Mouse immunisations: 
2.7.1 Preparation of antigen: 
Recombinant MSP2 proteins were mixed in an equal volume of Freunds 
adjuvant (either incomplete or complete) to give a concentration of 50pg of 
rAg per mouse. This mixture was then emulsified with an equal volume of 
Tween 80 solution (1% v/v Tween 80 in PBS), which promotes the 
formation of oil-in-water emulsions. A Sorvall Omnimixer was used for 
mixing. 
2.7.2 Immunisation protocol: 
Mice were given a primary immunisation with 0.2m1 of the antigen 
preparation intraperitoneally. The mice were boosted approximately 4 
weeks after the first immunisation. Mice were bled retro-orbitally at least 2 
weeks after each immunisation. The blood was allowed to clot, then the 
serum was separated, aliquoted and stored at -70°C. 
Immunisations were performed by a licensed animal technician. 
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3. Optimisation of enzyme-linked immunosorbent assays 
(ELISA) for use in malaria serology 
"There is plenty to challenge the intellect in this apparently simple method' 
D.M Kemeny 1991 [172] 
3.1 Introduction 
The introduction of enzyme labels in immunoassays by Engvall and 
Perlmann in 1971 [98, 99], represented a significant technical advance in 
diagnostic and serological assays. Since then, the enzyme-linked 
immunosorbent assay (ELISA) has been widely used for the assay of 
infection-specific antibodies and antigens [334, 336]. The technique has 
been shown to have an important role in the laboratory and in field studies, 
however, the scope of the assay is limited. Because the assay is quick and 
inexpensive it is widely used, but the data it generates is not always 
properly interpreted. Thus, it is essential to optimise the assay for its 
particular purpose. 
3.1.1 The indirect ELISA: 
In the indirect ELISA [98-100, 173, 175, 331, 333-336], antigen is 
immobilised by passive adsorption onto a solid phase. The antigen solid 
phase is then used to bind specific antibody in the test sample. Unbound 
material is removed by washing and bound antibody is detected with an 
enzyme-labelled anti-immunoglobulin antibody (figure 3.1a). When it is not 
possible to label this secondary antibody directly, an anti-species enzyme-
labelled immunoglobulin can be employed (figure 3.1b). 
In a direct ELISA, the antibody in the test sample is conjugated to the 
enzyme. This type of assay is used more for antigen detection than for 
antibody analysis. 
Inclusion of the additional steps leads to amplification of the reaction and 
therefore, increases sensitivity. However, there is the possible hazard that 





















Figure 3.1 b: Schematic representation of a two-step indirect ELISA 
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Bound antibody is visualised by the addition of an appropriate substrate 
and chromagen. The resulting colour change is detected. using a 
spectrophotometer which measures the amount of tight absorbed by a 
solution at a particular wavelength and converts this to an optical density 
(OD) or absorbance value. Absorbance is defined as the logarithm of the 
ratio of incident to transmitted light (Beer-Lambert Law) [117]. 
3.2 Principles of assay optimisation: 
It is necessary to ascertain the optimum conditions for each stage of the 
assay [173, 175, 334, 336], the objectives being robustness, reliability and 
specificity with maximum sensitivity [175, 188]. 
3.2.1. Antigen concentration: 
The optimal antigen concentration is the least quantity giving near-maximal 
binding [175]. If the capacity of the plate is exceeded, some of the protein 
will be weakly bound and become detached during the assay [172-175] or 
it can lead to overcrowding and concealment of epitopes [331], with 
subsequent loss of sensitivity and poor reproducibility. 
3.2.2. Antibody concentration: 
In an ELISA there are two components of the binding of antibodies in 
serum - non-specific binding to exposed sites on the plate or to antigen 
[176], and specific binding to epitopes on the antigen [331]. The aim of 
optimising the assay is to minimise non-specific binding and maximise 
specific binding. Non-specific binding can be reduced by blocking vacant 
sites with protein such as dried milk or bovine serum albumin [175]. 
However, care must be taken to choose a protein which is not recognised 
by naturally occurring antibodies. 
The choice of serum concentration depends on the assay procedure. 
i) End-point titration - all sera can be titrated by serial dilution. The end-
point may be defined as the titre at which the positive sample dilution 
equilibrates to a negative sample [331]. Alternatively, a specific absorbance 
value may be chosen and the dilution of serum yielding such an 
absorbance value is the "titre" [336]. This procedure involves more plates, 
reagents and time than a single dilution assay. 
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ii) Single-dilution assay - single-dilution assays are more economical and 
thus are suitable for large scale serological screening. Under carefully 
controlled conditions, the results may be expressed in absorbance values 
[336]. In choosing an appropriate single dilution, sera are titrated and a 
dilution on the steep or linear part of the curve is chosen, such that the 
background absorbance is minimal. It is possible to relate the absorbance 
value from a single-point dilution to a standard curve derived from a 
reference serum [336]. 
3.2.3. Antibody detection: 
In optimising the use of anti-immunoglobulin antibodies, specificity and 
sensitivity must be considered [159, 288]. The secondary antibody should 
be specific for the stated isotype and should not cross-react. The selected 
concentration must be sufficient to detect all specific antibody binding [331]. 
The concentration chosen is determined by reagent economy, obtaining a 
steep titration curve and minimising non-specific background [173, 331]. 
An ideal assay for the measurement of antigen-specific lgG subclass 
antibodies should possess the additional performance characteristic of 
equipotency [87]. Equipotency must be assured if one is to compare 
antibody titres or optical densities (OD) measured for different lgG 
subclasses. The aim is that similar concentrations of antibodies of different 
lgG subclasses produce the same signal. This is not easily achieved in lgG 
subclass assays because the anti-subclass antibodies have different 
affinities. To compensate for this, different concentrations of anti-subclass 
antibody are used to ensure equal signals [87]. However, there is a need to 
maintain equipotency over the whole analytical range, therefore titration 
curves must be parallel [138, 172, 188]. 
am 
3.2.4 Choice of conjugate: 
The conjugated enzyme and its substrate are chosen for sensitivity and 
convenience [331]. The relative merits of horse-radish peroxidase (HRP), 
alkaline phosphatase (AP) and 13-galactosidase (13-gal) have been 
compared [247]. The marker enzyme of choice is HRP as it was shown to 
have higher specific enzyme activity as well as immunological reactivity 
248]. The chromogenic hydrogen donors of choice for peroxidase 
depend on the system [188]; o-phenylenediamine (OPD) is one of the most 
satisfactory for ELISAs [175, 188]. 
3.2.5. Data analysis: 
There is no generally accepted way of expressing ELISA results; the 
methods for interpreting results from ELISA are without definition and are 
considered to be completely arbitrary [140]. A major problem in dealing 
with ELISA results is overinterpretation of the data and drawing quantitative 
results when only semi-quantitative or qualitative results are possible [331]. 
Detection of specific antibodies is much easier than their quantification 
334] and there is insufficient understanding of absorbance values 
among ELISA users [188]. 
Qualitative information on the presence or absence of antibody can be 
obtained by statistical comparison of ODs from test and control sera [138, 
140, 173, 331, 334, 336]. However, the determination of a baseline is 
complicated and there is no standard protocol. Several approaches are 
employed for dichotomising results [85, 136, 140, 188, 309]. The cut-off 
value may be set at a fixed OD, for example 0.150 or 0.200 [136], however 
this is purely arbitrary. Alternatively, the cut-off may be based on the OD 
values of a population of serologically negative sera tested in parallel, such 
as two or three times the mean OD for the controls, or the mean plus two or 
three standard deviations (SD) [85, 188]. To reduce expenditure and time 
involved in establishing a cut-off value, Van Loon [330] calculated the 
mean and SD of a large group of normal sera and, in parallel, tested a 
reference serum. They observed the mean plus three SD equalled 40% of 
the absorbance of the reference serum. This reference was included in 
subsequent tests as an internal standard to define the cut-off level. 
Whichever method is used, a compromise is generally necessary since, 
.irrespective of the cut-off value, false negatives or positives will occur [188]. 
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To avoid this, it has been suggested that intermediate results be classified 
as "doubtful" [140]. 
Semi-quantitative methods include expressing results as an end-point titre. 
This value is equivalent to the reciprocal dilution at which the test sample 
gives an OD the same as the reference negative sample [188, 334, 336]. A 
problem in determining the end-point titre is that the discrimination value 
cuts the dose-response curve in the tail of the sigmoidal curve and, 
consequently, low accuracy is obtained [188]. The effective-dose method 
[188] circumvents this problem by measuring the Antibody curves in the 
linear region (at maximum sensitivity) and to compare these results with a 
positive reference serum (figure 3.2). The result is then expressed as the 
logarithm of the difference in dilution of the two sera at the steepest part of 
the dose-response curves. 
Results can also be expressed as the ratio of the OD of the test sample to a 
group of known reference negative samples [334]. However, this can give 
highly variable results because low OD values are highly susceptible to 
variation. Similarly, results can be expressed as the percentile probability 
of the OD of the test sample being within the range of a predetermined 
"normal" population [334]. 
It may be that the analyst wants to know "how much" antibody is present. 
However, the ability of ELISAs to measure absolute concentrations is 
questionable. An indirect ELISA measures antibody binding which is a 
function of both antibody concentration and antibody affinity [248, 331]. 
Furthermore, the relationship between antibody binding and colour 
generated is not linear [173, 175, 331], and may vary from day-to day [172, 
331]. It is important to realise that antibody affinity may play a critical role in 
determining biological activities of antibodies [85] and may significantly 
influence ELISA results [43, 173, 248, 313]. In a single dilution assay, a 
serum sample with high affinity antibody present in low concentration may 
give the same binding (and OD) as a serum sample with low affinity 
antibody present in high concentration. End point titration curves would 
however differentiate the two sera (figure 3.3). 
Nonetheless, ELISA results are often expressed as absolute 
concentrations. Results are determined by reference to a standard curve 
prepared by plotting OD values obtained from a series of dilutions of the 
reference standard [100, 173]. The basic assumption underlying the use of 
a standard reference curve is that the samples being compared are 
T1 
essentially similar, i.e. that test and reference samples produce parallel 
dose-response curves [138, 172, 173, 188]; these criteria are rarely tested 
or fulfilled. Affinity may influence the slope of the linear part of the curve; 
high affinity antibodies give a steep curve and low affinity antibodies give a 
more gradual curve (figure 3.3). The composition of the test sample may 
differ from that of the reference serum [175]. For polyclonal sera, the relative 
amounts of high and low affinity antibodies will also influence the shape of 
the curve [85, 173]. Thus, unless test and reference samples are highly 
homogeneous, a standard indirect ELISA does not give absolute 
quantitative information [85, 331]. The best analysis is some sort of 
comparative evaluation, bearing in mind that a doubling in OD value does 
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Figure 3.2: The determination of the effective dose (ED). The 
optical density of a test serum was measured over a range of 
dilutions and compared with a reference serum of high activity at 
the steepest part of the dose-response curves. The difference in 
dilution of the sera to obtain the same optical density is expressed 
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Figure 3.3: Comparison of dose-response curves obtained for 
antibodies of different affinities. Solid line shows the curve for a 
serum of high affinity; dotted line shows the curve for a serum with 
low affinity antibodies. At a dilution of 10 3 , both sera give the same 
absorbance value. 
3.3 Optimisation of the ELISA for assessment of human 
antibody responses to MSP2 using recombinant GST fusion 
proteins: 
GST fusion proteins were coated onto solid phase, incubated with human 
sera and bound antibody was detected with HRP-conjugated rabbit anti-
human lgG and OPD. Each step was optimised for maximum sensitivity and 
specificity. 
3.3.1 Solid phase: 
Immu Ion®  4 96-well microtitre plates (Dynatech Laboratories, Inc.) were 
selected for their ability to bind high levels of protein in a reproducible 
manner and provide high optical clarity. This grade of plate is specially 
formulated for maximum protein adsorption. 
3.3.2 Reagent concentrations: 
Optimal concentrations of antigen and serum were determined by 
chequerboard titration [175, 334, 336]. Serial four-fold dilutions of serum 
from malaria-exposed Gambian adults were tested for recognition of 
varying concentrations of recombinant antigen. 
Antigen 
Initially a wide range of antigen concentrations was tested. Overlapping 
titration curves were then obtained for concentrations of antigen between 5 
and 0.5j.tg/ml (figure 3.4a). Therefore, 0.5 pg/ml was chosen to be the 
coating concentration of antigen. 
Serum 
A serum dilution of 1:1000 was selected to be the optimum dilution. For 
positive sera, this gave an OD value on the linear part of the titration curve 
and non-specific binding to the GST control was low (figure 3.4b). 
Detecting antibodies 
1. Rabbit anti-human lgG: 
For the determination of specific lgG, a peroxidase-conjugated rabbit anti-
human lgG specific for gamma chains (DAKO) was used. The antibody was 
tested at four dilutions - 1:3000, 1:6000, 1:9000 and 1:12000. 
At a dilution of 1:3000, background OD values were unacceptable and OD 
values greater than 2.000 were produced for test samples. When the 
conjugate was diluted 1:12000, there was insufficient to detect all the 
specific antibody bound. 
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The results obtained for 1:6000 and 1:9000 dilutions were similar. A 
dilution of 1:9000 was selected for subsequent assays in order to keep the 
background OD values low and thus increase the sensitivity of the assay. 
2. lgG subclass-specific reagents: 
For the detection of lgG subclasses, murine mAbs to specific human lgG 
subclasses were used, followed by an HRP-conjugated rabbit anti-mouse 
Ig antibody. A variety of commercially available lgG subclass-specific 
reagents were tested; many of these were unsuitable because of cross-
reactivity or low sensitivity. The subclass specificity of the mAbs finally 
chosen has been widely reported [161, 162, 194] and was reconfirmed 
prior to their use in our assay system: ELISA plates were coated with 
purified myeloma proteins of each human lgG subclass and then incubated 
with each of the murine mAbs. Each mAb was shown to be specific for the 
appropriate subclass. In addition, the HRP-conjugated rabbit anti-mouse Ig 
antibody was shown not to cross-react with the human antibodies. 
In order to determine the optimal working concentration of the murine 
mAbs, plates were coated with four-fold serial dilutions of purified myeloma 
proteins from 10pg/ml and mAbs were tested over a range of 
concentrations. 
For each mAb a working dilution was selected such that parallel titration 
curves were obtained for the different mAbs and these curves overlapped, 
such that the relationship between OD and IgG concentration was 
approximately equal for each subclass (figure 3.5). This was achieved for 
the mAb to IgGi, lgG3 and lgG4, however, the mAb to lgG2 was known to 
be less sensitive [104, 162]. The mAbs finally selected, their source and 
working concentration are shown in table 3.1. 
Subclass Clone number Supplier Working 
specificity dilution 
1 NL16/Hp6012 BDH 1:2000 
2 GOM1/HP6008 BDH 1:500 
3 HP6050 SEROTEC 1:1000 
4 RJ4/HP6011 BDH 1:500 































100 	1000 	104 	10 
serum dilution 
Figure 3.4a: Optimisation of Al recombinant antigen concentration. 
Serum was serially diluted from 1:50 to 1:12800 against four 
concentrations of coating antigen. 
00.5pg/ml, 01.5j.ig/mI, 03jtg/mI, U5pg/ml. 
Figure 3.4b: Optimisation of serum concentration. Serum was serially 
diluted from 1:50 to 1:12800 and tested for recognition of recombinant 
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Figure 3.5: Optimisation of anti-human lgG subclass murine monoclonal 
antibodies. Plates were coated with purified myeloma proteins of each lgG 
subclass and incubated with the mAbs. 
A IgGi, olgG2, .lgG3, 13IgG4. 
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3.3.3 Data analysis: 
ELISA plates were read at a wavelength of 492nm using an automated 
spectrophotometer (Titretek). OD values were transferred to a computer 
and analysed using the computer package ELISALITE. 
Data is expressed as specific OD values; the OD value of the GST control 
antigen is subtracted from the OD of the GST fusion protein. Thus, specific 
OD values can be negative if the OD value for the GST control exceeds that 
for the fusion protein. The GST control plates are run in parallel with the 
MSP2 fusion protein plates. 
Specific OD values obtained from malaria-unexposed European donors 
are used to establish a normal range for each antigen. Seropositivity is 
defined as a specific OD value greater than the mean plus two SD of the 
European control sera (95% confidence limit). 
To avoid day-to-day variability of results, all the assays were designed such 
that a specific hypothesis was tested on one batch of plates on the same 
day. 
3.4 ELISAs and malaria seroepidemiology 
Voller et a! 	[335] pioneered the application of ELISA in 
seroepidemiological studies of malaria and since then the method has 
been used extensively in studies of many parasitic diseases [332, 333]. In 
the first study on malaria, the tube or macro method was used with antigen 
prepared from P.knowlesi, a simian malaria parasite [338]. The microplate 
method was then developed [335], and P.falciparum antigen prepared from 
experimental infections of Aotus monkeys was used to compare 
seroreactivities of two Colombian populations. However, even at this early 
stage, the problem of standardisation was evident, particularly if 
comparable results were to be obtained at different times by different 
laboratories [335]. The source of antigen was the most variable factor [309, 
335]. One result of the recent emphasis on vaccine development has been 
a much improved understanding of the antigenic make-up parasites, and 
this is having a significant impact on immunodiagnosis [332]. Expression of 
these antigens as recombinant proteins allows the determination of 
antibody binding to specific malaria antigens. Nevertheless, there is still no 
standardisation of assay design and data interpretation. Table 3.2 
summarises the methods used for analysis of results obtained in 
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seroepidemiological studies of malaria using the indirect ELISA to measure 
IgG responses. 
A major problem with some of these analyses is extrapolation to a standard 
curve and expression of the results in terms of concentration of antibody. 
This assumes parallelism of test and reference sera [188]. These studies 
are measuring the recognition of malaria antigens by polyclonal sera which 
will contain antibodies of differing affinities and are thus unlikely to produce 
parallel titration curves. In addition, these seroepidemiological studies are 
screening large numbers of sera and it is highly unlikely that each serum 
was tested to ensure parallelism, therefore such extrapolations are invalid. 
Furthermore, indirect ELISAs measure antibody binding - a function of both 
antibody concentration and affinity [331]. 
The most robust way to express the data is in a semi-quantitative manner, 
reporting the data in terms of OD values and defining those which are 
positive and negative, with minimal manipulation of the data. The choice of 
cut-off level depends on the relative distributions of the control and test 
data. If the control values represent a distinct set of values below the test 
samples, then a cut-off value outside the upper range of the control values 
would be suitable. The choice of cut-off value is particularly difficult when 
the test data is a continuum of values from negative to positive, and the 
control and test values overlap. The selection of the cut-off should be one 
which keeps false negatives and positives to a minimum. The upper limit of 
a 95% confidence interval is a common choice. 
In this chapter, I have established the optimum conditions for the detection 
of MSP2-specific antibodies in ELISA. These conditions will be used 
throughout subsequent studies, unless otherwise stated. 
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ANTIGEN DATA ANALYSIS REFERENCE 
Crude 	parasite Seropositivity - reciprocal titre of last dilution giving OD>0.3 Spencer 	et 	a! 	1979; 
antigen 1981[307, 308] 
Seropositivity - OD > 0.2 Voller eta! 1980a  [337] 
Seropositivity - OD > 0.25 Wahlgren et al1 983   [ 40] 
Results expressed as OD values; cut-off not stated Marsh et a! 1988, 1989 [197, 
200] 
Antibody conc. (jig/ml) determined by reference to myeloma protein Wahlgren et a! 1983, 1986C 
SCs. Antibody concs. were corrected for amount of protein bound to [339 343] 
plate.  
Pf155/RESA % binding of high titred standard plasma. Antibody conc. of reference Perlmann 	1989 	[235]; 
plasma determined from SC of purified lgG; limit of positivity - mean Bjärkmann 1990, 1991 [26, 
+2SD of control sera 27]; Peterson 1990 [240] 
As above; positivity determined as Antibody. conc. outside range of Riley et a/l 991 [271] 
unexposed donors 
Seropositivity - OD > mean +2SD of negative controls Beck et a! 1995 [20] 
MSP1 0D492 converted to units/ml by comparison with SC of high titred Riley eta11992[266] 
standard serum; seropositivity - units/ml > mean +2SD of controls 
Assay was standardised using a set of positive and negative sera; cut- Früh et al1 991   [ 15] 
off = mean + 3SD of negative controls 
Seropositivity - OD > mean +SD of negative controls Egan et a! 1995 [93] 
Seropositivity - OD > mean +2SD of negative controls Riley et a! 1993 [270] 
Seropositivity - 00 > mean +3SD of negative controls Tolle et a! 1993 [324] 
Pf 1 55/RESA, 	CS, Seropositivity - OD> mean +3SD of negative controls Quakyi eta!1989 [253] 
parasite extract  
N 
MS P 1, 	A 	5. 1, Seropositivity - OD > mean +2SD or 3SD Srivastava et al1 989   [309] 
aldolase 
MSP1, 	41kDa Gabra eta11986 [116] 
rhoptry protein, 
parasite extract  
MSP2 Extrapolation from SC of high titred serum pool. Highest conc. of Al-Yaman eta11994 [2] 
positive control serum was assigned 1000 antibody units (AU); 
seropositivity AU > mean +2SD of AU of controls negative sera  
RESA as above, except AU converted to pjg/mI of lgG based on SC of known Al-Yaman et a! 1995 [3] 
IgG standard. Positive> mean + 2SD of Antibody. conc. of controls  
RESA, CS (P.f & Cut-off computed from the 95th percentile of ranked OD values for all Deloron eta! 1989 [83] 
P.m) serum tested against control antigen  
GLURP Normalised data with an OD value of 1.200 assigned to positive Dziegel et a! 1991[90] 
control serum. Cut-off determined as 99-percentile for reactivity of all 
sera with control antigen  
PfHRP-2 Cut-off equals highest OD value of controls plus 0.05 Taylor eta! 1993b  [318] 
Exoantigens Adjustment of data according to a reference positive OD reading of Luty et a! 1994c [196] 
1.000, 	followed 	by 	subtraction 	of 	background 	value. 	Cut-off 
determined by mean + 3 SE of controls  
Table 3.2: Summary of analysis of results for the detection of lgG antibodies to malaria antigens in indirect ELISAs 
a-lg detection; b-capture ELISA; c- lgG subclass determination; SD- standard deviation; SC- standard curve; conc.-
concentration 
P.! and P.m denote P.falciparum and P.malariae respectively 
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4. Characterisation of the immunogenicity and 
antigenicity of recombinant MSP2 proteins. 
4.1 Introduction: 
In order to study the immune recognition of MSP2 it is necessary to isolate 
and purify the protein in a form suitable for serological analysis. Isolation 
and purification of native MSP2 is impractical as it would require 
substantial amounts of parasite material and MSP2-specific mAb. An 
alternative is to express MSP2 as a recombinant polypeptide. 
Until 1987 the expression-purification systems available in E.coli required 
the use of denaturing reagents during purification, and it seemed likely that 
these might interfere with the immunogenicity and activity of expressed 
protein [294]. Smith et a! [296] found that a glutathione S-transferase 
(GST) from the helminth Schistosoma japonicum could be expressed as 
COOH-terminal fusions with foreign polypeptide. It has been shown that a 
variety of polypeptides can be expressed in E.coli as soluble GST fusion 
proteins and could be purified by absorption of crude cell lysates to 
glutathione-agarose under physiological conditions. The pGEX vectors 
were designed such that the GST component could be removed by 
treatment with site-specific protease thrombin or factor Xa [295]. Since the 
introduction of the pGEX vector, several refinements and modifications 
have been made to the original protocol (reviewed by [294]) and pGEX 
vectors have been used to generate polypeptides for biological, structural 
and biochemical analyses. 
Various recombinant MSP2 proteins have been produced by other groups. 
Thomas eta! [321] expressed the central region of CAMP MSP2 using the 
vector pMG42Kn. Immune monkey serum and human serum recognised 
the rAg in immunoblots. Smythe et a! [299] produced a rAg representing the 
full length molecule of FC27 MSP2, using the pGEX expression system. 
Anti-serum to the rAg, raised in rabbits, reacted in immunoblots with MSP2 
of FC27 parasite extracts. Rzepczyk et a! [279] used a recombinant MSP2 
protein in ELISA to measure the immune recognition of serogroup B in 
malaria-exposed Melanesian donors and found that most individuals had 
MSP2 specific antibodies. Recently Al-Yaman et a! [2] reported the use of 
three MSP2 rAgs in seroepidemiological studies in Papua New Guinea. 
The rAgs were produced using the plasmid vector pDS56/RBSII,6xHis and 
expressed in E.co!i. Analysis of the purified proteins showed in each case a 
dominant single band that reacted on Western blots with rabbit antibodies 
to MSP2. 
These studies indicate that rMSP2 expressed in bacterial systems may be 
appropriate for use in epidemiological studies. Nonetheless, it is critical to 
ensure that our panel of MSP2 rAgs mimicked the native antigen. For 
example, the tertiary structure of PfMSP119 has been shown to be essential 
for immune recognition [93] [38]. PfMSP119 has been expressed as a GST-
fusion protein in E.coli and studies with a panel of mAbs confirmed its 
structural integrity and antigenicity. The fusion protein contained epitopes 
that were conformation-sensitive and in this respect exhibited the same 
properties as the natural antigen [38]. 
In this chapter, I report the results of the validation of the structural integrity 
and antigenicity of recombinant MSP2 antigens. We have studied the 
immune recognition of the rAgs by a panel of MSP2-specific mAbs in 
ELISA. Also we have raised MSP2-specific antisera in mice and tested the 
specificity of these antibodies for rAg and native protein in ELISA, IFA and 
immunoblotting experiments. 
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4.2 Materials and methods: 
4.2.1 .Mouse immunisations: 
Recombinant antigens were prepared as described in Materials and 
Methods (chapter 2, section 2.7.1). 
Two immunisation protocols were used. 
Groups of 5-8 female, 8 week old, Balb/C mice were immunised 
intraperitoneally and boosted after 4 weeks, with 50j.tg/mouse and 
25pg/mouse respectively of fusion proteins in Freunds incomplete 
adjuvant. Sera for antibody determination were obtained 3-4 weeks after 
each immunisation. 
These immunisations were performed by Dr J McBride and she kindly 
provided access to the sera for serological analysis. 
Groups of 4-5 female, 8 week old, CBA and MF1 mice were immunised 
intraperitoneally with up to 50pg/mouse of fusion protein in Freunds 
complete adjuvant and challenged after 4 weeks with 25pg/mouse of 
fusion protein in Freunds incomplete adjuvant. Sera for antibody 
determination were obtained 3-4 weeks after each immunisation. 
These immunisations were performed by either K Samuel or Dr E Riley. 
Recombinant antigens used for these immunisations are listed in table 4.2. 
4.2.2. Monoclonal antibodies 
Monoclonal antibodies specific for MSP2 were used to probe recombinant 
MSP2 antigens in ELISA. The mAbs included; 12.3-2-2, 12.5-1-2, 12.7, and 
13.4 [55, 109, 110, 207], 8-51D and 4-417 [310] specific for group A and 
8G10/48 & 8F6/49 [283] specific for group B [109]. The specificities of these 
mAbs are shown in table 4.1 and Appendix lB. 
mAb Serogroup Isolate Epitope Reference 
12.3, 12.5, 12.7 	A T9/96 Group specific Fenton et a! 	1991 
[109] 
13.4 A T9/94 (GSAG) n Clark et a! 1989 [55] 
4-4F/8-5D A FVO Stanley et a! 	1985 
[310] 
8G10/48 B FC27 SINS (Ri repeats) Epping et a! 	1988 
[101] 
8F6/49 B FC27 DTPTATE (gp. spf.) Ramasamy 	et a! 
1990 [255] 
Table 4.1: MSP2 specific monoclonal antibodies. Hybridomas were raised 
against schizonts of P.falciparum isolates. The specificity of these mAbs is 
indicated by MSP2 serogroup and the amino acid sequence of the epitope 
or the region of the molecule which is thought to contain the epitope. 
4.2.3 Western blotting of Plasmodium falciparum schizont extracts: 
Schizonts from 31D7 and Dd2 isolates of P.falciparum were boiled for 10 
minutes in 10% SIDS sample buffer and centrifuged. Samples of the 
soluble fraction were loaded onto SDS-PAGE under non-reducing 
conditions. 
The samples were electrophoretically transferred to nitrocellulose as 
described in Materials and Methods (chapter 2, section 2.3). The 
nitrocellulose was probed with mouse sera (diluted 1:200 in blocking 
buffer) or mAb (diluted 1:100 in blocking buffer) specific for MSP2 and 
these antibodies were detected using HRP-conjugated anti-mouse 1g. 
Bands were visualised using 4-chloro-1-napthol as the substrate. 
4.2.4 Immunofluorescence assay: 
Sera from mice immunised with MSP2 recombinant proteins were tested 
using single-labelled IFA for recognition of P.falciparum schizonts. Sera 
were tested at 1:50, 1:200 and 1:800; dilutions were made in 1% BSA in 
PBS. 
4.2.5 ELISA: 
MSP2 specific antibody was measured in ELISA using HRP-conjugated 
rabbit anti-mouse Ig diluted 1:1000 in PBS/Tween. 
Mouse sera was diluted 1:500 and serial five-fold dilutions were made. 
mAb was diluted 1:500 and serial four-fold dilutions were made. 
Competition ELISAs: 
Selected sera were preincubated with increasing concentrations of 
inhibiting antigen from 0 p.g/ml upto 5pg/ml. Sera were diluted 1:20000. 
4.2.6 Recombinant MSP2 proteins: 
The rAgs used in this chapter are those described in Materials and 
Methods (chapter 2, section 2.1), plus variants of particular regions. The 
sequence differences of these variants have been described in table 4.2 
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Table 4.2: Recombinant MSP2 proteins. The isolates from which these 
proteins are derived, the region of MSP2 they represent and the sequence 
or number of repeats are shown. 
a denotes mice immunised using protocol a); b  denotes mice immunised 
using protocol b). * indicates that this sequence has not been fully 
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Figure 4.1a: Schematic representation of MSP2 serogroup A 
recombinant proteins, A2 and A3, indicating the isolates from which 


















Figure 4.1b: Schematic representation of MSP2 of serogroup B 
recombinant proteins B2 and B3, and indicating the isolates from 
which they were derived. 
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4.3 Results: 
4.3.1 Recognition of recombinant MSP2 proteins by MSP2-specific 
monoclonal antibodies or mouse serum, in ELISA: 
Monoclonal antibodies specific for MSP2 had been raised against native 
protein and recognised the surface of intact schizonts in IFA [55, 101, 109, 
110, 207, 255, 283, 310], and for some of these mAbs epitopes have been 
characterised (table 4. 1, appendix 1B). The mAbs were used in ELISA to 
probe rAgs to ensure that the rAgs contained native epitopes. 
All the rAgs were recognised by the appropriate mAbs as predicted (table 
4.3) with the exception of A2(CH12/12). This rAg was recognised by 
serogroup B-specific mAbs; there is no obvious explanation for this 
apparent cross-reactivity, as A2(CH12/12) does not have any sequence 
homology with the known epitopes of the mAbs. 
In addition, we have shown differential recognition of the A3 constructs by 
mAbs 12.3, 12.5, and 12.7. Epitopes recognised by these mAbs are shared 
by group A variants and are associated with the less variable, group 
specific parts of the central region [109]. The use of this panel of A3 
constructs has enabled us to elucidate possible epitopes of these mAbs. 
12.7 seroreactivity is dependent on a group specific region which is lacking 
in A3(CH105/9(i)) (table 4.3). Furthermore, a natural deletion occurs in this 
region in some alleles, but this does not affect the reactivity of this mAb 
[109]. Thus, the epitope of 12.7 lies in the region between the end of the 
deleted sequence and the conserved C-terminus region. Whereas the 
epitope(s) of 12.3 and 12.5 lies in the group specific region of serogroup A, 
but the reactivity of these mAbs is not dependent on the R2 repeats as they 
recognise rAgs lacking these repeats. 
Sera from mice immunised with MSP2 rAgs were tested for recognition of 
the immunising construct in ELISA. All the rAgs tested were shown to be 
immunogenic in mice, in that all sera recognised the immunising construct 
(table 4.4). In most mice, the antibody response was directed 
predominantly at the MSP2 epitopes of the rAg, rather than at the GST 
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Figure 4.2: Immunisation with MSP2-GST fusion proteins induces 
antibodies which are MSP2-specific. Mice were immunised with 
recombinant proteins A2(ThaiTn) and A2(7G8), representing the Ri repeat 
region of MSP2 serogroup A from isolates ThaiTn (a) and 7G8 (b). The 
sera obtained were tested in ELISA for recognition of the immunising 
construct and GST. The titration curves are shown. 
0-Thai Tn, •-7G8, A - GST. 	 87 
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Table 4.3: Recognition of MSP2 recombinant antigens using MSP2-specific mAbs in ELISA. mAb specificities are given in 
table 4.1 and appendix lB. 
- denotes negative result; ++ and +++ indicate moderately and strongly positive results, respectively. 
4.3.2. Recognition of native MSP2 by mouse antibodies raised against 
rMSP2: 
The sera raised in mice were also tested for the recognition of native MSP2 
by immunofluorescence of mature, schizont infected erythrocytes and by 
immunoblotting of SIDS-soluble extracts of P.falciparum schizonts. In all 
cases, with the exception of mice immunised with N, the murine antibodies 
gave specific parasite surface fluorescence of homologous isolates (figure 
4.3). 
Sera were used to probe Western blots of schizont extracts from two 
P.falciparum clones 31D7 (MSP2 serogroup A) and Dd2 (MSP2 serogroup 
B). Sera from mice immunised with rAgs representing the full length 
molecule and the group specific regions, and 132-specific sera recognised 
the schizont extract (figure 4.4). However, not all the A2-specific sera 
recognised the 31D7 schizont extract. Recognition may depend on 
sequence homology of the repeats. 
All positive reactions resulted in a single band of the expected molecular 
weight, as determined by recognition by mAbs. 
Parasite-specific staining was not seen with pre-bleeds (naive mouse 
serum) under the same assay conditions. 
4.3.3. Cross-reactivity of antibodies to serogroup A and B: 
Antibodies to Al were shown to cross-react with MSP2 serogroup B in IFA, 
Western blotting and ELISA, and vice-versa (table 4.4). These sera were 
seropositive for the conserved C-terminus but did not recognise the 
conserved N-terminus, indicating that cross-reactivity may be due 
predominantly to epitopes within the C-terminus (figure 4.5a & b). This was 
supported by the results of inhibition ELISAs. Sera from mice immunised 
with the full length constructs, Al and Bi, were preincubated with 
increasing concentrations of C (the C-terminal conserved region), and 
tested for recognition of Al and Bi in ELISA (figure 4.5c & d). The inhibition 
curves show that preincubation of anti-Al sera with C can inhibit the 
recognition of Bi and C; and vice versa. Thus, the cross recognition of the 
serogroups seems dependent on antibodies specific for the conserved C-
term in us. 
These results also show that recognition of the full length proteins by the 
mouse sera is not solely dependent on antibodies to the conserved C- 
EIM 
terminus, as preincubation with C does not appear to have a significant 
effect on the recognition of the same full length rAg. 
b) 
Figure 4.3: Photographs showing the double-stained fluorescence pattern 
of malaria parasites using serum from a mouse immunised with B2(K1 i). a) 
DAR stained nuclei; b) mouse anti-B2 serum plus anti-mouse lg-FITC. 
WE 
Figure 4.4: Western blot of schizont extracts from 3D7 (lanes 1-7) and Dd2 
(lanes 8-13) P.falicparum isolates probed with sera from mice immunised 
with Al, B1 and C. 
Lane 1,2,8,9: sera from mice immunised with Al (full length serogroup A); 
lanes 3,4,10,11: sera from mice immunised with Bi (full length serogroup 
b); lanes 5,6,12,13: sera from mice immunised with C (conserved C 
terminus). Lane 7: mAb 8-51D. 
Figure 4.5 (a-d): Cross-reactivity of antibodies to MSP2 serogroups A and B 
is due to recognition of epitopes within the C-terminal conserved region of 
the protein. 
Mice were immunised with recombinant proteins representing the full 
length molecule of MSP2 serogroup A (a) or B (b). The sera produced were 
tested for recognition of Al, B1 ,N and C. 
Inhibition curves obtained after preincubation of individual serum samples 
with the rAg representing the C-terminal conserved region are shown for 
the recognition of Al, Bi and C (c & d). 
- Al (full length serogroup A), • - Bl (full length serogroup B), 4 - N 
(N-terminal conserved region), A - C (C-terminal conserved region) 
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Figure 4.5 c & d. 
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Concentration of C (jig/ml) 
ml 
rMSP2 Native MSP2 
Antigen Isolate ELISA IFA WESTERN 
Al T9/96 + + + 
A2 T9/96 + + - 
ThaiTn + + - 
7G8 + + - 
A3 R033 + + + 
Bl Dd2 + + + 
B2 Kl(5/3) + + n.t 
Kl(13/3) + + + 
B3 19/105 + + + 
N Ki + - - 
C Ki + + + 
Table 4.4: Summary of reactivities of mice sera after immunisation with 
MSP2 recombinant proteins. Sera were tested for reactivity to homologous 
recombinant MSP2 proteins in ELISA. n.t - not tested 
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4.4 Discussion 
Immunity to the asexual stages of malaria parasites has been induced in 
primate models of human malaria both with whole merozoites [227] and 
with purified merozoite antigens [137, 237]. These studies indicate that 
native malaria antigens associated with the merozoite induce significant 
protective immunity. 
MSP2 has been identified as an important antigen on the surface of the 
merozoite and it is essential to determine the immune recognition of this 
molecule in malaria-exposed individuals. However, the use and purification 
of native MSP2 is impractical. Thus, it has become critical to identify 
appropriate methods to produce synthetic malaria antigens which are 
immunologically equivalent to their native counterpart. 
A large number of malaria antigens, or antigen fragments, have been 
expressed as recombinant polypeptides in E.coIi. The pGEX expression 
system has been used for the production of rMSP2 proteins. We have 
expressed a panel of rAgs representing the full length molecule of the two 
aiieiic forms of MSP2, plus fragments representing defined regions of the 
protein from various P.falciparum isolates/clones. It is important to 
determine whether the rAgs have been expressed in the correct 
conformation, i.e. whether the proteins accurately reflect the antigenic 
characteristics of native MSP2, before studies using human serum begin. 
Our approach was two-fold. Firstly, mAbs specific for MSP2 were used in 
ELISA to determine whether the rAgs contained native epitopes. With one 
exception, all those rAgs which were known to contain mAb epitopes 
(determined from sequence data) were recognised by the appropriate mAb 
in ELISA. Thus, at least some of the rAgs presented native epitopes. 
Secondly, we immunised mice intraperitoneally with the rAgs and tested 
the sera for reactivity with both recombinant MSP2 (by ELISA) and native 
MSP2 (by IFA and Western blotting). All the rAgs were shown to be 
immunogenic in mice and, in most cases, high titres of MSP2-specific 
antibodies were induced. The GST component was rarely recognised and 
if it was, low titres of Ab were induced allowing the distinction between 
MSP2-specific Ab and GST-specific Ab. 
All but two of the rAgs tested by mouse immunisation induced antibodies 
which were able to bind to native MSP2, indicating that the rAgs were 
conformationally correct. The apparently defective construct represents the 
conserved N-terminus. Previous studies have indicated that peptides 
we 
representing the N-terminus conserved sequence are immunogenic only 
when attached to a carrier protein [166, 278]. In our study, the GST fusion 
protein appeared to act as a suitable carrier, and the protein was 
immunogenic in mice, although the majority of mice produced low titres of 
antibody. However, the protein did not seem to mimic the structure of the 
native antigen. This tends to support the study of Jones et a! [166] who 
reported that sera from mice immunised with synthetic peptides 
representing the conserved N-terminus did not recognise native MSP2 in 
IFA or Western blotting. There is no obvious explanation why the rAg failed 
to present the same epitopes as the native protein, for example there are 
no cysteine residues in the N-terminus sequence. One could propose, that 
this region of the molecule is not available for Ab binding in the native 
antigen. 
Interestingly, antibodies from mice immunised with Al cross-react with Bi 
in ELISA, IFA and Western blotting, and vice versa. Competition ELISAs 
have shown that the cross-reactive antibodies are specific for the C-
terminal conserved region. This could also infer that the N-terminus is not 
available for immune recognition and antibody binding. 
In conclusion, we have established that rAgs of MSP2 produced in E.coli 
resemble the natural P.falciparum antigen very well. For the subsequent 
studies reported in this thesis, we will present data for a range of the rAgs, 
including N, in addition to those rAgs not tested in mouse immunisations, 
but the possibility that these do not accurately reflect native protein will be 
kept in mind. 
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5. Recognition of recombinant MSP2 proteins by 
malaria-immune sera 
5.1 Introduction: 
Recombinant proteins representing MSP2 have been produced as fusions 
with glutathione S-transferase in E.coIi. It has been established that many 
of these rAgs resemble the native protein and therefore are extremely 
useful tools for studying the naturally acquired immune response to MSP2 
(chapter 4). To date, there is very little published data on naturally acquired 
immunity to MSP2 and no information on the relative immunogenicity of 
conserved, group specific (dimorphic) and repetitive (polymorphic) regions 
of the molecule. The epitopes of MSP2-specific mAbs are within the 
dimorphic and polymorphic regions of the molecule [55, 101, 109, 255]. 
This indicates that these regions are immunogenic. However, it is important 
to determine which regions are recognised during natural infection. In order 
to better understand the nature of protective immunity to malaria it is 
necessary to determine whether naturally acquired antibody responses to 
MSP2 are cross-reactive within and between serogroups. Such information 
would also be useful for determining which, if any, regions of MSP2 might 
usefully be included in a malaria vaccine. A study of adult, malaria 
exposed, Melanesians showed that 82% had antibodies against MSP2 
serogroup B [279], but the specificity of these antibodies was not fully 
characterised. A recent study in a highly endemic area of Papua New 
Guinea found high antibody prevalence ( ~! 90%) to recombinant antigens 
representing the full length proteins of both MSP2 serogroup A (3D7) and 
serogroup B (FC27) [2]. Using a serogroup A construct lacking the central 
repeats, this study also showed that a proportion of immune individuals 
responded only to epitopes within the repeat region. Experimental 
immunisation of Aotus monkeys with P.faiciparum results in an anti-MSP2 
antibody response directed primarily to a recombinant antigen representing 
repeat and group-specific regions of MSP2 in Western blot [321]. 
Antibodies purified from immune clusters of merozoites also recognise 
group specific sequences, suggesting that this region is accessible at the 
surface of the intact parasite and may therefore be a target for parasite-
inhibitory immune responses [321]. However, immunoblotting studies using 
affinity purified human serum suggest that naturally immunodominant 
epitopes are encoded within the repetitive sequences of the molecule 
[299]. None of these studies has addressed the crucial question of whether 
sequence polymorphism gives rise to antigenic diversity and whether 
epitopes in one allelic form of the protein cross-react with similar epitopes 
from other parasites. 
The aims of this study are to determine: 
if MSP 2 is naturally immunogenic in man in an area of seasonal malaria 
transmission; 
the relative antigenicity of conserved, dimorphic and polymorphic 
regions of MSP2; and 
if the naturally acquired immune response to MSP2 is cross-reactive 
between serogroups. 
In this chapter, I report a comprehensive study of the immune recognition of 
MSP2 by sera from malaria-immune adults from The Gambia, and the 
identification of regions of the molecule which are immunogenic during 
malaria infections. Adults were chosen because they have had many years 
exposure to malaria and would be likely to have anti-MSP2 antibodies. 
a We 
5.2 Materials and methods: 
5.2.1 .Sera 
Serum samples were obtained from 70 adults (aged 15-65 years) living in 
rural and pen-urban areas of The Gambia. 
These serum samples were collected by Dr E Riley. 
Control serum samples were obtained from 15 European adults who had 
not been exposed to malaria. 
5.2.2. Recombinant antigens: 
The recombinant MSP2 antigens used in this chapter are listed in table 5.1 




A2 Thai Tn 
A2 7GB 
A2 T9/94 (i) 
A3 R033 
Bi Dd2 
B1 (short) Dd2 
B2 Kl(i) 
B2 K1 (ii) 
B3 T9/105 (i) 
N Kl 
C Ki 
MSP1 - P190.1 
As a positive control for prior exposure to Plasmodium falciparum, sera 
were also tested for reactivity with a conserved sequence from another 
merozoite surface protein, MSP1. p190.1 represents a non-variable region 
of MSP1 (gp190) which has previously been shown to be recognised by 
more than 90% of malaria exposed individuals [266] and was produced in 
E. co/iasa free polypeptide [llB]. p190.1 was a kind gift of DrJ.R.L Pink, F. 
Hoffman La Roche, Basel, Switzerland. 
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5.2.3. Enzyme-linked Immunosorbent Assay (ELISA): 
Sera were tested for lgG recognition of the recombinant proteins in ELISA 
using HRP-conjugated rabbit anti-human lgG antibody diluted 1:9000 in 
PBS/Tween. Sera were diluted 1:1000. 
Competition ELISA: 
Sera were preincubated with increasing concentrations of inhibiting 
antigen from Ogg/ml up to 5tg/ml. Sera were diluted 1:1000. 
5.2.4. Statistical analysis 
Determination of positivity: 
The reactivity of the sera with various MSP2 fusion proteins in ELISA was 
calculated by subtracting the OD value for the GST control from the value 
obtained for the MSP2 fusion protein, to obtain specific OD values. Positive 
samples were defined as those giving a specific OD above the normal 
range for control European sera. The normal range was taken as the mean 
± 2 standard deviations of 15 control sera. 
Spearman's Rank Correlation analysis: 
The reactivity of individual sera with different antigens was compared by 
means of Spearman's rank correlation test [305]. This is a non-parametric 
measure of the association between two numerical values. The parametric 
equivalent is the correlation coefficient. The values of each variable are 
independently ranked and the measure is based on the differences 
between pairs of ranks of the two variables [184]. 
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5.3 Results 
5.3.1. Reactivity of human serum lgG antibodies with recombinant MSP2 
proteins: 
Serum lgG antibodies from Gambian and European adults were tested for 
the recognition of a panel of MSP2 rAgs and a recombinant MSP1 protein, 
p190.1. The recognition of p190.1 has been included in this study to ensure 
that these Gambian adults have anti-malarial antibodies and thus have 
been exposed to malaria. 
The MSP2 rAgs were specifically recognised by sera from individuals who 
have been exposed to malaria (figure 5.1a-c). The cut-off levels for 
positivity, determined from the control sera OD values, ranged from 0.117 to 
0.384 OD units. 
These results show that MSP2 is well recognised (table 5.2). Serogroup A 
and serogroup B full length rAgs are recognised by 81% and 86% of sera, 
respectively, indicating that MSP2 is highly antigenic during natural 
infections with P.falciparum. The repeat regions and group specific regions 
are also well recognised. Of the four A2 rAgs used, the one representing 
the T9/96 sequence was recognised most often. However, the proportion of 
parasites expressing the A2(T9/96) Ri repeat sequence has not been 
determined, so whether this reflects the degree of exposure to this MSP2 
sequence or is a result of the T9/96 sequence being more immunogenic 
than the others is not known. A high percentage of individuals also 
recognise the A3 rAg which contains predominantly serogroup-specific 
sequences, indicating that the repetitive sequences are not recognised 
preferentially over the group-specific regions of serogroup A. The B2 and 
B3 rAgs of serogroup B seem less well recognised than the corresponding 
serogroup A constructs, even though these sequences are relatively 
conserved. However, each contains only one copy of the repeated 
sequence whereas higher antibody binding would be obtained if the 
epitopes were repeated. 
The conserved sequences at the N and C-termini seem to be poorly 
recognised. If the cut-off limit for positivity is strictly applied, thirty-six 
percent of these individuals are seropositive for the conserved C-terminus, 
however the OD values were very low and only 3 sera recognised this 
























































































































































































































































































































































































































































































































































































































Antigen Isolate %responders Range of OD values 
minimum maximum 
Al T9/96 81 -0.026 1.991 
A2 
T9/96 81 -0.053 2.157 
ThaiTn 59 -0.356 1.427 
7G8 40 -0.225 1.540 
T9/94(i) 51 -0.220 2.107 
A3 R033 73 -0.194 1.632 
131 Dd2 86 -0.140 1.981 
131 (short) Dd2 71 -0.218 2.147 
B2 Kli 64 -0.259 1.755 
K1 ii 34 -0.466 1.831 
B3 T9/105i 43 -0.339 1.044 
N Ki 10 -0.262 0.418 
C Ki 136 -0.439 10.542 
p190.1 163 10.117 2.754 
Table 5.2: Percentage of responders recognising MSP1 and MSP2 
recombinant proteins. The range of OD values obtained is stated for each 
rAg. Sera from 70 Gambian adults were tested at a dliution of 1:1000 in 
ELISA. 
5.3.2 Comparisons of the antibodies reactive with different MSP2 rAgs: 
i. Lack of antigenic cross-reactivity between serogroups A and B: 
Seventy-nine percent of sera from adult Gambians recognised both the A 
and B serogroups of MSP2 (proteins Al and Bi, which represent the full 
length molecules). To determine whether this 'dual' recognition was due to 
a single population of antibodies which react with epitopes common to both 
proteins or whether the serum contained two separate, non-cross-reacting, 
populations of antibody, the reactivity of individual sera was compared with 
each of the full length proteins (Al and Bi) (figure 5.2a). It is clear that 
although some sera recognise the two proteins to approximately the same 
extent, other sera clearly recognise one protein but not the other. 
Using Spearman's rank correlation test, a positive correlation was obtained 
between responses to Al and Bi (r=0.555; r5=0.307, p=0.005). However, 
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we consider that the high level of statistical significance is the result of the 
large sample size and the presence of double negative sera; the 
association is in fact quite weak and may simply reflect independent 
exposure to both serogroups of P.falciparum. As an estimate of association 
due to exposure, the recognition of MSP2 proteins with the recognition of a 
recombinant protein representing a conserved region of an unrelated 
merozoite surface protein (MSP1, p190.1) was compared (figure 5.2b). 
Correlation coefficients of up to 0.492 were obtained. Thus the correlation 
coefficient obtained for Al versus Bl was only slightly higher than that 
obtained for MSP2 versus MSP1, suggesting that the correlation is indeed 
due to exposure rather than to cross-reacting antibodies. 
To confirm that antibodies to the two serogroups are not cross-reactive, 
individual sera were tested in competition ELISAs. Sera which were known 
to contain antibodies to both Al and Bi were selected; these sera were 
preincubated with either Al or Bl and tested in ELISA for recognition of the 
other protein. The four example shown in figure 5.3 was typical of the sera 
tested: whiist preincubation with increasing concentrations of Al prevents 
subsequent binding of antibodies to Al-coated plates, it has no effect on 
binding of antibody to 131 -coated plates, and vice versa. Thus, in double 
positive sera, there appear to be two distinct populations of antibodies, one 
















-0.5 	1 - 
-0.5 




0 	 00000 
0 	0 
0 00 00 	0 
0 	 0 
0 
80 	 0  )0 	 0 0 
0 
p 
000 	to 0 0 
8.90 80 0 	0 0 0 %EP 
0 00 
0 	0.5 	1 	1.5 	2 	2.5 	 106 
OD VALUES - A3 




0 	 00 
0 	 0 
0 	 00 
0 	0 cPo 
0 0 
0 	00 	 0 




0 	 0 
0 00 	 cb o% 
p0 	 0 





0 	 0.5 	 1 	 1.5 	2 
OD VALUES - Al 
0 0 	0  
0 0 0 	
0 	




C00000 0 000 
0 	 02 






-- 	 I 	 I 	 I 	 U 
-0.5 	0 	0.5 	1 	1.5 	2 	2.5 	3 
OD VALUES - Al 
-0.5 	1 - 
-0.5 



























(d) rs = 0.848 



















0 	 0.5 	 1 	 1.5 	2 







0 	 000 	0 
	
0 80 09 
0  
4R 	0 
0 	c 0pe 
0 
0 
0 	 0.5 	1 	 1.5 	2 
OD VALUES - B2(K1 i) 
Figure 5.2 a-e: Comparison of OD values for sera from 70 
Gambian adults. (a) Al vs Bi, (b) Al vs MSP1, (c) A2(T9/96) vs 
A3, (d) Bi vs B1 (short) and (e) B3(Kli) vs B3(Klii). Spearman's 
values (re) are shown. 
Solid lines indicate the cut-off levels for each antigen. Each circle 
represents a single serum tested at a dilution of 1/1000. 
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Figure 5.3: Competition assay to determine the extent of cross-reactivity 
between antibodies recognising Al and Bl. The results for a single, typical, 
serum are shown. Sera were preincubated with antigen at concentrations 
from Opg/ml - 5ig/mI. Sera were tested at a dilution of 1/1000. 
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ii-Distinct populations of antibodies recognise different regions of MSP2 
serogroup A: 
Sixty-three percent of the Gambian adults were seropositive for A2(T9/96) 
and A3, but the dot plots show only a poor correlation between the two 
(figure 5.2c) and the correlation coefficient was lower than for MSP1 vs. 
MSP2. Inhibition ELISAs clearly demonstrate that there are two distinct 
populations of antibodies (figure 5.4). One population are specific for the 
Ri repeat region and the other for the R2 repeat/group specific region. 
These data fit with the demonstration that MSP2 serogroup A-specific mAbs 
recognise Ri repeats (13.4, 4-4F & 8-5D) or the group specific region (12.3, 
12.5 & 12.7), and therefore, distinct epitopes are present in both regions. 
iii. Lack of recognition of the conserved C and N-termini: 
The percentage of responders and the OD values obtained for the 
recognition of C and N indicate that these regions are not highly 
antigenic/immunogenic during a natural infection. However, for the N-
terminus at least, there is some question as to the antigenic integrity of this 
rAg (see chapter 4). Comparison of the recognition of two pairs of rAgs, 131 
and 131 (short), and B2(K1i) and B2(K1ii), allows further analysis of the role 
of the conserved regions in the recognition of MSP2. 131 (short) lacks a 
large proportion of the conserved sequences present in 131. B2(K1 i) lacks 
the N-terminal conserved sequence present in B2(K1ii). Despite the 
differences between the pairs of antigens, the recognition of the rAgs is 
very highly correlated (table5.3, figure 5.2 d and e). These data thus 
confirm the initial data and indicate that the conserved sequences do not 
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Figure 5.4 a & b: Competition assay to determine the extent of cross-
reactivity between antibodies recognising A2(T9/96) and A3, for two 
individuals. Sera were preincubated with antigen at concentrations 
from 0mg/mi - 1mg/mi. Sera were tested at a dilution of 1:1000. 
Key:• A2(on plate) vs A2 (in serum), 0 A2 vs A3, • A3 vs A3, 
13A3vsA2, t GSTvsGST. 
(a) 
111 












B2 (Ku) B2 




MSP1 1.000  
Al 0.457 1.000  
2(T9/96) 0.071 0.620 1.000  
A2(ThaiTn) 0.270 0.558 0.733 1.000  
A2 (7G8) 0.173 0.463 0.644 0.731 1.000  
A2 (1994i) 0.193 0.559 0.691 0.765 0.830 1.000  
A3 0.352 0.764 0.462 0.465 0.444 0.526 1.000  
BI 0.492 0.555 0.449 0.512 0.436 0.479 0.579 1.000  
B1 (short) 0.394 0.464 0.487 0.553 0.472 0.505 0.520 0.848 1.000  
B2 (Ku) 0.415 0.437 0.392 0.450 0.506 0.510 0.472 0.743 0.678 1.000  
B2(K1ii) 0.483 0.440 0.303 0.436 0.473 0.387 0.425 0.648 0.654 0.816 1.000  
B3(T9/105i) 0.226 0.350 0.367 0.249 0.166 0.215 0.339 0.527 0.498 0.380 0.344 1.000  
N 0.273 0.187 -0.041 -0.043 0.058 0.061 0.079 0.051 0.018 0.225 0.180 -0.014 1.000 
C -0.356 0.0291 0.362 0.350 0.394 0.394 0.245 0.050 0.154 0.072 0.027 0.058 -0.336 
Table 5.3: Comparison of the recognition of MSP1 and MSP2 rAgs using the OD values obtained from 70 Gambian adults' 
sera in Spearman's rank correlation tests. Critical value for n=70 is 0.307, p=0.005. 
t'.) 
5.4 Discussion 
The aim of this study was to characterise the reactivity of serum antibodies 
from malaria-exposed adult individuals with the merozoite surface protein, 
MSP2. Evaluation of MSP2 as a potential component of a subunit malaria 
vaccine requires an understanding of the naturally occurring immune 
response to MSP2 and, most importantly, the immunological significance of 
amino acid sequence polymorphisms. In particular, it is important to 
determine whether antibodies against one MSP2 serogroup will cross react 
with the other serogroup, or whether the Ab response is group-specific or 
allele-specific. Such information may also help us to understand the 
relative importance of allele-specific ("strain-specific") immune responses 
in the acquisition of clinically protective immunity to malaria by people 
living in malaria endemic areas. 
There are two main theories to explain the slow development of protective 
immunity to malaria which is typically seen in individuals living in endemic 
areas: (i) polymorphism of antigens which are the targets of protective 
immune responses and, (ii) intrinsically poor immunogenicity of the target 
molecules. The data presented here indicate that the latter explanation is 
not true, at least with respect to MSP2. Sixty seven of the 70 individuals 
tested had clearly detectable anti-MSP2 antibodies (to either serogroup A 
or B or both) with end point titrations of > 1/9,000 for most sera (data not 
shown). This is comparable with the level of recognition of MSP2 found in 
the Solomon Islands [279] and Papua New Guinea [2]. 
Antibodies tended to recognise epitopes within the dimorphic and 
polymorphic regions of MSP2; the conserved C-terminus seems to be 
poorly antigenic. This is in agreement with Thomas et a! [321] who 
reported that although intact MSP2 is recognised by monkey and human 
antibodies eluted from intact merozoites, such antibodies did not recognise 
peptides representing the N- and C-terminal regions of the molecule. 
Similarly, Saul et a! [284]were unable to detect antibodies against 
synthetic peptides representing the conserved regions of MSP2 in sera 
from 18 people with high titres of anti-parasite antibodies (as determined by 
immunofluorescence assays). 
Importantly, the sequences which are conserved within each allelic family 
(detected using A3 and B3 proteins) are highly immunogenic. Ninety 
percent of the sera tested contained antibodies which recognise either A3 
or B3 (or both); thus a vaccine based on MSP2 may need to contain only 
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two different antigens - representing the group-specific sequences of each 
serogroup. Interestingly the group-specific A3 protein is recognised by 
significantly more individuals than the B3 protein. This may reflect more 
frequent or more recent exposure of the donors to parasites of serogroup A 
since approximately 60% of parasites isolated in The Gambia belong to the 
A serogroup [66]. Antibodies eluted from immune clusters of merozoites 
recognise dimorphic MSP2 sequences [321], indicating that epitopes 
associated with these sequences are accessible at the surface of intact 
merozoites, and may therefore be a target for inhibitory antibodies. 
Proteins which represent the polymorphic Ri repeat regions of both 
serogroups (i.e. A2 and 132) were recognised by a substantial proportion of 
the sera, a greater proportion in fact than recognised the dimorphic regions. 
This finding was somewhat unexpected since, for serogroup A, the amino 
acid sequence of the repeats from different isolates varies extensively [201, 
250]. One likely explanation of this finding is that the antibodies detected 
were in fact recognising epitopes within a short N-terminal segment of 
4I 	 A' 	 A A- ­ 
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4.1). Alternative explanations include extensive immunological cross-
reactivity between different repeat sequences. Whichever explanation is 
the case, the association between the recognition of different A2 variants is 
evident from the Spearman's rank correlation values (table 5.3). 
Immunological cross-reactivity may occur among the Ri repeats of 
serogroup B, where the amino acid sequence is relatively conserved. 
Further studies will investigate the effect, on antibody recognition, of 
variation in the sequence and number of repeats (see chapters 9 and 10). 
Quantification of absolute amounts of Ab by ELISA is difficult since the OD 
value obtained is dependent on both the concentration of antibody and its 
affinity. It is not possible to compare the amounts of antibody in sera which 
react with different recombinant antigens since the number of epitopes in 
each assay (and thus the avidity of the reaction) is unknown [331] 
Therefore, in order to make comparisons between the Ab responses to 
different proteins, we used a nonparametric rank correlation test to 
compare specific OD values for individual sera, tested at a single dilution, 
against the rAgs. Comparison of the recognition of Al and Bl show that 
the correlation between the responses to the two serogroups is weak and is 
probably due to exposure to parasites of both serogroups rather than to 
cross-reactive antibodies. Competition ELISAs demonstrate that antibodies 
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to serogroup A and B are not cross-reactive, since protein Al cannot 
compete for binding of B1 -specific antibodies, and vice versa. It should be 
noted that there is a short sequence of limited sequence homology within 
the Ri repeat region of serogroup A and B [298, 299], but this does not 
appear to induce cross-reactive antibodies in a natural infection. 
It is apparent from studies in mice that antibodies specific for Al will cross-
react with serogroup B in ELISA, IFA and Western blot, and vice versa 
(chapter 4, section 4.3.3). The cross-reactivity appears to be due to 
recognition of the conserved C-terminus. Although this region appears to 
be antigenic in mice immunised with the rAg C, it is not recognised during 
natural malaria infections in humans and does not contribute to cross- 
reactivity. 
Therefore we have shown here that MSP2 is naturally antigenic and that 
the immune response is directed primarily to the dimorphic and 
polymorphic regions of the molecule. Correlation analysis and competition 
ELISAs have indicated that, in general, there is no serological cross-
reactivity between the two serogroups. 
Further work is required to determine the significance of the polymorphisms 
within the repeat sequences in their contribution to the slow development of 
protective immunity to P.falciparum (see chapter 9). 
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6. Population cross-sectional studies of antibody 
recognition of MSP2 - the relationship between age, 
malaria exposure and anti-MSP2 lgG 
6.1 Introduction 
In areas with stable, endemic P. falciparum malaria transmission, 
parasitaemia is most common in young children, and the incidence of 
parasitaemia declines steadily with age. The precise timing of events 
depends on the local patterns of malaria transmission and levels of 
endemicity. In The Gambia, where transmission is seasonal but stable from 
year to year, parasite rates do not begin to decline until the age of 10 to 12 
years, whereas the incidence of clinical disease peaks at age 6 [264]. In the 
same population, peak mortality from malaria occurs in children aged 4 
years [128]. Thus, as protective immunity to malaria is acquired gradually, 
and associated with age (and exposure to malaria), the prevalence of anti-
malarial antibodies would be expected to increase in parallel with 
increasing cnica! immunity. Why does it take so Ionq to become immune? 
Possible reasons for the slow development of immunity are: 1) children are 
unable to make appropriate antibody; adults may respond more 
appropriately and therefore acquire immunity more rapidly; 2) the antigens 
are poorly immunogenic; or 3) the antigens are polymorphic. 
As early as 1965, Brown & Brown [35] proposed that children may have a 
constitutional inability to respond appropriately to endemic infection 
pressure. They had observed that young rats infected with P.berghei 
relapse more frequently and with higher parasitaemia than older animals, 
indicating that the young of some hosts may have an inability to respond 
appropriately and develop generalised immunity. Baird et a! [15, 16] 
studied the effect of age on protection, independent of cumulative exposure 
to malaria antigens in a mixed-age population in The Philippines migrating 
into a malaria-endemic area from a non-endemic area. They propose that 
the protective acquired immune response to endemic falciparum malaria is 
governed by relatively brief exposure and some intrinsic immune factor(s) 
associated with age of the host. If this is true, antigenic polymorphisms in 
the parasite may only briefly influence susceptibility to infection. However, 
this data does not prove that adults acquire protective immunity faster than 
children, since the authors do not specifically address the issue of an age-
specific rate of development of clinical immunity. Certainly the number of 
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clinical episodes that are necessary before clinical immunity develops may 
differ in adults and children but they report age-specific differences in 
prevalence of parasitaemia which does not necessarily reflect age-specific 
differences in clinical episodes. Baird et a! [14-16] conclude that the 
degree of protection was governed by recent heavy exposure and age, 
independent of chronic heavy exposure. Clearly, immunologically naive 
adults suffer severe and life-threatening malaria. This fact argues against 
some purely physical consequence of the ageing process, i.e., people 
without prior exposure to malaria seem equally susceptible to the 
consequences of falciparum malaria, regardless of age. Furthermore, a 
study of epidemic malaria in Madagascar following a period of 20 years 
when the island was malaria free, has shown that all age groups, except 
those previously exposed to malaria were equally susceptible to disease 
[84]. 
Cohen & McGregor [62] suggested that the slow immunological response 
to malaria, which requires several years of repeated infection in order to 
reach a level sufficient enough to suppress the acute manifestations of the 
disease, is associated with the inherently poor antigenicity of the parasite. 
A modern interpretation of this is that immunological non responsiveness 
could be a result of the parasite antigens evolving to present limited T cell 
epitopes to the immune system and thus failing to give T cell help for 
antibody production [120]. 
Early observations on malaria infections therapeutically induced in 
neurosyphilitic patients showed that individuals convalescing from P.vivax 
infections acquire an effective immunity to the strain of the parasite that 
caused the infection but not to a heterologous strain [30]. These results 
imply that immunity may be strain- or variant-specific and targets of 
protective immunity are likely to be polymorphic, and importantly may 
depend on the immunogenicity of primary infections. Thus, susceptibility in 
children may mean that resistance depends on exposure to a wide, but 
finite range, of antigenic variants occurring in one locality [35]. 
The hypothesis that there is a constitutional and age-associated inability to 
respond appropriately to infection [14-16, 35] such that protective immunity 
to malaria is dependent on the age of the individuals rather than cumulative 
exposure to many variants over a number of years cannot be easily 
investigated in endemic populations. 
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However, the other two hypotheses can be investigated by comparing the 
antibody responses of relatively naive individuals with semi-immune and 
clinically immune individuals. 
The hypothesis that malaria antigens are inherently poorly immunogenic 
can be tested by looking at antibody in individuals convalescing from one 
or two malaria infections. Such data is presented in this chapter. Finally, the 
theory that protection is dependent upon cumulative exposure to many 
variants can be investigated by comparing antibody responses of children, 
who have limited exposure to malaria with adults who will have 
experienced infection with most or all of the variants present within the local 
population of parasites. 
Thus, in this chapter, the dynamics of the acquisition of antibodies to MSP2 
in Gambian populations is described, examining the effects of age and 
exposure to malaria infection. We have also examined the antigenicity of 
MSP2 in children and individuals from non-endemic areas who are known 
to have experienced a limited number of malaria infections. 
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6.2 Materials and Methods 
6.2.1 Serum samples: 
Malaria-exposed individuals 
178 serum samples were obtained from individuals (aged 1-75 years) 
living in rural villages around the town of Farafenni on the north bank of the 
Gambia river, about 100 km inland. The geographical and demographic 
features of this area have been described by Greenwood et a! [129]. The 
majority of clinical cases of malaria occur in the 3 month period from 
September to November each year. The serum samples used here were 
collected in October 1988, during the malaria transmission season. 
"Naive" Individuals 
Sera were obtained from individuals from non-endemic areas who had 
been infected with P.falciparum whilst visiting malaria endemic countries 
(table 6.1). These individuals were known to have been infected either for 
the first time or more than twice. Some sera were collected during 
conva!escence (CS). 
Serum samples were kindly provided by Prof. G Pasvol and Dr J Carlsson, 
Dept. of Infectious Diseases and Tropical Medicine, Northwick Park 
Hospital. 
Control serum samples were obtained from 25 European children and 
25 European adults who had not been infected with malaria. 
All serum samples were stored at -20°C. 
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SAMPLE NUMBER EXPOSURE COUNTRY VISITED 
92:21 N & CS Ghana 
92:35 N Nigeria 
92:51 N Ghana 
93:01 N Kenya 
93:28 N & CS Uganda 
92:11 >2 Nigeria 
92:30 >2 Ghana 
92:33 >2 Kenya 
92:41 >2 Ghana 
93:33 >2 Malawi-Zimbabwe-Zaire 
92:10 CS Nigeria 
92:12 CS Nigeria 
92:38 CS Liberia 
Table 6.1: Serum samples from individuals from non-endemic countries 
who became infected with malaria after visiting malaria endemic countries. 
Samples were taken after returning to Britain, on diagnosis of infection with 
P. falciparum. 
N indicates naive individual; >2 indicates second or more infection; CS 
indicates convalescent sera. 
6.2.2 Recombinant MSP2 proteins: 
The following rAgs were used in this work: Al, A2(T9/96), A3, Bl, B2 (Ki i), 
B3 (T9/105i); see Appendix 1A. 
6.2.3 Enzyme-linked immunosorbent assay (ELISA): 
MSP2 specific lgG antibodies were measured in ELISA as described in 
materials and methods (chapter 2, section 2.4). For screening, all sera were 
diluted 1/1000 in blocking buffer and tested in duplicate. 
For titration ELISAs, sera were diluted from 1/100 to 1/12800 with doubling 
dilutions. 
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6.2.3 Statistical methods: 
Determination of positivity: 
Positive samples were defined as those giving a specific OD above the 
normal range for control sera. The normal range was taken as the mean + 2 
standard deviations of the OD values obtained for the control sera. 
Kruskal-Wallis test: 
Kruskal-Wallis test were performed using MINITAB statistical software in 
order to determine differences in the median OD values to each for each 
age group. 
3: Chi-square for trend: 
X
2 
tests for trend were performed using Epi Info, a statistical software 
package, and are used to determine whether there is a trend in proportions 
of responders with age. 
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6.3 Results 
6.3.1. Age-specific recognition of MSP2: 
Anti-MSP2 lgG levels were measured in 178 individuals from the area 
around the village of Farafenni, The Gambia, West Africa. The median OD 
increases markedly with age for all the rAgs tested, reaching a peak after 
the age of 16 years. Kruskal-Wallis tests indicate this increase is statistically 
significant (p.<O.Ol) despite the large standard deviation (table 6.2). 
Thus, these data show that the median antibody level specific for MSP2 
increases with age, in a pattern which would be expected if immunity to 
MSP2 is associated with the acquisition of protective immunity. 
6.3.2. Age-specific prevalence of antibodies to MSP2: 
The large standard deviation for the analysis of variance (table 6.2) 
indicates a wide range of OD values in each age group. This reflects the 
number of non-responders in each age group. Table 6.3 and figure 6.1 
shows that the number of responders, i.e. the prevalence of antibodies, 
increases with age. In this analysis smaller age groups were used in order 
to reveal the pattern of antibody prevalence, particularly in those 
individuals still actively acquiring immunity to malaria. 
For all the rAgs, there is a gradual rise throughout childhood in the 
prevalence of seropositivity. The recognition of MSP2 reaches a peak in 
adolescence; depending on the antigen, between 71-100% of this 
population are eventually seropositive. 
The pattern of antibody prevalence varies between the antigens (figure 
6.1a & b). Al and A3 have similar profiles with seropositivity reaching > 
90% by adolescence and remaining >80% throughout adulthood. The 
prevalence of antibodies to A2(T9/96) is lower, reaching a maximum of 
71%. 
The recognition of serogroup B antigens reaches a peak of 100% 
responders by age 7-8 years for the full length protein Bi; the prevalence of 
antibodies specific for B2(K1 i) is >80% and for B3(T9/1 05i) >70% from 9-10 
years onwards. The prevalence of antibodies to the Ri repeat region of 
serogroup B, B2(Kii), reaches levels close to those for the full length 
protein; this is in marked contrast to the corresponding region of serogroup 
A. 




2 tests for trend indicate that the antibody prevalence for the recognition 
each antigen is strongly age related (table 6.3) 
Hence, the age trend is a reflection of the increase in prevalence of 
antibodies to MSP2 rather than an increase in the median OD with age. 
Analysis of the positive OD values showed that, except for Bi, there was 
no significant difference in the median of the positive OD values with age 
(table 6.4). Additional analysis of the data for Bi showed that there was no 
difference in the median OD value between the ages of 1-15 years, but that 
individuals older than this tended to have higher OD values. 
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Recombinant MSP2 Proteins ____  
AGE n Al A2(T9/96) A3 	( Bi B2(K1i) B3(T9/105i) 
1-5 33 0.126 (0.346) 0.037 (0.264) 0.143 (0.310) 0.208 (0.370) 0.069 (0.356) 0.111 (0.2721 
6-10 36 0.343 (0.434) 0.066 (0.283) 0.266 (0.342Y _0.365 (0.450) 0.191 (0.451) 0.338 (0.392) 
11-15 35 0.468 (0.383) 0.320 (0.309) 0.279 (0.368) 0.535 (0.386) 0.489 (0.399) 0.482 (0.481) 
16-30 35 0.528 (0.364) 0.402 (0.426) 0.526 (0.419) 0.715 (0.415) 0.615 (0.363) 0.874 (0.497) 
30+ 39 0.641 (0.435) 0.279 (0.441) 0.442 (0.432) 0.693 (0.420) 0.589 (0.495) 0.493 (0.512) 
H 22.01 30.27 14.00 - 22.69 33.90 27.32 
p 
____ 
_______ <0.001 <0.001 0.008 - <0.001 <0.001 <0.001 
Table 6.2: 178 serum samples from a cross-section of the population were tested for the recognition of a panel of rAgs 
representing MSP2. Median (SD) of OD values for Gambian sera (1/1000 dilution) for different age groups are shown. 
Differences between medians were analysed using Kruskal Wallis tests. 
Recombinant MSP2 proteins 
A2(T9/96) A3 AGE Ed- Al _ 
45(5) 
 Bi 	I 	B2(Kli) 	B3
1-2 -18(2) 
45(5) -73(8) 	-54.5(6) 	27(3) 
40(6) 53(8) 40(6) 47(7) 
3-4 15- 47(7) 13(2) 
61(11) 72(13) 	-61(11) 	67(12) 
5-6 
- 
18  -33(6) - 
69(9) 100 (13) 77 (10) 62 (8) - 
7-8 14 69(9) - 15(2) 
82 (9) -100(11) 	82(9) 	73 (8L  
9-10 - 11 100 (11) 54.5 (6) 
67(14) 100(9) 	100(21) 86(18t 
11-12 21  67(14)
- 
93(13) 100(21) 93(13) 	79(11) 
13-15 14 93(13) 71 	10 
81(21) 96(25) 	-96(25) 92(24j 
16-25 26 85(22) 65(24) 
- 
95(19) 90(18) 95(19) 	80(16) 
26-35 20 85(17) 44(11) 




19.811 13.821 - 	27.744 - 14.628 - 
- 
15.285 - 10.294 - 
>0.001 - - 	0.002 	>0.001 	>0.001 >0.001 >0.001 
Table 6.3: Prevalence of anti-MSP2 antibodies in sera from Gambian individuals aged 1-75 years. Percentage of positives 
for each age group and the number of positive samples (n) in each age group are given. Association between age and 





















c I 	• 	u IlIl •Il 	1 1111 1 1111 	I 	I 	 I 	 I 	I 
0 10 	20 	30 	40 	50 60 
age (years) 
Figure 6.1: Prevalence (% responders) of IgG positive 
sera, by age, for MSP2 serogroup A (a) and B (b). 
Age groups are 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-15,  
16-25, 26-35, 36+ years. 
(a)• full length protein, Al, U Rl repeat region, A2(T9/96), 
£ R2/group-specific region A3. 
(b)0 full length protein, Bl, 0 RI repeat region, B2(Kl i), 
R2/group-specific region B3 (19/1 05i) 
126 
Recombinant MSP2 prOtEflS  
AGE Al A2(T9/96) A3 Bl - B2(K1i) B3(T9/105i) 
1-5 0.541 0.455 0.555 0.581 - 0.402 0.523 
6-10 0.718 0.573 0.611 0.414_ 0.290 0.609 
11-15 0.629 0.400 0.403 0.535_ 0.500 0.525 
16-30 0.560 0.533 0.583 0.764 0.633 0.894 
30+ 0.777 0.706 0.503 0.723_ 0.666 0.687 
H 6.91 6.91 2.34 10.48 9.00 6.17 
p 0.142 0.142 0.674 0.034_ 
0.062 0.188 
Table 6.4: Analysis of positive responses to MSP2 rAgs; median of the positive OD values per age group. Differences 
between medians were analysed using Kruskal Wallis tests. 
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6.3.3 Immunogenicity of MSP2: 
It appears from the analysis above that children are capable of producing 
levels of antibodies equivalent to the levels in adults. However, the nature 
of the assay does not allow us to determine whether children produce the 
same quantity and/or affinity of antibody as adults when the serum is tested 
at a single dilution. Therefore, selected sera were titrated and comparison 
of the titration curves produced by these sera gives an indication of the 
differences in affinity and/or amount of MSP2-specific antibody (figure 6.2a 
&b). 
Al was strongly recognised by the three sera tested (figure 6.2a). Two 
donors were aged 5yrs (Fl and 172) and one was aged 42yrs (F3). The 
slope and the peak plateau of the titration curves were similar in all 3 
cases, indicating that the concentrations and affinities of antibodies specific 
for Al were similar in these individuals. 
Bi was well recognised by child F2 and adult F4, and it appears from the 
titration curves that the affinity and concentration of these antibodies is 
similar (figure 6.2b). Child F3, who was 1 years old, had antibodies specific 
for serogroup B with similar affinity but of a lower concentration. 
Therefore, in general, the MSP2-specific antibodies in children and adults 
are comparable in terms of concentration and affinity, indicating that MSP2 
is not poorly immunogenic. 
Table 6.5 summarises antibody recognition of MSP2 proteins by sera of 
individuals from non-endemic areas who have limited experience of 
P.falciparum infections. 6/13 of these individuals have detectable 
antibodies to the rAgs tested. Interestingly, all the convalescent sera were 
seropositive, indicating that, even after only very limited experience of 
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Figure 6.2 a & b: Titration curves for the recognition of Al (a) and Bi 
(b), to compare the relative concentration and affinity MSP2-specific 
antibodies in children and adults. Sera were diluted 1/100 to 1/12800 
with doubling dilutions. 
(a) • Fl (age 5 years), A  F2 (age 5 years), • F3 (age 42 years). 
.(b) o F5 (age 1 year), £ F2 (age 5 years), • F6 (age 69 years). 
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MSP2 SEROGROUP A MSP2 SEROGROUP B 












92:21 N - - +1- - + - 
Cs - - ++  
92:35 N - - - - - - 
92:51 N - - - - - - 
93:01 N - - - - - - 
93:28 N - - - - - - 
92:11 >2 - - - - - - 
92:30 >2 - - - - - - 
92:33 >2  
92:41 >2 - - - - - - 
93:33 >2 - - - - - - 
92:10 CS - - - ++ ++ + 
92:12 CS + + +++ +1- - - 
92:38 CS +++ ++ +++  
Table 6.5: Summary of results for antibody recognition of recombinant 
proteins of MSP2 by "naive" individuals. 
- indicates an OD was measured <mean +2SD of the control sera 
+1- indicates an OD was measured close to the mean + 2SD of the control 
sera 
+ indicates an OD was measured > mean +2SD of the control sera 
++ indicates an OD was measured > mean +4SD of the control sera 
+++ indicates an OD was measured > mean +6SD of the control sera 
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6.4. Discussion 
Serum samples were obtained from a cross-section of the population 
around the village of Farafenni, The Gambia. These individuals were aged 
between 1 and 75 years. The antibody recognition of recombinant MSP2 
antigens was determined in order to look at the dynamics of the acquisition 
of antibodies to MSP2 in a malaria endemic area. 
The recognition of the rAgs was shown to be markedly age dependent. The 
median 00 value for each age group increased with age and the 
association with age was statistically highly significant. This age 
dependency could possibly reflect the acquisition of protective immunity. 
Considerable variability in the recognition of MSP2 between individuals in 
each age group. The increase in the median OD with age was due to an 
increase in the prevalence of antibodies with age rather than to an increase 
in antibody concentration or affinity (table 6.2). 
The serum samples tested here have previously been tested for antibody 
prevalence to other malaria antigens, PfMSP1 [266] and soluble 
exoantigens [158]. The pattern of recognition observed for MSP2 (figures 
6.1a & b) is similar to that described for the recognition PfMSP1 and certain 
soluble antigens by these same sera. The humoral response to PfMSP1 
appeared to be acquired in an age-dependent manner, with peak 
prevalence occurring in late childhood or early adolescence [266]. The 
antibody responses to all the soluble antigens were strongly age-
dependent, but two different profiles were seen in the prevalence of 
antibodies. The age-related patterns of recognition of asexual stage 
antigens and the circumsporozoite protein were also studied in this region 
several years earlier [197, 200]. It was found that the immunological 
responses to blood-stages were all strongly age-dependent. Total blood-
stage antibodies (mean OD) increased with age, reaching a peak around 
15 years old [200]. This pattern was closely paralleled for the recognition of 
Pf 1 55/RESA. The development of anti-CS protein antibodies was also age-
related; both the prevalence of antibody positivity and mean antibody levels 
showed a progressive rise after the age of about 10 years [197]. The 
response reached a plateau in adulthood, however this pattern was distinct 
from that shown by antibodies to asexual blood-stage antigens, which 
developed more rapidly, suggesting that the CS protein is less 
immunogenic than the blood stage antigens. 
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The antibody profiles described by Jakobsen [158] represented the 
acquisition of anti-toxic and anti-parasite immunity. In this two stage 
development of naturally acquired immunity to malaria, the rate of 
acquisition of anti-toxic and anti-parasite immunity differ. The acquisition of 
resistance to the clinical effects (anti-toxic immunity) is reflected by a 
profound fall in the death rate in early childhood to much lower levels which 
are subsequently sustained. This precedes anti-parasite immunity which 
serves to reduce the prevalence and density of parasitaemia, occurring 
slowly throughout childhood to reach lowest levels in adult life. 
Anti-toxic immunity, also called anti-disease immunity, is an immune 
response which is effective against the clinical symptoms, targeting 
antigens such as those which induce TNF. The pattern of this anti-toxic 
immunity is such that the prevalence of antibodies increases very rapidly 
reaching its peak by age 5-8 years and remains high throughout life. Anti-
parasite immunity, which controls parasite multiplication and reduces 
parasitaemia, results in a low antibody prevalence in children under 7 
years but increases to a Plateau after age 25-35 years. It appears that the 
data for MSP2 fits with the latter profile i.e. antibody prevalence is low in 
children but increases to a plateau by adulthood, although the precise 
timing and level of response varies between antigens. This pattern has also 
been described for other studies of age-dependent recognition of 
P.falciparum antigens [158, 197, 241]. Indeed, the incidence of severe 
disease and death declines rapidly in young children (peak mortality in The 
Gambia occurs in children aged over 4 years [128]). Therefore, since the 
peak recognition of MSP2 occurs after the age of 4 years and antibodies to 
MSP2 are unlikely to play a role in anti-toxic immunity. 
It has been proposed that the slow immunological response to P.falciparum 
malaria may be associated with the intrinsically poor antigenicity of malaria 
parasites [62]. This does not appear to be the case for MSP2. Analysis of 
the median positive ODs (table 6.4) showed no significant difference with 
age, except for Bi. Thus, although the prevalence of antibodies to MSP2 
is strongly age dependent, the level of antibody does not depend on age. 
The affinity and concentration of antibody in the serum of children 
appeared to be comparable to the antibody of adults (figure 6.2a & b). 
Furthermore, convalescent sera from individuals who were known to have 
been exposed to malaria parasites a limited number of times, in some 
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cases only once, recognised MSP2 with OD values comparable to endemic 
sera. Therefore it can be concluded that MSP2 is naturally highly 
immunogenic. 
A2(T9/96) represents one variant sequence of the most polymorphic region 
of MSP2. The median OD and prevalence of antibodies to this antigen 
were strongly age-dependent, but in comparison to the other antigens, the 
antibody prevalence was lower. However, it is likely that this antibody 
prevalence is an underestimate of the recognition of this region of MSP2 
serogroup A reflecting the high degree of polymorphism in the Ri repeats 
rather than a lack of immunogenicity. 
To conclude, our data indicates that immunity to MSP2 is gradually 
acquired with age, with a prevalence profile that suggests a role in anti-
parasite rather than anti-toxic immunity. This antibody response is, in part, 
strain specific. The data indicate that poor immunogenicity is not the reason 
for the lack of MSP2 antibodies in children. Neither is constitutional 
non responsiveness in small children a prob!em However, several possible 
explanations remain for the relatively low prevalence of antibodies to 
MSP2 in children: 
seropositivity in children may be transient. When the serum samples 
were collected it is possible that a proportion of the children had not been 
infected since the previous transmission season and their immune 
responses to MSP2 had not been boosted, whereas adults have a more 
stable immune response due to the development of immunological 
memory; 
the antibody in some very young childrens' sera may be predominantly 
1gM, which could not be detected in this ELISA; 
immunity may be strain-specific - it may be necessary for an individual to 
be infected with all the isolates circulating in the local population. 
From this data it is not possible to determine whether the increased 
prevalence with age of anti-MSP2 antibodies is associated with 
protective immunity to P.falciparum. The prevalence of antibodies 
appears to correlate, at a population level, with acquired immunity, but this 
may not hold up at an individual level. Therefore, it is important to 
determine whether there is an association between antibody to MSP2 and 
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clinical status of children who are actively acquiring immunity to 
P.falciparum malaria. 
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7. Association of the immune recognition of MSP2 with 
malaria morbidity 
7.1 Introduction 
Individuals who are clinically immune to malaria are characterised by the 
rarity and mildness of clinical symptoms if an attack of malaria should 
occur. Acquired immunity is only partial, as parasites are often found in low 
densities in the peripheral blood of "protected" individuals, and immunity 
wanes once exposure to the parasites ceases [320] : Children suffer the 
most from clinical malaria, with the greatest prevalence of malaria-related 
deaths. Malaria is responsible for approximately 25% of deaths in children 
aged 1-4 years in The Gambia [128]. The first evidence of acquired 
immunity in children is often their ability to carry a relatively high parasite 
burden without suffering severe clinical symptoms [211]. With increasing 
age (and exposure), children and adolescents suffer fewer and less acute 
malarious episodes. By adulthood, the level of infection is subpatent and 
clinical manifestations are rare [2401. The clinical symptoms of Piasmodium 
infection are associated with the erythrocytic stages of the life cycle; 
episodes of fever coincide with the release of merozoites from the infected 
rbc. 
There are several pieces of evidence to suggest that anti-bloodstage 
antibodies play a role in protection against malaria. 
In vitro assays have examined the inhibitory effect of immune monkey 
serum, human serum or mAbs on parasite growth. Cohen et a! [61] 
demonstrated that serum from monkeys immune to P.knowlesi could 
specifically inhibit the cyclical proliferation of the parasite. This protective 
antibody was shown to be associated with lgG and 1gM, but its activity was 
complement independent and could be provided by F(ab')2 fragments [59]. 
The immune serum had little effect on the growth of the intracellular 
parasites but suppressed the cycle following schizogony, suggesting that 
merozoites were the target and antibody inhibited their invasion into rbc. 
After the development of improved methods for parasite culture, the effects 
of immune serum on P.falciparum growth in continuous culture could be 
assessed [45, 54, 105, 223, 258]. Aotus monkeys could be made immune 
to P.falciparum by drug-therapy after the development of high parasitaemia 
[45]. Immunity to P.falciparum could also be induced by injecting the 
animals with parasite suspensions enriched in merozoites emulsified in 
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Freund's complete adjuvant [226]. For example, Reese and Motyl [258] 
found that 0.5-3.5% immune monkey serum in the culture system caused 
29-56% inhibition of parasite growth after 4 days. This was increased to 
75% inhibition by the use of purified 1g. Although the animals were resistant 
to malaria and developed antibodies capable of inhibiting growth in vitro, 
suggesting that such antibodies were protective, it was not assumed that 
this was an absolute correlation [54]. Early passive transfer experiments 
using a primate system demonstrated that, in some instances, serum taken 
from monkeys with chronic infection and injected into those suffering from 
an acute attack could prevent death or at least prolong the course of the 
experimental disease [58]. However, Fandeur et a! [105] showed that the 
presence of inhibitory antibody, measured in vitro, was not correlated with 
the level of functional immunity or with the ability to confer protection upon 
in vivo passive transfer. It is possible that, in such cases, the effector 
function of antibody was dependent upon co-factors such as activated 
mononuclear cells to mediate antibody-dependent cell-mediated 
cytotoxicity (ADCC). 
The role of human immune serum, in resistance to malaria, has also been 
evaluated. Serum or purified Ig from individuals living in endemic areas 
has been tested for inhibitory effects in vitro on the growth of parasites 
originating from the same area or different geographical areas [33, 164, 
360]. The results of these studies indicated that antibodies from some, but 
not all, individuals can inhibit parasite growth in vitro. Therefore, studies of 
immunity to malaria have demonstrated that sera collected from 
experimentally infected animals, or from human living in malaria endemic 
areas, contain factors that inhibit parasite development in vitro. 
The role of antibody in protection against malaria in vivo has previously 
been inferred from the occurrence of neonatal immunity in the offspring of 
immune mothers and the presence of protective antibody in such newborn 
infants' sera. Edozien et a! [92] demonstrated a close correlation between 
levels of gammaglobulin in blood from the umbilical cord and from the 
mother, concluding that increased gammaglobulin in the blood of African 
mothers could be transferred across the placenta to their babies. Passive 
transfer of cord-blood gammaglobulin [92] was shown to dramatically 
decrease P.falciparum parasitaemia in a Nigerian infant. Also, passive 
transfer of gammaglobulin from Nigerian adults demonstrated antiparasitic 
properties with high parasite densities in patients consistently being 
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reduced within 4 days of starting treatment [92]. This confirmed the 
observation of Cohen et a! [63] who administered purified gammaglobulin 
from immune adult Gambians to Gambian children suffering from acute 
attacks of malaria; the treatment had a marked effect on parasitaemia and 
clinical symptoms. This was more recently demonstrated by passive 
transfer of African lgG antibodies to Thai patients [280]. 
The utilisation of hybridoma technology has permitted the description of 
mAbs active against different malarial parasites. In the rodent model, it has 
been possible to examine the in vivo protective capacity of such mAbs 
[114]. Protection was evident with the use of mAbs specific for determinants 
on the merozoite, thus it appears that antibody-mediated protection against 
malaria was acting at the level of the free merozoite, inhibiting invasion of 
the host erythrocytes. In the case of P.falciparum and P.knowlesi, antibody 
activity was measured in vitro and mAbs were shown to block invasion of 
merozoites into rbc [102, 238]. 
Thus, the target antigens of the protective immune response are thought to 
be antigens either on the surface of the merozoite [59, 102, 114, 238] or 
alternatively antigens expressed on the surface of infected erythrocytes 
containing late stage parasites. Antibody against merozoites could promote 
a number of possible anti-parasite effector mechanisms. In vitro studies 
have shown that immune serum or mAbs can prevent invasion of 
merozoites into erythrocytes. This could be mediated either by 
agglutination of free merozoites by immune serum [59, 102], or antibodies 
may bind to the surface and interfere with the parasite ligand-rbc receptor 
[114, 238]. Others suggest a direct interaction of protective antibodies with 
some cellular effectors through a mechanism like antibody-dependent 
cellular cytotoxicity; Cytophilic antibodies may act by stimulating blood 
monocytes through Fc receptors after binding to the parasite target [42, 88, 
105, 195]. 
Several epidemiological studies have examined the relationship between 
anti-malarial immune responses and protection from clinical malaria [158, 
197, 200, 264-266, 269]. The direct, causative relationship between 
antibody level to a specific antigen and malaria morbidity is difficult to 
prove. However, it would be expected that antibody levels would rise with 
age at approximately the same rate as clinical resistance, that these 
antibody levels would remain high throughout adulthood, and that 
antibodies to a particular antigen are directly associated with protection in 
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prospective longitudinal studies. Such studies are used to examine the 
relationship between naturally acquired immune response to malaria 
antigens and subsequent susceptibility to malaria infection and clinical 
disease. The serum samples which have been used in our study have 
previously been used to study the association of antibody recognition of CS 
protein [264], PfMSP1 [266], Pf 1 55/RESA [265] and soluble exoantigens 
[269] with the subsequent susceptibility to malaria infection. Significant 
levels of anti-CS antibodies were found in a minority of Gambian children 
and although the proportion increased gradually with age, no association 
could be demonstrated between the presence of antibody and protection 
from malaria [264]. A study in the same area a few years earlier, also 
indicated that the humoral immune response to the CS protein did not play 
a major role in the development of immunity to clinical malaria, despite 
seropositivity being age-related [197]. However, antibody to blood stages 
was found, in some cases, to be associated with protection from malaria. 
The prevalence and concentration of antibodies to PfMSP1 increased with 
age and it was found that high titres of antibody to the N-terminai conserved 
region and to the C-terminal PfMSP142 were significantly associated with 
resistance to clinical malaria and high parasitaemia. Antibody responses to 
soluble exoantigens have been shown to be strongly age-dependent [158]. 
Apparent associations were seen for antibody to Ag4 [158] and antibody to 
Ag2 [269] and resistance to clinical malaria, however, it was concluded that 
although antibody to these soluble exoantigens did not protect seropositive 
children against fever, these antibodies did seem to be associated with 
resistance to high levels of parasitaemia [269]. 
In The Gambia an association between increasing titres of anti-
Pf155/RESA antibodies and decreasing parasitaemia with age was found, 
but no association could be demonstrated at an individual level between 
the presence of erythrocyte membrane immunofluorescence (EMIF) 
antibodies and protection [200]. Riley et a! [265] confirmed the temporal 
association between the development of clinical immunity and the 
acquisition of EMIF antibodies. In addition, it was shown that the presence 
of antibodies binding to peptides containing B cell epitopes of Pf 1 55/RESA 
was associated with reduced susceptibility to clinical attacks of malaria and 
with resistance to high parasitaemia. Marsh et a! [200] also reported that 
between the ages of 3 and 8 years the development of antibodies to 
parasite-dependent rbc neoantigens (PDN) was rapid and that these 
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antibodies were associated with protection from clinical episodes of 
malaria. Thus in such longitudinal prospective studies it is possible to 
demonstrate significant associations of malaria specific antibodies with 
resistance to clinical malaria. 
There are several factors which suggest that antibodies to MSP2 may have 
a protective role in malaria infections. Antibodies to MSP2 are strongly age-
dependent, reaching peak prevalence in adolescence (chapter 6). The rate 
of acquisition of antibodies is consistent with the development of anti-
parasitic immunity. However, this is not an index of functional malaria 
immunity and does not mean that the increase in antibody prevalence and 
the decrease in malaria morbidity with age are causally related. The 
location of MSP2 on the merozoite surface makes it directly accessible to 
the immune effector mechanisms [298]. mAbs specific for MSP2 
serogroups A and B have been produced which inhibit parasite replication 
in vitro [101, 255] and prevent free merozoites from invading erythrocytes 
[55]. Rabbit anti-serum raised against MSP2 was also shown to inhibit 
merozoite invasion [220]. Furthermore, Saul et a! [284]report protective 
immunisation of mice with invariant peptides of MSP2: octapeptides from 
the conserved regions induced anti-MSP2 antibody which cross-reacted 
with a homologue in the rodent malaria parasite P.chabaudi. Vaccinated 
mice, challenged with an otherwise lethal inoculum of P.chabaudi, showed 
substantial resistance with most mice surviving. Recently, Al-Yaman et a! [2] 
studied the relationship between the humoral response to MSP2 and 
malaria morbidity in Papua New Guinea. The proportion of the population 
with antibodies to MSP2 increased significantly with age. The authors 
observed a negative association between antibody prevalence/ 
concentration and fever episodes and a positive association between a 
decrease in antibody and haemoglobin levels, indicating a possible 
protective role of antibodies against presumptive P.falciparum malaria. 
The aim of the study described in this chapter is to determine whether the 
acquisition of antibodies to MSP2 is associated with increasing resistance 
to malaria infection. The approach used is to examine the association 
between malaria morbidity and the immune recognition of MSP2 in a 
cohort of semi-immune children, in a prospective, longitudinal study. The 
study was designed to determine whether pre-existing antibodies to 
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defined MSP2 epitopes were correlated with the subsequent malaria 
history of the children. 
7.2 Materials and methods 
7.2.1 Study design 
Plasma samples were obtained from a previous study of antimalarial 
immunity [264]. 
In May 1988 (before the malaria transmission season), 355 children aged 
3-8 years from hamlets around the village of Farafenni, were recruited into 
the study and a blood sample collected. The children were examined by a 
physician; the spleen was palpated and any enlargement noted. Blood 
films were examined for malaria parasitaemia and all parasitaemic children 
received a curative dose of chloroquine and Maloprim®. Heparinised blood 
was centrifuged and plasma removed, aliquoted and stored at -40/-20°C. 
During the following six month period each child was visited once a week 
by a field worker who filled in a health questionnaire and recorded the 
child's axillary temperature. If the temperature was 37.5°C or greater, a 
blood film was made and examined for malaria parasites. Infected children 
were treated with chioroquine. The children were re-examined in 
November, at the end of the malaria transmission season, and a finqerprick 
blood sample was obtained and examined for malaria parasites. 
It was possible to allocate each child to one of four groups depending on 
their malaria experience during the preceding 6 months: 
Group 1 - 	 clinical episode of malaria, defined by fever> 37.5°C in the 
presence of P.falciparum parasitaemia ~!5000 asexual stage 
parasites/tl. 
Group 2- 	Indeterminate infection, defined by fever (> 37.5°C) in the 
presence of low parasitaemia (<5000 asexual stage 
parasites/ui). 
Group 3 - 	 Asymptomatic infection, defined as any child in whom an 
episode of fever had not been detected but who had a 
positive 	blood film at the second survey, or who had splenomegaly 
that had not been present in May or that had increased by > 
2cm. 
Group 4- 	no evidence of infection, defined as an individual who 
experienced no clinical episode of malaria, no parasitaemia 
and no splenomegaly. 
Control sera were obtained from European donors, children (n=19) and 
adults (n=12). These individuals had not been exposed to malaria. 
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7.2.2 Recombinant proteins 
The rAgs used for this study represented the Ri repeat region and the R2 
repeat/group specific region of serogroups A and B - A2(T9/96), A3, B2 
(Ku) and B3 (T9/105i). 
7.2.3 Enzyme-linked immunosorbent assay (ELISA): 
lgG antibodies were measured in ELISA as described in materials and 
methods. For screening, all sera were diluted 1/1 000 in blocking buffer and 
tested in duplicate. 
7.2.4 Statistical methods: 
Determination of positivity: 
Positive samples were defined as those giving a specific OD above the 
normal range for control sera. The normal range was taken as the mean + 2 
standard deviations of the OD values obtained for the control sera. 
Logistic regression analysis: 
Logistic regression analysis determines the "relative risk" of a particular 
outcome (in this case susceptibility malaria) in association with a measured 
variable (recognition of MSP2) and tests the difference in the relative risk in 
different groups. The difference is represented by an odds ratio (OR) which 
gives an indication of the strength of the association between the factor 
(antibody response to MSP2) and the susceptibility to malaria. In addition 
possible confounding factors can be included in the analysis to give the 
adjusted OR. If the 95% confidence interval for the adjusted OR includes 1, 
then there is no significant association between the measured variable and 
outcome of infection. 
The outcome variable in logistic regression is binary or dichotomous, in this 
cases responder or non responder. 
Generalised linear model: 
This analysis compares the mean OD of each group, to determine whether 
the magnitude of the response is different between groups. The 
significance of the particular variable (OD) is assessed by fitting two 
models, one including and the other excluding that variable. The test is 
based on the difference of the deviances of the two models. 
Possible confounding variables are included in the GLM and a gamma 




7.3.1. Association of the immune recognition of MSP2 rAgs with malaria 
morbidity: 
Serum samples were collected from 355 children aged 3 - 8 years during 
the dry season when malaria transmission is minimal. Morbidity surveys 
were carried out during the following transmission season and the children 
were allocated into one of four groups defined by their infection status. 
A x2  test for trend showed that the prevalence of MSP2 antibodies was 
strongly age-related (table 7.1), as previously described (chapter 6). 
LA g Age (years) I esi Tor irena 
3-4 5-6 7-8 Total X 2 p 
(n=129) (n=121) (n=105) (n=355)  
A2 25.6 28.1 43.8 31.8 8.42 0.004 
A3 13.2 24.8 43.8 26.2 27.64 <0.001 
B2 11.6 14.9 28.6 17.7 10.90 <0.001 
B3 39.5 53.7 69.5 53.2 120.85 <0.001 
Table 7.1: Prevalence (%) of anti-MSP2 antibodies in semi-immune 
children from The Gambia. 
Serum was collected from 355 children during the dry season (before 
malaria transmission season) and tested for recognition of MSP2 rAgs. The 
children were divided into 3 age groups: 3-4 yrs, 5-6 yrs and 7-8 yrs. A x2 
test for trend was performed on the % responders per age group to 
determine the association of anti-MSP2 antibodies with age. 
To determine whether antibody positivity was an indicator of protection, the 
antibody recognition of MSP2 by asymptomatic individuals (group 3) and 
by individuals who developed clinical malaria (group 1) was compared. 
Since it is not certain that children with no evidence of infection (group 4) 
had in fact been exposed to infected mosquitoes and since the status of 
children with fever and low parasitaemia (group 2) is also unclear as fever 
could be due to a different intercurrent infection, comparisons of immune 
responses and malaria morbidity were made between groups 1 and 3 only. 
Two analyses were used; the first compares the proportion of responders 
and nonresponders to each antigen between individuals with clinical 
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malaria and those with asymptomatic malaria, the second compares the 
mean OD to each antigen for groups 1 and 3. 
Both analyses are multivariate, thus age, sex, ethnic group, bednet status 
and sickle cell carriage can be included, as it is essential to adjust for their 
possible effects. 
The following analyses were performed by D McGuiness, ICAPB, 
Edinburgh University. 
1. Multiple logistic regression: 
The relationship between antibody recognition of rMSP2 and subsequent 
malaria morbidity was modelled by logistic regression to give an odds ratio 
(table 7.2). An adjusted OR was calculated to allow for the possible effect of 









Adjusted OR * 
(95% Cl) 
A2(T9/96) 34 (39.1) 36 (33.3) 0.78 0.97 
(0.43-1.40) (0.50-1.88) 
ns ns 
A3 30 (34.5) 26 (24.1) 0.60 0.89 
(0.32-1.12) (0.43-1.84) 
ns ns 
B2(K1i) 22 (25.3) 11(10.2) 0.34 0.42 
(0.15-0.74) (0.17-1.02) 
p<0.005 ns 
B3(T9/105) 58 (66.7) 49 (45.4) 0.42 0.43 
(0.23-0.75) (0.22-0.84) 
p<0.005 p<0.005 
Table 7.2: 	Multiple logistic regression analysis to determine the 
relationship between recognition of MSP2 and subsequent susceptibility to 
malaria. *An  adjusted OR was calculated to account for any possible effects 
of confounding by age, sex, ethnic group, bednet status and sickle-cell 
carriage. 
The analysis indicates that the presence of antibodies to B3 is significantly 
associated with asymptomatic infection i.e the proportion of responders to 
B3 is higher in asymptomatic malaria cases than in clinical cases. The 
association between malaria morbidity and antibodies to B2 approaches 
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significance; the influence of the confounding variables accounting for the 
association observed with the crude OR. 
No significant association is apparent for the recognition of the serogroup A 
rAgs, A2 and A3. 
2. Generalised linear model: 
For each antigen the mean OD for the asymptomatic group was compared 
with the mean OD for the clinical malaria group by means of a generalised 
linear model. The data is positively skewed (figure 7.1), with many OD 
values being close to zero. Therefore, a standard linear regression of the 
OD values would be inappropriate, as this assumes normal distribution of 
data. Instead the generalised linear model was fitted to the data using a 
gamma distribution to directly model the distribution of the OD values. 
Results from this linear regression assuming a gamma distribution are 
shown in table 7.3, with and without including the possible confounding 
variables. 
mean OD 	8 . dv  a 	est. 3 a 	8AV  b 	est. 3 b 
(s.e) (s.e) 
Asymp. 	Clinical 
n=86 n=107  
A2(T9/96) 0.354 0.286 +1.55 -0.083 +0.002 0.003 
(0.067) (0.070) 
A3 0.292 0.195 +4.98 -0.130 +1.426 -0.066 
(0.058) (0.061) 
B2(K1i) 0.204 0.103 +4.64 -0.111 +0.308 -0.028 
(0.052) (0.054) 
B3(9/105) 0.532 0.348 +7.14 -0.196 +5.21 § -0.156 
(0.074) (0.077) 
Table 7.3: Association of mean OD to rMSP2 with malaria status. Results 
were analysed using linear regression assuming a gamma distribution; 
.dv is the change in deviance when 'group' (i.e either 
asymptomatic/clinical ) is removed from the model; est.b is the estimated 
regression parameter. 
§ indicates d.dv>3.84, which is significant. 
a indicates analysis without allowing for confounding variables; b  indicates 
analysis including confounding variables. 
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Inclusion of the confounding variables in this analysis clearly indicates that 
they are exerting an effect on the outcome of infection. Overall, the results 
are essentially the same as for the multiple logistic regression. No 
significant association of antibody to A2, A3 and B2 with subsequent 
susceptibility to malaria morbidity was observed, whereas the mean OD to 
B3 was significantly higher in individuals who were asymptomatic. 




w 	 * 	06 
8' 86 	
0 
8* 	01 6 	 0 > 







A2 	A3 	B2 	B3 
Figure 7.1: Dot plot of the antibody recognition of MSP2 
rAgs. Serum samples were collected from a cohort of 
semi-immune children in May (pre-transmission) and 
individuals monitored during the malaria transmission 
season and subsequently classified as having clinical 0 
or asymptomatic A infections. 
Horizontal lines represent the cut-off level determined 
from OD values of control sera 
147 
7.4 Discussion 
Antibodies to MSP2 are strongly age-dependent, reaching a peak 
prevalence in adolescence (chapter 6). This rate of acquisition of 
antibodies reflected a pattern of anti-parasitic immunity rather than anti-
disease immunity. However, immunity resulting in decreased parasite 
densities would also lead to less severe symptoms. Many epidemiological 
studies show that antibody prevalence to a particular antigen increases 
with age, but it is unlikely that all of these are involved in protective 
immunity. An increase in antibody with age may be associated with 
protection or may just be a measure of exposure. Therefore, to determine if 
the age-dependent pattern of MSP2 antibody prevalence reflects a role for 
MSP2-specific antibodies in effective protective immunity, the immune 
recognition of MSP2 by a cohort of semi-immune children was studied and 
related to their subsequent susceptibility to malaria infection and disease. 
The antibody recognition of rAgs representing the Ri repeat region (A2 and 
A3) and the R2 repeat/group specific region (A3 and 133) of each serogroup 
was measured during the dry season, before the malaria transmission 
season. These children had already begun to develop immunity to malaria 
and the aim was to relate existing anti-MSP2 antibodies to their 
subsequent infection status. Care must be taken in the interpretation of the 
results as any apparent associations between antibody recognition and 
infection status do not prove a direct, causative relationship but do identify 
areas worthy of further investigation. 
In terms of estimating protective immunity against disease, it is appropriate 
to compare those children who were infected but did not become ill during 
the transmission season (group 3) with those who experienced at least one 
febrile episode associated with Plasmodium infection (group 1). 
Comparison of the proportion of responders in each group using logistic 
regression analysis allowing for confounders, showed a significant 
association between the presence of antibody to B3 and reduced risk of 
clinical symptoms. No such association occurred for the other antigens. A 
second analysis using a general linear model, taking into account the 
skewed nature of the data, showed that the mean OD of 133-specific 
antibodies was higher for individuals with asymptomatic malaria, whereas 
the mean OD to A2, A3 and B2 was not significantly different between the 
two groups. 
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The confounding variables were shown in both analyses to influence the 
outcome of infection, and therefore it is essential that such variables are 
included in analyses of this kind. 
Thus, in both analyses, the recognition of B3 is associated with protection 
from clinical malaria in this cohort of children. However no association was 
found for the other antigens tested. Possible explanations for this are: i) that 
under natural conditions, individuals do not have a focalised immune 
response, i.e. a response directed exclusively to one particular region or 
epitope of an antigen, thus antibody responses to different regions of MSP2 
(and possibly to other antigens) are closely associated preventing the 
demonstration of a protective effect to any one antigen or epitope i.e. MSP2 
may be necessary but not sufficient for protection; ii) antibody to the other 
regions of MSP2 may be associated with protection but that the sequence 
polymorphism precludes the demonstration of this with any one 
representative sequence. 
In this chapter the data suggest that the antibodies to epitopes in the 5' 
repeat/group specific region of MSP2 serogroup B (133) appear to confer 
resistance to clinical malaria. In previous studies of blood stage antigens 
[158, 200, 264, 269], few associations with protection have been found 
therefore, in terms of vaccine development, the results presented here are 
encouraging. However, additional aspects of the immune recognition of 
MSP2 need to be studied. Since the antibody-dependent killing of malaria 
parasites is, at least in part, cell-mediated, an important aspect in studying 
the induction of protective immunity is to assess the lgG subclass of the 
antibodies involved. Such studies are reported in chapter 8. 
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8. lgG subclass specificity of anti-MSP2 antibodies 
8.1 Introduction 
Human IgG subclasses are known to have a variety of biological effector 
functions [306, 361]. They have been designated lgG 1-4 based on their 
relative abundance in normal serum. The structure and function of each 
human lgG subclass protein has been studied extensively [39, 361], and 
they have been shown to differ in their abilities to fix complement and bind 
to cell surface Fc receptors [40]. The four subclasses of murine lgG, listed in 
( 	
order of serum concentration, are IgG2a, IgGi, lgG2b and lgG3 [306]. 
The subclass induceuring an infection can be dependent on the nature of 
the antigen being presented. In humans, IgGi and lgG3 are secreted in 
response to proteins [160], lgG2 is preferentially induced by 
polysaccharides [139] and lgG4 'would be induced after chronic exposure 
to proteins [139]. Since the biological effector functions of different lgG 
subclasses vary greatly, the serum concentrations of antibodies belonging 
to a given subclass may indicate their clinical role in the course of an 
infection. 
The study of lgG subclass responses in parasitic infections is limited; 
however, it is apparent that certain organisms preferentially induce 
antibodies of particular subclasses. These subclasses can be associated 
with effective, protective immune responses or immunopathology. This has 
been shown for human filariasis. Cabrera et a! [44] established a 
correlation between a particular clinical condition of onchocerciasis 
(Sowda) and a predominantly lgG3 antibody response to a low molecular 
weight antigen of Onchocerca volvulus. The lgG3 antibody appears to 
mediated a type Ill hypersensitivity reaction. During infection with 
Wuchereria bancrofti, lgG4 antibody responses are associated with 
asymptomatic microfilaraemia, whereas lgGl and IgG3 antibodies are 
associated with the clinical presentation of chronic pathology and 
elephantiasis [156]. Similarly, lgG4 antibodies are predominant in 
asymptomatic microfilaraemics during infection with Brugia malay! [187] 
whereas increased levels of IgG1-3 and IgE are associated with chronic 
disease. Therefore it appears that IgG4 may act as a blocking antibody, 
preventing the chronic outcome of infection. 
Protozoal infections predominantly induce antibodies that have cytophilic 
and complement fixing properties in mice and humans. Parasite-specific 
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IgGi and IgG3 are the predominant subclasses in visceral Leishmania 
infections [94, 95], and in Chagas' disease patients [287]. In the mouse 
model, lgG2a has been implicated as important in resistance to 
Trypanosoma cruzi infection [249]. 
A predominance of cytophilic antibodies has also been found in murine 
malaria models. White et a! [354] studied the response in mice to P.yoelii 
infection to determine if protective antibody was equally distributed among 
all the isotypes, and if a single isotype was capable of modulating infection. 
The data suggested that anti-malarial antibody of the cytophilic lgG2a 
subclass was predominantly responsible for protection in passive transfer 
experiments. Also, lgG2a mediated protection in P.berghei infected mice 
[1]. 
The role of malaria specific lgG antibody in protection from clinical malaria 
in humans has been described in chapter 7. Several mechanisms of 
parasite clearance were proposed and these could be dependent on the 
induction of the appropriate lgG subclasses. For example, an antibody-
dependent cellular cytotoxicity mechanism requires Cytophilic antibodies to 
stimulate effector cells through cross-linking of Fc receptors after binding to 
the parasite target. In fact, several studies have shown that in vivo 
protection from malaria correlates with an in vitro inhibition of parasite 
growth by immune lgG only in the presence of blood monocytes [183, 
195].Therefore, it is likely that if ancillary cells are required for biological 
function, then the isotype of the relevant antibodies is an important variable. 
Thus, the authors suggested that, in light of the monocyte-dependent effect 
of antibodies functional differences may exist among antibodies of the 
same specificity and this may contribute to the slow development of anti-
malarial immunity. This has been continued in studies which show that 
lgGl and 1g03 antibodies, specific for mature schizonts, predominate in 
individuals protected from clinical malaria, and that lgG2 and 1gM from non-
protected individuals could block the activity of immunoglobulins in immune 
sera [29]. In these studies the antigenic specificity of the antibodies was not 
established, however, it was speculated that the antibodies should 
recognise accessible antigen on the merozoite surface [88]. 
Groux and Gysin [131] proposed opsonisation as an effector mechanism in 
protection against blood stages of malaria parasites. In humans, IgGi and 
lgG3 are the most effective. opsonising subclasses. The results of their 
study suggested a correlation between immune protection, the ability of 
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serum to mediate opsonisation of infected erythrocytes and the 
predominance of IgGi and lgG3 over lgG2 and lgG4 directed against the 
surface of infected erythrocytes. 
The levels of human lgG subclasses to crude or defined malarial antigens 
have been investigated in several studies. The first report measured the 
response in three heavily parasitised P.falciparum patients from The 
Gambia to heat-stable (S) antigens of the red cell stages [357]. All 3 
patients had highest antibody titres in the IgGi subclass. Wahigren et a! 
[20] used a trophozoite/schizont-enriched culture antigen preparation of 
P.falciparum in ELISA studies of lgG subclass responses of infected 
Swedish patients and of African adults living in a malaria endemic region of 
Liberia. It was shown that antibodies occurred in all 4 subclasses with IgGi 
titres being highest. However, higher lgG3 levels were found in most 
Liberian sera than in the European sera. A preliminary study of antibody 
levels to a soluble blood stage antigen in children and adults in Pakistan 
found that in most sera the malaria specific antibody exists as IgGi, 
sometimes to the total exclusion of other subclasses. Malaria-specific lgG3 
antibody was present in about half the group, and lgG2 and lgG4 only 
rarely [48]. Using defined Pf155/RESA peptides in ELISA, Dubois eta! [89] 
found that IgGi and lgG3 subclasses were the most frequent and, when 
present, were coexpressed in almost all serum samples. However, in that 
study, IgGi levels were inversely correlated with protection [89]. In Papua 
New Guinea, Beck et a! [20] found that humoral responses directed against 
RESA were frequent in all lgG subclasses tested (IgGi, lgG2 and lgG3). 
RESA-specific lgG3 responses were shown to be age-dependent and 
cytophilic antibodies were associated with reduced P.falciparum 
prevalence [20]. Most recently, antibodies to a defined region of PfMSP1 
(PfMSP119) were shown to be predominantly IgGi; this study involved 
essentially the same Gambian population as the present MSP2 study, and 
the results are directly comparable [93]. 
Therefore, it is important to determine not only the antigen specificity of anti-
malarial antibodies, but also the isotype of these antibodies to ascertain 
their possible protective role against clinical malaria. 
I have already shown that anti-MSP2 antibodies are present in serum from 
individuals exposed to malaria. In this chapter I aim to determine 1) the lgG 
isotypic distribution of these antibodies in malaria-immune adults; 2) 
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whether the distribution of lgG isotypes changes with age (and might 
therefore be related to the acquisition of protective immunity); and 3) 
whether there is any association between isotype distribution and clinical 
outcome of infection. 
153 
8.2 Materials and methods: 
8.2.1 Serum samples: 
Sera which and been shown to have anti-MSP2 lgG antibodies were 
selected from 1) Brefet adults (chapter 5), 2) Farafenni cross-sectional 
survey (chapter 6), and 3) Farafenni longitudinal survey (chapter 7). 
8.2.2 ELISA: 
lgG subclass ELISAs were carried out as described in chapter 3, section 
3.3.2. Sera were diluted 1:1000, in duplicate, and tested for the presence of 
each of the lgG subclasses using anti-subclass reagents. 
lgG subclass standard curves were included as a positive control; purified 
myeloma proteins were diluted in four-fold dilutions from 1Opg/ml. 
8.2.3 MSP2 recombinant proteins: 
The rAgs used in this chapter were Al, A2(T9/96), A3, Bi, B2(Kli) and 
B3(T9/1 051). 
8.2.4 Statistical analysis: 
Determination of positivity 
Control sera, from individuals with no history of malaria, were tested at the 
same time. The cut-off level for positivity was taken to be greater that the 
mean + 2SD of the control sera OD values for each subclass. 
Kruskal-Wallis one-way analysis of variance 
This is the non-parametric equivalent of the ANOVA test, allowing 
comparisons of the median of a variable to be made between several 
groups. 
Mann-Whitney test: 
This test is the non-parametric equivalent of the Nest and is used to test the 
null hypothesis that the median of a variable is the same in two groups. 
x2  for trend test: 
X
2 tests for trend were performed using Epi Info, and are used to determine 
whether there is a trend in proportions of responders with age. 
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8.3 RESULTS: 
8.3.1 Isotypic distribution of anti-MSP2 antibodies in malaria-immune 
adults: 
The lgG subclass specificity of anti-MSP2 antibodies was determined for 
sera from adults that has been shown to contain MSP2-specific lgG. 
Figures 8.1, 8.2 and table 8.1 show the lgG subclass distribution of 
antibodies specific to each of the rAgs. Although the subclass distribution 
differs slightly for antibodies to the different rAgs, the predominant MSP2-
specific antibody subclass is lgG3. 
77% and 80%, respectively, of Al- and A3-positive sera contained lgG3 
only, whereas 28% and 38% of IgG3 positive A2-specific sera contained 
lgG2 and lgG4 antibodies, respectively. A2 is a fragment of Al, therefore 
one would have expected some lgG4 containing Al-positive sera. 
However, the majority of the A2-positive results were close to the cut-off, 
and gave values below the cut-off for Al-lgG4. Al-positive sera which do 
not contain lgG3 antibodies, are IgGi positive. 
The pattern of recognition is similar for the serogrou'b. proteins, in that 
lgG3 is the predominant subclass. However, 59% and 47% of Bi- and B2-
specific sera were IgGi positive; in the majority of cases this was 
coexpressed with lgG3. Although only a small number of sera were tested 
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rAg Number Antibody subclass 
Number of responders (%) 
IgGi 	IgG2 IgG3 IgG4 
Al 30 6 	1 26 0 
(20) (3) (87) (0) 
A2 25 8 	3 21 11 
(32) (12) (84) (44) 
A3 30 3 	2 30 2 
(10) (7) (100) (7) 
B  29 17 	1 28 3 
(59) (3) (97) (10) 
B2 17 8 	0 16 2 
(47) (0) (94) (12) 
B3 11 4 	2 8 2 
(36) (18) (72) (18) 
Table 8.1: Prevalence of anti-MSP2 IgG subclasses in Gambian adult 
donors 
8.3.2 Age-related distribution of anti-MSP2 lgG subclass antibodies in 
malaria exposed individuals: 
In all age groups, there is a predominance of antibodies which belong to 
the cytophilic and complement-fixing subclasses. 
In the adult sera from the age cross sectional study, the distribution of lgG 
subclasses was essentially similar to that shown for the Brefet adults sera, 
with a predominance of anti-MSP2 IgG3 antibodies. 
Table 8.2 shows how the distribution of MSP2-specific lgG subclass 
antibodies changes with age. There is an apparent decrease in frequency 
of IgG1 expression and an increase in lgG3 expression with increasing 
age. In general the number of lgG2- and lgG4-positive sera are too small 
for any valid conclusions to be drawn about their association with age. 
However, x2 for trend analysis indicates that the increase in lgG3 
expression with is statistically significant for A2-, A3-, 131 -, and 133-specific 
antibodies, and the decrease in prevalence of IgGi antibodies is significant 
for the recognition of A2, Bi and B2. It seems that no trend was apparent for 
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a) 	 b) 
C) 	 U) 
/ 	 F 
the lgG3 recognition of Al and B2 because even in the youngest age group 
a large percentage of individuals expressed anti-MSP2 of this subclass. 
The mean OD for each subclass has been plotted against age (figure 8.3) 
There is no obvious trend for IgGl, lgG2 and lgG4. However, the mean OD 
of lgG3 antibodies clearly increases with age. To determine whether any of 
these observations were statistically significant, data were analysed using 
a non-parametric Kruskal-Wallis test to compare the OD values of each age 
group, for each rAg (table 8.3). With one exception, recognition of B2, the 
level of anti-MSP2 lgG3 antibodies was shown to be age-related. Whereas 
anti-MSP2 lgGl antibodies were shown to be age-related only for rAgs A2, 
Bi and B2. 
Figure 8.2: Photograph showing the distribution of anti-Al lgG subclass 
antibodies in ELISA. 48 samples were tested in duplicate at a dilution of 
1:1000. a) IgGi, b) lgG2, c) lgG3, d) lgG4. 
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LAg ft e Number Antibody subclass 
group Number of responders (%) 
IgGi lgG2 IgG3 IgG4 
Al :510 20 12(60) 3(15) 11 (55) 0(0) 
11-20 25 15 (60) 1 (4) 17 (68) 0 (0) 
21+ 18 7 (39) 0 (0) 13 (72) 0 (0) 
x2  for trend 1.605 3.601 1.244 N/A 
p 0.205 0.058 0.265 
A2 :5 10 14 12 (86) 1 (7) 4 (29) 4 (29) 
11-20 16 11 (67) 2(13) 13(81) 2(13) 
21+ 17 6 (35) 1 (6) 13 (82) 4 (24) 
X2  for trend 8.287 0.027 9.103 0.077 
p 0.004 0.870 0.003 0.781 
A3 :5 10 15 8 (53) 3 (20) 7 (47) 1 (7) 
11-20 18 10 (56) 2 (11) 12 (67) 4 (22) 
21+ 13 6 (46) 1(8) 12 (92) 1(8) 
2  for trend 0.129 0.935 6.603 0.858 
p 0.720 0.334 0.010 0.354 
131 :5 10 14 8 (57) 0 (0) 8 (57) 5 (36) 
11-20 19 5 (26) 1 (5) 15 (79) 3 (16) 
21+ 14 2(14) 1(7) 14(100) 1(7) 
2  for trend 7.513 0.858 7.513 3.612 
p 0.006 0.354 0.006 0.058 
B2 :5 10 13 10 (77) 2 (15) 9 (69) 0 (0) 
11-20 26 11 (42) 0(0) 21 (81) 0(0) 
21+ 14 5(36) 0(0) 12 (86) 0(0) 
2  for trend 4.386 4.158 1.077 N/A 
p 0.036 0.041 0.299 
B3 :5 10 20 14 (70) 0 (0) 12 (60) 0 (0) 
11-20 22 8 (36) 2 (9) 19 (86) 1 (5) 
21+ 21 11 (52) 3 (14) 20 (95) 1 (5) 
2  for trend 1.195 2.803 8.052 0.732 
P 0.274 0.095 0.005 0.392 
Table 8.2: Prevalence (%) of anti-MSP2 lgG subclass antibodies in different 
age groups. x2  for trend values are given. 
160 
rAg Age Number Antibody subclass 
group Median OD 
IgGi IgG2 IgG3 lgG4 
Al 10 20 0.267 0.014 0.378 0.005 
11-20 25 0.403 -0.025 0.771 0.006 
21+ 18 0.308 -0.017 1.068 0.021 
H 0.34 3.13 12.15 1.41 
p 0.842 0.210 0.002 0.494 
A2 10 14 0.357 -0.030 0.134 0.024 
11-20 16 0.329 0.033 0.739 -0.009 
21+ 17 0.145 0.054 1.157 0.011 
H 7.12 4.96 19.13 2.20 
p 0.029 0.084 0.000 0.334 
A3 10 15 0.223 0.044 0.291 0.025 
11-20 18 0.247 0.022 0.434 0.068 
21+ 13 0.192 0.047 1.259 0.004 
H 0.92 0.69 8.13 3.62 
p 0.633 0.710 0.017 0.164 
131. 10 14 0.336 0.003 0.371 0.110 
11-20 19 0.091 0.049 0.529 0.012 
21+ 14 0.071 0.040 0.936 0.028 
H 6.69 0.80 10.77 3.32 
p 0.036 0.671 0.005 0.191 
B2 10 13 0.459 -0.133 0.515 -0.030 
11-20 26 0.159 -0.103 0.665 0.005 
21+ 14 0.191 -0.037 0.977 0.028 
H 7.61 2.88 3.26 9.27 
p 0.023 0.237 0.196 0.010 
B3 15 10 20 0.197 0.013 0.106 -0.009 
11-20 22 0.086 0.009 0.275 0.005 
21+ 21 0.155 0.032 0.936 -0.010 
H 2.16 1.29 20.94 1.61 
p 0.341 0.525 0.000 0.447 
Table 8.3: Median OD of anti-MSP2 lgG subclass antibodies. Kruskal 
Wallis tests were used to determine the association of median OD with age 











































































































































































































































































































































8.3.3 Distribution of anti-MSP2 lgG subclass antibodies in relation to 
subsequent susceptibility to clinical malaria: 
The lgG subclass distributions of MSP2-specific antibodies were 
compared, using Mann Whitney tests, for individuals who had 
asymptomatic malaria infections and those with clinical malaria, for the 
recognition of Al and Bi. No significant differences between the groups 
were evident for the median OD values for each of the antibody subclasses. 
However, on comparing the proportion of responders (table 8.4), two 
significant results occurred. For the recognition of Al, igG3 antibodies were 
associated with asymptomatic infection and for the recognition of Bi, lgGl 
antibodies were associated with a clinical outcome of infection. 
Eft 	igG subclass Number of responders (%) XZ value 
Asymptomatic Clinical 
Al n=25 n=28 
1 24 (86) 19 (76) 0.81 0.367 
2 12 (43) 9 (36) 0.26 0.610 
3 26 (93) 17 (68) 5.33 0.021 
4 3(11) 1(4) 0.85 0.356 
Bi n=19 n=32 
1 25 (78) 19 (100) 4.82 0.028 
2 4(12.5) 2(10.5) 0.04 0.832 
3 24(75) 13(68) 0.26 0.611 
4 1 (3) 0 (0) 0.61 0.436 
Table 8.4: Proportion of responders with lgG subclasses specific for rAgs 
Al and Bi. x 2  tests. were used to determine if there were significant 
differences in the prevalence of Al- and 131 -specific antibodies of each lgG 
subclass between individuals who developed clinical malaria and those 
who had asymptomatic infections. 
These ELISAs were kindly done by Dr E Riley. 
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8.4 Discussion 
It has previously been shown that malaria exposed individuals have MSP2-
specific antibodies and that the prevalence of these antibodies is age-
dependent (chapter 5 & 6). The acquisition of antibodies to MSP2 parallels 
the overall slow development of immunity to malaria. It has been proposed 
that this slow development of immunity also depends on the acquisition of 
the appropriate lgG subclass(es) of antibody [29]. Effective anti-malarial 
immunity may require a predominance of antibodies with particular 
functions [131]. 
In theory, antibodies specific for MSP2 could inhibit merozoite invasion of 
erythrocytes by a number of mechanisms including merozoite 
agglutination, complement-mediated lysis, opsonisation or blocking of 
receptors involved in the adherence of merozoites to erythrocytes. These 
various mechanisms would be mediated by antibodies of different lgG 
subclasses - only IgG1 and lgG3 are opsonising and complement-fixing but 
all four subclasses could mediate agglutination or receptor blocking. Since 
functional differences may exist among antibodies of the same specificity, 
the subclass of MSP2-specific lgG in sera from adults naturally immune to 
malaria has been determined. The antibodies which recognise MSP2 are 
predominantly of the lgG3 subclass. This is surprising in view of the fact that 
this subclass accounts for less than 10% of normal serum lgG [306]. It has 
been suggested that the ratio of lgGl and lgG3 to IgG2 and lgG4 may be 
important in immunity to asexual blood stages of P. falciparum [29, 131] 
since, whilst lgGl and IgG3 can mediate opsonisation and phagocytosis of 
parasitised erythrocytes or free merozoites, lgG2 and lgG4 antibodies (of 
the same epitope specificity) may block the binding of the protective 
subclasses. lgG3 is considered to be the most effective subclass for 
activating the complement pathway [40], and it is known to mediate cell 
lysis by monocytes or Fc receptor bearing lymphocytes, so called antibody-
dependent cell-mediated cytotoxicity (ADCC) [306]. 
The distribution of lgG subclasses was measured in relation to age, to 
determine whether there was a change in the IgG subclass profile with age 
which might explain the changes in susceptibility to clinical malaria with 
age. Overall, lgG3 was the predominant subclass in adolescents and adults 
but IgG1 was more common in children under the age of 10 years. Both the 
prevalence and median OD of lgG3 antibodies increased with age and 
there was a corresponding decrease in the prevalence of lgGl antibodies. 
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The shift in IgG subclass distribution with age, and the predominance of the 
lgG3 response in adults - who tend to have a higher degree of protective 
immunity to malaria - suggested that lgG3 antibodies to MSP2 may be able 
to mediate protective immune effector mechanisms. Therefore, the lgG 
subclass of anti-MSP2 antibodies (in a cohort of Gambian children) was 
compared with their subsequent susceptibility to clinical malaria infection. 
Two significant differences were detected between individuals who 
subsequently developed asymptomatic malaria and those with clinical 
malaria; these were a higher prevalence of Al-specific IgGi in individuals 
with clinical malaria, and of 131-specific lgG3 in individuals with 
asymptomatic malaria. Although the result is not consistent between the 
two antigens tested, it does indicate that lgG subclass differences occur 
and may influence the outcome of infection. 
The predominance of the lgG3 response to MSP2 is unusual and is 
noticeably different from the response to MSP1[93]. The only other 
examples, of which we are aware, of an antibody response which is 
significantly skewed towards lgG3, are the responses to the streptolysin M 
protein where lgG3 predominated in the response of more than half the 
individuals tested [104], and the response to the outer membrane protein of 
Branhamella cattarhalis where lgG3 antibodies represent approximately 
70% of the total response in children over 4 years old [119]. Interestingly, in 
the case of B.cattarhalis, the switch to lgG3 production was age related, 
specific lgG3 being essentially absent in children under 4 years of age. The 
reason for the absence of lgG3 during the first few years of life and the 
subsequent "switch" to significant levels of lgG3 synthesis is unclear since 
synthesis of lgG3 is already approaching adult levels by the age of 2 years 
[192]. 
IgGi and lgG3 are typically produced in response to protein antigens [160] 
with IgGi present in significantly greater amounts than lgG3 but, as yet, 
little is known about the factors which may preferentially induce the 
production of lgG3. Ig class switching is the process whereby B cells that 
initially express either 1gM and/or lgD switch, on immunisation, to the 
expression of IgE, lgA or one of the 4 lgG subclasses [301]. In the mouse, 
specific switch factors have been described for different lgG subclasses. In 
particular, T cells can play a pivotal role in regulating the Ig isotype switch 
by their ability to secrete cytokines such as, IL-4, IFN-g and TGF-13 [76, 111, 
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244, 251, 275, 300, 302, 303, 312, 319]. For example, IL-4 released by Th2 
cells upon activation is known to induce B cell proliferation in resting B 
cells, to enhance MHC class-11 expression on B cells, and to mediate the Ig 
class switch to IgGi and IgE [104, 244]. Current evidence suggests that 
cytokines act as switch factors by selectively inducing transcriptional 
activation of the constant heavy chain (CH) genes that encode the Ig class 
that is subsequently expressed [303]. CH gene activation is believed to 
make the DNA accessible to a switch recombinase [311]. However, 
cytokines are probably insufficient in themselves to effect class switching 
but must act in concert with a B cell activator such as bacterial 
lipopolysaccharide (LIPS) [303, 311], an antigen receptor [31, 275], an 
activated T cell or another cytokine [251]. 
Much less is known about the trigger factors for specific class switching in 
humans, however, cytokines are presumed to play a critical role. Isotype 
switching to both lgGl and lgG3 appears to be controlled by similar 
processes which may be regulated by the T-cell derived cytokine IL-1 0 [31]. 
Falconer et al proposed that the preferential induction of lgG3 may be a 
result of the mode of antigen presentation which could have consequences 
for the quality of the T-cell response to the antigen i.e. in the nature and 
amounts of the cytokines produced, which in turn could influence lgG 
subclass production [104]. Similarly, Goldblatt et al suggested that the 
membrane bound nature of B.cattarhalis proteins, and their mitogenic 
activity for B cells, may be partly responsible for the lgG3 antibody 
response [119]. The fact that MSP2 is a membrane bound protein, and 
contains tandemly repeated amino acid sequences which are believed to 
activate B cells independently of T cells [285] may therefore account for its 
propensity for induction of lgG3. Antigens such as MSP2 are a useful tools 
for investigating subclass specific switch mechanisms in human B cells. 
Thus it has been shown that in individuals who are likely to be immune to 
malaria i.e. adults from a malaria endemic area, the predominant anti-
MSP2 subclass is lgG3, the prevalence of which tends to increase with 
age. Furthermore, lgG subclass responses may differ between individuals 
who develop clinical malaria and those who have asymptomatic infections. 
It is obviously important to determine if the subclass of anti-MSP2 
antibodies correlates with an inhibitory effect, in vitro, on P.falciparum 
growth and whether this is dependent on the presence of blood monocytes. 
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9. Antigenic polymorphism of MSP2 and immune 
recognition 
9.1 Introduction 
The existence of diversity among Plasmodium strains has been evident for 
many years. Early observations on malaria infections therapeutically 
induced in neurosyphilitic patients showed that individuals convalescing 
from P.vivax infections acquire a potent immunity to the strain of parasite 
that caused the infection but not to a heterologous strain [30]. Jeffery [163] 
also demonstrated that individuals were significantly more protected after 
reinoculation with a homologous strain of parasite, but that reinoculation 
with a heterologous strain gave variable results ranging from no apparent 
effect to a fairly substantial modification. 
Antigenic differences among malaria parasites in humans were first 
demonstrated in studies of soluble antigens detected in the serum of 
infected individuals or extracts of infected placental blood [358]. Further 
characterisation of malaria antigens has revealed extensive heterogeneity 
of malaria antigens (reviewed in [7, 9, 10, 177]), including soluble parasite 
antigens [24, 154, 281, 359], surface antigens - CSP [77, 79, 96], MSP1 
and MSP2 [55, 108, 201-203, 205, 217, 219, 221, 250, 298, 299, 304, 315, 
321]- and infected erythrocyte surface components [71, 72, 106, 157, 199]. 
The diversity of Plasmodium in the natural parasite population has been 
clearly demonstrated. Many patients are infected with mixtures of 
genetically distinct parasite clones which differ in characters such as 
antigens, response to drugs, and other biochemical markers [11-13, 74]. 
For example, Creasey et a! [74] found that extensive polymorphism in 20 
genetic markers occurs in isolates from Thailand, Zimbabwe and Brazil, 
and multiple infections with >1 parasite phenotype were common. Babiker 
et a! [12] characterised 29 isolates from Sudan, for variation in 18 different 
genetically controlled characters, each of the patients contained parasites 
of different genotypes. 
The extent of diversity in Plasmodium is thought to contribute to the slow 
development of immunity, such that immunity only develops after repeated 
infections over a number of years and exposure to the repertoire of 
circulating genotypes is necessary for protection; this assumes that different 
sequences are antigenically distinct with little or no cross-reactivity. 
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However, Baird et a! [14-16, 250, 257] contest this idea, proposing that a 
protective immune response to endemic malaria is governed by relatively 
brief heavy exposure plus some intrinsic immune factors associated with 
the age of the host. If this were true, antigenic polymorphism may only 
briefly govern susceptibility. 
In general, antigenic diversity is generated in two ways [8]: 
antigenic variation, whereby a clonal population of parasites periodically 
changes its antigenic profile. Antigenic variation has been shown to be a 
feature of antigens expressed on the surface of infected red blood cells [25, 
35, 273]. 
antigenic polymorphism which occurs in allelic genes giving rise to the 
expression of structurally and antigenically distinct forms of a particular 
protein in different strains of parasite. 
Diversity among the antigens of asexual blood stages predominantly 
occurs through antigenic polymorphism. Further diversity is generated 
through recombination, reassortment and mutation of these genes during 
meiosis [182, 347]. As a result, there is the potential for a very large number 
of different genotypes within one species. Many of the polymorphic asexual 
stage antigens have been shown to contain regions of tandem repeats and 
polymorphic residues tend to be more common in repetitive regions rather 
than in non-repetitive regions e.g. S-Ags, MSP1 and MSP2. However, not 
all repetitive sequences are polymorphic. CS protein and RESA have 
sequence repeats which are conserved within the species, and SPAM 
(secreted polymorphic antigen associated with merozoites) has repeat 
sequences which clearly encodes a structural motif, with the alanine 
residues being highly conserved in positions 1 and 4 of the heptad repeats 
[8]. The overall picture is one of great tolerance by the parasite for diverse 
repetitive structures of different amino acid sequences and sizes in a wide 
range of proteins. 
Repeat sequences may reflect some adaptation of the parasite to its host. 
Schofield [285] proposed that repetitiveness causes T-cell-independent B 
cell activation by cross-linking hapten-specific surface 1g. Schofield 
undertook an investigation into the regulation of the antibody response to 
the repetitive domain of the CS protein on intact sporozoites, and observed 
that the parasite induced a thymus-independent B-cell response to the 
repeats [285]. This is beneficial to the parasite since lack of T cell help 
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leads to poor immunological memory and inefficient class switching to 
protective isotypes. It is a common belief that repeats also provide the 
parasite with a mechanism for immune evasion. Epitopes with repeats may 
be immunodominant, but antibody responses to them may have no serious 
effects on parasite survival. Furthermore, the repeats present the immune 
system with an extensive network of cross-reactive epitopes which promote 
polyclonal B and I cell activation and prevent affinity maturation of the 
response to protective epitopes [7, 177, 179]. 
It has been proposed that some repetitive sequences may have evolved as 
efficient ligands, specialised to mediate interactions of the parasite with 
host components [179]. The binding units are repeated because this allows 
multimeric high-avidity interactions between parasite and receptor [285]. 
However, the proposal that repeats are immunodominant does not 
reconcile with this concept of ligand-receptor interactions since ligand-
receptor interactions are likely to be highly sensitive to the presence of 
blocking antibodies and it is thus likely that such epitopes would be 
concealed from the immune system in some way. In addition, radically 
different repeat sequences occur in the same region of allelic variants of a 
protein which presumably have the same function. It may be that the 
repeats in some gene products may have no function other than immune 
evasion, whereas other repetitive genes may retain critical functions. 
Polymorphism in the repeats may therefore be a marker for 
immunologically irrelevant sequences; conserved repeats on the other 
hand may be functional. 
Diversity in MSP2 has been demonstrated in many studies both at the 
protein level using mAbs [12, 55, 69, 74, 109, 299], and at the genetic level 
by hybridisation analysis [201, 219, 298] and RFLP techniques [108, 217, 
250]. Several alleles of MSP2 have been sequenced from different 
isolates/clones, revealing extensive polymorphism [109, 201, 202, 250, 
298, 299, 321]. The molecule has been classified into two allelic prototypes 
- serogroup A or CAMP allelic family and serogroup B or FC27 allelic family 
- defined by regions of nonvariable, group-specific sequence. Within each 
group a number of variants have been described and these are 
characterised by tandem repeats which vary in number, length and 
sequence. Further diversity is created by intragenic recombination ([203, 
231]; unpublished data); with crossover appearing to occur within the 
repetitive variable regions. 
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Polymorphism is most extensive among the serogroup A alleles; the Ri 
repeat region is glycine-, serine- and alanine-rich with repetitive sequences 
of 4-8 amino acids occurring up to 13 times [201] (see chapter 1, figure 1.3 
& figure 9.1). Although the repeats can vary dramatically from isolate to 
isolate, some underlying patterns can be seen [298]. Indeed, Fenton et a! 
[109] suggested that the repeat sequence of serogroup A could be derived 
from some common ancestor. Point mutations may have arisen in this 
postulated ancestral gene and these mutations accumulate until a new 
repeat spreads through the sequence [109]. Although there is a 
considerable microheterogeneity in MSP2 [201, 250] there must be some 
constraints which limit the diversity as the same repeat sequences occur in 
isolates from different geographical areas and there is a striking 
conservation of the overall amino acid composition, net charge and 
hydrophobicity of the molecule [299]. In addition the permisiveness for 
variation in size of MSP2 is much less than for S-antigens; changes in 
repeat number are often compensated for by deletions or insertions 
elsewhere in the non-variable region [109, 299, 321]. 
The repeat sequences of MSP2 have been shown to be immunogenic - 
mAbs and naturally acquired antibodies recognise this region ([2, 55, 101, 
299, 321]; Chapters 5 & 6). However, the repeats are not necessarily 
immunodominant, unlike the repeats of the S-antigens which can encode 
upto 90% of the molecule and against which the entire antibody response 
is directed [7]. Al-Yaman et a! [2] compared the recognition of a 
recombinant antigen representing the full length molecule of 31D7 
(serogroup A) and a recombinant antigen of 31D7 which lacked the Ri 
repeats (d3D7). The majority of individuals were seropositive for both of the 
constructs%owever, there was a small proportion of individuals among all 
age groups who responded only to the variable region. Monoclonal 
antibodies are known to recognise group-specific sequences as well as 
repetitive sequences [109]. 
The function of MSP2 repeats remains to be elucidated. One could propose 
that MSP2 may be involved in merozoite invasion of the erythrocyte due to 
its location on the merozoite surface and the ability of MSP2 specific mAbs 
to inhibit parasite growth in vitro [55, 220, 283]. However, the repeat region 
of the molecule may not be essential for parasite survival as isolates have 
been found which lack some of the repetitive sequences [250, 257, 321]. 
For example, Thomas et a! [321] reported the absence of tandemly 
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repeated sequences within the GSA-rich region of CAMP isolate. The 
authors suggest that this may occur as a result of continual in vitro 
cultivati orvflowever, others have reported wild isolates which lack the 12- 
mer repeats of serogroup B [250, 257]. 
In this chapter the aim was to determine whether sequence diversity within 
MSP2 serogroup A results in antigenic diversity. A significant association 
between the recognition of four variant sequences of serogroup A by 
malaria immune adults was observed (chapter 6). In this chapter I will 
investigate whether this association is due to cumulative exposure or cross-
reactivity by looking at the recognition by a number of immune sera of a 
panel of A2 rAgs representing the Ri repeats (plus short group-specific 
regions flanking the repetitive sequences) of MSP2 serogroup A. Nine rAgs 
were produced from 8 different isolates. Two of these rAgs were shown to 
have deletions in the expected sequence - A2(CH12/12) lacks 8 amino 
acids in the C-terminal group specific region and A2 (T9/94ii) lacks the N-
terminal sequence (figure 9.1). 
Sera from mice immunised with single constructs were tested in ELISA for 
the recognition of the panel of A2 variants. Also, sera from individuals with 
limited exposure to P.falciparum and from children and adults from a 
malaria endemic area were tested for their seroreactivity with this panel of 
rAgs. 
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9.2 Materials and methods 
9.2.1 Serum samples 
MSP2-specific mouse serum: 
Mice were immunised with A2(T9/94i), A2(TTn), A2(7G8), A2(R033) or 
A2(T9/96) as described in chapter 4. The sera produced were tested in 
ELISA for recognition of the panel of A2 rAgs. 
Naive sera: 
Sera was obtained from individuals from non-endemic areas who had 
been infected with P.falciparum whilst visiting malaria endemic countries; 
details are provided in chapter 6. 
Malaria-exposed sera: 
Sera was obtained from individuals aged 1-75 years living in rural villages 
around the town of Farafenni on the north bank of the Gambia river (as 
described in chapter 6). 
9.2.2 Recombinant proteins: 
The recombinant antigens used in this study represent the Ri repeat region 
of MSP2 serogroup A from eight different isolates (figure 9.1). Nine 
constructs were produced; two of the proteins have deletions in the group 
specific sequences flanking the repeat region A2(T9/94 ii) and 
A2(CH1 2/12). 
9.2.3 Enzyme-linked immunosorbent assay: 
MSP2-specific antibodies were detected in the mouse serum and human 
serum using HRP-conjugated anti-mouse Ig or HRP-conjugated anti-
human lgG antibodies, respectively. 
Human serum was diluted 1:1000 or serial two-fold dilutions from 1:250. 
Mouse sera were titrated with serial ten-fold dilutions from 1:500. 
9.2.4 Statistical methods: 
L Kruskal-Wallis one way analysis of variance: 
This non-parametric one way analysis of variance was performed using 
MINITAB statistical software in order to determine the differences in 
seroreactivity with age. 
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Figure 9.1: Schematic representation of A2 recombinant proteins of MSP2 derived from different isolates. 
A2 Predominant repeat sequence Country of isolation 
GAVAGSGA Thailand 
T9196 
Thai Tn GSAGRAGA 
Thailand 
Gi The Gambia 
7G8 GSAGGS Brazil 
T91102 GSAGGS Thailand 
CH12/12 GSAGGS/A Thailand 
R033 GSAG Ghana 
T9194(i) GSAG Thailand 
T9194 (ii) GASG Thailand 
KEY 	
conserved 	 Ri repeats Ea serogroup A specific 
9.3 Results 
9.3.1 Recognition of serogroup A Ri repeats by anti-A2 antibodies induced 
in mice: 
Mice were immunised with a selection of A2 rAgs (as described in chapter 
4) and their serum was tested for the recognition of the panel of A2 rAgs in 
ELISA. In each case, the anti-serum produced recognised all the rAgs. 
Thus, after immunisation with a particular A2 rAg, the antibodies induced 
recognised epitopes which were cross-reactive between variants. 
In the majority of cases, the titration curves were overlapping indicating that 
the antibodies produced had the same affinity for all the constructs (figure 
9.2a). In some cases, the affinity of the antibodies varied, with the 
recognition of A2(T9/94i1) being the poorest (figure 9.2b). 
It appears that mice immunised with one particular sequence produced 
antibodies which cross-react with the panel of A2 rAgs which have varying 
sequences. The group-specific sequences are not essential for this cross-
reactivity since the constructs which lack these regions (A2(CH12112) and 
A2 (T9/94ii)) are also recognised. Although in some cases, A2(T9/94ii) is 
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Figure 9.2: Recognition of A2 proteins by sera from mice 
immunised with (a) A2(T9196) and (b) A2 (R033). Sera 
were titrated with ten-fold dilutions from 1:500. 	176 
9.3.2 Recognition of A2 rAgs after limited exposure to malaria: 
Sera from individuals known to have had only one malaria infection or a 
limited number of infections, were tested in ELISA for recognition of A2 
rAgs in ELISA (table 9.1). 
Sera collected at the time of infection were all seronegative, with the 
exception of donor 92:33. This individual recognised one rAg, A2 (T9196). 
These antibodies appear to be of low affinity and concentration, indicated 
by the low OD value, and this may limit the ability of the antibodies to cross-
react with other sequences. 
In four out of five individuals, convalescent sera were seropositive for this 
region. Two of these individuals recognised only one rAg - donor 93:28CS 
recognised A2 (19/102) with an OD value very close to the cut-off level, and 
donor 92:21 CS was seropositive for A2(T9/94ii). Donor 92:12 had 
antibodies which recognised A2(T9/94i) and A2(T9/96). There is no 
sequence similarity between T9/96 and T9/94 suggesting that this 
individual was exposed to a mixed genotype infection or two separate 
infections. 
Sera from donor 92:38 recognised eight of the rAgs, being seronegative for 
A2(CH12/12). This construct is known to have a deletion in the group-
specific sequence at the C-terminus. Therefore, it appears that in this case 
antibodies are directed to an epitope in the group-specific region rather 
than the repetitive sequences. 
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MSP2 recombinant proteins 
Isolate 	T9194ii 	T9/94i 	T9/102 	7G8 	CH12112 	R033 	Tin 	T9/96 
	
Sequence GSAG 	GSAG GSAGGS GSAGGS GSAGGS/A GSAG GSAGRAGA GAGSGA 
GAVASA GAVASA GAVAGSGA 
Donor Status 
92:21 N 	 - 	- 	- 	- 	- 	- 	- 	- 
Cs - + - - - - - - 
92:35 N 	 - 	- 	- 	- 	- 	- 	- 	- 
92:51 N - - - - - - - - 
93:01 N 	 - 	- 	- 	- 	- 	- 	- 	- 
93:28 N - - - - - - - - 
Cs 	- 	- 	- 	- 	- 	- 	- 	+ 
92:11 >2 - - - - - - - - 
92:30 >2 	 - 	- 	- 	- 	- 	- 	- 	- 
92:33 >2 - - - - - - - + 
92:41 >2 	 - 	- 	- 	- 	- 	- 	- 	- 
93:33 >2 - - - - - - - - 
92:10 CS 	- 	- 	- 	- 	- 	- 	- 	- 
92:12 CS - ++ - - - - - ++ 
92:38 CS 	+++ 	+++ 	+++ 	+++ 	- 	+++ 	+++ 	+++ 
Table 9.1: Summary of results for antibody recognition of MSP2 recombinant A2 proteins by sera from individuals from non 
endemic countries. N indicates one infection; >2 indicates more than two infections; CS indicates convalescent serum. 
--1) 	 - indicates an OD value less than the mean + 2SD of the control sera; + indicates an OD value greater than the mean + 2SD 
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of the control sera; ++ indicates an OD value greater than the mean + 4SD of the control sera; +++ indicates an OD value 
greater than the mean + 6SD of the control sera. 
9.3.3 Recognition of serogroup A Ri repeats by malaria-exposed children 
and adults: 
Forty-four individuals, aged 1-75 years, were tested for recognition of A2 
rAgs. The individuals selected had previously been tested for recognition of 
A2(T9/96) in ELISA (chapter 6) and seroreactivity ranged from low 
responders to high responders. The association in recognition of these A2 
sequences was determined using a non-parametric Spearman's rank 
correlation test (table 9.2). In all cases, the recognition of the A2 rAgs was 
significantly associated. 
ISOLATE T9/94ii T9/94i T9/102 7G8 CH12/12 R033 Gi TIN 
T9/94ii 1.000  
T9/94i 0.725 1.000  
T9/102 0.639 0.907 1.000  
7G8 0.720 0.926 0.971 1.000  
CH12/12 0.311 0.644 0.644 0.616 1.000  
R033 0.624 0.607 0.617 0.631 0.630 1.000  
Gi 0.352 0.595 0.677 0.634 1 0.794 0.767 1.000  
TIN 0.407 10.582 0.647 0.604 0.774 0.781 0.970 1.000 
T9/96 0.395 10.340 10.402 0.434 10.318 0.662 1 0.597 0.535 
Table 9.2: Spearman's rank correlation analysis of the recognition of MSP2 
serogroup A Ri repeat regions from different isolates. 
Forty-four individuals, aged 1-75 years, were tested for the recognition of 
this region in ELISA using recombinant proteins. 
Critical Spearman's rank correlation value = 0.251, p=0.05. 
The recognition of certain rAgs was very strongly associated and this 
appeared to reflect sequence similarities. A2(TTn) and A2(G1) are known 
to be identical in sequence and a correlation value of 0.970 (p<0.005) was 
obtained; this also confirms the robustness and reliability of the assay. 
A2(7G8) and A2(T9/102) have the same sequence repeated 5 and 3 times, 
respectively; the recognition of these rAgs was strongly associated 
(rs=0.971, pcz0.005). Strong associations were also shown between 
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Figure 9.3: Number of variants of MSP2 A2 proteins 
recognised by sera (n=44) from children and adults from The 
Gambia. Recognition of nine rAgs was tested for each 
individual. 
The number of variants recognised by each individual was determined and 
related to age (figure 9.3). The number of variants recognised was shown 
to be age dependent. Despite this, some older individuals (e.g. donor 1617, 
47 years old) only recognised 3 variants, and some children recognised the 
majority of A2 rAgs. 
Nine of the 44 individuals apparently recognised group-specific sequences 
rather than the tandem repeats since seropositivity was dependent on 
sequences which are absent in either A2(T9/94ii) or A2 (CH12/12) (table 
9.3). A further three individuals , who were seropositive for all the rAgs, had 
the lowest titres for either A2(T9/94ii) or A2 (CH12/12), indicating that 
recognition may be partly dependent on these group-specific sequences, 
for example epitopes overlapped with the group specific sequences. This 
data makes it clear that humans see antigens individually and do not 
preferentially recognise the short group specific regions, i.e. humans do 
develop sequence-specific immune responses. 
For certain individuals it is apparent that the rAgs recognised have 
sequence similarities in the repeats (table 9.3). For example, donor 1574 is 
seropositive for rAgs from the isolates T9/96, Gi, TTn and R033, which all 
contain the sequence GAVASA. 
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Donor T9/941111 T9/94i T9/102 	7G8 
1574 0.004 0.217 -0.006 -0.020 
1649 0.034 0.161 0.103 0.143 
1610 0.749 1.342 1.122 1.158 
1568 1.102 1.193 1.106 0.969 
1528 0.203 0.924 0.823 0.645 
MSP2 A2 rA 
CH12/12 R033 Gi ThaiTn T9196 
-0.011 0.607 0.832 0.731 1.028 
0.157 0.634 0.528 0.474 0.740 
0.084 0.063 0.093 0.024 1.043 
0.194 1.204 1.185 1.051 1.492 
0.618 0.722 0.659 0.374 0.722 
Table 9.3: Examples of recognition of MSP2 A2 rAgs by individuals from The Gambia. Underlined OD 
values are greater than the mean + 2SD of the control sera. 
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9.3.4 Cross-reactive antibodies 
To investigate the hypothesis that antibodies to closely related sequences 
are cross-reactive, competition ELISAs were performed. Sera were 
preincubated with increasing concentrations of rAg and tested for 
recognition of the other rAgs. 
Donor 1535 (aged 5 years): This individual recognised all the A2 rAgs 
with approximately the same affinity, except A2(CH12/12) (which lacks the 
C terminal group specific region) (figure 9.4a). Therefore, it was 
hypothesised that this serum recognised an epitope in the C terminal group 
specific region. The serum was preincubated with A2(T9/94ii), A2(TTn), 
A2(7G8) or A2(T9/96) and tested against the A2 antigen panel. Recognition 
of all antigens was inhibited (example for incubation with A2(TTn) is shown 
in figure 9.4b) confirming our hypothesis. 
Donor 1638 (aged 12 years): This serum recognised all the A2 rAgs, 
except A2 (T9/94ii), but the affinity of the reaction varies from antigen to 
antigen. When the serum was preincubated with A2(T9/94i), A2(T9/94ii), 
A2(CH12/12), A2(TTn) or A2(T9/96) antigen recognition was inhibited, but 
the degree of inhibition varied (figure 9.5). 
The titration curves (figure 9.5a) and inhibition ELISAs indicate that there 
may be two populations of antibodies with different specificities, but both 
are dependent on the presence of the N-terminal group specific 
sequences. One group of antibodies appears to recognise T9/102, 7G8 
and CH12/12, and the other group recognises R033, ThaiTn, T9/94i and 
T9/96. In fact, competition assays indicate that the two groups of antibodies 
recognise sequences in A2(7G8), A2(T9/102), A2(T9/94i) and A2(CH12/12) 
or sequences present in A2(T9/96) and A2(RO33). An example is shown in 
figure 9.5b. A2(TTn) inhibits the recognition of all the rAgs to some extent; 
this may be due to the partial homology of the repeat sequence GRAG and 
GSAG, the latter is present in A2(7G8), A2(T9/102), A2(T9/94i) and 
A2(CH12/12), and to the sequence GAVASA which is present in A2(T9196) 
and A2(R033). 
Donor 1610 (aged 27 years): This individual was shown to recognise 5 
of the A2 proteins (figure 9.6a). In the inhibition ELISAs, preincubation with 
either A2(T9/94i), A2(T9/94ii), A2(7G8) or A2(T9/102) inhibited the 
recognition of the other rAgs, whereas preincubation with A2(T9196) 
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inhibited the recognition of A2(T9/94ii) only (table 9.4, figure 9.6b). The 
common sequence in A2(T9/94i), A2(T9/94ii), A2(7G8) and A2(T9/102) is 
'N GSAGhowever, this occurs once in A2(CH12112) but this construct is not 
recognised. There is no obvious explanation, in terms of sequence 
similarities, for the inhibition of recognition of A2(T9/96). 
Antigen on plate 
Antigen in T9/94i T9/94ii T9/102 7G8 T9/96 
serum 
T9/94i + + +1- +1- + 
T9/94ii +1- + +1- +1- + 
7G8 + + + +1- 
T9/1 02 +1- + + + +1- 
T9/96 - + - - + 
Table 9.4: Inhibition of recognition of A2 rAgs in ELISA, by donor 1610, 
after preincubation with either A2(T9/94i), A2(T9/94ii), A2(7G8), A2(T9/102) 
or A2(T9/96) in increasing concentrations from 0-5 .tg/ml. - indicates no 
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Figure 9.4: Recognition of A2 proteins by donor 1535, aged 5 
years. 
Titration curves showing the recognition of A2 rAgs. Sera was 
titrated by four-fold dilutions from 1:400; 
Example of inhibition ELISA curves, after preincubation of sera 
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Figure 9.5: Recognition of A2 proteins by donor 1638, aged 12 
years. 
Titration curves showing the recognition of A2 rAgs. Sera was 
titrated by four-fold dilutions from 1:400; 
Example of inhibition ELISA curves, after preincubation of 
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Figure 9.6 Recognition of A2 proteins by donor 1610, aged 27 
years. 
Titration curves showing the recognition of A2 rAgs. Sera 
was titrated by four-fold dilutions from 1:400; 
Example of inhibition ELISA curves, after preincubation of 
sera with increasing concentrations of A2(T9/96) from 0-5 
p.gImI. 	 187 
9.4 Discussion 
In chapter 5 we observed that the recognition of 4 different A2 proteins was 
significantly associated within individuals, but were not able to tell whether 
this was due to the presence of multiple, non overlapping, antibody 
specificities or to the presence of a single, cross-reactive antibody. Here, I 
have studied the recognition of MSP2 serogroup A2 rAg repeat sequences 
from different isolates to determine whether amino acid sequence 
polymorphism reflected antigenic polymorphism and whether associations 
in recognition are a reflection of cumulative exposure or cross-reactive 
epitopes. Although the isolates present in The Gambia and the other areas 
of Africa where these individuals were infected, may not be fully 
represented in our panel of rAgs, these rAgs do represent a worldwide 
distribution of isolates (figure 9.1). 
Anti-sera from mice immunised with the rAgs were tested in ELISA against 
the panel of A2 rAgs. In all cases, sera from mice immunised with any one 
of the rAgs, recognised all of the other A2 rAgs, irrespective of sequence. 
This indicates that these sequences have the potential to encode cross-
reactive epitopes and that such epitopes may be immunodominant in mice. 
However, we also determined the reactivity of malaria immune human sera 
and observed considerable diversity in antigen recognition after natural 
malaria infections. 
The overall associations in recognition were confirmed (reported in chapter 
5) and the strongest correlations were shown to be between rAgs with the 
most sequence homology. In other words, the degree of cross-reactivity 
could, in some cases, be related to the degree of sequence similarity. 
However, it is difficult to clearly differentiate the effects of cumulative 
exposure and possible variant-specific immune recognition just by looking 
at statistical corrrelations. The data indicate that sera from individuals with 
infrequent malaria-exposure (i.e. individuals from non-endemic areas and 
children from endemic areas) recognise fewer variants than do individuals 
with life long malaria exposure. The data from semi-immunes confirm that 
MSP2 A2 sequences are recognised in a sequence specific manner; data 
from the adults confirm that the number of variants recognised is cumulative 
and related to the diversity of parasite exposure. Although immune 
recognition of MSP2 A2 repeats is strain specific, some cross-reactive 
antibodies are present. Several individuals were shown to recognise 
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several A2 proteins. For one of these individuals, preincubation of the 
serum with A2 proteins was shown to inhibit the recognition of the other 
rAgs in ELISA, indicating that these antibodies were recognising cross-
reactive epitope(s). A proportion of individuals were shown to have 
antibodies specific for epitopes in the group specific regions flanking the 
repeats rather than for the repetitive sequences, indicating that the repeats 
of MSP2 are not necessarily immunodominant. Therefore, "cross-
recognition" can occur due to recognition of either the group-specific 
sequences or due to cross-reactive antibodies recognising truly variable 
sequences. 
Thus, the correlation in recognition of different Ri repeat sequences, and 
the increase in number of variants recognised with age, could arise as a 
consequence both of cumulative exposure to different genotypes and 
limited cross-reactivity of repeat sequences. Protective immunity may 
therefore depend upon exposure to a number of parasite isolates which, 
between them, induce antibodies which cross-react with the whole range of 
sequence diversities. 
10. Strain-specific immune recognition of MSP2 
10.1 Introduction 
In areas with endemic malaria transmission, immunity to malaria is acquired 
gradually with increasing age and is reflected by a decline in both parasite 
density and prevalence and the incidence of clinical disease. The long 
period required to develop immunity to malaria has been interpreted, by 
some, as a consequence of antigenic diversity of the parasite, such that 
exposure to the local repertoire of circulating "strains" in the parasite 
population is necessary for effective immunity. This assumes that immunity 
to malaria is essentially strain-specific. However, direct evidence for strain-
specific immunity is limited and rather speculative. 
Jeffery [163] examined the significance of repeated experimental human 
infections with homologous and heterologous "strains" of P.falciparum. In 
general, the homologous reinfections were considerably milder than those 
where heterologous strains were used. The asexual parasite and 
gametocyte densities were considerably lower in those given homologous 
infections than in those who received heterologous reinoculations. The 
author interpreted the data as an indication of the presence of strain-
specific antibodies. 
To dissect the relative importance of serotype-specific immune responses 
to different polymorphic antigens, an obvious strategy is to relate the 
prevalence/incidence of a particular serotype of P.falciparum to the 
prevalence of immunity to that serotype. This can be done both at the 
population level and at an individual level. In the last decade the 
characterisation of polymorphic antigen genes and their expression as 
recombinant polypeptides has allowed more detailed study of strain-
specific immune recognition of malaria parasites. 
Naturally acquired antibodies to MSP1 appear to be serotype-specific, in 
that the antibody prevalence against the dimorphic regions of the molecule 
1 The genes encoding different polymorphic antigens of P.falciparum lie on different 
chromosomes and will undergo genetic recombinantion independently of each other during 
meiosis [180, 181]. The term strain which implies a stable clonal lineage, is not a particularly 
useful epidemiological description of parasites with non-linked polymorphic antigen loci that 
may be rapidly interbreeding [13, 78]. The terms genotype and serotype are more 
useful, where genotype refers to the presence of a particular allele of a polymorphic locus 
and serotype refers to the presence of a serological reactivity to a gene product of a 
particular allele [78]. 
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appears to correlate with the prevalence of the corresponding allelic type in 
the infecting parasite population [115, 228, 324]. Similarly, the transmission 
dynamics of the FC27 S-antigen serotype in village communities in 
Madang, Papua New Guinea, have been related to the prevalence of 
antibodies to that serotype [78, 112, 11 3]. Measurement of lgG antibody 
responses to repeat sequences of the FC27 S-antigen showed a marked 
age-dependent increase in prevalence. Recent transmission of the 
serotype in one village induced specific lgG, particularly in children under 
15 years of age. Spatial and temporal variation in the transmission of the 
FC27 S-antigen serotype was considered to be consistent with the 
hypothesis that serotype-specific immunity occurs and contributes to the 
changes in frequencies over time [78, 112, 113], although it has been 
argued that random fluctuations in allelic frequencies are inevitable in 
P.falciparum populations in villages due to genetic drift imposed by a 
restricted population size [66, 69]. Furthermore, as genes for other 
polymorphic asexual blood stage antigens are on different chromosomes, 
parasites of a particular S-antigen serotype will undoubtedly be 
heterogeneous with respect to some of these antigens, and, if immune 
responses to these antigens have any protective effect, transmission of a 
particular S-antigen serotype will vary independently of anti-S-antigen 
responses [112, 113]. 
Marsh and Howard [199] demonstrated isolate-specific antibody responses 
to determinants on the surface of malaria-infected erythrocytes. Antibody 
specificities of Gambian children recovering from acute malaria infections 
were related to the antigen phenotypes on the surface of their own 
P. falciparum-infected erythrocytes. Children developed isolate-specific 
antibody responses against the parasites with which they had recently 
been infected, but in general these antibodies did not react with infected 
cells from other children. However, sera from uninfected Gambian adults 
contained antibodies that cross-reacted with the surface antigen(s) of many 
isolates. The authors proposed that the differences in reactivity between 
sera from children and adults could be due to the adults having 
experienced previous infections with many different malaria "strains". 
Although the surface antigens were not characterised, it was concluded 
that they were extremely diverse and that this diversity may represent a 
strategy by the parasite for evasion of the host's immune response. 
According to this concept of immune evasion, the susceptibility of the 
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acutely infected children to P.falciparum was due, at least in part, to the fact 
that they had not previously experienced infection with the same "strain". 
Evidence for serotype-specific immune recognition of MSP2 is limited. 
Specific murine mAbs differentiate variants of MSP2, giving isolate specific 
reactions [109]. The pattern of recognition by different mAbs allows the 
characterisation of isolates into MSP2 serotypes [66-69, 109]. Thus, the 
mAb reactivities can delineate variant forms of MSP2, some more 
serologically related than others. The extent of MSP2 polymorphism and 
the frequency of different serotypes has previously been determined by 
indirect immunofluorescence analysis with a panel of mAbs to identify 
allelic variants of the 3 polymorphic blood stage antigens, MSP1, MSP2 
and Exp-1 [66-69]. The frequencies of polymorphic epitopes and serotypes 
of these antigens were shown to remain stable for several years (1982-
1989) in The Gambia; epitope variants remaining either rare or common, 
suggesting that immunity to these antigens does not lead to detectable 
frequency-dependent selection, even though naturally acquired antibodies 
are serogroup specific (chapter 5). 
The recognition of MSP2 serogroup A variants was investigated in chapter 
9, to determine whether serotype-specific antibodies were present in 
children and adults from The Gambia. Non-immunes and semi-immunes 
were shown to recognised a limited number of variants but the number of 
variant sequences recognised increased with age, indicating that an 
individual may need to experience the local repertoire of parasites in order 
to develop antibodies capable of recognising all MSP2 serotypes. 
In this study, variant-specific immune recognition of MSP2 is investigated 
further at an individual level. To study the relationship between MSP2 
polymorphism and naturally acquired immunity to malaria, the humoral 
immune response to MSP2 variants is examined in sera obtained from 
children with acute, uncomplicated malaria and compared with the 
antigenic characteristics of the infecting parasites. The antigenic profile of 
the infecting parasites is determined by lEA using a panel of mAbs specific 
for the major merozoite surface protein, MSP1, MSP2 and an exported 
protein Exp-1. These antigens are each encoded by a single locus within 
the haploid genome, and the loci have been mapped to different 
chromosomes [180, 181]. The antibody profile of the infected patients is 
determined in ELISA using MSP2 rAgs. 
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10.2 Materials and methods 
10.2.1 Study design: 
Children with acute, uncomplicated malaria2 who attended the outpatients 
department at the Medical Research Council clinic, Fajara, The Gambia, 
over a six week period from October 1992, were recruited for our study, with 
parental consent. A sample of blood was obtained from each patient by 
fingerprick or as part of a venous sample obtained for other studies. 
74 complete sample sets (serum and multispot parasite slides) were 
collected from children attending the clinic, after identification of 
P.falciparum infection and successful in vitro culture of the isolated 
parasites. Of these, 51 children were re-examined 4 weeks after treatment 
and follow-up serum samples obtained. 
After centrifugation of the blood sample, the serum and buffy coat were 
removed and stored at -20°C. The rbc were retained for parasite culture. 
10.2.2 Parasite culture 
Erythrocytes were washed and parasites were grown in approximately 3m1 
culture volumes at a 5% haematocrit (section 2.5.3.), in covered petri 
dishes. They were cultured for 24-48 hours until the majority had matured 
to schizonts (as determined by periodic microscopic examination of Geimsa 
stained thin smears). 
Multispot slides were prepared (section 2.6.1.) for immunofluorescence 
typing. 
10.2.3 Indirect immunofluorescence assay (IFA): 
All mAbs were first used individually in indirect IFA (section 2.6.3.) to 
determine the MSP1, MSP2 and Exp-1 variants expressed by the schizonts 
of each isolate. The epitope site of MSP1 mAbs are shown in figure 10.1, 
and the putative epitopes sites of MSP2 mAbs have been described in 
chapter 4, table 4.1 and figure 10.1 and appendix lB. Details of 
monoclonal antibodies are given in appendix 2. 
Those isolates which appeared to contain more than one genotype were 
subsequently tested using pairs of mAbs (with different isotypes and 
21ndividuals who have a temperature >37.5°C and a parasitaemia of >5000 parasites/pi. 
These patients show no signs of cerebral involvement or severe anaemia and do not require 
hospitalisation. 
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epitope specificities) in a double-labelled IFA (section 2.6.4.) Allelic 
serotypes for each of the antigens was distinguished according to their 
different profiles of reactivity with the mAbs [66, 67, 109]. Each allelic 
serotype was assigned a number according to a classification scheme 
based on combinations of individual mAb specificities (tables 10.1 & 10.2). 
10.2.4 Enzyme-linked immunosorbent assay (ELISA): 
Sera were tested for lgG recognition of MSP2 rAgs in ELISA, at a dilution of 
1:1000. Acute sera were tested for recognition of Al and Bl; acute and 
convalescent sera were tested, in parallel, against Al, Bi, A2 variants and 
B3 variants. 
10.2.4 Data analysis: 
I. Determination of seropositivity 
Positive serum samples were defined as those giving a specific OD above 
the normal range for control European sera. The normal range was taken 
as the mean ± 2 standard deviations of European control sera. 
Mann-Whitney test 
A non-parametric two sample rank test was performed to test the difference 
between the median OD values of two groups. 
2-test 
This analysis was used to determine if an observed distribution differed 
from the expected distribution. 
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Figure 10.1a: Alternative epitope specificities at different domains of 
MSP1 are shown in boxes. 
Polymorphism in MSP1 is also shown schematically, indicated by the 
numbered blocks, according to Tanabe etal(1987). 
I 	13.4 	I 
4-4F/8-5D I 1 12.3,12.5,12.7 	 Serogroup A mAbs 
I 8F6/49 I 
	
Serogroup B mAbs 
Figure 10.1b: Epitope specificties of MSP2 mAbs for serogroup A and B 
dimorphic and polymorphic domains. 
=denotes conserved sequences 
...: denotes semi-conserved/dimorphic sequences 
denotes polymorphic sequences 
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10.3 Results 
10.3.1 Parasite serotyping: 
Blood-stage parasites from patients with acute, uncomplicated malaria 
were cultured in vitro until they matured to schizonts. Multispot slides were 
prepared of each isolate. At least 200 schizonts from each isolate were 
scored for reactions with the mAbs and mouse sera by indirect IFA. All 
schizonts in every isolate gave specific reactions with the control mAb 9.8, 
a conserved epitope of MSP1 [204]. Each of the other mAbs identified 
some isolates within which all schizonts were positive, some isolates within 
which all parasites were negative, and some isolates within which only a 
proportion of schizonts gave specific fluorescence (i.e multiple-clone 
infections). 
74 isolates were serotyped and a total of 111 clones were identified, more 
than half of the isolates being apparently single genotype infections. 
i. MSP1 serotypes 
Clones were assigned a serotype on the basis of reactivity with MSP1-
specific mAbs and their frequency recorded (table 10.1). For the sake of 
comparability between studies, serotypes which had been described 
previously were given the same number as in the published studies [66, 
67]. 6 clones remain unclassified due to difficulty in interpretation of 
reactivity with particular mAbs. 29 different MSP1 serotypes were identified; 
individual serotypes were found in up to 9 different isolates. 
The frequency of these serotypes can be compared with previous studies 
carried out in the area by Conway et a! [66, 67, 69] from parasite isolates 
from patients presenting to the outpatients department of the MRC, Fajara 
and the Royal Victoria Hospital, Banjul. Overall, the frequency of serotypes 
was comparable, particularly the strong bias towards the MAD20-type block 
6-16 (reactivity with mAbs 1 27F1 .1, 127B1 1, 9.2, 9.7 and 10.3). 
Two serotypes, 22 and 30, which had not been observed previously in The 
Gambia [66, 67], occurred at low frequency in our study population. 
However, x2  tests indicate that there are no significant differences in the 
frequencies of MSP1 serotypes observed in this study and previous studies 
[66, 67,69]. 
Eight serotypes (53-60) are based on lack of seroreactivity with mAbs 
specific for block 4 (12.1 and 10-2B). These two mAbs are mutually 
196 
exclusive in their reactivity, iowever, parasites negative for both have 
previously been observed [67]. The single example that has been 
sequenced has a third alternative sequence corresponding to this region. 
In this study, 4 of these additional serotypes were observed and designated 
53, 56, 58 and 59. 
Block 2 is the most polymorphic region of MSP1. mAb 12.2 defines the 
3D7-type sequence, 31D3 defines the CAMP-type sequence and 31.1 is 
specific for the R033-type sequence. mAb 31.1 was included in our study, 
but reactivity with this mAb was not used in the definition of the MSP1 
serotypes. Reactivity with 31.1 appears to be mutually'exclusive of reactivity 
with 122.2 and/or 3D3; of those clones which were negative with 12.2 
and/or 303, 32 out of 49 were positive for 31.1. Previous studies in The 
Gambia have not used this mAb, therefore no comparisons in frequency of 
reactivity can be made. 
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Monoclonal antibody 
12.2 	3D3 	13.2 	9.5 	10-2B 12.1 	127F1 	
1-1c 111.4 
Block 	2 2 3 3 4 	4 6-16 	
6-16 16-17 









- 	+ 	+ - 
+ 
4 	 - 	- 	+ 	- 





6 	 - 	+ 	+ 	- - 	+ 	+ - 3 2.7 
- + + 	- 	
- 
7 + - + - 
- 	+ 	- 	- 	+ 	+ - 
- 4 3.6 
8 	 - 
9 + 	+ + 




- 	+ 	- 	
+ 
10 	 - + 	+ 	- 	+ 
- + - + 	- + - 
+ 9 8.1 
11 + 





13 + + + - + 	- + - 2 1.9 
- 	+ - 	+ 	- 	
- 
14 	 - 	+ 	+ 
- + 	- + 	- + - 
- 3 2.7 
15 + 





20 - - - 	+ - 	+ + - 
+ 
1 0.9 
- + 	- + 	+ 	- 	
- 
22 	 - 	+ 





28 	 - 	- - + 	+ - 	+ 	- 	
+ 
1 0.9 
- 	+ + 	- + - 
- 
30 - + 





33 + + - 	- - 	+ + - 
+ 
- 	- + 	+ 	- 	
+ 2 1.9 
36 	 - 	- 	- 





44 	 - 	- 	- - 	+ - 	+ 	- 	
+ 
- 	+ - + 
+ 1 0.9 
52 - - + 	- 




56* - 	- 	+ 	- 	- 	- 	+ 	- 	
+ 
4 3.6 
- - + - 
- 
58* 	 - + + - 
- 	- 	+ 	- 	- 2 1.9 59 * + 	- 	+ 	- 
Table 	10.1: 	Serotypes, 	and their frequencies, 	
of MSP1 	defined by 
combinations of reactivities with individual mAbs [11, 16]. 
* denotes those 
serotypes not previously defined by Conway et a! [11, 1 6]. 
ReactivitieS with mAbs 127B11.1, 9.2, 9.7, 10.3 and 127F1.1 all give the 
same pattern of recognition; to save space serotypes are defined as + or - in 
reactivity to 127F1.1 only. 
ReactivitieS with 1-1C, 6.1, 13.1 and 17.1 are the same for each serotype; 
1-1C reactivities only are recorded here. 
ii. MSP2 
MSP2 serotype frequencies are given in table 10.2. The results appear 
consistent with the frequencies in 1988 and 1989 [66, 67], in that serotypes 
3 and 9 have not been detected. However, fluctuations in the frequencies of 
the other serotypes are apparent (table 10.2). In particular, there is an 
increase in the frequency of serotype 7 from less than 15% (in 1989) to 
33% (in 1992), which is statistically significant (x2=89.7 d.f=1, p<0.001). 
This increase in serotype 7 (serogroup B) is compensated for by a 
decrease in the frequency of several other serotypes. The decrease in 




13.4 851D 12.3 8GlO/488F6/49 isolate* N=111 °"° 
Serogroup A A A B 	B 
Serotype 
1 + + + - 	- - 	T9/94 4 3.6 
2 - + + - 	- 	CH12/12, R033 30 27 
3 + - + - 	- 0 0 
4 - - + - 	- 	T9/96 19 17.1 
5 - + - + 	+ 7 6.3 
6 - + - + 	- 	K29 1 0.9 
7 - - - + 	+ 	Ki, FC27 37 33.3 
8 - - - + 	- 9 9.1 
9 + + - - 	- 0 0 
10 - + - - 	- 2 1.8 
Table 10.2: MSP2 serotypes, and their frequencies, defined by 
combinations of reactivity with individual mAbs [66, 67] collected from 
patients with acute, uncomplicated malaria in The Gambia. 
* determined from Fenton et a! [109] 
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10.3.2 Antibody recognition of serogroup A and B by acute sera and the 
relationship with the antigenic profile of the infecting parasites: 
74 sera from children with acute, uncomplicated malaria were tested for 
recognition of MSP2 rAgs Al and Bi. The frequency of antibodies to these 
proteins is given in table 10.3. Table 10.4 gives the frequency of parasites 
expressing serogroup A and B, including mixed infections. 
To examine the relationship between the presence of parasites expressing 
a particular serogroup of MSP2 and the presence of antibodies to that 
serogroup x2 tests were performed (table 10.5). Individuals infected with 
parasites of MSP2 serogroup A were divided into those with antibody to Al 
and those without (and similarly for serogroup B). Antibodies to B1 were 
significantly associated with infection with malaria parasites expressing 
MSP2 serogroup B. No such association was observed for anti-Al 
antibodies and serogroup A parasites. However, a greater than expected 
number of individuals who had antibodies to Al were not infected with 
serogroup B parasites. 
A Mann-Whitney test was performed to compare the median OD values to 
each rAg of individuals infected with the corresponding, or alternative, 
serogroup (table 10.6). The median OD to Bi was greater if an individual 
was infected with serogroup B parasites, and no association was observed 
between the median OD to Al and serogroup A parasites. 
Taken together, the data indicates that there is evidence for boosting of the 
antibody response to serogroup B, after infection with parasites expressing 
MSP2 serogroup B. The results for serogroup A are inconclusive. 
Importantly, there was no evidence that children with high titres of antibody 
to one serogroup were less likely to be infected by parasites expressing 
that serogroup - as one would expect if "strain-specific" immunity was 















Frequency 	Number 	Frequency 
(N=51) 
29.7 15 29.4 
35.1 19 37.3 
6.8 3 5.9 
6.8 1 2.0 
























Al and Bi 
neither 
Table 10.3: Frequency of antibodies to rAgs Al and Bi in acute samples 
(N=74) and acute and convalescent samples (N=51). 
Acute 
	
Acute and Convalescent 
Table 10.4: Frequency of parasite serogroups and mixed infections in acute 
samples only, and paired acute and convalescent samples. 
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Parasite 	Antibody 	 n 	 x2 	P 
MSP2 specificity Ab+ Ab- 
serogroup 
A 	 Al 	21 	22 	2.03 	0.154 
A Bi 15 28 13.07 >0.001 
B 	 Al 	15 	32 	5.26 	0.022 
B Bl 30 17 6.40 0.011 
Table 10.5: x2 analysis to determine the association between antibody 
specificity of an individual and serogroup of parasites infecting that 
individual, for 74 acute samples collected from children with acute, 
uncomplicated malaria in The Gambia. 
Median OD 
Antibody Parasite Parasite Parasite U p 
specificity serogroup positive negative (n=74) 
Al A 0.130 0.221 0.045 0.355 
Bl B 0.549 0.117 0.239 0.018 
Al B 0.109 0.316 0.132 0.027 
Bi A 0.117 0.639 0.414 0.0005 
Table 10.6: Mann-Whitney analysis to determine the association between 
median OD to Al or 131 and infection with parasites expressing serogroup 
A and/or B, for 74 acute samples collected from malaria patients attending 
the MRC outpatients clinic, Fajara. 
10.3.3 Antibody recognition of MSP2 by acute and convalescent sera 
and the relationship with the parasite serotype: 
The recognition of MSP2 was studied for paired acute and convalescent 
serum samples. Table 10.3 shows the pattern of antibody recognition of Al 
and Bi in these individuals and the characteristics of the infecting parasites 
(table 10.4). The antibody profile of acute and convalescent sera was 
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significantly correlated, as determined by Spearman's rank correlation tests 
(data not shown). 
Mann-Whitney analysis of both acute and convalescent samples again 
showed no association between the median OD to Al and the presence of 
serogroup A parasites, whereas the median OD to Al was greater if an 
individual was infected with parasites that were not serogroup B. The latter 
association implies that the median OD to Al should be greaterif the 
parasites are expressing serogroup A. This apparent contradiction could 
arise due to the extensive polymorphism in the Ri repeat region of MSP2 
serogroup A. Therefore we tested the sera for recognition of the panel of A2 
rAgs. 8 individuals who were seronegative for Al, but infected with 
serogroup A parasites, were seropositive to some of the A2 variants (table 
10.7). 
Some individuals were seronegative for Al (T9/96) but recognised 
A2(T9/96). A possible explanation for this is that A2-specific antibodies 
were in low concentration (indicated by a low OD) and the epitope density 
when the plate is coated with the larger Al molecule is lower, therefore 
these antibodies are not detected. 
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Donor Age 









227 1 7,2 - - - +1- 
R033(c), 
0H12/12(c) 
230 6 4,2,1 + +1- - - T9/96(a),7G8(a) 
237 1 7 +1- + + + 








248 7 7 - +1- - ++ T9/96(a&c) 
249 6 7 - - + ++ 
251 4 7,2 * , 10 ++ + ++ ++ T9/96(a&c) 
262 4 4 - +1- - + T9/96(a&c) 
266 6 7 - +1- ++ ++ 





292 4 8 - - ++ ++ 
306 5 4 + - + + 
310 1 2 - - - - T9/96(a&c) 
311 1 4 ++  
342 2 7 ++ + ++ ++ 









354 9 7 + - ++ ++ 
355 5 7,10 ++ + ++ ++ 
356 1 8 + + ++ ++ 
367 2 7 - - - - 
369 2 7,2 - - ++ 
375 8 5 + - - + 
377 4 7,1 - + - + T9/94(c) 
380 1 7 
386b 4 8 +1- - ++ ++ T9/96(a&c) 
387 6 7 +1- +1- - ++ T9/96(a&c) 
389 3 5,7 + + ++ ++ 19/96(c) 
390 9 5 - - ++ 4+ 
ThaiTn(c) 
393 1 2 - ++ - + R033(a&c), 
ThaiTn(c) 
394 4 2 +1- + + + T9/96(c) 
R033(a&c), 
400 6 8,2°° - + - + 19/102(c), 
T9/94(a&c) 
401 3 2 + + - ++ 
T9/96(a), 





407 1 2,4 ++ + + - ThaiTn(a) 
414 3 8 - - +1- +1- 
415 3 2°°'8 - - + ++ T9/96(c) 
416 5 2 
T9/96(a&c) 
421 2 7 ++ + ++ R033(a), 
CH1 2/12(a), 
T9/94i(a) 
424 4 2 
426 0 2 ++ - ++ + 
429 4 7 +1- - ++ ++ 
430 6 4,8 - - +1- + T9/96(a&c) 
435 7 4 ++ + - - 
441 1 2 - -i-I- ++ +4- 
455 9 7 +1- - + ++ R033(a) 
457 14 2°°,5 + - + - 
CH12/12(a&c), 
458 6 2 + - - T9/102(a&c), 
T9/94i(a&c) ,7G8(a& 
C),_ThaiTn(a&c) 
460 3 7,4 - - - ++ :1 
Table 10.7: Details of parasite serotype (major serotype first) and antibody specificity for 51 
children aged 10 months -10 years from the villages around Fajara, The Gambia. Samples were 
collected in October - November 1992. 
* denotes positive reactivity with anti-ThaiTn mouse serum 
denotes positive reaction of parasites in IFA with anti-T9/96 mouse serum 
b denotes recombinant allele determined by DNA sequencing 
1) a & c denote acute and convalescent samples, respectively. 
Antibody recognition is denoted by - (negative), +1- (OD value close to cut-off), + (seropositive), 
++ (strongly positive). 	 205 
10.3.4 Recognition of A2 rAgs and the relationship with serogroup A 
parasites: 
The variant-specific antibody profiles of individual sera could be compared 
with the serotype of the infecting parasites by measuring antibodies to A2 
rAgs (table 10.7). Several examples are given below: 
Donor 227 was seropositive for A2(R033) and A2(CH12/12) 4 weeks after 
infection. The majority of infecting parasites expressed serogroup B 
;< 
 
however a subpopulation of the parasites (approximately 7%) were shown 
to express epitopes 12.3 and 8-5D (serotype 2). This combination of 
epitopes is characteristic of MSP2 alleles in R033 and CH12/12 strains 
[109] (table 10.2). Thus this child shows clear evidence of boosting of the 
immune response to the parasites with which it was infected. 
Donor 238 was seropositive in convalescence for T9/96, R033, CH12/12 
and T9/94. Approximately 97% of the infecting parasites were MSP2 
serotype 4, the sequenced expressed by T9/96.,9espite this the OD for 
A2(T9/96) was very low. Approximately 3% of the parasites were serotype 2 
and strong antibody responses were detected for the corresponding A2 
proteins - R033 and CH12/12. In addition, a high OD was measured for 
A2(T9/94i), although no parasites of this particular serotype were detected. 
However, partial sequence homology does occur between R033 and 
T9/94. Thus, a small proportion of parasites boosted the antibody response 
to a construct with similar sequences to those predicted by the mAb 
reactivity pattern of the parasites infecting this child. 
Donor 353 was seropositive, in the convalescent sample, for A2(R033), 
A2(CH12/12) and A2 (T9/94i) although the OD values were low. The 
parasites were an apparently single genotype infection of serotype 2 
(R033/CH1 2/12), which appears to have boosted the antibody response. 
Donor 377 was seronegative at the time of infection, however became 
seropositive to T9/94 4 weeks later. This individual was infected with a 
mixed isolate; 35% of the parasites were serotype 1, characteristic of T9/94. 
The majority of parasites were serotype 7 (serogroup B) and antibodies to 
Bi were detected during convalescence. 
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Donor 430 was seropositive for A2(T9/96) in the acute and convalescent 
samples. Approximately 80% of the infecting parasites were serotype 4 
(T9/96-type). The remainder of the parasites were serotype 8 and this child 
was weakly seropositive to Bi in the acute sample and clearly seropositive 
in the convalescent sample. Thus the antibody profile of this child is clearly 
related to the MSP2 serotypes expressed on the parasites with which it was 
infected. 
Donor 458 was seropositive for A2 variants CH12/12, T9/102, T9/94i, 7G8 
and ThaiTn, with OD values very similar for acute and convalescent 
samples. This individual had an apparently homologous infection with 
serotype 2, characteristic of CH12/12. Isolates CH12/12, T9/102, T9/94 and 
7G8 all contain the sequence GSAG and there is partial homology with the 
sequence GRAG of ThaiTn. There is no obvious boosting of the immune 
response during convalescence. However, boosting may have already 
occurred by the time the acute sample was obtained if this child did not 
attend the clinic early during infection. 
There were individuals who had antibodies to serogroup A variants but 
were not infected with serogroup A parasites. For example, donor 284 is 
seropositive for A2(R033), A2(CH12112), A2(T9/94i) and A2(ThaiTn), 
however only serogroup B parasites were detected. There was a decrease 
in the OD values to these constructs after 4 weeks, which may indicate that 
this individual had made a response to a previous infection with serogroup 
A parasites and the antibody levels were beginning to decline. This 
individual did have anti-131 antibodies. 
10.3.5 Recognition of B3 variants by acute and convalescent sera: 
Four of the serogroup B parasites collected during this study were 
subsequently shown to lack the 12-mer R2 repeat sequence (sequencing 
carried out by Dr. P. Roberts and C. Dobano). Because of this observation, I 
investigated the recognition of this region by the childrens' sera. Three rAgs 
were used - B3(K1), B3(T9/105i) and B3(T9/105ii) which are serogroup B 
proteins with 5, 1 and 0 12-mer sequences, respectively. 
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The construct with 5 12-mers was recognised more often by acute and 
convalescent sera than were the constructs with 1 or 0 12-mers (figure 
10.2). Thus, it seems as though a dominant epitope in this construct is 
dependent on the presence of more than 3 12-mer repeats. 
Ten sera, which were positive for at least one of the B3 rAgs, were selected 
and titrated against each of the B3 constructs to compare the relative 
affinities and concentrations of antibodies to this region. Examples of three 
such sera are shown in figures 10.2 & 10.3. Varying patterns were seen. 
Some individuals appeared to recognise epitopes outwith the 12-mer 
sequence as titrations curves were virtually overlapping for each of the 
rAgs including the one with no 12-mers (figure 10.3a). In others, the 
recognition of the 12-mers occurred in a "dose-dependent" manner, with 
the greatest antibody binding to B3(K1) (figure 10.3b). In others, the epitope 
recognised was completely dependent on the presence of more than 1 12-
me rs. 
Interestingly, donors 248, 249, 354 and 387 were strong responders to 
B3(K1) but low or non responders to B3(T9/105i) and B3(T9/105ii) (figure 
10.2 - closed circles; for example figure 10.3c) and yet were infected with 
parasites which lacked the 12-mer sequence which perhaps enables the 
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Figure 10.2: Recognition of B3 rAgs by acute (A) and 
convalescent (C) sera from 51 mild malaria patients. Each circle 
represent one individual. Closed symbols represent donors who 
were infected with parasites which lacked the 12 mer repeat. 








Figure 10.3: Recognition of B3 rAgs by acute 
sera titrated from 1:250 in doubling dilutions. 
a) donor 405, b) donor 389 and c) donor 248. 
1i) C63 (19/1050 	03 (T9/lO5ii) 
-0.54 































Immune recognition of MSP2 is acquired in an age-dependent manner 
(chapter 6). Data from chapter 9 demonstrate variant-restricted immune 
recognition of MSP2 polymorphic sequences in non-immune individuals 
and children, in particular. The data is consistent with the hypothesis that 
the gradual development of immunity to MSP2 requires that an individual 
experiences a range of MSP2 serotypes and that clinical immunity 
develops once an individual has experienced a representative sample of 
parasites and possesses antibodies which cross-react with all potential 
sequences. 
In this study the objective was to look for correlations between such variant-
specific antibodies in children and the antigenic profiles of the parasites 
responsible for the clinical episode to see, firstly, whether boosting of the 
antibody response to specific MSP2 sequences could be observed and 
secondly, whether pre-existing antibody protected against subsequent 
infections with parasites carrying that sequence. Parasites were typed for 
MSP1 and MSP2 [66, 67]. Each of these antigens exhibits allelic 
polymorphisms. The frequencies of the serotypes were comparable to the 
frequencies observed by Conway et a! [66, 67] in the same region in 1988 
and 1989. Some fluctuations were observed for certain serotypes of MSP1 
and MSP2. We are aware that considerable microheterogeneity occurs in 
MSP2 [201, 250] and that typing with mAbs will tend to underestimate the 
extent of this diversity. However, within the limits of the assays used, we do 
not believe that major shifts in allelic frequencies are occurring over time, in 
this population. 
The antibody profile of each individual at the time of infection and during 
convalescence was determined by ELISA, primarily using rAgs Al and Bi, 
the full length recombinant proteins of each serogroup. We compared the 
antibody profile and the serogroup of MSP2 expressed by the parasites 
with which that child was infected. 
Interpretation of serogroup B associations were straightforward, whereas 
the serogroup A data were more complicated - probably because MSP2 
serogroup A sequences are more heterogeneous. A significant correlation 
was observed between the presence of antibody to Bi (during the acute 
and convalescent stages) and infection with serogroup B parasites. 
However, there was no direct association between presence of anti-Al 
antibodies and presence of serogroup A parasites. However, individuals 
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were shown to have a higher median 00 to Al if they were not infected 
with serogroup B parasites. Since, if the parasites are not serogroup B, they 
must be serogroup A MSP2 (excluding recombinant forms). The data 
indicate that antibodies to serogroup A are associated with infection with 
serogroup A parasites. 
A panel of rAgs representing the Rl repeat region of MSP2 serogroup A 
were used to investigate the recognition of polymorphic repeat sequences. 
Several individuals who were seronegative for Al (T9/96), but were infected 
with serogroup A parasites, were shown to have antibodies specific for 
other serogroup A variants. In many cases, the antibody profiles of the 
children, particularly in convalescence, corresponded to the antigenic 
profiles of the parasites with which they had been infected. 
Therefore, overall, the data show a strong relationship between the 
antibody profile of an individual and the MSP2 serogroup expressed by the 
malaria parasite, with the antibody response to a particular serotype being 
boosted by the infection. 
A few children were seronegative to all proteins tested, however these 
children may have antibodies specific for sequences which are not 
represented by our panel of proteins. Some individuals were seropositive 
for either Al or Bi, but were not infected with the corresponding serogroup 
of parasite. These antibodies had obviously persisted from a previous 
infection, but it is not known whether these antibodies protected against 
infection with parasites expressing that serogroup of MSP2 or whether 
these children had simply not been exposed to those parasites in the 
interim. 
It is not known whether polymorphisms in MSP2 enable the parasite to 
evade variant-specific immune responses. If so, such polymorphisms might 
be subject to frequency-dependent selection. In this context, it is of interest 
that MSP2 alleles that lack the 12-mer repeat sequence of serogroup B 
were identified. Such variants have been reported elsewhere [201, 250] 
and these parasites appear to be viable (similar have been sequenced in 
oocysts [257]). The individuals harbouring these novel variants were shown 
to have high antibody responses to a rAg containing 5 copies of the repeat 
sequence. It is therefore tempting to conclude that parasites lacking the 12-
mer sequence were able to evade the immune responses in these 
individuals, and were therefore at a selective advantage. In serogroup B 
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polymorphism within the R2 repeats is minimal with isolates varying in 
repeat number rather than in sequence, therefore not having the repeats 
may be very advantageous. 
More extensive longitudinal studies are now required to investigate the 
dynamics of individual serotypes of P.falciparum in parallel with a 
description of the dynamics of the immune response to these serotypes, to 
determine whether polymorphisms arise as a result of immune selection 
pressure or due to random genetic drift, and to see whether pre-existing 
antibody protects against infection. 
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11: Longitudinal studies of antibody responses to 
PfMSP1 and MSP2 
11.1 Introduction 
In chapter 6, describing the age profiles of anti-MSP2 antibodies, I found 
that there was a significant increase in the prevalence of anti-MSP2 
antibodies with age, whereas the overall mean OD for positive samples did 
not increase. Many children were essentially negative for one or both 
MSP2 serogroups; the proportion of seronegative adults was lower than in 
children, but a significant proportion of adults do appear to be 
nonresponsive to MSP2 antigens. In children this could be explained by a 
lack of exposure to malaria, whereas in adults this is unlikely. 
The antibody prevalence data was collected by cross-sectional analysis of 
a population at a single point in time, in this case during the malaria 
transmission season in 1988. Malaria transmission in The Gambia is 
seasonal and it is possible that antibody levels fluctuate over time 
depending on the frequency of re-exposure to infection. In order to obtain a 
realistic evaluation of responders and non-responders to an antigen or 
epitope, it is necessary to conduct longitudinal studies collecting serum 
samples from the same individual over a period of months or years. 
Several such studies have been carried out for P.falciparum antigens from 
various stages of the life cycle [26, 27, 83, 115, 228, 235, 241, 267, 270, 
348]. In general, it appears that variation in antibody levels within one 
individual over time is less common in individuals who are clinically 
immune to malaria, than in those who are still actively acquiring immunity or 
who have only recently been exposed to malaria; in such individuals, 
antibody levels do fluctuate over time [26, 53, 253, 348]. Furthermore, 
among those individuals who are clinically immune, a proportion are 
consistently seronegative to particular antigens or epitopes within an 
antigen, whilst being stable responders to other antigens. Riley et a! [270] 
found that at any one time, up to 70% of clinically immune adults were 
seronegative to PfMSP142 and around 40% of the donors tested in a 
longitudinal study were persistent non-responders. This phenomenon of 
non-responsiveness has been observed for other antigens of P.falciparum. 
The ability of an individual to produce, or not to produce, antibodies to the 
230kD gamete surface antigen was a consistent phenotype which 
appeared early in life [267]. Quakyi et a! [253]observed widespread 
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restricted immunogenicity to antigens from the sporozoite and blood stages. 
Responses to peptides representing different repeat sequences of 
Pf155/RESA show highly consistent differences between individual 
Liberian donors [235]. 
Several explanations have been proposed for this selective non-
responsiveness to certain antigens or epitopes. The detection of MHC-
dependent genetic restriction of immune responses to defined peptide 
epitopes of malaria antigens in mouse models has led to the fear that 
genetically determined non-responsiveness to malaria antigens may be 
widespread in human populations [120, 124a]. However, in outbred human 
populations, polymorphism of HLA antigens is extensive compared to 
inbred laboratory mice. Genetic regulation of antibody responses to 
Pf155/RESA has previously been inferred from longitudinal studies which 
showed that, under conditions of continual year-round malaria 
transmission, heterogeneous antibody profiles were observed [27, 235, 
253]. Serological data [27] indicated a higher degree of variability in 
seroreactivity between individuals, the more specific the antigen tested (i.e. 
crude parasite antigen versus synthetic oligopeptides of Pf155RESA). In 
addition, the seroreactivity remained consistent within an individual even 
though the parasitaemia, and hence the antigenic load, varied between 
surveys. Thus, the restricted but consistent recognition indicated that 
genetic regulation might be involved. A study on the recognition of 
candidate vaccine antigens by malaria exposed sera concluded that their 
observations of differential non-responsiveness were consistent with the 
concept that poor responsiveness was the result of immune response (Ir) 
genes mapping within the human MHC, but no direct evidence of MHC 
restriction was presented [253]. 
In an effort to determine the practical importance of genetic constraints in 
the development of anti-malarial immunity in endemic human populations, 
Riley et a! [270a] examined the naturally acquired cellular and humoral 
immune responses to defined P.falciparum antigens in individuals of 
differing HLA class II genotypes. They concluded that non-responsiveness 
is not primarily due to HLA class 11-mediated genetic restriction. However, it 
has not been excluded that non-MHC genes may influence immune 
responses to malaria Ags. For example, variation could be due to allotype 
restriction of the donors' antibody repertoire, genetic regulation of 
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lymphokine production, or antigen processing or at the B- or T-cell level [27, 
235, 271]. 
An alternative approach to determine the importance of genetic versus 
environmental factors in the immune recognition of malaria antigens is to 
compare responses in identical and non-identical twin pairs. Sjaberg et a! 
[293] investigated twins for possible genetic restriction of T-cell and B-cell 
responses to defined, repetitive epitopes of Pf 1 55/RESA. They found that 
anti-peptide responses were more concordant within monozygous twin 
pairs than within either dizygous twins or sibling pairs who were matched 
for age, sex and exposure to malaria. The data implied that the antibody 
response to Pf155/RESA came under genetic regulation but further 
analysis showed no associations with HLA class II type. They conclude that 
regulation of antibody response reflects the impact of factors encoded by 
genes outside the HLA class It region. 
Non-responsiveness could also be attributed to such factors as antigenic 
polymorphism, immunosuppression, temporal variation in antibody levels 
and/or inadequate exposure to malaria. Antigenic polymorphism is a 
common feature of malaria antigens. Since memory T cells primed by 
exposure to one parasite strain will not respond to a variant strain bearing a 
non-cross-reacting epitope, such polymorphism may account for this 
apparent non-responsiveness and presumably represents a parasite 
adaptation for immune evasion [271]. Temporal variation in antibody levels 
could be due to low transmission rates during long dry periods in some 
endemic areas and poor T cell memory. Specific serum antibody titres may 
fall below detectable levels, particularly in children and in areas of low 
endemicity [115, 200, 348]. Thus cross-sectional surveys are likely to miss a 
proportion of responders since sampling occurs at one point in time. 
Down-regulation of the immune response due to repeated infection and 
chronic exposure of the individual could result in apparent non-
responsiveness to particular antigens. Riley et a! [267] have observed that 
a stable responsiveness phenotype is fixed early in life and is apparent in 
children as young as 3-5 years of age for Pfs230. Thus tolerance might be 
induced following prenatal or perinatal exposure to malaria antigens [246a]. 
It is well recognised that specific unresponsiveness to immunisation can be 
induced by prolonged exposure to antigenic proteins [286a]. It would be 
expected that exposure of the foetus or new-born to malaria antigen, at a 
time when the immune system is immature, would have an influence on 
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subsequent malaria immunity and may play a partial role in the lack of 
childhood immunity to malaria [246a]. 
A novel explanation for the selective recogniton of malaria antigens is a 
mechanism, originally proposed to explain the restricted antibody response 
to influenza viruses, known as Original Antigenic Sin [107] or clonal 
imprinting [118a]. Clonal imprinting has been proposed as part of the 
explanation for the limited antibody repertoire seen in patients with HIV-1 
infections [118a]. Clonal imprinting is a phenomenon in which a primary 
infection with a particular variant leads to the clonal expansion of B-cells 
specific for certain antigen epitopes. During a secondary infection, antigens 
which cross-react with those presented in the original infection are 
recognised by memory B-cells and antibody of the original specificity is 
produced. Epitopes which were not present in the primary infection are 
effectively ignored because naive B-cells cannot compete for Ag with 
higher affinity memory cells. As a result certain antigens and epitopes are 
persistently recognised and others are not recognised. 
The questions which need to be addressed concerning the recognition of 
MSP2 are:- 
is non-responsiveness to particular epitopes of MSP2 a stable 
phenotype in adults and children who have been exposed to endemic 
malaria? 
is non-responsiveness to MSP2 genetically determined? 
In this chapter, I report the results of two longitudinal serological studies 
conducted in The Gambia. Samples were collected at six month intervals 
from adults and children from the villages of Brefet and Farafenni, 
respectively. Surveys were made at the end of the dry season (when 
malaria transmission is minimal) and at the end of the wet season (when 
transmission is at its maximum) over several transmission seasons. 
Antibody responses to the two major P.falciparum merozoite surface 
proteins, PfMSP1 and MSP2, were measured in ELISA. The rAgs used 
represented regions of the proteins that were conserved, dimorphic or 
polymorphic. In this way we examined the temporal variation of antibody 
responses in individuals who are clinically immune and in individuals who 
are still actively acquiring their immunity to malaria. Furthermore, we 
examine whether the regulation of immune recognition of MSP2 is 
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genetically determined by comparing antibody recognition of pairs by 
monozygous and dizygous twins and examining the relationship between 
human leukocyte antigen (HLA) class II genotype and anti-MSP2 immune 
responses. 
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11.2 Materials and methods 
11.2.1 Subjects 
Malaria exposed adults 
Sera were collected from 27 adults (aged 16-65) living in the village of 
Brefet, The Gambia. Samples were collected at 6 month intervals (dry 
season and wet season) from November 1990 to November 1993. For each 
individual at least 4 serum samples were obtained. The age, sex and 
number of samples obtained for each individual is detailed in table 11.1. 
Malaria exposed children 
Sera were collected from children (aged 3-8 years in 1988) living in the 
villages near the town of Farafenni, The Gambia. Sera were collected at 6 
month intervals from June 1988 to November 1991. For each individual at 
least 4 samples were collected. The age, sex and number of samples 
obtained for each individual is detailed in table 11.2. 
These samples were collected by Dr S Allen. 
Malaria exposed twins 
Serum samples were obtained from 36 pairs of adult twins living all over 
the Eastern region of The Gambia. 15 pairs of twins were shown to be 
monozygous. Zygosity was determined using cloned human DNA 
minisatellites as locus-specific hybridisation probes [362]. 
Samples and zygosity data were kindly provided by Dr. Annette Jepson. 
4 Controls 
Control serum samples were obtained from European adults (n=12) and 
children (n=12). These individuals have not been exposed to malaria. 
All serum samples were stored at -20°C. 
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Donor 	No. of 	Age 	Sex 
samples (in 1990) 
1 5 59 m 
4 6 34 
7 6 36 f 
12 6 64 m 
13 5 65 m 
15 4 45 m 
28 6 57 
31 6 44 m 
35 6 37 f 
45 5 57 m 
50 5 38 m 
53 5 59 m 
69 5 49 m 
79 5 50 m 
95 5 41 f 
104 4 16 f 
105 5 24 f 
109 5 16 f 
110 5 17 
112 6 16 f 
114 5 16 f 
116 6 28 m 
117 6 17 f 
120 6 65 f 
125 6 28 f 
127 4 41 m 
167 5 16 f 
Table 11.1: Longitudinal recognition of merozoite surface proteins - adult 
serum samples. Donor details giving the number of samples collected for 
each individual, their age (at beginning of study) and sex. 
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Donor No. of Age Sex 
samples (in 	1988) 
E07008 6 5 m 
E08018 7 7 m 
E09009 5 3 m 
E17004 7 3 m 
E18003 6 7 f 
E20015 5 5 m 
E24008 7 6 m 
E24009 7 4 m 
E25007 6 3 m 
E25009 7 6 f 
P06008 5 7 m 
P06009 6 5 m 
P10016 6 7 m 
P10017 5 4 m 
P11005 4 6 m 
P12009 5 5 f 
001008 4 7 m 
003005 5 4 m 
N05034 4 4 m 
Table 11.2: Longitudinal recognition of merozoite surface proteins - 
childrens serum samples. Donor details giving the number of samples 
collected for each individual, their age (at beginning of study) and sex. 
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11.2.2 Recombinant proteins: 
The following rAgs were used for this work: MSP2 - A2(T9/96), A3, B2(K1 i) 
and B3(T9/105i); MSP1 - see tablel 1.3. 
rAg Serogroup Region 




Mad-20 19kDa 	(1st 	EGF-like 
motif) * 
19IGST Wellcome 19kDa (both motifs)* 
Table 11.3: Summary of recombinant proteins MSP1 used in this chapter. 
Proteins kindly provided by A.Egan; for further details see Egan et a! [93] 
and figure 11.1. 
11.2.3 Enzyme-linked immunosorbent assay (ELISA): 
lgG antibodies were measured in ELISA as described in materials and 
methods. For screening, all sera were diluted 1/1000 in blocking buffer and 
tested in duplicate. 
11.2.4 Statistical methods: 
Determination of positivity: 
Positive samples were defined as those giving a specific OD above the 
normal range for control sera. The normal range was taken as the mean + 2 
standard deviations of the OD values obtained for the control sera. 
HLA analysis: 
The overall association of HLA class II genotype with antibody prevalence 
was determined by logistic regression allowing for age and sex. 










of MSP1 19 
EGF-1A 
EGF-1B 
Figure 11.1: Schematic representation of PfMSP1 
recombinant proteins. 
Hatched boxes indicate rAgs used. 
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11.3 Results 
11.3.1 Longitudinal study of antibody responses to P.falciparum merozoite 
surface antigens by Gambian adults: 
Sera collected over a period of 3 years from adults from the village of 
Brefet, were tested for recognition of the two major merozoite surface 
antigens, MSP1 and MSP2, in ELISA. The rAgs of MSP1 represented the 
relatively conserved 19kDa C-terminal fragment of PfMSP1 (which contains 
two EGF-like motifs) and two rAgs representing the alternative allelic 
sequences of the first of the two EGF-like motifs (see figure 11.1). 
In order to minimise intra- and inter-assay variation, all samples from a 
single individual were tested against all the proteins on one plate. 
Table 11.4 and figures 11 .2a-c show a representative sample of results; a 
complete set of results is given in appendix 3, table 1. There is very little 
seasonal variation in Ab concentration in adults despite the varying 
transmission conditions during the year. Where seasonal variation is 
observed, it tends to be for variant rather than conserved antigens and is 
more cornonly seen in the younger donors. 
The most striking finding is that, despite lifelong exposure to malaria, there 
are a number of individuals who are consistently non-responders to some 
of the rAgs, whilst consistently recognising other rAgs. In other words, these 
individuals show differential recognition of antigens and epitopes within 
those antigens. For example, donor 45JK differentiates between MSP1 and 
MSP2, being consistently seronegative for PfMSP1 and consistently 
seropositive for all of the MSP2 proteins (table 11.4, figure 11.2a). In this 
donor, there is some evidence of boosting during the transmission season 
in 1993 to MSP2 serogroup B epitopes. The Ab recognition of MSP2(B) 
increases but there is still no response to MSP119. Other donors, for 
example 1 2TS and 500S, also differentiate between the recognition of 
MSP119 and MSP2 antigens, being consistently seronegative for MSP119 . 
However, donor 79AJ (figure 11.2b) recognises all the rAgs strongly, and 
remains seropositive throughout the period of the study, although the titre 
decreases suggesting that there has been no boosting for some time. Thus, 
all the rAgs are immunogenic and non-recognition of any of the rAgs is not 
due to poor immunogenicity. 
Donor 11OBS differentiates between epitopes within MSP2 (table 11.4). 
She is seronegative for the A2(T9/96), but seropositive for the group 
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specific region of the same protein. She also shows differential recognition 
of the serogroup B rAgs and there appears to be a boosting of the response 
to B3(T9/105i); this is likely to have occurred in November 1992, however 
no serum sample was available from that collection time. This donor is 
unusual in that she differentiates between the slightly different allellic 
sequences of MSP1-EGF1 and MSP1-EGF2 (figure 11.2c); Egan eta! [93] 
have shown that the recognition of these two rAgs is usually highly 
correlated within individual donors. 
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DONOR DATE EGF-1A EGF-1B 19flT A2 
(T9/96) 
A3 	IB2(Kli) B3 
 (9/105 
12 TS 11/90 0.090 -0.054 -0.031 0.020 0.063 -0.056 -0.058 
11/91 -0.350 -0.352 -0.250 0.305 0.538 1.113 1 0.573 
4/92 -0.187 -0.199 -0.213 0.171 0.520 0.238 0.188 
11/92 -0.242 -0.173 -0.279 -0.060 0.526 0.435 0.689 
4/93 -0.168 -0.027 -0.121 0.061 0.487 1.048 0.842 
11/93 -0.088 -0.113 0.125 0.125 0.399 1 0.996 0.952 
45 JK 11/91 0.171 0.017 0.159 1.042 0.912 0.490 1.114 
4/92 -0.032 -0.008 0.100 0.791 0.775 0.521 1.127 
11/92 0.103 0.132 0.311 0.677 0.635 0.451 1 	0.95.5 
4/93 0.089 0.009 0.072 0.821 0.734 0.387 0.880 
11/93 0.040 0.036 0.037 0.640 0.737 0.826 1.300 
50 OS 11/90 0.140 -0.053 -0.067 1.122 1.170 0.590 0.139 
11/91 -0.268 -0.277 -0.294 0.660 0.447 0.391 0.121 
4/92 -0.154 -0.157 -0.110 1.004 0.957 0.508 0.351 
4/93 -0.208 -0.196 -0.210 1.184 1.173 0.549 -0.017 
11/93 -0.261 -0.267 -0.256 0.936 1.082 0.463 0.101 
79 AJ 11/91 0.740 0.625 0.971 1.355 1.286 1.437 1.259 
4/92 0.810 0.806 1.035 1.071 1.170 0.890 1.340 
11/92 0.909 0.886 0.971 0.800 1.212 1.129 1 	1.654 
4/93 0.589 0.536 0.919 0.803 0.792 0.873 1.281 
11/93 0.253 0.296 0.757 0.418 . 0.453 0.565 1.194 
110 BS 11/90 0.121 0.218 0.482 -0.140 0.990 0.786 0.321 
11/91 0.072 0.438 0.501 -0.159 1.025 1.261 0.286 
4/92 -0.012 0.406 0.504 0.105 0.793 0.665 0.195 
4/93 0.111 0.360 0.500 -0.007 0.677 0.701 1.043 
11/93 -0.017 1 	0.338 0.442 1 	0.180 0.824 0.848 0.630 
Table 11.4: Longitudinal recognition of merozoite surface proteins by adults 
from Brefet, The Gambia. Serum samples were collected at 6 month 
intervals during the dry season (April) or the wet, transmission season 
(November). Sera was diluted 1/1000 and IgG recognition of rAgs 
measured by ELISA. Positivity is determined as OD values above the 
mean+2SD of the European control sera. EGF-1A = 0.249, EGF-113 = 
0.229, 19/GST = 0.196, A2(T9/96) = 0.290, A3 = 0.139, B2(K1i) = 0.111 and 
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Figure 11.2: Longitudinal study of anti-malarial antibody levels in Gambian 
adults. Samples were collected at 6 month intervals from November 1990 to 
November 1993. The horizontal lines represent the upper limit of the normal 
range for non-immune sera. 	 227 
a) Donor 45JK; b)Donor 79AJ; c)Donorl 1 OBS 
11.3.2 Longitudinal recognition of P.falciparum merozoite surface antigens 
bj malaria exposed children: 
The recognition of merozoite surface antigens was determined for 20 
children from the village of Farafenni, using sera collected over a period of 
4 years during the dry seasons (June) and the wet seasons (November) 
(table 11.5). 
As expected, the overall recognition of these proteins is much lower in 
children but in contrast to the adults, the recognition of these rAgs was also 
less stable in children (Appendix 3, table 2). Few of the donors had a stable 
"responder" phenotype to any of the antigens. Donor 001008 was one of 
the few indivduals to show consistent positive recognition of some of the 
rAgs (table 11 .5, figure 11.3a) but even here, boosting of antibody 
concentration was evident in the wet season. 
The general pattern of recognition is that the antibody response fluctuates 
and is often boosted during the transmission season. This was apparent for 
donor E18003 (figure 11.3b); the antibody concentration is boosted during 
the transmission season in 1988, declines and is boosted again in 1991. 
Boosting of the antibody response can be seen clearly for donor P10016 
(figure 11.3c); the antibody response to the group specific regions of MSP2 
(A3 and 133) increases during the transmission season of 1989 and to a 
lesser extent in 1991. Donor E24009 also showed boosting of the antibody 
response to MSP2 in the 1990 and 1991 transmission seasons, but 
remains seronegative for MSP119. 
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DONOR IDATE I EGF- 1A EGF-1B 1 9/T 9/96) B2 (Ku) 
001008 5/88 0.002 0.022 0.013 6.170 1.182 0.614 1.356 
11/88 -0.117 0.051 0.199 ).226 1.342 0.593 1.689 
3/89 -0.041 0.011 .0.012 0.244 0.862 1.436 1.448 
111/89 0.121 0.435 0.513 0.799 1.358 0.873 0.839 
E18003 5/88 •0.073 0.127 .0.155 FO.222 0.185 0.239 0.067 
11/88 0.957 L906 0.764 0.081 1.317. 0.118 0.259 
3/90 •0.238 0.220 0.202 0.200 0.209 0.184 0.198 
11/90 -0.197 0.131 0.036 0.061 0.004 0.068 0.112 
6/91 0.025 0.030 0.031 10.211 •0.034 0.041 0.069  
111/91 0.672 0.701 0.446 0.074 0.214 0.075 10.316 
P10016 6/88 -0.107 0.122 0.119 0.049 0.319 0.044 0.121 
11/88 -0.051 0.073 0.4,619 0.113 1.995 0.026 1.031 
3/89 0.118 0.139 0.116 0.059 0.512 0.074 0.152 
11/89 -0.047 0.242 0.104 0.042 1.910 0.527 1.117 
6/91 -0.001 0.044 0.164 0.036 0.683 0.155 ).432 
11/91 -0.196 0.256 0.126 10.361 1.126 -0.180 ).656 
E24009 6/88 0.022 0.006 0.022 0.222 0.096 0.120 0.064 
11/88 0.021 0.006 0.026 0.005 0.115 0.156 0.107 
3/89 0.125 0.113 0.135 0.026 0.094 0.203 0.028 
3/90 0.004 0.131 0.089 0.125 0.000 0.179 0.028 
111/90 0.002 0.034 0.008 0.373 0.092 0.954 1.824 
5/91 -0.022 0.105 0.146 0.070 0.182 0.140 0.074 
11/91 0.028 ).230 ).611 6.179 1.064 -0.060 1.453 
Table 11.5: Longitudinal recognition of merozoite surface proteins by 
children from Farafenni, The Gambia. Serum samples were collected at 6 
month intervals during the dry season (June) or the wet, transmission 
season (November). Sera was diluted 1/1000 and lgG recognition of rAgs 
measured by ELISA. Positivity is determined as OD values above the 
mean+2SD of the European control sera; EGF-1A = 0.186, EGF-1B = 0.264, 
19/GST = 0.200, A2(T9/96) = 0.138, A3 = 0.245, B2(Kli) = 0.194 and 
B3(T9/105i) = 0.126. Positive responses are shaded. 
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Figure 11.3: Longitudinal study of anti-malarial antibody levels in Gambian 
children. Samples were collected at 6 month intervals from June 1988 to 
November 1991. The horizontal lines represent the upper limit of the normal 
range for non-immune sera. 	 230 a) Donor 001 008; b)Donor El 8003; c) Donor P10016 
11 .3.3 Is the pattern of recognition of MSP2 genetically determined?: 
i) Recognition of MSP2 by twins: 
The data from the adult donors suggested that some individuals were 
unable to make an Ab response to some of the rAgs. To investigate whether 
this is due to a genetically determined "non-responder" status, serum from 
15 pairs of monozygous (mz) twins and 21 pairs of dizygous (dz) twins were 
tested for recognition of MSP2 rAgs. Typical OD values are shown in table 
11.6. It is clear from this data that individual mz twin pairs can have very 
different antibody patterns to MSP2. 
Table 11.7 gives the number of concordant pairs i.e. the number of pairs of 
twins that are either both positive or both negative to individual rAgs. A x2 
test showed that there was no significant difference in the numbers of 
concordant (and discordant) mz or dz twins. Furthermore, if one looks at the 
difference in the specific OD values within individual twin pairs, there is no 
significant difference in the closeness of recognition of the rAgs by mz and 
dz twins (table 11.8). This data suggests that mz twins are no more likely to 
have similar anti-MSP2 Abs than are dz twins, suggesting that genetic 
factors are not a major determinant of recognition of MSP2. Furthermore, 
mz twins (with essentially identical malaria exposure, since in all cases they 
lived together for all their lives) can have markedly different antibody 
responses. 
The twins study and data analysis was carried out by R.Adair, an 
undergraduate student, as part of his Immunology Honours project, under 
my supervision. 
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Table 11.6: Examples of specific OD values for the Ab recognition of 
B3(T9/105i) by monozygous (mz) and dizygous (dz) twin pairs. Positive 
responders are shaded. 
* indicates discordant pairs. Concordancy was defined as OD values of a 
pair both being above or below the cut-off value (0.092), calculated as the 
mean +2SD of 8 European control sera. 
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rAg No. of concordant pairs X2 value p 
mz (n=15) dz (n=21) 
A2(T9/96) 7 16 3.14 >0.05 
A3 12 17 0.038 >0.5 
B2(K1i) 11 17 0.038 >0.5 
B3(T9/105i) 11 1 10.073 1 >0.5 
Table 11.7: Concordancy of Ab recogition of MSP2 rAgs by mz zand dz 
twins. 
Critical x2 value= 3.84, p=0.05. 
rAg Rank sum  Mann-Whitney 
U value 
p 
mz (n=15) I dz (n=21) 
A2(T9/96) 295.0 371.0 137.5 0.53 
A3 250.0 416.0 140.0 0.59 
B2(K1i) 301.0 365.0 134.5 0.47 
B3(T9/105i) 1257.5 1408.5 1137.0 10.57 
Table 11.8: Comparison of the median values for the ranked differences in 
OD value within pairs of mz and dz twins to each antigen, using a non-
parametric Mann-Whitney U-test. 
The difference in the specific OD value between paired samples of both mz 
and dz twins were calculated and ranked. The sum of the ranks was 
calculated for mz and dz pairs separately. The Mann-Whitney test was 
performed to determine the difference in the sum of the ranks. 
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ii) Relationship between presence of anti-MSP2 antibodies and HLA classil 
genotype: 
HLA class II typing had previously been performed (by Dr 0. Olerup, Center 
for BioTechnology, Karolinske Institute, Sweden) for the individuals 
recruited for the cross sectional study (sera collected from the villages 
around Farafenni, October 1988) and the morbidity study (sera collected 
from the villages around Farafenni, May 1988) [15]. Allelic RFLP patterns at 
each locus (DRB, DQA, DOB) were designated by Roman numerals and 
individual DRB -DQA -DOB haplotypes have been ascribed Arabic 
numerals; the HLA class II haplotypes in the Gambian population are 
shown in table 11.9. For the analysis, associations between immune 
responses and RFLP-defined DRB -DQA -DOB haplotype rather than 
individual class II alleles or associated serological specificities were 
determined, and only those DRB -DQA -DOB haplotypes present in the 
sample in sufficient numbers were included (i.e. at least 20 individuals for 
May 1988 samples and at least 10 indivivals for October 1988 samples). 
Antibody responses to all antigens were dichotomised into responders and 
nonresponders; a x 2  statistic was calculated from multiple logistic 
regression (table 11.9 and 11.10). The logistic regression allows for 
confounding effects of age, sex, and previous malaria control interventions. 
Ethnic group was not included as a confounder because its causal 
association with haplotype would have led to a masking of the association 
between haplotype and disease [270a]. 
Gambian villages are made up of compounds which accommodate large 
extended families. Therefore, these related individuals share HLA 
haplotypes, a variable number of background genes and also the same 
environment [270a]. The effect of shared environment and background 
genes were removed by stratifying on compound using conditional logistic 
regression, which restricts the analysis to the effect of HLA differences 
between individuals of the same compound (tables 11.9 and 11.10). 
Since the production of anti-MSP2 antibodies appears to be a consistent 
phenotype within one individual the possibility that non-responsiveness to 
MSP2 might be due to HLA class II dependent genetic restriction of the 
immune response was investigated. No significant associations were 




Haplotype RFLP pattern Associated Antibody recognition of MSP2 rAg 
number seologic specificity Phenotype number (frequency) 
DRB DOA DOB DR DO n A2 A3 B2 B3 
1 I I I 1 w5 8 3(0.38) 2(0.25) 1 (0.13) 4(0.50) 
2 II II II w15 w6 7 1(0.14) 1(0.14) 1(0.14) 1(0.14) 
7 * VII IV III w17 w2 31 13 (0.42) 9(0.29) 6(0.19) 17 (0.55) 
8 XV VI IV w18 w4 13 3(0.23) 2(0.15) 1(0.08) 5(0.38) 
9 XXII VI IV 3 w4 5 1 (0.20) 1 (0.20) 1 (0.20) 2(0.40) 
11 XII V IV 4 w8 18 8(0.44) 7(0.39) 6(0.33) 12 (0.67) 
12 * XII V VI 4 w2 26 12 (0.46) 9(0.35) 6(0.23) 15 (0.58) 
14 XIII V VI 7 w2 16 3(0.19) 3(0.19) 3(0.19) 10(0.63) 
15 * XIV V VI 7 w2 58 21(0.36) 21(0.36) 13 (0.22) 31(0.53) 
17 * V VI V w8 w7 30 11(0.37) 6(0.20) 4(0.13) 13 (0.43) 
18 V IV V w8 w7 18 6(0.33) 8(0.44) 5(0.28) 12 (0.67) 
21 * XVII V IX 9 w2 43 18(0.42) 11(0.26) 9(0.21) 21(0.49) 
22 * III I I wlO w5 60 17 (0.28) 14 (0.23) 6(0.10) 27 (0.45) 
23 VI IV V wil w7 14 6(0.43) 2(0.14) 4(0.29) 10(0.71) 
26 XX IV V W11 w7 9 2(0.22) 3(0.33) 0(0.00) 4(0.44) 
29 * XXI IV V W11 w7 119 38 (0.32) 25 (0.21) 15 (0.13) 62 (0.52) 
34 IX III II w13 w6 10 1(0.10) 0(0.00) 0(0.00) 1(0.10) 
35 IX III I w13 Wi 11 4(0.36) 4(0.36) 4(0.36) 5(0.45) 
37 XI III II w13 w6 9 3(0.33) 2(0.22) 2(0,22) 3(0.33) 
38 * X II I w13 w6 62 26 (0.42) 9(0.15) 9(0.15) 35 (0.56) 
39 XV IV V w13 w7 13 3(0.23) 3(0.23) 3(0.23) 9(0.69) 
7.29 8.66 7.08 5.31 
p 0.51 0.37 0.53 0.72 
2)X 2 4.35 7.34 
9.47 7.50 
p 0.82 0.50 0.50 0.48 
Table 11.10: Association between class II haplotypes and immune 
responses to MSP2 rAgs for a cross-section of the population aged 1-75 
years (n=119). Samples were collected at the end of the malaria 
transmission season (October 1988). 
* denotes those haplotypes which were present in the study population in 
sufficient numbers (>10) to allow evaluation of their association with 
immune responses. 
1) denotes standard logistic regression and 2)  denotes conditional logistic 
regression. 
a indicates d.f=3 as haplotypes 14 and 21 were not included due to small 
group sizes. 
N/A - the conditional model was not applicable to this set of data because 









DR 	DO n 
Antibody recognition of MSP2 rAg 
Phenotype number (frequency) 
A2 	A3 	B2 	B3 
1 I I I 1 w5 8 5(0.63) 8(1.00) 8(1.00) 6(0.75) 
2 II II II w15 w6 7 2(0.50) 4(1.00) 4(1.00) 4(1.00) 
7 VII IV III w17 w2 4 4(0.57) 7(1.00) 7(1.00) 7(1.00) 
8 XV VI IV w18 w4 1 1(1.00) 0(0.00) 0(0.00) 0(0.00) 
9 XXII VI IV 3 w4 7 2(0.29) 6(0.86) 6(0.86) 5(0.71) 
11 XII V IV 4 w8 5 2(0.40) 5(1.00) 5(1.00) 4(0.80) 
12 XII V VI 4 w2 1 1(1.00) 1(1.00) 1(1.00) 1(1.00) 
14 * XIII V VI 7 w2 11 7(0.64) 9(0.82) 9(0.82) 8(0.73) 
15 XIV V VI 7 w2 3 1(0.33) 3(1.00) 3(1.00) 3(1.00) 
17 V VI V w8 w7 5 3(0.60) 5(1.00) 3(0.60) 3(0.60) 
18 V IV V w8 w7 3 3(1.00) 3(1.00) 3(1.00) 2(0.67) 
21 * XVII V IX 9 w2 12 7(0.58) 12(l.00). 11(0.92) 11(0.92) 
22 * III I I wlO w5 16 10 (0.63) 14 (0.88) 13 (0.81) 13 (0.81) 
23 VI IV V W11 w7 5 4 (0.80) 5 (1.00) 4(0.80) 4(0.80) 
26 XX IV V W11 w7 4 2(0.50) 4(1.00) 4 (1.00) 1 (0.25) 
29 * XXI IV V W11 w7 60 31(0.52) 54 (0.90) 54 (0.90) 44 (0.73) 
34 IX III II w13 w6 4 2(0.50) 4 (100) 3 (0.75) 4(1.00) 
35 IX III I w13 wi 0 
37 XI III II w13 w6 3 2(0.67) 3(1.00) 3(1.00) 3(1.00) 
38 * X II I w13 w6 28 16 (0.57) 25 (0.89) 26 (0.93) 25 (0.89) 
39 XV IV V w13 w7 9 7(0.78) 9 (1.00) 9 (1.00) 7 (0.78) 
1 )X 2 2.44 4.67 
3.43 5.27 
p (d.f=5) 0.79 0.46 0.63 0.38 
5.48 0.05 N/A 2.69 
p (d.f =5) 0.36 1.00 a 0.75 
11.4 Discussion 
In this chapter I have examined the recognition of the major merozoite 
surface proteins of P.falciparum, MSP1 and MSP2, by longitudinal analysis 
of the seroreactivities of adults and children over a period of time. 
Cross-sectional analysis of the recognition of MSP2 indicated that antibody 
prevalence increased with age and that in each age group there were a 
number of non-responders. Longitudinal analysis enables us to determine 
if this non-responsive phenotype is stable. Serum samples were collected 
from adults and children from The Gambia during the dry season (minimal 
malaria transmission) and at the end of the wet season (maximum malaria 
transmission) for a period of 4 years. We found that the recognition of 
MSP119 and MSP2 in adults is, in general, a stable response. A stable 
antibody response is one which persists over time, even when malaria 
transmission is minimal. A possible explanation for this is that in these 
adults there is a persistence of antigen due to asymptomatic infections. 
Alternatively, adults may have developed an efficient memory response to 
malaria antigens and low level infections, when malaria transmission is 
minimal, are sufficient to boost the antibody levels to certain malaria 
antigens. The antibody levels were constant over time and many adults 
showed differential recognition of the antigens, and of specific epitopes 
within those antigens (table 11.4, figure 11.2a-c). There were certain 
donors who, despite being clinically immune to malaria, were consistently 
seronegative to certain rAgs whilst consistently recognising others. 
However, all the rAgs are known to be immunogenic and some individuals 
were consistently positive to all the rAgs tested. 
In contrast to the adults, children, who were still actively acquiring immunity 
to malaria, had more heterogeneous antibody profiles. There was clear 
evidence of seasonal variation in antibody concentration, with the Ab 
response being boosted during the malaria transmission season (figure 
11 .3b-c). It is possible to make an educated guess as to the genotype of the 
infecting parasites, based on the increase in antibody to the MSP2 
serogroup A or B proteins. In addition, it was evident from the data that 
MSP1 19  was less immunogenic in children than the MSP2 rAgs, despite 
the fact it is the least polymorphic. 
Thus our data follow the patterns observed for other P.falciparum antigens 
with a proportion of adults being consistently seronegative and boosting of 
antibody levels being more apparent in children and non-immunes. The 
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phenomenon of persistent non-responsiveness to specific malaria antigens 
has been reported in previous studies [27, 53, 253, 267, 270]. Riley et a! 
[267] found that non-responsiveness to the sexual stage antigen Pfs230 
was a stable phenotype which is fixed early in life and is apparent in 
children as young as 3-5 years of age. Also, around 40% of malaria-
immune adults tested from The Gambia were shown to be persistently 
seronegative to PfMSP1 with little seasonal variation despite major 
differences in parasite transmission rates throughout the year [270]. This is 
in contrast to the findings of Fruh et a! [115] who reported that seasonal 
differences were evident in the antibody levels in children and adults from a 
rural community in Mali, West Africa. However, this data was presented as a 
summary of the recognition of an age group rather than the antibody profile 
of an individual donor and as such, persistent non-responders may have 
been overlooked. Thus, in general, a stable non-responder phenotype 
occurs in clinically immune adults. Non-immunes (i.e. children and recently 
exposed adults) are more likely to have fluctuating Ab levels which are 
boosted during the transmission season, although persistent seropositivity 
has been observed in children as young as 3 years [267]. 
In the introduction to this chapter several possible explanations were 
outlined for this consistent non-responsiveness in adults who have had life-
long exposure to malaria. 
Antigen polymorphism may play a role as the recognition of variant 
epitopes is lower than for some less variant epitopes, but non-recogniton of 
the 1 9kD conserved region means it is not the whole answer. 
If confirmed, genetic regulation of the immune recognition of malaria 
antigens would have important implications for vaccine design. 
Comparison of the recognition of MSP2 by mz and dz twins indicates that 
non-responsiveness to MSP2 is not genetically determined; mz twins can 
clearly have discordant antibody recognition of the same rAg. Furthermore, 
the level of exposure to infection does not appear to be a major factor which 
regulates the recognition of MSP2 by these twin pairs: all twins had 
essentially identical malaria exposure since, in all cases, they had lived 
together for all their lives. In addition, the relationship between the 
presence of anti-MSP2 antibodies and HLA class II genotype was 
investigated for 444 individuals from The Gambia. A logistic regression 
analysis, considering the most frquent haplotypes, showed that there was 
no difference in the overall distribution of haplotypes between responders 
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and nonresponders. Furthermore, Rzepczyk et a! [279] analysed the 
responsiveness of T-cells from donors in Papua New Guinea and the 
Solomon Islands to peptides of MSP2. They found that no peptides were 
preferentially recognised in association with specific HLA class II antigens. 
I would like to propose an alternative explanation for stable non-
responsiveness in adults. 
A primary humoral immune response to most antigens results in the 
development of a long-lasting state of immunity. This state of immunity 
influences the secondary immune response to the priming antigen and may 
also alter subsequent immune responses to antigens that are structurally 
related to this priming antigen. This phenomenon has been termed "original 
antigenic sin" [107]. This cross-reactive property of immunity results in the 
previous immune experience of an individual having a direct bearing on the 
immune recognition of antigens that may be encountered in the future 
[111 a]. 
The phenomenon of original antigenic sin, also referred to as clonal 
imprinting [11 8a], was first observed when humans vaccinated against 
influenza virus were shown to produce antibodies of a higher titer against 
variants experienced in childhood than against the immunising antigen. It 
appears that the primary antibody response to the initial infecting strain 
becomes clonally dominant and may limit, suppress or prevent the effective 
triggering of other B cell clones that have the potential to respond to virus 
variants that are presented subsequently. Thus, epitopes that are cross-
reactive between the primary and boosting strain are recognised by 
memory B cells and antibody of the original specificity is produced. New 
epitopes are effectively ignored. 
There are certain criteria which need to be fulfilled in order for original 
antigenic sin to occur; 1) the antigens must have conserved and variable 
regions in order for cross-reactivity to occur, 2) there should be a number of 
variants in the infecting population so that subsequent infections are likely 
to be of differing strains, and 3) antigen should be present in limiting 
concentrations since competition for antigen between B cells with Ag 
receptors of differing affinity is a crucial factor in clonal selection [107]. 
One can envisage how malaria infections could induce a state of clonal 
imprinting resulting in persistent restricted responsiveness. Firstly, many 
malaria Ags have conserved and polymorphic epitopes, therefore cross-
reactions would be expected between variant Ags. Secondly, 
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polymorphisms are extensive and so it is likely that successive infections 
would be with parasites of differing genotypes. Thirdly, although initially 
there is a high antigenic load since individuals are exposed to repeated 
infections of high parasitaemia, as clinical immunity sets in, individuals 
experience infections with low, frequently subpatent parasitaemias and 
consequently Ag availability becomes a limiting factor, resulting in boosting 
of memory to cross-reactive epitopes. Thus, the observed differential 
recognition of epitopes in malaria-immune individuals could be the result of 
clonal imprinting. 
This explanation is virtually impossible to confirm in the field. One would be 
required to follow the antibody profiles of individuals form birth and 
determine the genotype of the infecting malaria parasites. However, the 
possibility that imprinting may occur in the perinatal period, following low 
doses of antigen in utero, cannot be ignored. In terms of vaccine design, 
one would be required to find an antigen that was universally immunogenic 
and could induce an effective immune response. The phenomenon of 
clonal imprinting could be utilised to redirect the immune response against 
epitopes which could induce protective immunity. This could be achieved 
more easily in young vaccinees, as less imprinting would have occurred. 
However, in those who have had long term exposure to malaria, target 
antigens would need to be presented in the absence of epitopes to which 
the immune system has already become imprinted. 
In summary, longitudinal studies have shown that patterns of malaria 
epitope recognition tend to become fixed in immune donors. Our data 
cannot easily be explained by a theory of genetically determined non-
responsiveness but do fit with a model of clonal imprinting. 
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12. General conclusions 
The purpose of this thesis has been to investigate and evaluate the 
immune recognition of the P.falciparum merozoite surface protein MSP2 by 
serum antibodies from a population in West Africa exposed to stable, 
endemic malaria. Such epidemiological studies facilitate our 
understanding of naturally acquired immune responses to malaria, and this 
knowledge is necessary for the assessment of malaria proteins for 
inclusion in a vaccine against malaria. 
12.1 Recombinant proteins representing P.falciparum MSP2 
Recombinant proteins representing various regions of MSP2 have been 
successfully expressed in E.coli and these have been used to investigate 
the immunogenicity and antigenicity of MSP2 in mice, after immunisation 
with rAgs, and in humans, after natural exposure to P.falciparum malaria. 
The antisera raised in mice were used to ensure that the rAgs reflected the 
antigenic characteristics and integrity of the native molecule, determined by 
IFA of mature schizont-infected erythrocytes and immunoblotting using 
SIDS-soluble schizont extracts (chapter 4). The antibody specificities of 
these antisera were investigated to evaluate the serological relationship 
between MSP2 serogroups A and B. Serological cross-reactivity was 
observed in mice, mediated through epitope(s) within the conserved C 
terminus. However, this does not reflect the antibody specificity in humans 
after natural infection. Antibodies to both serogroups of MSP2 are prevalent 
in adults from The Gambia (chapter 5). These antibodies are serogroup-
specific and do not cross-react. In this population, the conserved regions 
are poorly immunogenic whereas the central group-specific and repetitive 
sequences are immunodominant. Thus, I have shown that MSP2 rAgs are 
useful tools for detecting MSP2-specific antibody in individuals naturally 
exposed to malaria and that they permit mapping of the antibody response 
to defined regions of MSP2. These rAgs were used for the further 
investigation of qualitative and quantitative aspects of the serological 
immune recognition of MSP2. 
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12.2 Immune recognition of MSP2: 
Clinical immunity to malaria has characteristic features: 1) it develops after 
multiple infections and 2) it requires frequent boosting; the resulting 
immunity is not sterile and does not completely prevent reinfection. 
Many epidemiological studies have been carried out to investigate these 
characteristics of the development of clinical immunity to malaria. In doing 
so, the immune responses to particular malaria antigens are measured and 
their possible contribution to immunity to malaria is assessed. Individuals 
who have high levels of antimalarial antibodies in their serum may still be 
susceptible to attacks of malaria. These sera either lack antibody 
specificities that are critical to resistance, the antibodies are of low affinity or 
they have the wrong isotype to confer protection. Thus, although a large 
number of malaria proteins are recognised by the host's immune system 
during natural exposure to infection, it is likely that the immune responses 
to the majority of these antigens play no role in protecting the host from 
clinical malaria. 
In The Gambia, immune responses to MSP2 are acquired in an age-
dependent manner; antibody prevalence increases with age and mirror the 
decline in parasite density and prevalence in this population (chapter 6). In 
this respect, MSP2 is similar to many other P.falciparum antigens that have 
been studied [177, 263, 292]. 
Several hypotheses have been proposed for the slow development of 
immunity to malaria, these include a) poor immunogenicity, b) genetic 
restriction, c) induction of inappropriate immune responses, and d) 
antigenic diversity. I will discuss these hypotheses with regard to the 
immune recognition of MSP2. 
Firstly, the data indicate that MSP2 is not poorly immunogenic. Individuals 
known to have limited experience of malaria mount high antibody 
responses to the molecule and young children have MSP2-specific 
antibodies of comparable concentration and affinity to adults (chapter 6): 
Secondly, the immune recognition of MSP2 does not appear to be 
genetically restricted, although a proportion of individuals in all age groups 
remain seronegative to particular epitopes (chapter 11). 
Inappropriate immune responses may also contribute to the slow 
development of immunity. For instance, the presence of repeat sequences 
in many of the immunodominant antigens may act as a decoy mechanism 
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which allows the parasite to escape protective immunity, inhibiting the 
maturation of high affinity B cells and creating a "smokescreen" effect 
hiding more functionally important epitopes [7, 177]. However, the repetitive 
domains of MSP2 are not the only immunodominant regions; there is a 
high prevalence of antibodies to both repetitive and group specific 
sequences (chapter 5). This is in contrast to RESA and the S-antigens, for 
example, in which the repeated sequences are immunodominant. In MSP1, 
the repeat region represents a small proportion of the molecule and 
although these sequences are immunogenic they do not appear to be 
immunodominant. 
Therefore, I can discount several of the hypotheses mentioned above. 
MSP2 is immunogenic, immune responses to MSP2 are not genetically 
restricted and they are not necessarily inappropriate. However, the 
antigenic diversity of the molecule may well contribute to the gradually 
acquired immune recognition of MSP2. 
Many P.falciparum proteins are antigenically diverse. It is proposed that the 
chronically exposed host accumulates a repertoire of memory and effector 
cells capable of controlling infection by any given strain or variant of the 
parasite, immunity thus being essentially "strain-specific". If this were true, it 
would be extremely difficult to estimate how many infections would be 
necessary to develop immunity to the repertoire of MSP2 genotypes 
circulating in a community, particularly considering the extent of 
microheterogeneity of MSP2. It appears that although immune recognition 
of MSP2 is essentially strain-specific in non-immunes and semi-immunes, 
adolescents and adults develop "serotype-transcending" immunity to MSP2 
(chapter 9, 10). In adults, this presumably reflects exposure to multiple 
variants leading to a wide enough range of responses to cope with new 
infections. The rate at which this serotype-transcending immunity develops 
presumably depends on transmission rates and the frequency of mixed 
genotype infections. 
Strain-transcending immunity could arise in two ways, due to: 1) antibodies 
which recognise cross-reacting epitopes within the repeats, such that a few 
antibody clones could recognise the whole repertoire, or 2) antibodies 
which recognise group specific regions. The development of anti-group 
specific antibody may arise by continual restimulation of some B cell 
clones. In addition, cross-reacting antibodies may arise by chance after 
many infections, but these would probably be of lower affinity. 
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An alternative view to the accepted convention of gradually acquired 
immunity to malaria is that a few episodes of malaria are sufficient to induce 
naturally acquired immunity in adults, while the immune system of a child 
may be constitutionally less capable of mounting a protective response 
against the parasite [14-16]. However, in areas such as The Gambia, where 
all individuals are regularly exposed to malaria infection from infancy 
onwards, the effects of cumulative exposure cannot be separated from any 
possible effects of age itself. Differences between the immature and mature 
immune systems which might affect the rate of development of protective 
immunity may include the ability to recognise complex carbohydrate 
antigens, the relative prevalence of Thi versus Th2 cells and the capacity 
to induce switching to certain lg isotypes. 
Studies on the immune response to natural malaria infections have so far 
focused almost exclusively on the specificity of a response. Another 
important aspect is the quality of that response. Some antibody-mediated 
mechanisms of parasite clearance require cooperation with accessory cells 
and therefore it is necessary that antibodies of an appropriate subclass are 
produced to allow this interaction. The predominant subclass involved in 
the recognition of MSP2 is lgG3, an antibody subclass with cytophilic 
properties and high affinity for Fc receptors on monocytes and neutrophils 
(chapter 8). By examining a cross-section of the population, I have shown 
that the prevalence and mean OD of lgG3 antibodies increases with age. 
MSP2-specific lgG3 is the predominant subclass in adolescents and adults, 
but IgGi is more common in children under 10 years old (chapter 8). A 
similar trend for lgG3 antibody to increase with age was observed for the 
response to RESA by Beck et a! [20], but does not occur in response to 
MSP1 19  where the antibody response is predominantly IgGi in all age 
groups [93]. 
The data for MSP2 supports the hypothesis that qualitative differences in 
the antibody responses to malaria antigens may be important in the 
development of protective immunity [29]. It is tempting to propose that the 
immune protection in children is less efficient due to the lgG subclass 
distribution; although IgGi antibodies also have cytophilic properties and 
could also contribute to parasite clearance, it is possible that lgG3 
antibodies may be more efficient at cooperating with the accessory cells 
[329]. Whether this reflects a constitutional difference between children and 
adults or is simply the result of frequent re-exposure to antigen leading to 
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differential class switching is not known. Further investigation is required to 
elucidate the cytokines which trigger the subclass switch and induce the 
propensity for lgG3 antibodies to MSP2. 
In summary, the diversity of MSP2 appears to contribute to the gradually 
acquired immune response to the antigen, whereas the rate of 
development of serotype-transcending immunity and the rate of induction of 
a predominance of MSP2-specific lgG3 antibodies may well contribute to 
the rate at which protective immunity to malaria develops. 
Another accepted characteristic of clinical immunity to malaria is that its 
development and maintenance requires frequent boosting. I investigated 
the requirement for frequent boosting of the antibody response to MSP2 
(chapter 11). Malaria transmission is seasonal in many endemic areas, 
including The Gambia, and it is possible that antibody levels fluctuate over 
time, depending on the frequency of re-exposure to infection. If variation in 
antibody levels is considerable, then certain people may appear to be non-
responders on some occasions and responders on other occasions, 
particularly using samples taken during cross-sectional surveys. In order to 
obtain a realistic estimate of antibody prevalence, serum samples need to 
be collected from the same individuals over a period of months or years in 
longitudinal studies. I found that antibody responses vary seasonally in 
children whilst antibody levels in clinically immune adults remain stable 
(chapter 11). Therefore, it appears that in semi-immune children boosting is 
required, whereas in adults antibody responses remain stable irrespective 
of recent boosting. I also found that epitope recognition is selective, with 
individuals consistently recognising some epitopes whilst failing to 
recognise adjacent epitopes from the same antigen or epitopes from 
distinct antigens. These patterns of antibody recognition differed from 
person to person but were not genetically regulated. This selective 
recognition of MSP2 epitopes is a stable phenotype within a single 
individual and is reminiscent of the clonal imprinting or original antigenic 
sin observed for influenza virus [107]. It seems likely that prior exposure to 
one form of MSP2 primes an individual for an enhanced immune response 
when exposed to a closely related, antigenically cross-reactive form of 
MSP2 in a subsequent infection. This priming phenomenon may result in a 
lowered response to novel, antigenically distinct epitopes encountered at 
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the same time since low affinity naive B cells will compete poorly with 
memory B cells for antigen. 
The pattern in children was not unexpected; there was clear evidence of 
seasonal variation in antibody titres with antibody levels rising at the end of 
the malaria transmission season. Specific antibody boosting is apparent in 
the children who attended the MRC outpatients clinic with acute, 
uncomplicated malaria (chapter 10). The antibody profile of these children 
can be clearly related to the antigenic profile of the parasites with which an 
individual was infected. However, even in children it was evident that 
responses to some epitopes were being boosted more readily than for 
other epitopes. For example, the antigenically conserved epitope MSP1 19 
would have been present during every infection but the response to it was 
boosted in some children but not in others. 
The phenomenon of selective immune recognition has been observed for 
other malaria antigens: MSP1 [115, 270],RESA [26, 27, 240] and Pfs230 
[267].Children lose their MSP1-specific antibodies rapidly after cessation of 
infection, while the adult humoral response remains high throughout the 
year [115]. Selective recognition of MSP1 epitopes has also been 
observed, with a proportion of individuals remaining persistently 
seronegative [270]. The level of recognition of RESA varies among the 
population [27, 240], and this is not readily explained by differences in 
exposure to malaria [253]. The authors conclude that the most probable 
explanation for the existence of a group of adults with low RESA response 
is an inherent difference in the antibody response to the antigen. The 
genetic regulation of the RESA antibody responses is thought to reflect the 
impact of factors encoded by genes outwith the HLA class II region [293, 
327]. The fact that the prevalence of antibodies to RESA differs among 
different ethnic groups in The Gambia supports this conclusion [265]. 
However, there is no real evidence for genetic regulation of the response to 
RESA. 
In Madagascar, where there was an epidemic outbreak of P.falciparum 
after 20 years without malaria transmission, clear seasonal variation in the 
titre of anti-RESA antibodies in children and adults was observed [53]. This 
supports the idea that antibody levels stabilise in malaria-immune 
individuals but fluctuate according to recent exposure in non-immunes or 
semi-immune individuals. The age at which the antibody levels stabilise 
would probably depend on the intensity of malaria transmission and on the 
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diversity of the antigen. Seropositivity to both RESA and Pf230, essentially 
conserved antigens, stabilise in children aged 3-5 years [26, 267], whereas 
the responses to MSP1 and MSP2, variable antigens, seem not to stabilise 
until later in life. 
Hence, recognition of MSP2 does not appear to be genetically determined, 
but that antibody repertoires tend to become fixed in clinically immune 
adults as a result of clonal imprinting. 
12.3 MSP2 as a vaccine candidate: 
The evaluation of potential vaccine antigens requires the understanding of 
several factors. Information about the structural characteristics of the 
antigen is essential in order to select the most appropriate expression 
system to produce a recombinant protein which is antigenically equivalent 
to its native counterpart. Studies are required to elucidate the 
immunogenicity of the antigen during natural infection, the effect of host 
genetics on the ability of an individual to mount an immune response, the 
stability of the immune response and, importantly, the correlation between 
the development of the immune response and clinical markers of 
resistance. In addition, the effect of antigenic diversity on all of the above 
must be assessed. 
Many of the asexual stage antigens described in section 1.4 have been 
structurally defined and expressed as synthetic polypeptides. The 
importance of conformation to protein structure, and consequently to 
protein antigenicity, is greatest for proteins in which secondary structure is 
stabilised by multiple intrachain disulphide bonds [49]. Despite the 
presence of multiple cysteine residues, MSP1 has been successfully 
expressed in eukaryotic and prokaryotic systems [38, 228, 266] and AMA-1 
has been expressed using the baculovirus system [65, 323]; in both cases, 
immunogenicity is dependent on the correct conformation of disulphide 
bonds [38, 65]. The structure of MSP2 is not dependent on the formation of 
disulphide bonds, nevertheless, it is still necessary to ensure the structural 
integrity of recombinant proteins (chapter 4). Stable, soluble polypeptides 
of MSP2 (expressed as fusions with GST), have been produced which 
reflect the antigenic characteristics of native MSP2. One exception is a 
short rAg representing the conserved N-terminus; after immunisation, mice 
produced antibody of low titre against the immunogen and these antibodies 
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did not recognise the native protein in IFA or immunoblotting. Thus, the N-
terminus appears to be poorly immunogenic. Contradictory results have 
been obtained in other studies. In agreement with our results, Rzepczyk et 
a! [277] found that immunisation of mice with an N terminal peptide 
produced essentially no antibody response. In contrast, others found that 
peptides from the N terminus are capable of raising appropriate antibodies 
in mice, even in the absence of a carrier protein [167, 168, 284]. Thus, it 
appears that although murine B cell epitopes are present in the N terminal 
sequence, our construct was not recognised, even though T cell help can 
be provided by GST and both inbred and outbred strains of mice were used 
(chapter 4). 
Previous studies have identified epitopes within the dimorphic and 
polymorphic regions of MSP2 as targets of invasion inhibitory mAb [55, 
101, 109, 220, 255, 310]. These mAbs also recognised the rAgs (chapter 
4). Naturally acquired antibodies to MSP2 are directed against dimorphic 
and polymorphic domains rather than the conserved domains. The reasons 
for this are not clear. Conserved epitopes of other malaria antigens are 
immunogenic during natural infection. For example, RESA is antigenically 
conserved among different strains [235] but is recognised at high frequency 
with repeat sequences being immunodominant [235]. Like MSP2, MSP1 
contains conserved and variable regions, but antibodies are directed 
against epitopes mapping to polymorphic, dimorphic and conserved 
regions of the molecule [93, 115, 228, 266, 270, 324]. However, conserved 
epitopes located very close to the C terminus of MSP1 are recognised less 
frequently than upstream dimorphic epitopes [93, 266] suggesting that 
there maybe a physical or structural reason for poor immunogenicity, in that 
epitopes in membrane associated regions of the protein are inaccessible. 
Epitopes in the N terminal region of the native MSP2 molecule are perhaps 
also inaccessible for immune recognition and antibody binding. 
Another possibility is that during the evolution of the parasite, some malaria 
antigens/epitopes have been selected for because they contain few T and 
B cell epitopes [124]. 
Antibody recognition of MSP2 in immune adults is stable and persists even 
when malaria transmission is minimal. Distinct patterns of recognition 
occur, but this does not reflect differences in exposure or genetic regulation 
(chapter 11). Stable antibody response in adults is encouraging for vaccine 
development 'as it suggests that there is good immunological memory. In 
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addition, the antibody response is rapidly boosted by reinfection in 
children, therefore vaccination in early childhood should induce a level of 
immunity equivalent to that occurring naturally in adults and may be 
enough to provide life time protection against malaria. 
It is important to evaluate whether acquired immunity to a particular antigen 
contributes to immunity to malaria. The analysis of the association of 
immune recognition with resistance to clinical malaria is complex. 
Overinterpretation of the data must be avoided, but statistically significant 
associations obviously warrant further investigation. The interpretation of 
epidemiological studies is complicated by difficulties in defining and 
measuring morbidity due to malaria [266], and the assessment of the 
immune response is confounded by such factors as polymorphism of the 
host and parasite populations. 
As parasite frequency and density, and severity of clinical symptoms are 
age-dependent, many seroepidemiological studies concentrate on the 
dynamics of the acquisition of antibodies with age. The acquisition of 
antibodies to MSP2 parallels the decline in parasitaemia and parasite 
density (chapter 6), suggesting a role for MSP2-specific antibodies in 
parasite clearance; however, the data do not indicate a direct, causative 
relationship. Most epidemiological studies show that antibodies to 
particular malaria antigens increase in childhood, but it is unlikely that all of 
these are involved in protective immunity. An increase in antibody with age 
may be associated with protection or may just be a measure of exposure. 
To separate these two effects, longitudinal studies of individuals, their 
immune responses and clinical status are required. Therefore, the immune 
recognition of MSP2 was correlated directly with the clinical status of a 
cohort of semi-immune children in a longitudinal, prospective study 
(chapter 7). Antibodies to epitopes in the 5' repeat/group specific region of 
serogroup B (133) appear to confer resistance to clinical malaria. However, 
no association was found for the other antigens tested (A2, A3 and 132). 
There are three possible explanations for this finding: 1) only antibodies to 
B3 are in fact able to mediate MSP2-associated protection; 2) antibody to 
the other proteins are protective, but the extensive sequence and antigenic 
diversity in these regions precludes the demonstration of the protective 
effect of any one representative sequence; 3) antibody responses to 
different regions of MSP2 (and possibly other merozoite surface proteins) 
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are closely associated, so preventing the demonstration of a protective 
effect of any one antigen or epitope, i.e. MSP2 may be necessary but not 
sufficient for a protective antibody response. 
Antibodies to MSP1 [93, 115, 265], AMA-1[323] and RESA [341] are also 
acquired in an age-dependent manner. Antibodies to certain regions of 
MSP1 are associated with reduced malaria morbidity [228, 266]. 
Contradictory results have been reported for antibodies to RESA; 
increasing antibody titres are associated with decreasing parasitaemia and 
resistance to high parasitaemia [3, 240, 265, 341] however, antibodies to 
RESA epitopes have also been associated with clinical attacks of malaria 
[265], but this may well reflect antibody boosting by concurrent infection. In 
contrast, antibody responses to some antigens (such as the CS protein) 
have been shown repeatedly to have no association with protective 
immunity [197, 264]. Epidemiological studies, although not perfect, do 
however differentiate non protective antigens from possibly protective ones. 
More conclusive evidence for protection relies on clinical studies. 
It can be argued that if antigenic polymorphism is indeed an important 
immune evasion mechanism for the parasite, it should correlate with the 
degree of immune pressure imposed on the parasite antigens by naturally 
acquired anti-parasite immunity [215]. This is true, to the extent that the 
highest degree of antigenic polymorphism has been shown in stages of the 
parasite, including the asexual blood stages, against which potent 
immunity is eventually mounted, particularly antigens on the surface 
membrane of extracellular forms of the parasite exposed to the vertebrate 
immune system. However, there are also some relatively invariant 
antigens/epitopes that are thought to be the targets of anti-parasite 
immunity. Many of the parasite molecules that are critical for biological 
function are probably conserved. Any change in the antigenicity of critical 
molecules to avoid immune attack would need to preserve this function. 
Ironically, the deployment of antimalarial vaccines itself may provide the 
most direct evidence as to whether polymorphism is an important immune 
evasion mechanism in malaria [215]. 
Polymorphism of malaria antigens among natural parasite populations is 
extensive and has been described for both B and T cell epitopes of many 
antigens of all stages of the parasite. The extent to which this diversity 
could affect the efficiency of a vaccine would depend on the degree of 
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variability (in natural isolates) of the targets of immunity and the extent to 
which mutations in the target genes are compatible with parasite viability. 
Malaria antigens can be divided into three groups with regard to their 
antigenic polymorphism: 
those that are essentially conserved, perhaps exhibiting minor 
polymorphisms involving point mutations; 
those that exhibit allelic dimorphism, with regions (which are usually 
repetitive) of truly polymorphic sequence; 
those where the polymorphism is extensive, and where only limited C 
and N terminal sequence conservation indicates that these genes are in 
fact alleles at a single locus, e.g. S antigens and probably also PfEMP1. 
Any of these antigens may also contain regions of tandemly repeated 
sequences. 
Each group has advantages and disadvantages for vaccine development. 
Those antigens which are essentially conserved make attractive targets 
because immune responses induced against such antigens would be 
effective against all isolates. However, it may be that minor amino acid 
changes could significantly alter the antigenicity whilst maintaining the 
biological function of the molecule. Therefore, the trick is to identify 
functionally important molecules. 
Antigens that exhibit allelic dimorphism have the advantage that the 
dimorphic sequences are conserved within each allelic family. The fact that 
these genes can be grouped into allelic families indicates that some 
selective constraints apply [10]. The different allelic forms of these antigens 
would not become fixed in the parasite population and be widely dispersed 
unless they provide a biologic advantage for the parasite. However, these 
dimorphic sequences often flank repetitive sequences which could divert 
the immune response from critical epitopes through immunodominance or 
induce T-independent responses by cross-linking surface Ig on B cells. It 
may be that immunisation with epitopes from the dimorphic domains, 
delivered in the absence of repetitive sequences, could enable the rapid 
development of protective immunity [179]. 
Antigens that are extremely polymorphic would be less useful as targets of 
vaccine induced immunity, as the immune responses would only be 
effective against a limited repertoire of parasites. On the other hand, a 
vaccine may be able to selectively exploit any sequence conservation at 
the N and C termini. 
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Among current contenders, EBA-175, the rhoptry protein complex antigen 
RAP-1 and RESA are non-polymorphic [263, 292]. AMA-1 exhibits limited 
polymorphisms (diversity is generated by non-conservative point 
mutations) [8] and MSP1 consists of 17 blocks of conserved, dimorphic or 
polymorphic sequences [315] with additional polymorphism is created by 
intragenic recombination. However, it appears that the conserved 19kDa 
fragment may be an important target of MSP1-specific antibodies [28, 38, 
93]. Of these, several clinical and preclinical trials with RESA have been 
disappointing and this antigen is now generally considered as unsuitable 
for a malaria vaccine. Evaluation of the other antigens is continuing, with 
particularly promising recent results for AMA-1 and PfMSP1 ig. 
The extent of diversity in MSP2 is considerable; although the molecule can 
be classified into two basic prototypes, the tandemly repeated sequences 
can vary extensively in number and sequence. Like MSP1, within an allelic 
family point mutations, insertions, deletions and intragenic recombination 
increase variability. The effect of antigenic diversity of MSP2 on immune 
recognition remains to be fully elucidated, but the data presented in this 
thesis indicates that polymorphism plays a major role in the immune 
recognition of the molecule. Preliminary studies indicate that the antibody 
profile of semi-immune children is clearly related to the specific serotype of 
the parasite with which that child was infected (chapter iO). Nonetheless, 
antibodies to epitopes in the dimorphic regions are prevalent and, if these 
were associated with protection (as may be the case for serogroup B), it 
may only be necessary to include sequences from the two major 
serogroups in a vaccine. Success may come from artificially raising 
antibodies to the conserved or semi-conserved sequences to which the 
natural immune response is rare or suppressed, thus circumventing the 
problem of antigenic diversity. Studies in mice have shown the conserved 
C-terminus of MSP2 to be immunogenic (chapter 4) and to induce 
protective antibodies [284]. The fact that the natural immune response to 
these regions is poor and the sequence is highly conserved, indicates that 
these domains may be essential for parasite survival. 
12.4 Future directions: 
To conclude, I think that MSP2 is an antigen worthy of further investigation 
to fully clarify its potential as a vaccine candidate. 
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I have proposed that antibodies to MSP2 may be important in parasite 
clearance and the subclass of these antibodies may be critical in conferring 
protection. Protective antibodies may have a limited direct effect upon 
parasite growth and invasion, but rather act in cooperation with accessory 
cells. Therefore, it would be of interest to investigate the ability of MSP2-
specific antibodies to exert an antibody-dependent inhibitory effect on 
parasite growth in cooperation with normal blood monocytes. 
In addition I have shown that antibody levels in children are boosted by 
current infection and the specificity of these antibodies can be clearly 
related to the antigenic profile of the infecting parasites. The effect of these 
antibodies on subsequent infections needs to be assessed in longitudinal 
epidemiological studies. The hypothesis would be that pre-existing 
antibody to a particular MSP2 serotype would prevent further infection with 
that serotype, but would not protect against infection with an antigenically 
distinct serotype. 
Direct immunisation studies are also required in animal models and 
humans. In practical terms it is necessary to determine the factors which 
influence the switch to production of lgG3 antibodies and the immunisation 
methods required to mimic this. Of course vaccination against MSP2 may 
encourage the emergence of mutant forms of the parasite. We have already 
seen that the parasite is viable without the R2 repeat region of serogroup B 
(chapter 10). Thus, identification of regions of the molecule that are 
functionally important and on which parasite survival is dependent , is a 
strategy by which we may prevent the evolution of such variants. 
To vaccinate against malaria is to interfere in a host-parasite system of 
evolutionary success. Measures that sustain a selection pressure on the 
parasite may be countered by the parasite through the evolution of new 
variants. The use of a multi-stage vaccine may prevent this, or at least slow 
it down, and inclusion of a transmission-blocking component would stop 
the transmission and spread of these mutants. 
Whatever the vaccine of choice, the interest of science and society should 
not take precedence over the consideration of the individual's well-being. It 
is possible that while a malaria vaccine trial may reduce transmission and 
benefit the community as a whole, the vaccinated individual may, as 
artificial immunity wanes, become more susceptible to severe malaria than 
he was before being vaccinated. Furthermore, short-lived immunity could 
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result in a shift of the age related pattern of malaria-related disease and 
mortality. An unsuccessful vaccination campaign could convert an area of 
stable endemic malaria to one which is subject to unstable epidemic 
malaria. Thus, vaccine trials have to be considered in an environmental 
and sociological setting, where controlling malaria may eliminate some 
problems and introduce new ones. For example, significant reduction in 
childhood mortality may worsen the effects of overpopulation in some 
communities. 
Whilst awaiting the results of trials of the synthetic malaria vaccine SPf66 in 
The Gambia and Thailand, the results from Tanzania are encouraging, 
showing at the very least that vaccination against malaria is a reality [5]. Of 
course modifications and improvements will be needed. By normal 
standards, a vaccine that reduces cases by only one third (as obtained for 
SPf66) would not be acceptable. Vaccines against polio or measles, for 
example, would be expected to reduce cases by 90%. But malaria is 
perhaps a special case because even natural immunity is only partial, 
years of research have failed to produce a vaccine and the world situation 
worsens. We need to ask: is the need to tackle the disease so great that a 
suboptimal vaccine (such as SPf66) should be given to all those that want it 
in the hope that millions of cases of malaria might be averted? Or should 
scientists regard SPf66 as the first step, the proof of a principle that should 
now be refined and therefore redouble their efforts to find a more effective 
vaccine? [36]. There are ethical arguments for and against the use of a 
suboptimal vaccine. Arguments for are that infections (and therefore 
presumably deaths) would be prevented. Arguments against are the false 
feeling of security engendered by vaccination and the possible decrease in 
alternate malaria prevention methods, the use of limited Third World 
resources for an ineffective vaccine and the difficulty of subsequently 
introducing a (possibly) more effective alternative. 
SPf66 does have its limitations. It currently cannot be recommended for use 
before a child's first birthday, since there is no evidence that it is safe or 
efficacious in this age group [316]. An age restriction would seriously limit 
vaccine effectiveness in areas of extremely high transmission where a 
large proportion of the malaria morbidity is in infants. Furthermore, it is not 
known how SPf66 mediates protection, and there is no evidence that the 
vaccine protects against death due to malaria. The duration of SPf66- 
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mediated protection under different levels of exposure is not known, nor is it 
known to what extent natural boosting occurs [316]. There is a danger that 
public opinion, in assuming that there is now an effective vaccine against 
malaria, will turn against investment of scientific resources in further 
malaria vaccine research. It is vital therefore that researchers in the field 
stress that SPf66 - whilst a vindication of previous attempts to make a 
vaccine - is only the beginning of the process. 
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Appendix 1 
1A: Schematic representation of MSP2 recombinant proteins - see inside 
back cover. 
113: Schematic representation of putative epitopes of MSP2-specific 
monoclonal antibodies - see inside back cover. 
Appendix 2 
Antib ody * Working dilution Isotype Epitope and location 
Anti-MSP1 
9.8-4-4-1 1000 IgGi conserved 
12.2-1-1 200 lgGl block 2 (3D7-type) 
123D3.10 1000 lgG2b block 2 (CAMP-type) 
CE2.1 § 50 IgGi block 2 (CAMP-type) 
31.1-8t neat IgGi block 2 (R033-type) 
13.2-3 2000 IgGi block 3 (Ki-type) 
9.5-1-5-1 500 lgG2b block 3 (MAD-20-type) 
10-2B 1000 lgG2a block 4 (Ki -type) 
12.1-5-4 2000 IgGi block 4 (MAD-20-type) 
127B1 i.ia 300 lgGl block 6-16 (MAD-20-type) 
9.262a 1000 IgGi 
9.7_1a 500 IgGi 
10.32a 500 lgGl 
127F1.1a 100 IgGi 
iiCb 500 IgGi block 6-16 (K1 -type) 
73...7b 500 lgG2a 
7 • 62b 1000 IgGi 
1000 IgGi 
104 lgGl 
17.13b 1000 IgGi 
111 .4 1000 IgGi block 16-17 (Ki -type) 
Anti-MSP2 
13.4-2-1 500 IgGi T9/96 specific -Ri repeat 
GSAG 
440 200 1gM FVO specific - Al repeat 
85Dd 200 1gM 
500 IgGi Serogroup A specific - 
dimorphic 
500 IgGi 
12.7-1-2-4 500 IgGi 
8G10/48 1000 lgG2b Serogroup B - STNS 
8F6/49 50 lgG3 Serogroup B - DTPTATE 
anti-7G8 300 Serogroup A -Ri repeats 
anti-ThaiTn 300 mouse sera Serogroup A -Ri repeats 
anti-T9/96 400 Serogroup A -Ri repeats 
Anti-Exp 1 
5.1-4 500 lgGl 
Characteristics of monoclonal antibodies used for parasite typing. 
mAb epitopes marked by idenctical symbols (a,b,c,d,e) exhibit identical 
allelic distributions. 
Mouse sera were pooled from bleeds 2 & 3 after the second 
immunisation. 
*Details  of mAbs are given in Conway et a! [66] and references therein. 
§ mAb produced by Locher, Hawaii; t mAb produced by McBride, 
Edinburgh. 
Access to mAb and serum stocks was kindly provided by Dr J McBride. 
Appendix 3 
MSP1 rAgs MSP2 rAgs 
Donor Sample EGF-1A EGF-1B 19/GST A2 A3 Bi B3 
date 
Mean + 0.249 0.229 0.196 0.290 0.139 0.111 0.146 
2SD 
12 TS 11/90 0.090 -0.054 -0.031 0.020 0.063 -0.056 -0.058 
11/91 -0.350 -0.352 -0.250 0.305 0.538 1.113 0.573 
4/92 -0.187 -0.199 -0.213 0.171 0.520 0.238 0.188 
11/92 -0.242 -0.173 -0.279 -0.060 0.526 0.435 0.689 
4/93 -0.168 -0.027 -0.121 0.061 0.487 1.048 0.842 
11/93 -0.088 -0.113 0.125 0.125 0.399 0.996 0.952 
13 	A 11/90 
11/91 0.264 0.042 0.786 -0.004 0.582 1.609 1.020 
4/92 0.067 0.125 0.761 -0.022 0.624 1.573 0.866 
11/92 -0.003 0.197 0.861 0.033 0.460 1.156 0.470 
4/93 0.051 0.244 0.824 0.051 0.421 1.309 0.639 
11/93 -0.110 -0.113 0.701 -0.084 0.326 1.073 0.706 
127 	J 11/90 
11/91 0.866 0.999 0.378 0.425 0.675 1.133 0.221 
4/92 0.940 1.474 0.701 0.189 0.459 0.267 0.021 
11/92 0.819 0.834 0.498 0.061 0.475 0.332 -0.035 
4/93 
11/93 0.816 0.836 0.417 0.304 0.430 0.498 0.034 
109 	11/90 0.321 0.145 0.179 0.222 0.081 0.051 0.129 
FWS 
11/91 0.036 0.189 0.469 0.114 0.507 0.094 0.057 
4/92 0.120 0.011 0.095 0.024 0.021 -0.004 0.064 
11/92 0.047 0.057 0.442 0.122 0.329 0.090 0.076 
4/93 
11/93 0.153 0.033 0.456 0.109 0.209 0.062 0.095 
31 S 	11/90 0.316 0.101 0.264 0.233 0.385 0.312 0.046 
11/91 0.093 0.077 0.411 0.168 0.552 0.580 0.038 
4/92 -0.088 -0.112 0.112 -0.045 0.346 0.406 -0.025 
11/92 -0.062 -0.040 0.218 0.033 0.363 0.706 0.011 
4/93 0.224 0.485 0.613 0.372 0.825 0.598 0.000 
11/93 0.350 0.319 0.596 1.155 0.621 0.552 -0.044 
104 FK 11/90 0.153 0.143 0.199 0.984 0.148 0.379 0.240 
11/91 0.110 -0.034 0.008 0.250 0.054 0.370 -0.067 
4/92 0.152 0.132 0.090 0.209 0.214 0.933 0.105 
11/92 0.676 0.727 0.476 0.872 0.457 0.614 0.095 
4/93 
11/93 0.453 0.285 0.322 0.036 0.772 0.498 0.210 
53 MC 11/90 	0.02.0 -0.034 -0.026 0.594 0.433 0.001 0.107 
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MSP1 rAgs MSP2 rAgs 
Donor Sample EGF-1A EGF-1B 19/GST A2 A3 Bi B3 
date 
Mean+ 0.249 0.229 0.196 0.290 0.139 0.111 0.146 
25D 
12 TS 11/90 0.090 -0.054 -0.031 0.020 0.063 -0.056 -0.058 
11/91 -0.350 -0.352 -0.250 0.305 0.538 1.113 0.573 
4/92 -0.187 -0.199 -0.213 0.171 0.520 0.238 0.188 
11/92 -0.242 -0.173 -0.279 -0.060 0.526 0.435 0.689 
4/93 -0.168 -0.027 -0.121 0.061 0.487 1.048 0.842 
11/93 -0.088 -0.113 0.125 0.125 0.399 0.996 0.952 
13 	A 11/90 
11/91 0.264 0.042 0.786 -0.004 0.582 1.609 1.020 
4/92 0.067 0.125 0.761 -0.022 0.624 1.573 0.866 
11/92 -0.003 0.197 0.861 0.033 0.460 1.156 0.470 
4/93 0.051 0.244 0.824 0.051 0.421 1.309 0.639 
11/93 -0.110 -0.113 0.701 -0.084 0.326 1.073 0.706 
127 	J 11/90 
11/91 0.866 0.999 0.378 0.425 0.675 1.133 0.221 
4/92 0.940 1.474 0.701 0.189 0.459 0.267 0.021 
11/92 0.819 0.834 0.498 0.061 0.475 0.332 -0.035 
4/93 
11/93 0.816 0.836 0.417 0.304 0.430 0.498 0.034 
109 11/90 0.321 0.145 0.179 0.222 0.081 0.051 0.129 
FWS 
11/91 0.036 0.189 0.469 0.114 0.507 0.094 0.057 
4/92 0.120 0.011 0.095 0.024 0.021 -0.004 0.064 
11/92 0.047 0.057 0.442 0.122 0.329 0.090 0.076 
4/93 
11/93 0.153 0.033 0.456 0.109 0.209 0.062 0.095 
31 S 11/90 0.316 0.101 0.264 0.233 0.385 0.312 0.046 
11/91 0.093 0.077 0.411 0.168 0.552 0.580 0.038 
4/92 -0.088 -0.112 0.112 -0.045 0.346 0.406 -0.025 
11/92 -0.062 -0.040 0.218 0.033 0.363 0.706 0.011 
4/93 0.224 0.485 0.613 0.372 0.825 0.598 0.000 
11/93 0.350 0.319 0.596 1.155 0.621 0.552 -0.044 
104 F 11/90 	0.153 0.143 0.199 0.984 0.148 0.379 0.240 
11/91 0.110 -0.034 0.008 0.250 0.054 0.370 -0.067 
4/92 0.152 0.132 0.090 0.209 0.214 0.933 0.105 
11/92 0.676 0.727 0.476 0.872 0.457 0.614 0.095 
4/93 
11/93 0.453 0.285 0.322 0.036 0.772 0.498 0.210 












0.039 -0.030 0.000 0.493 0.434 0.027 -0.007 -0.020 -0.076 -0.100 0.245 0.210 -0.093 -0.040 0.004 -0.065 0.080 0.217 0.120 -0.090 -0.012 0.143 -0.015 0.039 0.908 0.431 -0.012 0.005 
0.139 0.229 0.426 0.449 0.121 0.073 0.487 0.175 0.199 0.760 0.240 0.218 0.144 0.818 0.057 0.136 0.479 0.188 0.169 0.048 0.515 0.429 0.425 0.777 0.486 0.146 0.130 0.550 
-0.062 -0.083 0.004 0.177 
0.091 0.077 0.010 0.152 
0.051 0.045 0.129 0.185 
0.035 0.118 -0.013 0.130 
-0.181 -0.181 -0.223 -0.080 
0.107 0.003 0.101 0.045 
0.245 -0.034 -0.021 
0.734 0.158 0.129 
0.546 0.168 0.077 
0.541 -0.014 0.078 
0.244 -0.119 -0.032 
0.535 0.089 0.112 















1.355 1.286 1.437 1.259 
















0.803 0.792 0.873 1.281 
0.418 0.453 0.565 1.194 









1.042 0.912 0.490 1.114 
















0.821 0.734 0.387 0.880 
0.640 0.737 0.826 1.300 









0.252 0.021 1.170 0.016 














0.047 0.195 -0.004 0.545 0.021 
-0.198 0.470 -0.104 0.789 -0.096 
35 BS 	11/90 
11/91 






0.279 0.674 0.258 0.427 0.016 
















0.033 0.297 0.120 1.057 -0.134 
0.409 0.473 0.202 0.366 -0.024 
114 	11/90 
MSS 
11/91 0.722 0.743 0.407 1.072 0.660 0.087 0.435 
11/92 0.044 0.004 0.059 -0.038 0.429 0.912 0.674 
4/93 -0.108 -0.123 0.277 -0.104 0.269 1.375 0.541 
11/93 -0.125 -0.148 0.300 0.394 0.893 1.143 0.053 
34 BS 11/90 
11/91 	-0.064 -0.150 0.109 0.858 0.805 1.235 0.264 
4/92 -0.135 -0.048 0.023 0.756 0.409 0.990 0.082 
11/92 	-0.136 -0.148 0.026 0.910 0.344 1.201 0.254 
4/93 
11/93 
4 FB 11/90 0.331 0.353 0.268 0.079 0.005 0.240 0.202 
11/91 0.700 0.633 0.692 0.032 -0.009 0.973 0.178 
4/92 0.391 0.425 0.482 0.064 -0.036 0.339 0.064 
11/92 0.370 0.584 0.447 0.134 0.301 0.549 0.122 
4/93 0.189 0.261 0.304 0.027 -0.045 0.238 0.214 
11/93 0.363 0.373 0.388 0.049 0.169 0.263 0.453 
117 KB 11/90 0.047 0.057 -0.009 0.066 0.500 0.022 0.180 
11/91 -0.065 -0.037 -0.056 -0.040 0.953 0.489 0.646 
4/92 -0.061 -0.004 0.000 0.266 0.656 0.253 0.123 
11/92 0.103 0.298 0.216 0.374 1.167 0.924 0.668 
4/93 -0.052 0.020 0.042 1.075 0.797 0.141 0.375 
11/93 0.049 0.138 0.106 1.030 1.097 1.521 0.198 
1 MS 11/90 
v. high 11/91 -0.529 -0.723 -0.659 -0.246 -0.185 -0.200 -0.325 
GST 
4/92 -0.881 -0.875 -0.778 -0.202 -0.403 -0.408 -0.616 
11/92 -0.850 -0.853 -0.783 -0.154 0.080 -0.610 -0.732 
4/93 -0.829 -0.901 -0.812 -0.509 -0.279 -0.733 -0.747 
11/93 -0.743 -0.684 -0.623 -0.170 0.437 -0.192 0.288 
















0.121 0.218 0.482 -0.140 0.990 0.786 0.321 
0.072 0.438 0.501 -0.159 1.025 1.261 0.286 
-0.012 0.406 0.504 0.105 0.793 0.665 0.195 
0.111 0.360 0.500 -0.007 0.677 0.701 1.043 
-0.017 0.338 0.442 0.180 0.824 0.848 0.630 
0.234 0.440 0.240 0.487 0.191 1.267 0.825 
-0.017 0.089 0.313 1.553 1.031 1.131 0.005 
-0.058 -0.044 -0.039 0.144 0.023 0.841 0.073 
-0.104 -0.096 -0.139 0.158 -0.045 0.896 0.223 
-0.468 -0.410 -0.409 0.145 0.001 0.549 0.440 
0.140 -0.053 -0.067 1.122 1.170 0.590 0.139 
-0.268 -0.277 -0.294 0.660 0.447 0.391 0.121 
-0.154 -0.157 -0.110 1.004 0.957 0.508 0.351 
4/93 	-0.208 -0.196 -0.210 1.184 1.173 0.549 -0.017 
11/93 -0.261 -0.267 -0.256 0.936 1.082 0.463 0.101 
Table 1: Longitudinal recognition of merozoite surface proteins by malaria 
exposed adults from The Gambia. Samples were collected at 6 month 
intervals from November 1990 to November 1991. 
MSP1 rAgs MSP2 rAgs 
Donor 	Sample EGF-1A EGF-1B 	19/GST A2 A3 B2 B3 
date 
mean + 2SD 0.186 0.264 0.200 0.138 0.245 0.194 0.126 
E07008 6/88 0.198 0.114 0.076 0.162 0.167 -0.027 0.172 
11/88 
6/89 0.187 0.013 0.117 0.110 -0.069 -0.039 -0.079 
11/89 0.856 1.045 0.657 -0.051 1.739 0.168 0.175 
6/90 -0.089 0.162 -0.104 -0.167 0.789 -0.200 -0.003 
11/90 0.023 -0.023 -0.054 -0.195 0.106 -0.105 -0.130 
6/91 -0.235 -0.181 -0.182 -0.172 -0.013 -0.121 -0.153 
11/91 
E08010 6/88 0.359 0.603 0.173 -0.322 0.199 -0.473 0.671 
11/88 -0.152 -0.133 0.619 0.513 1.664 1.567 0.517 
6/89 1.389 1.352 0.937 -0.027 0.101 -0.055 1.197 
11/89 
6/90 0.163 0.336 0.174 -0.176 -0.011 -0.154 0.779 
11/90 0.085 0.210 0.230 -0.229 -0.098 -0.177 0.488 
6/91 0.004 0.078 0.001 -0.061 -0.066 -0.202 0.097 
11/91 0.232 0.242 0.104 -0.043 0.000 -0.025 0.250 
E09009 6/88 -0.229 -0.171 -0.108 -0.165 -0.236 -0.218 -0.105 
11/88 
6/89 -0.059 -0.141 -0.055 -0.035 -0.015 0.051 0.129 
11/89 
6/90 
11/90 -0.081 -0.143 -0.168 -0.160 -0.170 -0.177 -0.126 
6/91 -0.282 -0.267 -0.250 -0.261 -0.289 -0.215 -0.185 
11/91 -0.117 -0.125 -0.086 -0.059 -0.107 -0.075 -0.101 
E17004 6/88 0.020 -0.139 -0.159 -0.175 -0.158 -0.148 -0.177 
11/88 
6/89 -0.283 -0.241 -0.261 -0.123 0.014 -0.023 -0.092 
11/89 -0.188 -0.254 -0.244 -0.025 0.192 -0.040 -0.016 
6/90 -0.147 -0.166 -0.150 -0.023 0.145 -0.119 0.064 
11/90 -0.170 -0.143 -0.130 -0.075 -0.103 -0.161 0.089 
6/91 -0.104 -0.035 -0.111 -0.066 -0.060 -0.064 -0.062 
11/91 -0.132 -0.288 -0.271 -0.185 -0.255 -0.301 -0.181 
E18003 6/88 -0.073 -0.127 -0.155 -0.222 -0.185 -0.239 -0.067 
11/88 0.957 0.906 0.794 -0.081 1.317 -0.118 0.259 
6/89 
11/89 
6/90 -0.238 -0.220 -0.202 -0.200 -0.209 -0.184 -0.198 
11/90 -0.197 -0.131 -0.036 -0.061 0.004 -0.068 0.112 
6/91 0.025 0.030 -0.031 0.211 -0.034 0.041 0.069 
11/91 0.672 0.701 0.446 0.074 0.214 -0.075 0.316 
E20015 6/88 	0.007 0.233 0.201 -0.011 -0.041 0.111 0.176 
11/88 
6/89 -0.061 -0.106 0.016 -0.062 -0.077 0.186 0.101 
11/89 0.196 0.229 0.349 0.163 0.340 1.633 1.705 
6/90 
11/90 -0.077 -0.028 -0.099 0.963 0.160 1.181 1.154 
6/91 
11/91 -0.085 -0.061 -0.179 1.151 0.029 0.110 1.686 
E24008 6/88 -0.035 -0.205 -0.239 0.111 -0.080 -0.191 -0.233 
11/88 0.112 0.062 0.190 0.477 0.428 0.262 0.562 
6/89 0.087 0.293 0.214 0.280 0.208 -0.013 0.910 
11/89 
6/90 -0.176 -0.173 -0.204 -0.079 -0.058 -0.089 -0.054 
11/90 0.000 -0.073 -0.042 0.055 0.062 0.092 0.260 
6/91 -0.174 -0.239 -0.150 -0.109 -0.125 -0.091 -0.113 
11/91 -0.196 -0.181 -0.327 -0.246 -0.198 0.027 -0.189 
E24009 6/88 0.022 0.006 0.022 0.222 0.096 0.120 0.064 
11/88 0.021 0.006 0.026 0.005 0.115 0.156 0.107 
6/89 -0.125 -0.113 -0.135 -0.026 -0.094 0.203 -0.028 
11/89 
6/90 0.004 -0.131 -0.089 0.125 0.000 0.179 -0.028 
11/90 0.002 -0.034 0.008 0.373 0.092 0.954 1.824 
6/91 -0.022 -0.105 -0.146 -0.070 -0.182 -0.140 -0.074 
11/91 0.028 0.230 0.611 0.179 1.064 -0.060 1.453 
E25007 6/88 -0.102 -0.079 0.058 -0.038 -0.021 -0.086 -0.046 
11/88 
6/89 -0.050 -0.131 -0.131 0.095 -0.104 0.015 0.007 
11/89 -0.451 -0.431 -0.450 -0.447 -0.215 -0.402 -0.389 
6/90 0.008 -0.024 -0.033 0.075 -0.012 -0.004 0.094 
11/90 
6/91 -0.082 -0.149 -0.159 0.007 -0.145 -0.168 -0.149 
11/91 -0.016 -0.042 -0.063 -0.124 -0.056 0.019 0.175 
E25009 6/88 -0.068 -0.037 -0.049 -0.056 0.094 0.030 -0.014 
11/88 -0.065 0.029 0.231 0.018 0.012 -0.059 0.189 
6/89 -0.135 -0.138 -0.088 0.087 0.326 -0.050 0.208 
11/89 
6/90 -0.191 -0.283 -0.218 -0.179 0.082 -0.166 0.047 
11/90 -0.359 -0.304 -0.336 -0.295 0.027 -0.154 0.072 
6/91 -0.042 0.017 0.040 0.010 0.116 -0.015 0.038 
11/91 -0.196 -0.119 -0.211 -0.156 -0.190 -0.227 -0.259 
P06008 6/88 0.086 0.216 0.071 0.104 0.133 0.059 0.056 
11/88 -0.026 0.080 0.176 0.388 0.205 0.056 0.395 




6/91 -0.037 -0.049 -0.048 0.232 0.146 0.002 0.126 
11/91 	0.058 0.032 0.112 0.000 1.362 0.193 0.617 
P06009 6/88 -0.117 -0.046 0.318 -0.056 -0.061 -0.034 -0.008 
11/88 -0.135 -0.030 -0.044 -0.059 1.185 -0.106 0.631 
6/89 -0.320 -0.200 -0.267 -0.262 -0.203 0.000 -0.003 
11/89 0.028 -0.017 -0.030 0.038 -0.043 0.062 -0.031 
6/90 
11/90 
6/91 0.211 -0.051 -0.022 0.045 -0.097 -0.021 0.099 
11/91 -0.182 -0.190 -0.104 -0.027 -0.167 -0.168 0.446 
P06010 6/88 -0.098 -0.092 -0.073 0.156 0.108 0.002 -0.032 
11/88 -0.337 -0.242 -0.216 -0.248 0.389 -0.174 0.451 
6/89 
11/89 -0.076 -0.032 -0.074 -0.010 0.036 -0.018 0.135 
6/90 
11/90 
6/91 0.021 0.077 0.216 -0.018 -0.045 0.008 0.130 
11/91 0.262 0.169 0.222 0.626 0.666 0.001 0.924 
P10016 6/88 -0.107 -0.122 -0.119 -0.049 0.319 -0.044 0.121 
11/88 -0.051 -0.073 0.469 -0.113 1.995 -0.026 1.031 
6/89 -0.118 -0.139 -0.116 0.059 0.512 0.074 0.152 
11/89 -0.047 0.242 0.104 0.042 1.910 0.527 1.117 
6/90 
11/90 
6/91 -0.001 0.044 0.164 0.036 0.683 0.155 0.432 
11/91 -0.196 -0.256 0.126 0.361 1.128 -0.180 0.656 
P10017 6/88 -0.003 -0.072 -0.066 -0.067 0.015 0.019 0.162 
11/88 0.002 -0.018 0.041 -0.165 0.416 -0.106 0.398 




6/91 0.021 -0.029 -0.016 0.101 0.034 -0.009 0.275 
11/91 0.396 0.379 0.594 0.055 2.322 0.654 1.095 
P11005 6/88 -0.047 -0.020 -0.052 -0.005 -0.005 -0.046 0.030 
11/88 0.019 -0.002 0.002 0.158 0.109 0.067 0.071 
6/89 -0.091 -0.032 -0.062 0.035 0.045 0.078 -0.038 





P12009 6/88 	-0.217 -0.196 -0.112 -0.044 -0.023 -0.140 0.523 
11/88 0.548 0.669 0.556 0.240 0.593 -0.008 1.567 




6/91 0.176 0.128 0.159 0.471 0.811 0.015 0.721 
11/91 -0.093 -0.050 0.138 0.977 0.660 0.665 0.408 
001008 6/88 0.002 0.022 0.013 0.170 1.182 0.614 1.356 
11/88 -0.117 0.051 0.199 0.226 1.342 0.593 1.698 
6/89 -0.041 0.011 -0.012 0.244 0.862 1.436 1.448 





003005 6/88 -0.132 -0.024 -0.029 0.006 0.206 -0.042 0.284 
11/88 
6/89 -0.217 -0.107 -0.146 -0.189 -0.082 -0.139 0.024 
11/89 0.269 0.476 0.247 0.134 0.911 -0.023 0.305 
6/90 
11/90 
6/91 -0.159 -0.222 -0.078 -0.142 -0.166 -0.120 -0.079 
11/91 1.065 1.092 0.970 0.213 1.157 -0.157 1.086 
N05034 6/88 -0.079 -0.106 -0.078 -0.108 -0.038 -0.091 -0.012 
11/88 -0.164 -0.060 -0.102 0.697 0.749 -0.036 0.396 




6/91 -0.119 -0.088 -0.059 0.280 0.112 -0.095 -0.012 
11/91 
Table 2: Longitudinal recognition of merozoite surface proteins by malaria 
exposed children from The Gambia. Samples were collected at six month 
intervals from June 1988 to November 1991. 
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ABSTRACT 
MSP2 is a merozoite surface protein of Plasmodium fàlciparum and, as such, 
is a potential component of a malaria vaccine. In this study we have used a 
panel of recombinant MSP2 antigens in ELISA assays to investigate the 
recognition of MSP2 by antibodies from malaria-immune human serum. 
These recombinant antigens include full length proteins of serogroups A and 
B, and fragments representing the conserved, group-specific or repeat 
regions of each serogroup. Ninety five percent of the sera tested contained 
MSP2-specific antibodies; 81% of sera tested responded to serogroup A and 
86% responded to serogroup B. 
The antibody response is directed almost exclusively towards dimorphic and 
polymorphic regions of MSP2; the conserved regions are rarely recognised 
and antibodies to serogroups A and B do not cross-react. Interestingly, the 
antibody response is predominately of the cytophilic and complement fixing 
subclass IgG3. 
INTRODUCTION 
Antigens on the surface of malaria merozoites are of interest as potential 
targets for vaccine induced immune responses. Since these antigens may 
be involved in merozoite adherence to, and invasion of, red blood cells [1], 
antibodies specific for merozoite surface antigens could prevent invasion of 
erythrocytes and thereby interrupt the asexual cycle of parasite 
proliferation. 
One such antigen, of the human malaria parasite Plasmodium falciparum, 
is the merozoite surface protein 2 (MSP2 , also called MSA2, gp35-56 or 
G3). Several pieces of evidence suggest that antibodies to MSP2 may be 
involved in protective immunity to malaria. Monoclonal antibodies (mAb) to 
MSP2 have been shown to inhibit parasite growth in vitro [2, 3], MSP2 is 
among the antigens recognised by antibodies that inhibit merozoite 
dispersal [4] and mice immunised with peptides corresponding to the 
conserved regions of MSP2 of P.falciparum are protected against 
challenge with the rodent parasite P.chabaudi [5]. 
Sequencing data and serological characterisation of malaria parasites with 
MSP2-specific mAbs [4, 6-9] show that MSP2 is a polymorphic protein 
which can be classified into two allelic families corresponding to two 
antigenically distinct serogroups. Serogroup A includes the isolates T9/96, 
Camp, 3D7 and IC1, and serogroup B includes the isolates FCQ-27, Ki 
and Dd2. The protein has conserved sequences, at the amino- and 
carboxy-termini, which are common to both serogroups. These conserved 
regions flank dimorphic, group-specific sequences containing two central 
regions of polymorphic, tandemly arranged repetitive sequences. Fenton et 
a! [9] designated the two regions of tandem repeats as Ri and R2. The Ri 
region of serogroup A is glycine, serine and alanine rich and varies 
considerably from isolate to isolate; the R2 region is a relatively conserved 
repeat, rich in the amino acid threonine. The repeat sequences of 
serogroup B are unrelated to those of serogroup A and consist of either 32 
amino acids (Ri) or 12 amino acids (R2). Although the sequences of group 
B repeats are relatively conserved between isolates, they vary in number. 
The extensive sequence polymorphism of MSP2 raises the important 
question of whether immune reponses to the protein might be sequence 
specific. If this is the case, then responses to MSP2 may be implicated in 
the notion that the slow development of protective immunity to malaria, in 
people living in malaria endemic areas, is due to gradual acquisition of 
specific immunity to all the variant genotypes of the parasite circulating in 
the community [10]. In order to better understand the nature of protective 
immunity to malaria it is neccessary to determine whether naturally 
acquired antibody responses to MSP2 are cross-reactive within and 
between serogroups. Such information would also be useful for 
determining which, if any, regions of MSP2 might usefully be included in a 
malaria vaccine. To date, there is very little published data on naturally 
acquired immunity to MSP2 and no information on the relative 
immunogenicity of conserved, group specific (dimorphic) and repetitive 
(polymorphic) regions of the molecule. A study of adult, malaria exposed, 
Melanesians showed that 82% had antibodies against MSP2 serogroup B 
[11], but the specificity of these antibodies was not fully characterised. A 
recent study in a highly endemic area of Papua New Guinea found high 
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antibody prevalence (2! 90%) to recombinant antigens representing the full 
length proteins of both MSP2 serogroup A (3D7) and serogroup B 
(FC27)[12]. Using a serogroup A construct lacking the central repeats, this 
group also showed that a proportion of immune individuals responded only 
to epitopes within the repeat region. Experimental immunisation of Aotus 
monkeys with P.falciparum results in an anti-MSP2 antibody response 
directed primarily to repeat and group-specific regions of MSP2 [4]. 
Antibodies purified from immune clusters of merozoites also recognise 
group specific sequences, suggesting that this region is accessible at the 
surface of the intact parasite and may therefore be a target for parasite-
inhibitory immune responses [4]. However, immunoblotting studies using 
affinity purified human serum suggest that naturally immunodominant 
epitopes are encoded within the repetitive sequences of the molecule [7]. 
None of these studies has addressed the crucial question of whether 
sequence polymorphism gives rise to antigenic diversity and whether 
epitopes in one allelic form of the protein cross-react with similar epitopes 
from other parasites. 
Here we report a comprehensive study of the recognition of MSP2 by sera 
from malaria-immune adults from The Gambia, West Africa, and the 
identification of regions of the molecule that are immunogenic during 
malaria infections. We find that MSP2 is naturally immunogenic in man, 
inducing lgG antibodies which predominantly recognise epitopes located in 
the dimorphic and polymorphic regions of the molecule. Importantly, 
antibodies to the two main serogroups of MSP2 (A and B) do not appear to 
cross-react. Anti-MSP2 antibodies were found to belong mainly to lgG 
subclasses that have opsonising and complement fixing properties, 
suggesting that they might play a role in regulating the proliferation of 
intraerythrocytic parasites. 
MATERIALS AND METHODS 
Sera 
Serum samples were obtained from 70 adults (aged 15-65 years) living in 
rural and pen-urban areas of The Gambia, West Africa, where malaria 
transmission is intense during the short wet season (from July to 
November) and minimal at other times of the year [13]. Control serum 
samples were obtained from 15 European adults who had not been 
exposed to malaria. 
Antigens 
Recombinant MSP2 proteins 
pGEX expression vectors were used to direct the synthesis of MSP2 
polypeptides in E.coii as fusions with the C-terminus of glutathione S-
transferase (GST) of Schistosoma japonicum [14, Smith et a!, in 
preparation]. This permits the purification, on a glutathione column, of 
recombinant antigens as stable, soluble fusion polypeptides. Expression of 
the protein was initiated by the addition of isopropyl-b-D-
thiogalactopyranoside (IPTG) to cultures of transformed E.coIi. After 3-5 
hours, cells were pelleted, resuspended in PBS and lysed on ice by mild 
sonication in the presence of 10% (v/v) Triton X-100 (BDH Chemicals, 
Poole, UK.). The fusion proteins were purified from the supernatant by 
absorption onto glutathione agarose beads (Sigma, Poole, UK.). The 
proteins were eluted by competition with free glutathione and their 
concentrations estimated by the intensity of coomassie blue staining on 
acrylamide gels. 
As a control, the fusion protein partner, GST, was purified from pGEX 
plasmids lacking an MSP2 insert. 
The immunogenicity and antigenic integrity of the fusion proteins were 
assessed by mouse immunisation and testing of the mouse sera in ELISA, 
Western blotting and immunofluoresence assays (using acetone-fixed, 
mature P. falciparum schizonts) [Smith et a!, in preparation]. All the 
recombinant proteins used in this study were shown to reflect the antigenic 
character of the native protein and are represented in figure 1. It has not yet 
been possible to produce a recombinant protein which accurately reflects 
the antigenic structure of the N-terminal conserved sequence of the protein, 
hence no analysis of responses to this region is reported. 
MSP1 - p190.1 
As a positive control for prior exposure to Plasmodium falciparum, sera 
were also tested for reactivity with a conserved sequence from another 
merozoite surface protein, MSP1. p190.1 represents a non-variable region 
of MSP1 (gplgO) which has previously been shown to be recognised by 
more than 90% of malaria exposed individuals [15] and was produced in E. 
coil as a free polypeptide [16]. p190.1 was a kind gift of Dr J.R.L Pink, F. 
Hoffman La Roche, Basel, Switzerland. 
Enzyme-linked Immunosorbent Assay (ELISA) 
Microtitre plates (lmmulon-4 (Dynatech)) were coated overnight at 4C with 
lOOpi/well of antigen at 0.5jig/ml in 0.11VI carbonate (Na2CO3/NaHCO3) 
buffer (pH9.6), and blocked for 5 hours at room temperature with 200j.tl/well 
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of blocking buffer (1% (w/v) milk powder in PBS/0.05 9/` Tween 20). At the 
same time, sera were diluted in blocking buffer and incubated at room 
temperature for 5 hours. Plates were washed three times with PBS/Tween 
and lOOpi/well of diluted serum was added to duplicate wells and 
incubated overnight at 4°C. Plates were washed and incubated with horse-
radish peroxidase-conjugated rabbit anti-human lgG antibody (Dako Ltd., 
High Wycombe, UK) for 3 hours at room temperature. 
For the detection of specific lgG subclasses, plates were incubated for 3 
hours with murine monoclonal antibodies to specific human lgG 
subclasses, followed by HRP-conjugated rabbit anti-mouse lg antibody for 
3 hours. The subclass specificity of these mAbs [IgGi (NL16, Boehringer 
Mannheim, Germany), lgG2 (ROM1, Boehringer), lgG3 (HP6050, Serotec, 
Oxford, England), lgG4 (RJ4, Boehringer)] has been widely reported [17-20] 
and was reconfirmed before their use in this study. Each mAb was titrated 
against varying concentrations of purified lgG of the appropriate subclass; 
all mAbs gave parallel titration curves. For each mAb, a working 
concentration was selected such that the relationship between OD and lgG 
concentration was approximately the same for each subclass. This allows 
the amounts of antibody in each subclass to be assessed, on a roughly 
quantitative basis, by comparing the OD values. 
All plates were developed with H202 as substrate and o-phenylenediamine 
(OPD) as chromagen at 4°C and the reaction was stopped after 10 minutes 
with 20jtl/well of 2M H2SO4.  The optical density (OD) was measured at a 
wavelength of 492 nm. 
Optimal concentrations of antigen and antibody were determined by 
chequer board titrations. 
Statistical analysis 
The reactivity of the sera with various MSP2 fusion proteins in ELISA was 
calculated by subtracting the OD value for the GST control from the value 
obtained for the MSP2 fusion protein, to obtain specific OD values. Positive 
samples were defined as those giving a specific OD above the normal 
range for control European sera. The normal range was taken as the mean 
± 2 standard deviations of 15 control sera. 
The reactivity of individual sera with different antigens was compared by 
means of Spearman's rank correlation test [21]. 
RESULTS 
Reactivity of human serum antibodies with MSP2 fusion 
proteins. 
Serum lgG antibodies from Gambian and European adults were tested for 
recognition of recombinant MSP2 proteins in ELISA. MSP2 proteins were 
specifically recognised by sera from individuals who have been exposed to 
malaria (Fig 2). The cut-off level for positive sera for each antigen ranged 
from 0.117 to 0.384 OD units (Fig 2). The proportion of sera recognising 
each of the proteins is shown in table I. 
These results show that MSP2 is well recognised by sera from individuals 
who have been exposed to malaria. Serogroup A and serogroup B are 
recognised by 81% and 86% of sera respectively, indicating that MSP2 is 
highly antigenic during natural infections. MSP2-specific antibodies 
predominantly recognise polymorphic and dimorphic regions of the protein; 
the conserved C terminus is recognised by only 36% of sera and the OD 
values obtained with this protein were significantly lower than for the full 
length and group specific proteins (only 3 sera recognised this protein with 
an OD value greater than 0.300). 
Lack of antigenic cross-reactivity between serogroups A and 
B: 
Seventy-nine percent of sera from adult Gambians recognised both the A 
and B serogroups (proteins Al and Bl, which represent the full length 
molecules). To determine whether this 'dual' recognition was due to a 
single population of antibodies which react with epitopes common to both 
proteins or whether the serum contained two separate, non-cross-reacting, 
populations of antibody, we compared the reactivity of individual sera with 
the full length proteins from both serogroups (Al and Bi) (Fig 3). It is clear 
that although some sera recognise the two proteins apparently equally, 
other sera clearly recognise one protein but not the other. 
Using Spearman's rank correlation test, a positive correlation was obtained 
for responses to Al and Bl (r=0.555; r5=0.307, p=0.005). However, we, 
consider that the high level of statistical significance is the result of the large 
sample size and the considerable number of double negative sera; the 
association is in fact quite weak and may simply reflect independent 
exposure to both serogroups of P.falciparum. As an estimate of association 
due to exposure, we compared the recognition of MSP2 proteins with the 
recognition of a recombinant protein representing a conserved region of an 
unrelated merozoite surface protein (MSP1, p190.1). Correlation 
coefficients of up to 0.492 were obtained. Thus the correlation coefficient 
obtained for Al versus Bl was only slightly higher than that obtained for 
MSP2 versus MSP1, suggesting that the correlation is indeed due to 
exposure rather than to cross-reacting antibodies. 
To confirm that antibodies to the two serogroups are not cross-reactive, 
individual sera were tested in competition ELISAs. Sera which were known 
to contain antibodies to both Al and Bl were selected; these sera were 
preincubated with either Al or Bl and tested in ELISA for recognition of the 
other protein. The example shown in Figure 4 was typical of the sera tested: 
whilst preincubation with increasing concentrations of Al prevents 
subsequent binding of antibodies to Al-coated plates, it has no effect on 
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binding of antibody to 131 -coated plates, and vice versa. Thus, in double 
positive sera, there appear to be two distinct populations of antibodies, one 
specific for serogroup A and the other specific for serogroup B. 
3. Subclass of anti-MSP2 IgG antibodies: 
The IgG subclass of anti-MSP2 antibodies was determined for sera that had 
been shown to contain MSP2-specific lgG. Figure 5 shows the lgG 
subclasses of antibodies to proteins Al, A2 and A3. The distribution was 
similar for the corresponding serogroup B proteins (data not shown). 
Although the lgG subclass pattern differs slightly for antibodies to the 
different proteins (Fig. 5) the predominant MSP2-specific antibody subclass 
is lgG3. 77% and 80%, respectively, of Al and A3 positive sera contained 
only lgG3. The remainder of the Al and A3-positive sera contained only 
IgGi. In comparison, 44% of A2-positive sera contained A2-specific lgG4. 
The pattern of recognition is similar for the serogroup B proteins, in that 
lgG3 is the predominant subclass. However, approximately 57% of 
serogroup B positive sera were IgGi positive; in the majority of cases, IgGi 
was coexpressed with lgG3. 
This predilection for induction of lgG3 antibodies is unusual and suggests 
that there may be something about the antigenic structure of the MSP2 
molecule which preferentially triggers isotype switching to lgG3 in MSP2-
specific plasma cells. 
DISCUSSION 
The aim of this study was to characterize the reactivity of serum antibodies 
from malaria-exposed adult individuals with the merozoite surface protein, 
MSP2. Evaluation of MSP2 as a potential component of a subunit malaria 
vaccine requires an understanding of the naturally occuring immune 
response to MSP2 and, most importantly, the immunological significance of 
amino acid sequence polymorphisms. In particular, it is important to 
determine whether Abs against one MSP2 serogroup will cross react with 
the other serogroup, or whether the Ab response is group-specific or allele-
specific. Such information may also help us to understand the relative 
importance of allele-specific ("strain-specific") immune responses in the 
acquisition of clinically protective immunity to malaria by people living in 
malaria endemic areas. 
There are two main theories to explain the slow development of protective 
immunity to malaria which is typically seen in individuals living in endemic 
areas: (i) polymorphism of antigens which are the targets of protective 
immune responses and, (ii) intrinsically poor immunogenicity of the target 
molecules. The data presented here indicate that the latter explanation is 
not true, at least with respect to MSP2. Sixty seven of the 70 individuals 
tested had clearly detectable anti-MSP2 antibodies with end point titrations 
of > 1/9,000 for most sera (data not shown). It is possible that the three 
seronegative individuals had not been exposed to parasites carrying the 
MSP2 variants tested here. In addition, we have screened a small number 
of sera collected 2 to 4 weeks after a known primary malaria infection and 
all contained detectable levels of antibody to MSP2 (R. Taylor and J. 
Carlsson, unpublished data). 
Antibodies tended to recognise epitopes within the dimorphic and 
polymorphic regions of MSP2; the conserved C-terminus seems to be 
poorly antigenic. This is in agreement with Thomas et al [4] who reported 
that although intact MSP2 is recognised by monkey and human antibodies 
eluted from intact merozoites, such antibodies did not recognise peptides 
representing the N- and C-terminal regions of the molecule. Similarly, Saul 
et a! [5] were unable to detect Abs against synthetic peptides representing 
the conserved regions of MSP2 in sera from 18 people with high titres of 
anti-parasite antibodies (as determined by immunofluorescence assays). 
Importantly, the sequences which are conserved within each allelic family 
(detected using A3 and B3 proteins) are highly immunogenic. Ninety 
percent of the sera tested contained Abs which recognise either A3 or B3 
(or both); thus a vaccine based on MSP2 may need to contain only two 
different antigens - representing the group-specific sequences of each 
serogroup. Interestingly the group-specific A3 protein is recognised by 
significantly more individuals than the B3 protein. This may reflect more 
frequent or more recent exposure of the donors to parasites of serogroup A 
since approximately 60% of parasites isolated in The Gambia belong to the 
A serogroup [22; R.Taylor, unpublished]. Antibodies eluted from immune 
clusters of merozoites recognise dimorphic MSP2 sequences [4], indicating 
that epitopes associated with these sequences are accessible at the 
surface of intact merozoites, and may therefore be a target for inhibitory 
antibodies. 
Proteins which represent the polymorphic Ri repeat regions of both 
serogroups (i.e. A2 and 132) were recognised by a substantial proportion of 
the sera, a greater proportion in fact than recognised the dimorphic regions. 
This finding was somewhat unexpected since the sera were tested against 
only one variant for each serogroup and, at least for serogroup A, the amino 
acid sequence of the repeats from different isolates varies extensively [23, 
24]. One likely explanation of this finding is that the antibodies detected 
were in fact recognising epitopes within a short N-terminal segment of 
group specific sequence contained in the protein A2 (see figure 1). 
Alternative explanations include extensive immunological cross-reactivity 
between different repeat sequences or a very high frequency of parasites in 
The Gambia expressing the tested Ri repeat sequence. This latter 
explanation is unlikely since considerable microheterogeneity within 
repetitive sequences has been reported for parasite populations and 
isolates from all over the world [7-9, 23-25; R. Taylor, unpublished]. 
Immunological cross-reactivity may well occur among the Ri repeats of 
serogroup B, where amino acid sequences are relatively conserved, but is 
less likely for serogroup A. Further studies are underway to study the effect, 
on antibody recognition, of variation in the sequence and number of 
repeats. 
Quantification of absolute amounts of Ab by ELISA is difficult since the OD 
value obtained is dependent on both the concentration of Ab and its' 
affinity. It is not possible to compare the amounts of Ab in sera which react 
with different recombinant antigens since the number of epitopes in each 
assay (and thus the avidity of the reaction) is unknown [26]. Therefore, in 
order to make comparisons between the Ab responses to different proteins, 
we used a nonparametric rank correlation test to compare specific OD 
values for individual sera, tested at a single dilution, against the full length 
proteins of serogroup A and serogroup B. Such comparisons show that the 
correlation between responses to the two serogroups is weak and is 
probably due to exposure to parasites of both serogroups rather than to 
cross-reactive antibodies. Competition experiments clearly demonstrate 
that antibodies to serogroup A and B are not cross-reactive, since protein 
Al cannot compete for binding of 131 -specific antibodies, and vice versa. 
In theory, antibodies specific for MSP2 could inhibit merozoite invasion of 
erythrocytes by a number of mechanisms including merozoite agglutination, 
complement-mediated lysis, opsonisation or blocking of receptors involved 
in the adherence of merozoites to erythrocytes. These various mechanisms 
would be mediated by antibodies of different lgG subclasses - only IgGi 
and lgG3 are opsonising and complement-fixing but all four subclasses 
could mediate agglutination or receptor blocking. Since functional 
differences may exist among Abs of the same specificity, we have 
determined the subclass of MSP2-specific lgG in sera from individuals 
immunised by natural exposure to malaria. Our work indicates that 
antibodies which recognise MSP2 are predominantly of the lgG3 subclass. 
It has been suggested that the ratio of IgGi and lgG3 to lgG2 and lgG4 may 
be important in immunity to asexual blood stages of P. falciparum [27, 28] 
since, whilst IgGi and lgG3 can mediate opsonisation and phagocytosis of 
parasitised erythrocytes or free merozoites, lgG2 and lgG4 antibodies (of 
the same epitope specificity) may block the binding of the protective 
subclasses. lgG3 is considered to be the most effective subclass for 
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activating the complement pathway [29], and it is known to mediate cell 
lysis by monocytes or Fc receptor bearing lymphocytes [30]. Thus, the 
predominance of the 1g33 response to MSP2 in adults with a high degree 
of protective immunity to malaria, suggests that this molecule may be a 
target of protective antibody reponses. 
The predominance of the lgG3 response is unusual and is noticeably 
different from the response to MSP1 [31]. The only other examples of which 
we are aware, of an antibody response which is significantly skewed 
towards lgG3, are the response to the outer membrane protein of 
Branhamella cattarhalis where lgG3 antibodies represent approximately 
70% of the total response in individuals over 4 years of age [32] and 
responses to the streptolysin M protein where lgG3 predominated in the 
response of more than half of the individuals tested [33]. Interestingly, in the 
case of Branhamella, the switch to lgG3 production seemed to be age-
related, specific lgG3 being essentially undetectable in children under the 
age of 4 years [32]. IgGland IgG3 are typically produced in response to 
protein antigens [34] with lgGl present in significantly greater amounts than 
lgG3 but, as yet, little is known about factors which may preferentially 
induce the production of lgG3. Although specific switch factors have been 
described for different lgG subclasses in the mouse, much less is known 
about this system in humans. lsotype switching to both lgGl and lgG3 
appears to be controlled by similar processes which may be regulated by 
the T cell-derived cytokine IL-1 0 [35]. Goldblatt eta! [32] suggest that the 
membrane-bound nature of the Branhame!Ia proteins, and their mitogenic 
activity for B cells, may be partly responsible for the lgG3 antibody 
response. The propensity for MSP2 to induce lgG3 antibodies suggests that 
this antigen may be a useful tool for investigating subclass specific switch 
mechanisms. 
The most important question regarding the potential of MSP2 as a vaccine 
antigen is whether or not MSP2-specific immune responses are involved in 
protective immunity to malaria. We have shown here that MSP2 is naturally 
antigenic, that the immune response is directed to dimorphic as well as 
polymorphic regions of the molecule and that these antibodies are of 
appropriate subclasses. Longitudinal epidemiological studies are now 
underway to determine whether these antibodies are able to mediate 
immunity to clinical malaria and to investigate the hypothesis that 
polymorphism within the repeat sequences of MSP2 is a significant factor in 
the slow development of protective immunity to P. falciparum. 
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LEGENDS 
Figure 1: Schematic representation of the MSP2 fusion proteins. Isolates 
from which the recombinant proteins were derived are indicated in bold. 
Al -A3 and Bl -133 are the codes for the rAgs. 
KEY: 	AR1 REPEATS 	1 BR1REPEATS 
	
A R2 REPEATS 	 B R2 REPEATS F----] 
GROUP A SPECIFIC 	GROUP B SPECIFIC 
CONSERVED I 	I 
Figure 2: Dot plots showing specific lgG responses (OD 492)  to MSP2 
fusion proteins of serogroup A (a) and B (b) in 70 Gambian sera. 
The cut off level for positive sera is indicated by a horizontal line. 
Sera were tested at a dilution of 1/1000. 
Figure 3: Comparison of OD values for Al versus Bi for sera from 70 
Gambian adults. Solid lines indicate the cut-off level as determined from the 
mean+ 2SD of 15 European sera. Arrow indicates the serum shown in the 
competition ELISA (Figure 4). 
Each circle represents a single serum tested at a dilution of 1/1000. 
Figure 4: Competition assay to determine the extent of cross-reactivity 
between antibodies recognising Al and Bi. The results for a single, typical, 
serum are shown. Sera were preincubated with antigen at concentrations 
from 0Ig/mI -5 ig/ml. Sera were tested at a dilution of 1/1 000. 
Key: • Al (on plate) vs Al (in serum), 0 Al vs 131, • Bi vs Bl, 0 Bl 
vs Al, EGST vs, GST. 
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Figure 5: Dot plots of lgG subclass of antibodies to serogroup A proteins: 
a) Al (n=30) 	b) A2 (n=25) 	c) A3 (n=30) 
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SUBCLASS 
SEROGROUP A SEROGROUP B CONSERVED 
PROTEIN Al A2 A3 B1 B2 B3 C 
% RESPONDERS 81 81 73 86 64 
43 36 
RANGE -mm. -0.026 -0.053 -0.194 -0.140 -0.256 -0.339 
-0.493 
-max. 1.911 2.157 1.632 1.981 1.755 1.044 0.542 
TABLE 1: The percentage of malaria immune sera recognising recombinant MSP2 
proteins. 
70 Gambian sera were tested in ELISA for recognition of MSP2 proteins. The percentage of 
responders was calculated as those sera giving OD values greater than the mean+2SD of 
the OD values obtained for 15 European (malaria non-exposed) sera (see figure 2). The 
range of OD values (minimum and maximum) obtained for each protein are shown. 
(Negative values occur when the 00 value of the GST control protein exceeds the OD value 
of the fusion protein). 
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Malaria infection induces the production of serum antibodies to a variety of malaria 
antigens but the prevalence of antibodies to any particular antigen is typically much less 
than 100%. It has been assumed that non-responsiveness to defined antigens in malaria 
immune subjects is due to HLA-mediated restriction of the immune response, but 
numerous studies of the relationship between antibody responses and HLA genotype 
have failed to show any significant associations. In this study we show that whilst 
antibody levels vary in accordance with seasonal variations in malaria transmission in 
semi-immune children, antibody levels remain stable in clinically immune adults. 
Antigen recognition is selective with individual donors showing consistent high titre 
responses to some antigens/ epitopes whilst consistently failing to recognise adjacent 
regions/epitopes from the same protein. We have investigated the role of HLA and non-
HLA genes in the antibody response to two merozoite surface antigens (MSP1 and MSP2) 
and a sexual stage antigen (Pfs260/230) of Plasmodium falciparum and conclude that 
host genotype is not a major determinant of responsiveness. Thus, we propose that clonal 
imprinting (original antigenic sin) is an alternative explanation for selective antibody 
responses to malaria antigens in immune individuals. 
INTRODUCTION 
Protective immunity to blood stage malaria parasites is at least partly antibody dependent 
(1). Inhibition of merozoite invasion into erythrocytes, opsonisation and/or antibody-
dependent cellular cytotoxicity are believed to be the principle mechanisms of antibody-
mediated immunity (2-4) and antibody responses to a number of defined erythrocyte or 
merozoite surface antigens correlate with acquisition of clinical immunity to malaria 
(5- 8). 
Malaria infection induces antibodies directed against both conserved and variable 
epitopes of merozoite antigens. However, the prevalence of antibodies to any particular 
antigen or epitope is typically much less than 100%, even where the epitope is highly 
conserved between parasite isolates and where malaria transmission rates are high enough 
to ensure that the study population is frequently re-exposed to infection (9-15). Since 
immunization of MHC (H-2) congenic mice with short polypeptides derived from 
malaria antigens has shown that non-responsiveness can, in certain circumstances, be 
linked to H-2 genotype (16,17) it has been assumed that non-responsiveness to malaria 
antigens in humans is also the result of HLA-dependent genetic restriction of the 
immune response (10,18,19). However, when immune responses of humans immunised 
by natural exposure to malaria are compared with their HLA class II genotype very few 
associations are found between responsiveness (or non-responsiveness) and HLA gene 
expression (14,20-24). Since widespread non - responsiveness to defined malaria antigens 
could pose difficulties for the implementation of subunit vaccines, it is important that 
alternative explanations for individual non-responsiveness should be explored. 
Most antibody prevalence data has been collected by cross-sectional analysis of a 
population at a single point in time. Malaria transmission is seasonal in many endemic 
areas and it is possible that antibody levels fluctuate over time such that people appear 
to be non-responders on some occasions and responders on other occasions. To obtain 
reliable estimates of antibody prevalence it is neccessary to conduct longitudinal studies, 
collecting serum from the same individuals over a period of months or years. Few such 
studies have been reported. 
It is clear that some regions of any given protein are more potent activators of B cells 
than are other regions, giving rise to immunodominant epitopes. For example, the 
repetitive amino acid sequences which are common in malaria proteins tend to be 
immunodominant (25). However, even epitopes which are immunodominant at a 
population level are not universally recognised (11,26,27), so immunodominance (or lack 
thereof) is not, in itself, a sufficient explanation for selectivity of antibody responses. 
In this study we have investigated the effect of three potential causes of apparent non-
responsiveness to malaria antigens, (i) poor immunogenicity of malaria antigens (ii) 
temporal variations in antibody levels and (iii) host genotype, on the antibody response 
to conserved or semi-conserved sequences of two P. falciparurn merozoite surface 
proteins (PfMSP1 and PfMSP2) and a sexual stage specific antigen (Pfs260/230). The 
inherent immunogenicity of the antigens has been assessed by looking for specific 
antibody in the serum of individuals recovering from a primary malaria infection. In 
longitudinal serological studies, we have found that whilst antibody responses vary 
seasonally in children antibody levels remain stable in clinically immune adults. Antigen 
recognition is selective, with some individuals consistently recognising specific regions 
of some antigens whilst failing to recognise adjacent epitopes from the same protein. To 
determine whether selective recognition of malaria antigens is primarily due to host 
genetic factors, or to external 'environmental" factors, we have looked for associations 
between HLA class II genotype and antibody responses in malaria immune donors and 
have compared antibody responses in identical and non-identical twins. Antigen 
recognition does not appear to be genetically regulated. We therefore propose an 
alternative explanation for selective antibody responses in malaria immune individuals - 
clonal imprinting, or original antigenic sin. 
MATERIALS AND METHODS. 
1. Subjects 
Naive donors 
Serum samples were obtained from six patients convalescing from primary malaria 
infections at the Department of Infectious Diseases and Tropical Medicine, Northwick 
Park Hospital. Samples were obtained 14-21 days after successful chemotherapy and 
were stored at -20 °C. 
Malaria immune/ semi-immune donors 
All subjects lived in rural areas of The Gambia, West Africa, where malaria transmission 
is seasonally endemic with the majority of new infections occurring during and after the 
annual rainy season (July to October) (28). The level of malaria transmission is such that 
individuals are exposed to between one and five infective mosquito bites per year (28). 
HLA class II study: Blood samples were obtained from a group of 355 semi-immune 
children (group A) and a separate group of 283 children and adults (Group B) (for details 
see (22)). HLA typing for DRB, DQA and DQB was performed by Southern blot analysis 
of Taq 1-cleaved DNA from peripheral blood leucocytes as described previously (22). 
Carriage of the sickle cell trait, which is a potential confounder of the immune response 
to malaria, was determined by haemoglobin electrophoresis. 
Twin study: Serum samples were obtained from 36 pairs of same-sex adult twins. In 
each case, the twins had been raised together and were still living in the same, or 
adjacent, house(s); thus it is likely that their past history of malaria infection is very 
similar. 
Fifteen pairs were shown to be monozygous by DNA probing with five separate 
minisatellite probes (29). Sera were collected during the dry season, when malaria 
transmission was minimal and stored at -20 °C. 
Longitudinal studies 
The first longitudinal study involved 20 children, all of whom were under the age of 10 
years at the end of the study. The second study was of 22 adults (all over the age of 16 
years at the beginning of the study). Serum samples were collected twice yearly - at the 
end of the dry season (when malaria transmission is minimal) and at the end of the wet 
season (when transmission is maximal). 
iv. Controls 
Control sera were collected from 12 European (malaria unexposed) adults and 12 
European children (aged 3-8 years). 
2. Antigens 
All the antigens (Figure 1) were recombinant proteins, fused to glutathione S transf erase 
(GST) or maltose binding protein (MBP), expressed in E. coli, transfected with either 
pGex or P111-902 plasmids(30,31). Previous studies have confirmed that the recombinant 
proteins express essentially the same B cell epitopes as the native proteins (15,31) (R. 
Taylor et al submitted for publication). 
PfMSP1 is the major merozoite surface protein of P. falciparunz and, except for a 
short N terminal polymorphic region, is dimorphic. The two allelic types are defined as 
MAD20 - type and Wellcome - type. The C-terminal 42kDa region of PfMSP1 is processed 
into a dimorphic 33kDa fragment and a 19kDa fragment which is composed of two 
epidermal growth factor-like motifs and which is essentially antigenically conserved 
(15,32). 19-GST represents the Wellcome sequence of the 19kDa fragment (33) and was 
a gift of Dr P. Berghaus, NIMR, London. EGF-1 and EGF-2 represent the MAD20 
sequences of the first and second EGf-like motifs respectively and were a gift from Dr 
J. Chappel, NIMR, London (34). Finally, MAD33 represents the MAD20 sequence of the 
C-terminal, 33kDa dimorphic region (Egan et a!, in preparation). All the PfMSP1 
antigens were GST fusion proteins. 
PIMSP2 
Four polypeptides, derived from a second dimorphic merozoite surface protein PfMSP2 
(35) and fused to GST, were a kind gift of Dr Jana McBride, University of Edinburgh. 
A2 represents the amino-terminal group- specific sequence of the A (3137-like) serogroup 
of PfMSP2 together with the highly polymorphic tetrapeptide Ri repeat region from the 
Thai isolate T9/96. A3 represents the carboxy- terminal group-specific and R2 repeat 
region of serogroup A. B2 and B3 represent the equivalent regions of MSP2 serogroup 
B (FCQ27-like). All four MSP2 antigens thus contain both semi-conserved (group-
specific) sequences and repetitive sequences which show varying degrees of 
polymorphism. 
Pfs260/230 
The r260 construct (31) represents the glutamic acid-rich tetrapeptide repeat region of 
the gametocyte /gamete surface antigen Pfs260/230 (36) fused to MBP and was kindly 
provided by Dr Kim Williamson, Loyola University, Chicago. The repeats ([EEVG]) 
share sequence homology with other glutamic acid-rich malaria proteins and appear to 
be immunodominant in natural human infections (31). 
Fusion protein controls. 
For all immunoassays, ) a control GST or MBP peptide, purified from E. coli transformed 
with vectors lackingn insert, was used to determine the response to the fusion protein 
alone. 
Enzyme linked immunosorbent assays (Elisa) 
Microtitre plates (Immulon-4, Dynatech) were coated at 4 °C with 1000/well of antigen 
at 0.5igIml in 0.1M carbonate (Na 2 CO3 /NaHCO 3) buffer (pH9.6), blocked at room 
temperature with 200i.&l/well of blocking buffer (1% w/v milk powder in PBS/0.05% 
Tween 20) and washed three times in PBS/Tween20. Sera were diluted 1:1,000 in 
blocking buffer. One hundred il of diluted serum was added to duplicate wells and 
incubated at 4 °C overnight. Plates were washed and incubated with an optimal 
concentration of horse - radish peroxidase - conjugated rabbit anti - human IgG antibody 
(Dako Ltd, High Wycombe, UK) for 3 hours at RT. Plates were developed with H 202 
as substrate and o-phenylenediamine (OPD, Sigma, UK) as chromagen and the reaction 
was stopped after 10 minutes with 20p1/well 2M H 2SO4 . The optical density (OD) was 
measured at a wavelength of 492 nm. 
To minimise interassay variation, sera from each pair of twins were tested in parallel on 
the same microtitre plate. For the longitudinal studies, consecutive samples from the 
same donor were all tested on a single plate. 
Data analysis 
The reactivity of the sera with malaria antigens was calculated by subtracting the OD 
value for the GST or MBP control from the value obtained for the fusion proteins, to 
obtain specific OD values. Positive sera were defined as those giving a specific OD above 
the normal range (mean plus 2 SD) for 24 control European sera. 
The association between HLA class II genotype and antibody response was tested as 
described previously (22). Briefly, HLA genotype was defined by the DRB-DQA-DQB 
haplotype and only those haplotypes which were present in at least 20/355 children in 
group A or 10/283 people in group B were included in the analysis. Individuals were 
classified as either responders or non-responders to each antigen and the probability of 
an immune response in individuals of any particular haplotype was estimated by multiple 
logistic regression allowing for the potential confounding effects of age, sex and, in 
group A, sickle cell status. To allow for linkage of HLA genotype and malaria exposure 
within members of a single family group, the data were stratified by household and 
analysed by conditional logistic regression. 
Differences between monozygous (mz) and dizygous (dx) twins were assessed in two 
ways. Firstly, the proportion of discordant pairs (i.e. where one twin was seronegative 
and the other seropositive for any particular antigen) in each group (mz vs dz) was 
compared by Fisher's exact test. Secondly, the absolute difference in OD values for each 
twin pair (for each antigen) was calculated and the significance of the median difference 
between mz and dz pairs was assessed using a non-parametric Mann-Whitney test. 
RESULTS 
How immunogenic are merozoite and gametocyte surface proteins? 
In determining the significance of apparent non-recognition of malaria antigens by 
serum antibodies from malaria exposed individuals it is important to assess the relative 
immunogenicity of the antigens. It is not necessarily appropriate to assess the 
immunogenicity of a particular antigen on the basis of the proportion of responders in 
an immune population since even poorly immunogenic antigens may be recognised after 
long term exposure. Alternatively, down regulation of responses following frequent re-
infection may underestimate the initial immunogenicity of the antigen. An alternative 
method for assessing the natural immunogenicity of these antigens is to examine 
convalescent serum samples from people who are known to have had only one or two 
malaria infections. We have examined convalescent sera from six such individuals (Table 
1). 
MSP2 is highly immunogenic, with all six convalescent sera recognising either the 
serogroup A or serogroup B proteins. Five sera recognised the highly conserved double 
EGF motif construct (19-GST) whilst the individual EGF motifs and the dimorphic 
MAD33 protein were each recognised by 3 sera. None of the sera from non-immune 
malaria patients recognised the Pfs260/230 construct, suggesting either that the sequence 
is poorly immunogenic or that their infections had been cleared (by drug therapy) before 
significant differentiation of the asexual parasites into sexual stages. 
Thus, with the possible exception of Pfs260/230, poor immunogenicity seems an unlikely 
explanation for non-responsiveness to these particular proteins in malaria-immune 
individuals. 
Are antibody levels, within one individual, stable over time? 
In order to confirm that non-responsiveness to malaria antigens is a real phenomenon, 
it is important to determine whether responder or non-responder status is a consistent 
phenotype within an individual. To do this we collected multiple serum samples from 
children and adults, at intervals of approximately six months, i.e. both high and low 
malaria transmission seasons. 
In children there was clear evidence of seasonal variation in antibody responses with 
oscillation between seropositivity and seronegativity (Table 2) and boosting of the 
antibody response during the malaria transmission season (Figure 2). It is possible to 
make a shrewd guess as to the MSP2 genotype of the infecting parasites, based on the 
rise or fall of antibodies to MSP2 serogroup A or B proteins. For example, donor E07008 
shows boosting of antibodies to serogroup A whilst E24009 shows boosting of the 
response to serogroup B in 1990 and to A and B in 1991. It is also clear that some 
antigens are more frequently recognised than others. Surprisingly, the dimorphic antigens 
(MAD33, MSP2-A3 and MSP2-B3) appear to be more frequently recognised than the 
conserved antigens (MSP1 19 , r260, EGF-1 and EGF-2) but this may simply reflect the 
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fact that they are somewhat larger and presumably express a more diverse array of 
epitopes. 
In contrast to the variable responses seen in children, adult responses were much less 
variable over time (Figure 3; Table 3). Individuals tend to be either consistently 
seropositive or consistently seronegative for specific antigens. What is evident in the 
adults however, is some kind of epitope selection. Donor 13 (Fig 3a) is consistently 
antibody positive for MSP2-A3, B2 and B3 but negative for MSP2-A2. Donor 45 (Table 
3, Fig 3b) recognises MAD33 and MSP2 but fails to recognise the MSP1 19 proteins. Some 
donors (e.g. 79) make strong antibody responses to all the antigens tested and all donors 
(with the exception of donor 109) make consistent responses to at least one of the 
antigens tested. 
3. Is the pattern of antibody recognition of MSP1 and MSP2 genetically determined? 
To determine whether 	persistent non-responder status in adults is genetically 
determined, the effects of HLA Class II genes and non-HLA genes on antibody 
responses were examined. Table 4 summarises the results of the statistical analysis of the 
relationship between HLA class II haplotype and antibody responses to MSP1 and MSP2. 
No significant associations were seen between any of the antigens tested and any HLA 
class II antigen. One marginally significant association was observed, for MAD33, in 
Group A but this was not apparent in Group B and is therefore unlikely to be a true 
association. r260 was analysed for Group B only but few individuals were tested for each 
haplotype (data not shown) and although no association was found (x2 = 3.04, p = 0.55), 
the group sizes were too small for any definitive conclusions to be drawn. 
Sera from 15 pairs of adult monozygous (mz) twins and 21 pairs of adult dizygous (dz) 
twins were tested for recognition of MSP1 19 and MSP2 (Table 5). Overall, the level of 
concordance is high (36 pairs tested against 5 antigens = 180 comparisons, of which 142 
were concordant, = 79%), this presumably reflects the similarity of past malaria exposure 
within the pairs. However, some pairs are clearly discordant with one twin showing a 
strong antibody response to a particular antigen and the other twin being seronegative. 
If these differences were the result mainly of genetic differences between the twins, one 
would expect that more dz than mz pairs would be discordant, but this is not the case. 
There was no significant difference between mz and dz twins in either the number of 
discordant pairs (Fisher's exact test, p > 0.05 for all antigens) or the median difference 
in OD values (Mann-Whitney; p >0.07 for all antigens). In other words, mz pairs are no 
more alike than are dz twins and genetically identical mz twins can have very different 
antibody responses. 
Sufficient serum was available from eight pairs of twins (3 mz, 5 dz) for testing for 
responses to r260. All eight pairs gave concordant responses (i.e. both negative or both 
positive). However, in a larger number of twins, we have demonstrated discordant 
responses to native Pfs260/230 within monozygous pairs (14). 
DISCUSSION 
Limited antibody recognition of malaria merozoite antigens is a potential problem for 
vaccine development, particularly if non-responsiveness is genetically determined, since 
a proportion of any given population may be unable to respond to vaccination. Although 
non-responsiveness to malaria antigens has been widely reported (9,10,14,18,20) there 
has been little attempt to determine the cause. In this study we have investigated the role 
of three factors - immunogenicity of the antigens, temporal fluctuations in antibody titre 
and host genotype - in the response to defined epitopes of two merozoite surface 
antigens, MSP1 and MSP2 and a gametocyte surface antigen Pfs260/230. In order to 
overcome the confounding effects of antigenic polymorphism and heterogeneity of 
malaria exposure, we have deliberately selected antigens representing semi-conserved 
or conserved protein sequences which are commonly expressed by parasites circulating 
in the study area (37). We also selected antigens which we believed would be highly 
immunogenic in that more than 50% of immune adults have antibodies to them (15,31) 
7 
(R. Taylor et al, submitted for publication, A. Egan et a!, unpublished). The 
immunogenicity of the antigens used is confirmed by our finding that high titre antibody 
responses can be detected during the convalescent phase of primary malaria infections. 
Previous studies in human populations have not shown any significant association 
between naturally acquired antibody responses to defined malaria antigens and HLA 
class II genotype (14,20-24). Similarly, in this study, we have looked for relationships 
between HLA class II and responses to MSP1, MSP2 and r260 antigens in some 500 
malaria-immune individuals and found no significant associations between the two 
variables. However, demonstration of HLA associated non-responsiveness in outbred 
human populations is hindered by the extreme genetic diversity of even quite small 
communities (38-40) and by the heterogeneity of antigenic challenge, particularly for 
polymorphic micro-organisms such as malaria parasites (37). In this study we have 
overcome this problem by comparing immune responses of twins which have a shared 
genetic background and similar malaria exposure histories. Although the number of twin 
pairs tested was rather small, comparison of antibody responses in identical and non-
identical twins indicates that genetic background is not a major factor in determining 
responsiveness to MSP1, MSP2 and r260. This is in agreement with data from a much 
larger twin study (see below) and with our previous observations for antibody responses 
of twins to native Pfs260/230 (14). We have shown that, despite life long exposure to 
malaria, monozygous twin pairs can have clearly discordant antibody responses to the 
same antigen. (Recent boosting of the antibody response in one twin but not the other 
is unlikely since samples were collected several months after the end of the transmission 
season.) 
In this, rather small, twin study it is not possible to dissociate the MHC (HLA class II) 
effects from non-MHC effects. However, in a related, but much larger, study of 
antimalarial immune responses in Gambian twins (41), it was found that although T cell 
responses to a wide variety of malaria antigens are influenced by genetic factors lying 
outside the HLA class II region, neither HLA or non-HLA genes contributed 
significantly to antibody responses. This is probably because environmental factors 
outweigh genetic factors in determining the level of the antibody response at any 
particular point in time. Thus, we conclude that genetic factors do not play a major role 
in determining serological responsiveness or non-responsiveness to these particular 
malaria antigens. We therefore turned to an examination of temporal (environmental) 
factors which may influence the response. 
We compared patterns of antibody responsiveness over time in a group of 20 partially-
immune children who were still susceptible to clinical malaria infection (and who 
experience high levels of parasitaemia when infected) with the pattern of responses in 
clinically immune adults who experienced only asymptomatic, low level, infections. The 
pattern of responses in children was not unexpected - there was clear evidence of 
seasonal variation in antibody levels with titres rising at the end of the malaria 
transmission season. However, even in children it was evident that responses to some 
antigens were being boosted more readily than others. For example, epitopes within 
MSP1 19 would have been present during every infection but the response to this protein 
was boosted in some children but not in others. Antibody levels were remarkably stable 
in adults with individuals remaining consistently seropositive or consistently seronegative 
with respect to individual antigens. Individual donors were clearly able to recognise 
different antigens in a selective manner, recognising some regions of an antigen but 
failing to recognise adjacent regions of the same protein. 
Few immuno- epidemiological studies have examined antibody responses to malaria 
antigens over a period of months or years in the same person, but in a two year study in 
Liberia Bjorkman et a! (42) found that antibodies to the erythrocyte membrane antigen 
Pf155/RESA were consistent on consecutive surveys and they were able to divide their 
cohort into responders or non-responders. These workers ascribed the stability of 
responses to genetic restriction but provided no supporting evidence. Interestingly, in a 
longitudinal study conducted in Madagascar, where an epidemic outbreak of Plasmodium 
falciparum occurred after 20 years without malaria transmission, clear seasonal variation 
in the titre of anti-Pf155/RESA antibodies was seen in both children and adults (43). 
This supports our conclusion that antibody levels stabilise in malaria- immune individuals 
but fluctuate according to recent malaria exposure in non-immunes or semi-immunes. 
The age at which antibody levels begin to stabilise may depend on the intensity of 
malaria transmission and on the antigen in question. In an area of perennial, holoendemic 
malaria transmission, Björkman et a! (44) found that seropositivity to Pf155/RESA was 
consistent from season to season in children aged 3 to 5 years. We have previously found 
stable antibody responses to Pfs260/230 in children as young as 3 to 5 years old (14), and 
in this study responses of some children to MSP2-B3 were very consistent, but on the 
whole responses to merozoite surface antigens, and to the repeat region of Pfs260/230, 
do not seem to stabilise until later in life. 
Since recognition of malaria epitopes does not appear to be genetically determined, and 
since antibody repertoires appear to become fixed in clinically-immune adults, we have 
considered the possibility that the selective recognition of these antigens may be the 
result of clonal imprinting (original antigenic sin). 
The term "original antigenic sin" was first used to explain the observation that adult 
humans vaccinated against influenza produced antibodies with higher affinity for strains 
to which they had been exposed in childhood than for the vaccine strain (45,46). The 
molecular basis of original antigenic sin was subsequently shown to be the presence of 
cross-reactive epitopes within the polymorphic viral haemagglutinin (47,48). On primary 
infection, specific clones of naive T and B cells proliferate and transform into memory 
cells. Memory B cells have higher avidity for antigen than naive B cells since they 
express more surface Ig (slg) and somatic mutation of the Ig genes results in expression 
of slg of higher affinity (49). On secondary infection, memory B cells successfully 
compete with naive B cells for antigens which cross-react with the original infection and 
antibody of the original specificity is produced. Epitopes which were not present in the 
original infection, or which induced memory cells of lower affinity, are effectively 
ignored. Since relative affinity of slg for antigen is crucial to this process, it follows that 
the effect can be overcome by high doses of antigen (48). 
There are many features of malaria infection which make clonal imprinting a likely 
explanation for the selective antibody responses seen in malaria-immune individuals. 
Firstly, malaria antigens are composed of both conserved (or semi-conserved) and 
polymorphic epitopes (50), so cross-reactive immune responses would be expected. 
Secondly, people are infected many times by malaria and polymorphism within malaria 
parasite populations is extensive enough (51) that it is highly likely that successive 
infections would be of differing genotypes. Finally, in clinically immune individuals 
blood stage infections are of very low density, such that competition for antigen may 
occur between B cells of differing affinity. In this case, high affinity responses would 
be boosted and low affinity responses would eventually be lost. This may explain why 
the prevalence of antibodies to, for example, MSP1 19 , appears to be higher in individuals 
recovering from a primary malaria infection (5/6 in this study) than in immune or semi-
immune individuals. 
As yet, there is no direct evidence that clonal imprinting occurs to malaria antigens, but 
the data presented here are consistent with such an explanation. Confirmation requires 
longitudinal studies where the development of antibody responses can be monitored in 
individuals whose infection history is carefully documented in terms of parasite 
genotype. We have recently initiated such a study in West Africa to confirm or refute the 
clonal imprinting hypothesis. 
If the low prevalence of antibodies to certain antigens is due to clonal imprinting, 
injudicious vaccine design may cause problems. However, antibody responses to a 
synthetic vaccine antigen may be more widespread than responses to the same antigen 
following natural infection since presentation of an antigen in the absence of the epitope 
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Figure legends. 
Figure 1: Schematic representation of the MSP1 and MSP2 antigens 
used in this study. 
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Figure 2: Longitudinal study of anti-malarial antibody levels in 
Gambian children. Samples were collected at 6 month intervals 
from June 1988 to November 1991. Values are OD units for serum 
tested in ELISA at a dilution of 1/1000. The horizontal lines 
represent the upper limit of the normal range for non-immune 
sera. 
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Figure 3: 
Longitudinal study of anti-malarial antibody levels in Gambian 
adults (aged more than 20 years). Samples were collected at 6 
month intervals from November 1991 to November 1993. Values are 
OD units for serum tested in ELISA at a dilution of 1/1000. The 
horizontal lines represent the upper limit of the normal range 
for non-immune sera. 
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Table 1: Antibody recognition of recombinant MSP1 and MSP2 antigens by acute and convalescent sera 
from individuals experiencing their first or second attack of P. falciparum malaria. Sera were 
tested at a dilution of 1:1000. Values given are specific OD values. Values shown in bold are 
positive (i.e. greater than the mean plus 2SD of the naive European control sera). 
M0 1 	 MSP2 	 Pfs260/230 
Serum 	EGF-1 	EGF-2 	19-GST 	MAD33 	A2 	 A3 	B2 	B3 	r260 
92/21 	0.343 	-0.005 	0.865 	0.701 	0.002 	0.722 	0.278 	-0.125 	-0.104 
93/28 0.047 -0.084 0.285 0.403 0.425 0.615 0.374 -0.300 0.160 
92/10 	0.049 	0.166 	0.028 	0.149 	0.312 	-0.042 	0.807 	0.396 	-0.254 
92/38 2.119 0.501 2.113 1.523 1.288 1.079 0.271 0.639 0.126 
92/12 	0.423 	0.322 	0.723 	1.123 	0.909 	1.108 	-0.144 	-0.402 	-0.005 
92/33 0.071 0.439 0.285 0.086 0.536 0.082 0.113 -0.195 -0.301 
Cut off 	0.150 	0.300 	0.100 	0.614 	0.509 	0.330 	0.311 	0.167 	0.186 
for +ve 
Table 2: Longitudinal survey of antibody responses to MSP1 and MSP2 antigens in Gambian children. 
Each symbol represents a separate serum sample. Samples were collected at six month intervals. 
- = antibody negative, + = antibody positive, + = strongly antibody positive. 
MS?] 
	
MSP2 	 Pfs260/230 
Donor Age EGF-i. MSP119 MAD33 A2 A3 B2 B3 r260 
E07008 5 --4 --+--- -++ +----- --++-- +-+--- 
E08010 7 +-++-+ _++-+- ++ -+ -k -+---- ++++++ 
E09009 3 -+--- 
E17004 3 
E18003 6 -+---+ -+---+ ++++-+ ---+- +---+- 
E20015 5 -++++ --+++ --+ --++- +-+++ 
E24008 6 --+ --+--- +- ...... -+ -+---- -++-+- 
E24009 4 + -+-+-+ +---i---+ -----+ ---+-- ---+-+ ++---- 
E25007 3 ----+- 
E25009 6 -+---- +--++ --+--- -++--- --+--- 
N05034 3 ---- -+-+ -+ ---- 
?06008 7 -+++ 
-----+ -+--+ 
P06009 4 +----- -+ -+---- -+---+ 
P06010 3 ---++ -+--++ +---+ -+--+ -++++ 
P10016 6 _------ ++++++ -----+ ++++++ ---+-- -+++++ --+-+- 
P10017 3 ----+ ----+ +++-+ -+--+ ----+ ++-++ 
P11005 6 ---- -+ ---- ---- 
P12009 5 -+ -+--- ++-++ -++++ -+-++ --+-+ +-t-+++ 
Q01008 6 ---+ ---+ ++++ -+++ ++++ +.+. ++.+ 
Q03005 4 --+--+ --+-+ --+-+ --+--+ +-+-+ -+-++ 
Table 3: Longitudinal study of antibody responses to MSP1 and MSP2 antigens in Gambian adults. Each 
symbol represents a separate serum sample. Samples were collected at six month intervals. 
- = antibody negative, + = antibody positive, + = strongly antibody positive. 
MSP1 MSP2 Pfs260/230 
Donor Age EGF-1 MSP119 MAD33 A2 A3 B2 B3 
r260 
12 60 +++++ +++++ 
+++++ +++++ ----+ 
13 55 +++++ nd nd +++++ +++++ 
+++++ 
45 45 --+ +.+++ +++++ +++++ +++++ 
+++++ nd 
50 38 +++-f-+ +++++ +++++ +++++ 
--+-- 
79 50 +++++ +++++ +4-+++ +++++ +++++ +++++ 
+++++ +++++ 
110 17 +++++ +++++ +++++ +++++ +++++ 
+++++ 
167 16 +++++ ----+ +-+++ 
109 16 -+-+ -+-+ _ __ 
31 44 ---++ +-+++ +++++ ---++ +++++ +++++ 
104 16 ---++ ----++ +++++ ---+ +-+++ 
+++++ nd 
53 60 -------------- ++++++ ++--++ ++++-+ 
15 45 -+ ++++ ++++ +--+ -+++ 
++++ 
120 65 ---++ ---+++ --+-+ 
--+++- 
95 41 +++++ +++++ +++++ +++++ 
+-++- +++++ 
4 34 ++++++ ++++++ +++.++ + ++++++ 
+++-++ 
117 17 --+ --+ ++++++ ---+++ ++++++ ++++++ 
++++++ +-+++ 
28 55 ++++++ +++-+ ++++++ 
-++--++ +++++ 
69 35 ---+ +-+++ 
+++++ 
116 28 +++++ --+++ +++ +++++ 
125 28 +-+-+ +---+ +++++ +++++ ++.++ 
+++++ +---- 
112 18 +++++ 
-++-i-+ 
105 24 +---- ++--- +++++ ++--- -+--- 
+++++ +--++ 
Table 4: Association between HLA class II haplotype and antibody responses to MSP1, MSP2 and r260 
proteins. Number (proportion) of individuals expressing each haplotype who were seropsitive for each 
antigen. x2 is conditional logistic regression statistic for overall association between HLA type 
and immune response. 










w5 8 4(0.50) 5(0.63) 2(0.25) 4(0.50) 3(0.38) 2(0.25) 1(0.13) 4(0.50) 
2 w15 w6 7 2(0.29) 1(0.14) 0(0.00) 1(0.14) 1(0.14) 1(0.14) 1(0.14) 1(0.14) 
7 w17 w2 31 16(0.52) 16(0.52) 16(0.52) 14(0.45) 13(0.42) 9(0.29) 6(0.19) 17(0.55) 
8 w18 w4 13 7(0.54) 7(0.54) 4(0.31) 4(0.31) 3(0.23) 2(0.15) 1(0.08) 5(0.38) 
9 3 w44 5 0(0.00) 2(0.40) 2(0.40) 2(0.40) 1(0.20) 1(0.20) 1(0.20) 2(0.40) 
11 w8 18 11(0.61) 10(0.56) 9(0.50) 11(0.61) 8(0.44) 7(0.39) 6(0.33) 12(0.67) 
12 4 w2 26 16(0.62) 11(0.42) 14(0.54) 17(0.65) 12(0.46) 9(0.35) 6(0.23) 15(0.58) 
14 7 w2 16 7(0.44) 8(0.50) 4(0.25) 11(0.69) 3(0.19) 3(0.19) 3(0.19) 10(0.63) 
15 7 w2 58 28(0.48) 26(0.45) 27(0.47) 33(0.60)
a 21(0.36) 21(0.36) 13(0.22) 31(0.53) 
17 w8 w7 30 13(0.43) 14(0.47) 12(0.40) 15(0.50) 11(0.37) 6(0.20) 4(0.13) 13(0.43) 
18 w8 w7 18 14(0.78) 11(0.61) 8(0.44) 9(0.50) 6(0.33) 8(0.44) 5(0.28) 12(0.67) 
21 9 w2 43 27(0.63) 25(0.58) 21(0.49) 19(0.44) 18(0.42) 11(0.26) 9(0.21) 21(0.49) 
22 w1Ow5 60 36(0.60) 29(0.48) 
33(055)25(042)b17(028) 14(0.23) 6(0.10) 27(0.45) 
23 w1lw7 14 11(0.79) 7(0.50) 5(0.36) 8(0.57) 6(0.43) 2(0.14) 4(0.29) 10(0.71) 
26 w1lw7 9 5(0.56) 2(0.22) 3(0.33) 4(0.44) 2(0.22) 3(0.33) 0(0.00) 4(0.44) 
29 w1lw7 119 53(0.45)54(0.45)50(0.42)53(0.45)c38(0.32)25(0.21) 15(0.13) 62(0.52) 
34 w13 w6 10 4(0.40) 4(0.40) 2(0.20) 3(0.30) 1(0.10) 0(0.00) 0(0.00) 1(0.10) 
35 w13wl 11 4(0.36) 4(0.36) 3(0.27) 
4(0•44)d 4(0.36) 7(0.64) 4(0.36) 5(0.45) 
37 w13 w6 9 3(0.33) 4(0.44) 1(0.11) 4(0.44) 3(0.33) 0(0.00) 2(0.22) 3(0.33) 
38 w13 w6 62 31(0.50) 29(0.47) 24(0.39) 27(0.44)e26(0.42) 18(0.29) 9(0.15) 35(0.56) 
39 w13 w7 13 10(0.77) 9(0.69) 5(0.38) 9(0.69) 3(0.23) 2(0.15) 3(0.23) 9(0.69) 
x2 11.99 10.14 5.00 13.23 4.35 7.34 9.47 7.50 
df 8 8 8 8 8 8 8 8 
P 0.15 0.26 0.76 0.10 
0.82 0.50 0.30 0.48 
-' el 	, 









DR 	DQ n EGF-1 EGF-2 MSP1 19 MAD33 A2 A3 B2 B3 
1 1 w5 8a 1(0.14) 6(0.86) 5(0.71) 5(0.71) 5(0.63) 8(1.00) 
8(1.00) 6(0.75) 
2 w15 w6 4 2(0.50) 3(0.75) 4(1.00) 4(1.00) 2(0.50) 4(1.00) 
4(1.00) 4(1.00) 
7 w17 w2 7 4(0.57) 5(0.71) 7(1.00) 7(1.00) 4(0.57) 7(1.00) 
7(1.00) 7(1.00) 
8 w18 w4 1 1(1.00) 1(1.00) 1(1.00) 1(1.00) 1(1.00) 
0(0.00) 0(0.00) 0(0.00) 
9 3 w4 7a 1(0.17) 4(0.67) 2(0.33) 6(1.00) 2(0.29) 
6(0.86) 6(0.86) 5(0.71) 
11 4 w8 5a 2(0.50) 3(0.75) 4(1.00) 2(0.50) 2(0.40) 
5(1.00) 4(0.80) 4(0.80) 
12 4 w2 1 1(1.00) 1(1.00) 1(1.00) 1(1.00) 1(1.00) 
1(1.00) 1(1.00) 1(1.00) 
14 7 w2 ha 3(0.30) 10(1.00) 8(0.80) 10(1.00) 7(0.64) 
9(0.82) 9(0.82) 8(0.73) 
15 7 w2 3 a 1(0.50) 2(1.00) 2(1.00) 2(1.00) 1(0.33) 3(1.00) 
3(1.00) 3(1.00) 
17 w8 w7 5a 2(0.50) 3(0.75) 4(1.00) 4(1.00) 3(0.60) 5(1.00) 
3(0.60) 3(0.60) 
18 w8 w7 3 2(0.67) 3(1.00) 3(1.00) 3(1.00) 3(1.00) 
3(1.00) 3(1.00) 2(0.67) 
21 9 w2 12' 3(0.30) 9(0.90) 9(0.90) 9(0.90) 7(0.58) 
12(1.00) 11(0.92) 11(0.92) 
22 w1Ow5 16 5(0.31) 14(0.88) 13(0.81) 15(0.94) 10(0.63) 
14(0.88) 13(0.81) 13(0.81) 
23 w1lw7 5b 1(0.33) 3(1.00) 3(1.00) 3(1.00) 4(0.80) 5(1.00) 
4(0.80) 4(0.80) 
26 w1lw7 4 2(0.50) 2(0.50) 3(0.75) 
3(0.75) 2(0.50) 4(1.00) 4(1.00) 1(0.25) 
29 w1lw7 60c 22(0.41) 46(0.85) 42(0.78) 53(0.98) 31(0.52) 54(0.90) 
54(0.90) 44(0.73) 
34 w13 w6 4 0(0.00) 3(0.75) 2(0.50) 
4(1.00) 2(0.50) 4(1.00) 3(0.75) 4(1.00) 
37 w13 w6 3 0(0.00) 3(1.00) 3(1.00) 
3(1.00) 2(0.67) 3(1.00) 3(1.00) 3(1.00) 
38 w13 w6 28a 10(0.37) 23(0.85) 24(0.89) 27(1.00) 16(0.57) 25(0.89) 
26(0.93) 25(0.89) 
39 w13 w7 9 3(0.33) 7(0.78) 6(0.67) 
9(1.00) 7(0.78) 9(1.00) 9(1.00) 7(0.78) 
2.82 6.13 2.79 4.44 5.48 0.05 
3•43* 2.69 
df 5 5 5 5 5 3 5 
5 
p 0.73 
0.29 0.73 0.49 0.36 1.00 0.63 0.75 
a n = 1 less for MSP1 proteins; b n = 2 less for MSP1 proteins; c n = 3 less for MSP1 proteins. 
* results for unconditional (standard) logistic regression since conditional model did not converge 
for anv combination of haplotypes. 
Table 5: Comparison of antibody responses to MSP1 and MSP2 
antigens in adult, monozygous and dizygous Gambian twins. The 
first figure in each column represents the OD value for one twin, 
the second figure is the OD value for the other twin in the pair. 
Discordant results (one above and one below cut off) are 
underlined. * Cut off values for positive responses (mean + 2SD 
of control sera). 
MSP1 19 MSP2-A2 MSP2-A3 MSP2-B2 MSP2-B3 
MZ1 0.123 0.138 0.010 0.569 0.068 0.086 0.010 0.637 0.189 0.880 
MZ2 0.769 0.822 1.992 1.854 1.088 1.184 2.481 2.228 1.462 1.480 
MZ3 0.114 0.163 0.509 0.849 0.223 0.269 0.680 0.850 0.171 1.512 
MZ4 0.128 0.106 0.526 0.311 0.172 0.002 0.007 0.069 0.128 0.094 
MZ5 0.289 0.138 0.461 1.216 0.120 0.792 0.121 1.747 0.084 0.279 
MZ6 1.220 0.482 0.700 0.601 0.254 0.072 0.418 2.313 1.751 1.383 
MZ7 0.047 0.681 0.718 0.986 1.472 0.970 1.760 2.219 0.718 1.935 
MZ8 1.358 1.738 1.986 0.254 2.261 0.150 1.932 1.359 1.354 1.135 
MZ9 0.079 0.341 0.881 1.050 1.571 1.241 0.361 2.482 0.967 1.864 
NZ10 0.075 0.085 0.053 0.513 0.059 0.213 0.049 0.300 0.061 0.359 
MZ11 0.315 0.129 0.792 0.957 0.560 1.173 1.758 0.339 2.339 0.012 
MZ12 0.457 0.843 0.181 0.788 2.185 2.039 1.267 0.434 2.083 1.673 
M213 0.153 0.205 0.100 0.841 0.689 0.929 0.082 0.636 1.029 2.055 
MZ14 0.230 0.571 0.148 0.480 1.425 2.165 1.675 0.544 2.188 1.159 
MZ15 0.225 0.103 0.387 0.129 0.858 0.404 1.357 0.673 0.694 0.455 
DZ1 0.171 0.139 0.486 0.374 0.265 0.052 0.328 0.613 ' 0.576 0.109 
DZ2 0.339 0.147 0.541 0.266 0.237 0.248 2.140 0.329 1.600 0.162 
DZ3 0.146 0.157 0.301 1.837 0.107 0.305 0.576 2.273 0.370 0.508 
DZ4 0.099 0.106 0.203 0.163 0.537 0.092 0.021 0.084 0.694 0.246 
DZ5 0.105 0.256 0.185 0.077 0.010 0.054 0.393 0.120 0.214 0.374 
DZ6 0.140 0.123 1.176 0.596 0.506 0.486 0.411 0.704 0.030 1.096 
DZ7 0.369 0.806 0.873 1.066 0.555 0.285 0.148 0.744 0.352 1.712 
DZ8 0.096 0.082 1.391 0.936 1.874 1.250 0.089 0.819 0.041 0.327 
DZ9 0.222 0.390 0.858 2.118 1.291 2.166 0.751 2.290 0.292 1.919 
DZ10 0.097 0.076 1.411 0.417 1.703 2.267 1.215 1.514 2.193 0.826 
DZ11 1.414 0.197 0.557 0.486 1.136 0.958 1.935 0.754 1.842 1.607 
DZ12 0.348 0.145 0.120 0.027 0.808 0.121 0.301 2.121 1.957 2.076 
DZ13 0.579 0.607 1.164 1.989 1.500 1.449 0.958 1.379 0.828 1.341 
DZ14 0.181 0.332 1.558 0.674 1.077 1.990 1.374 1.031 1.407 2.023 
DZ15 0.073 0.168 0.119 1.146 0.321 2.069 1.976 0.649 1.194 2.264 
DZ16 0.123 0.115 0.072 0.109 2.035 0.542 2.078 0.051 2.101 0.128 
DZ17 0.067 0.077 0.029 0.032 0.495 0.716 0.030 0.561 0.574 0.997 
DZ18 0.086 0.080 0.607 0.125 .0.831 0.723 0.194 0.045 0.478 0.227 
DZ19 0.332 0.167 0.087 0.351 0.739 0.256 0.322 0.433 0.763 1.214 
DZ20 0.086 0.163 0.574 0.657 1.497 0.722 0.603 0.622 1.694 0.452 
DZ21 0.061 0.061 0.030 0.270 0.117 0.369 0.148 0.148 0.124 0.104 
* 	> 0.098 0.296 0.185 0.096 0.130 
0.129 3.14 0.038 0.038 0.073 
p > 0.5 >0.05 >0.5 >0.5 >0.5 
U 101.5 137.5 140.0 134.5 137.0 
p 0.07 0.53 0.59 0.47 0.5 
Epitope specificities of MSP2 monoclonal antibodies for serogroup A and B 
dimorphic and polymorphic domains. 
I 	13.4 	I 
I 4-4F/8-5D I 12.3,12.5,12.7  I 
	










Serogroup B mAbs 
Appendix 1A 
Schematic representation of MSP2 recombinant proteins 
Serogroup A 
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